<SEC-DOCUMENT>0001640334-20-002732.txt : 20201106
<SEC-HEADER>0001640334-20-002732.hdr.sgml : 20201106
<ACCEPTANCE-DATETIME>20201106165054
ACCESSION NUMBER:		0001640334-20-002732
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		61
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201106
DATE AS OF CHANGE:		20201106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emerald Bioscience, Inc.
		CENTRAL INDEX KEY:			0001516551
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450692882
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-55136
		FILM NUMBER:		201295100

	BUSINESS ADDRESS:	
		STREET 1:		5910 PACIFIC CENTER BLVD, SUITE 320
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(949) 480-9051

	MAIL ADDRESS:	
		STREET 1:		5910 PACIFIC CENTER BLVD, SUITE 320
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Nemus Bioscience, Inc.
		DATE OF NAME CHANGE:	20141030

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD LOGISTICS, INC.
		DATE OF NAME CHANGE:	20121107

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LOAD GUARD TRANSPORTATION, INC.
		DATE OF NAME CHANGE:	20110324
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>embi_10q.htm
<DESCRIPTION>FORM 10-Q
<TEXT>
<html><head><title>embi_10q.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:12pt">UNITED STATES</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:12pt">SECURITIES AND EXCHANGE COMMISSION</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:12pt">Washington, D.C. 20549</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">FORM 10-Q</font></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(Mark One)</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="margin:0px">&#9746;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</strong></p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td> <p style="margin:0px">For the quarterly period ended <strong><u>September 30, 2020</u></strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>or</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td> <p style="margin:0px">For the transition period from ___________ to ___________</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Commission File Number: <strong><u>000-55136</u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:50%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:center;"><strong><font style="font-size:18pt">Emerald Bioscience, Inc.</font></strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;">(Exact name of registrant as specified in its charter)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>Nevada</strong></p></td> <td style="width:10%;"></td> <td style="BORDER-BOTTOM: 1px solid;width:45%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>45-0692882</strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(State or other jurisdiction</p> <p style="MARGIN: 0px; text-align:center;">of incorporation or organization)</p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(I.R.S. Employer</p> <p style="MARGIN: 0px; text-align:center;">Identification No.)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><u>5910 Pacific Center Blvd, San Diego, CA 92121</u></strong></p></td></tr> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(Address of principal executive offices) (Zip Code)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><u>(949) 480-9051</u></strong></p></td></tr> <tr style="height:15px"> <td style="width:100%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">(Registrant&#8217;s telephone number, including area code)</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>_____________________________________________________________</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">(Former name, former address and former fiscal year, if changed since last report)</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">Title of each class</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Name of each exchange </p> <p style="MARGIN: 0px; text-align:center;">on which registered</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">None</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">None</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">None</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Securities registered pursuant to Section 12(g) of the Act:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">Title of each class</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:center;">Trading Symbol(s)</p></td> <td style="width:5%;"> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Name of each exchange </p> <p style="MARGIN: 0px; text-align:center;">on which registered</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">Common Stock, par value $0.001</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">EMBI</p></td> <td> <p style="MARGIN: 0px; text-align:center;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">OTCQB</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&nbsp;&#9746; Yes&nbsp;&nbsp;&nbsp;&nbsp; &#9744; No</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#9746; Yes&nbsp;&nbsp;&nbsp;&nbsp; &#9744; No</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%" cellpadding="0"> <tr style="height:15px"> <td style="width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Large accelerated filer</p></td> <td style="width:20%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td> <td style="width:30%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Accelerated filer</p></td> <td style="width:20%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Non-accelerated filer</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9746;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Smaller reporting company</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">&#9746;</p></td></tr> <tr style="height:15px"> <td colspan="2"></td> <td> <p style="MARGIN: 0px; text-align:justify;">Emerging growth company</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&#9744;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&nbsp;&#9744; Yes &#9746; No</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of November 5, 2020, there were&nbsp;250,074,415&nbsp;shares of the issuer&#8217;s $0.001 par value common stock issued and outstanding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <table style="font-size:1px;width:100%"> <tr > <td style="BORDER-BOTTOM: 2px solid;"></td></tr> <tr > <td style="BORDER-BOTTOM: 5px solid;"></td></tr></table> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="TEXT-INDENT: 0px;"></td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td>&nbsp;</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="TOC">TABLE OF CONTENTS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td colspan="5"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#P1">PART I-FINANCIAL INFORMATION</a></strong></p></td></tr> <tr style="height:15px"> <td style="width:9%;"></td> <td></td> <td style="width:1%;"></td> <td style="width:9%;"></td> <td style="width:1%;"></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#I1">Item 1.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#I1">Financial Statements:</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">4</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#BS">Condensed Consolidated Balance Sheets as of September 30, 2020 (Unaudited) and December 31, 2019</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">4</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#CL">Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended September 30, 2020 and 2019 (Unaudited)</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">5</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#CF">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019 (Unaudited)</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">6</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#SE">Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit) for the Three and Nine Months Ended September 30, 2020 and 2019 (Unaudited) </a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">7</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#Note">Notes to the Unaudited Condensed Consolidated Financial Statements</a> </p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">8</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#I2">Item 2.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#I2">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">26</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#I3">Item 3.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#I3">Quantitative and Qualitative Disclosures about Market Risk</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">33</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#I4">Item 4.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#I4">Controls and Procedures</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">33</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="5"> <p style="MARGIN: 0px; text-align:center;"><strong><a href="#P2">PART II - OTHER INFORMATION</a></strong></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td></td> <td></td> <td></td> <td></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT1">Item 1.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT1">Legal Proceedings</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#ITA">Item 1A.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#ITA">Risk Factors</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT2">Item 2.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT2">Unregistered Sales of Equity Securities and Use of Proceeds</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT3">Item 3.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT3">Defaults Upon Senior Securities</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT4">Item 4.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT4">Mine Safety Disclosures</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT5">Item 5.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT5">Other Information</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT6">Item 6.</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="#IT6">Exhibits</a></p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">34</p></td> <td></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">2</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>FORWARD-LOOKING STATEMENTS</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Statements in this Quarterly Report on Form 10-Q that are not descriptions of historical facts are forward-looking statements that are based on management&#8217;s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, you can identify forward-looking statements by terminology including &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;potential,&#8221; &#8220;predicts,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these terms or other comparable terminology. Factors that could cause actual results to differ materially from those currently anticipated include those set forth in the section titled &#8220;Risk Factors&#8221; including, without limitation, risks relating to:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the results of our research and development activities, including uncertainties relating to the discovery of potential product candidates and the preclinical and clinical testing of our product candidates;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the early stage of our product candidates presently under development;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our need for substantial additional funds in order to continue our operations, and the uncertainty of whether we will be able to obtain the funding we need;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to obtain and, if obtained, maintain regulatory approval of our current product candidates, and any of our other future product candidates, and any related restrictions, limitations, and/or warnings in the label of any approved product candidate;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to retain or hire key scientific or management personnel;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to protect our intellectual property rights that are valuable to our business, including patent and other intellectual property rights;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our dependence on the University of Mississippi, third-party manufacturers, suppliers, research organizations, testing laboratories and other potential collaborators;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">our ability to develop successful sales and marketing capabilities in the future as needed;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the size and growth of the potential markets for any of our approved product candidates, and the rate and degree of market acceptance of any of our approved product candidates;</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">competition in our industry;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">the duration and impact of the novel coronavirus (&#8220;COVID-19&#8221;) pandemic; and</p></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">regulatory developments in the United States and foreign countries.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We operate in a rapidly-changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, such as the COVID-19 outbreak and associated business disruptions including delayed clinical trials and laboratory resources, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. The forward-looking statements included in this report speak only as of the date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to actual results or to changes in our expectations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">3</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><a name="P1">PART I - FINANCIAL INFORMATION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><a name="I1"><strong><u>Item 1. Financial Statements</u></strong><strong> </strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong><a name="BS">CONDENSED CONSOLIDATED BALANCE SHEETS</a></strong></p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Note 2)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>ASSETS</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current assets</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Cash </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,224,601</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,829,977</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Restricted cash </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Prepaid expenses </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,226</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">152,695</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Other current assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,333</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">7,550</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 22.5pt; text-align:justify;">Total current assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,348,698</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,994,760</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Property and equipment, net </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">887</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,983</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 22.5pt; text-align:justify;">Total assets </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,349,585</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,996,743</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current liabilities </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Accounts payable </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">731,632</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">129,809</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Accounts payable to related party </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">21,400</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Accrued interest due to related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">81,813</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">PPP loan current</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">71,102</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Other current liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">263,830</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">420,406</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Derivative liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">41,149</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">410,603</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 22.5pt; text-align:justify;">Total current liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,210,926</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">970,818</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Noncurrent liabilities </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">PPP loan non-current</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">45,598</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Multi-draw credit agreement - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Convertible multi-draw credit agreement - related party, net of discount </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">789,694</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">387,070</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Derivative liabilities, non-current </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 22.5pt; text-align:justify;">Total liabilities </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">2,496,218</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,448,685</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Commitments and contingencies </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Stockholders&#8217; equity</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019 </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Common stock, $0.001 par value; 500,000,000 shares authorized; 250,074,415 and 182,895,247 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">250,074</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">182,895</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Additional paid-in-capital </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">38,835,167</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">32,538,445</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Accumulated deficit </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(37,231,874</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(32,173,282</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 22.5pt; text-align:justify;">Total stockholders&#8217; equity</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,853,367</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">548,058</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 22.5pt; text-align:justify;">Total liabilities and stockholders&#8217; equity</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,349,585</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,996,743</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="10" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the condensed consolidated financial statements. </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">4</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="CL">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Three Months Ended</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong> </p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Nine Months Ended</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Operating expenses</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Research and development</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">346,217</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">513,004</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,574,357</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,522,031</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">General and administrative</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,192,003</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">990,110</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,395,729</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,267,037</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Total operating expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,538,220</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,503,114</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,970,086</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,789,068</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Operating loss</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,538,220</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,503,114</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,970,086</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,789,068</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Other expense (income)</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Change in fair value of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(424,138</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,126,464</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(433,688</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,024,660</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Fair value of derivative liabilities in excess of proceeds</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,644</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Interest expense </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">182,614</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">301,547</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">520,594</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">711,575</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 33.75pt">Total other expense (income), net</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(241,524</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,428,011</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">86,906</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(990,441</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Loss before income taxes</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,296,696</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,931,125</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,056,992</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,798,627</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Provision for income taxes</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net loss and comprehensive loss </strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(1,296,696</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(4,931,125</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(5,058,592</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">(3,800,227</td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Loss per common share:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Basic</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.01</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.04</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.02</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.03</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.01</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.04</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.03</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(0.03</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Weighted average shares of common stock outstanding used to compute earnings per share:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Basic</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">256,758,472</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">133,001,746</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">207,536,173</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">132,885,675</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">257,255,653</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">133,001,746</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">208,434,966</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">167,690,989</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See accompanying notes to the condensed consolidated financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">5</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="CF"><strong>CONDENSED</strong> <strong>CONSOLIDATED STATEMENTS OF CASH FLOWS</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>For the Nine Months Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash flows from operating activities:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Net Loss </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,058,592</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,800,227</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Adjustments to reconcile net loss to net cash used in operating activities:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Depreciation</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,096</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,096</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">241,216</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">514,683</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Change in fair value of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(433,688</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(2,024,660</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Fair value of derivative liabilities in excess of proceeds</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">322,644</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Amortization of debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">402,624</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">438,964</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Changes in assets and liabilities:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 33.75pt">Prepaid expenses</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">36,469</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(302,248</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 33.75pt">Other current assets</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,217</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(766</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 33.75pt">Accounts payable</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">601,823</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">191,333</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 33.75pt">Accounts payable to related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,400</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 33.75pt">Accrued interest due to related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">81,813</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 33.75pt">Other current liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(156,576</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134,469</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 45pt">Net cash used in operating activities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,268,198</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(4,524,712</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash flows from financing activities:</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt"><strong>Proceeds from the sale of common stock and warrants &#8211; net of $854,078 issuance costs for September 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">6,085,589</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Proceeds from multi-draw credit agreement &#8211; related party, net of $0 and $9,301 issuance costs for the September 30, 2020 and September 30, 2019 periods, respectively</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,990,699</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Proceeds from PPP loan</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,700</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Proceeds from pre-funded warrant exercises</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">10,533</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Net cash provided by financing activities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">6,662,822</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,990,699</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Net increase (decrease) in cash and restricted cash</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,394,624</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(534,013</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash and restricted cash</strong>,<strong> beginning of period</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,834,515</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,857,885</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Cash and restricted cash, end of period</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,229,139</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,323,872</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>Supplemental disclosures of cash-flow information:</em></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Reconciliation of cash and restricted cash:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Cash </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,224,601</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,319,360</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Restricted cash</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,538</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">4,512</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 22.5pt">Total cash and restricted cash shown in the consolidated statements of cash flows</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">4,229,139</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">1,323,872</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cash paid during the period for:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Interest</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">35,645</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">272,611</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Income taxes</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,600</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><em>Supplemental disclosures of non-cash financing activities:</em></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Reclassification of warrant liabilities to equity from exercise of warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,563</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,375</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">193,414</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Beneficial conversion feature on convertible multi-draw credit agreement</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td colspan="9" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;">See accompanying notes to the condensed consolidated financial statements. </p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">6</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong><a name="SE">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY (DEFICIT)</a></strong></p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Additional</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Paid-In</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Stockholders&#8217;</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Amounts</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, January 1, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>133,907,747</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>133,908</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>17,528,947</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(33,225,107</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(15,562,252</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,493</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">171,493</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants issued in connection with convertible multi-draw credit agreement, related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">716,110</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,584,850</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net loss for the three months ended March 31, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,774,392</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(14,774,392</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, March 31, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>133,907,747</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>133,908</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>20,001,400</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(47,999,499</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(27,864,191</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">173,084</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">173,084</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B warrant exercises</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">187</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,188</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,375</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net income for the three months ended June 30, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,905,290</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">15,905,290</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, June 30, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>134,095,247</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>134,095</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>20,318,672</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(32,094,209</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(11,641,442</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>170,106</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>170,106</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net loss for the three months ended September 30, 2019</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid; PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(4,931,125</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(4,931,125</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Balance, September 30, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>134,095,247</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>134,095</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>20,488,778</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(37,025,334</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(16,402,461</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Common Stock</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Additional</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Paid-In</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Accumulated</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Total</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Stockholders&#8217;</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Equity</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Amounts</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Capital</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Deficit</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>(Deficit)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Balance, January 1, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>182,895,247</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>182,895</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>32,538,445</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(32,173,282</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>548,058</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,142</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">64,142</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Series B warrant exercises</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">312,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">313</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,250</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26,563</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Net loss for the three months ended March 31, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,341,660</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(2,341,660</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Balance, March 31, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>183,207,747</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>183,208</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>32,628,837</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(34,514,942</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(1,702,897</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,709</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">28,709</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Net loss for the three months ended June 30, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,420,236</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(1,420,236</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Balance, June 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>183,207,747</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>183,208</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>32,657,546</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(35,935,178</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(3,094,424</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Stock-based compensation expense</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>148,365</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>148,365</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Common stock and</strong><strong> </strong><strong>warrants issued</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>56,333,334</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>56,333</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>6,029,256</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>6,085,589</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Exercise of pre-funded warrants</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>10,533,334</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>10,533</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>10,533</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Net loss for the three months ended September 30, 2020</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(1,296,696</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: black 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: black 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>(1,296,696</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Balance, September 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>250,074,415</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>250,074</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>38,835,167</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>37,231,874</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>1,853,367</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">See accompanying notes to the condensed consolidated financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">7</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>EMERALD BIOSCIENCE, INC. AND SUBSIDIARIES</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><a name="Note"><strong>NOTES TO THE CONDENSED</strong> <strong>CONSOLIDATED FINANCIAL STATEMENTS</strong></a></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>(UNAUDITED)</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>1. Nature of Operations and Business Activities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Nature of Operations</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Emerald Bioscience, Inc. (the &#8220;Company&#8221;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &#8220;Merger&#8221;) pursuant to which Nemus, a California corporation (&#8220;Nemus Sub&#8221;), became the Company&#8217;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus Sub to form a Nevada company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#8220;Emerald Health Sciences&#8221;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &#8220;Emerald Financing&#8221;). As part of the transaction, the Company&#8217;s Board members, with the exception of Dr. Brian Murphy, the Company&#8217;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&#8217;s Board. On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 11, 2019, the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) and majority stockholder unanimously approved an amendment to the Company&#8217;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&#8217;s name to Emerald Bioscience, Inc. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&#8220;EMBI Australia&#8221;), in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&#8217;s product candidates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&#8217;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 8 - Related Party Matters for additional information. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is a biopharmaceutical company located in San Diego, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&#8220;UM&#8221;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away from potentially being able to do so.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Liquidity and Going Concern</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company has incurred operating losses and negative cash flows from operations since inception and as of September 30, 2020, had an accumulated deficit of $37,231,874, stockholders&#8217; equity of $1,853,367 and working capital of $3,137,772. The Company anticipates operating losses and negative cash flows from operations into the foreseeable future in order to advance and develop potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of September 30, 2020, the Company had unrestricted cash in the amount of $4,224,601 as compared to $1,829,977 as of December 31, 2019.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">8</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As the Company approaches its first clinical trial, it expects to ramp up research and development spending and to increase cash used in operating activities. However, based on the Company&#8217;s expected cash requirements, without obtaining additional funding management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to carry out its research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &#8220;Credit Agreement&#8221;) with Emerald Health Sciences (See Note 4). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &#8220;Amended Credit Agreement&#8221;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000, and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of Common Stock, in accordance with the terms of the Credit Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2020, the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. The advances bear interest at 7% per annum and mature on October 5, 2022. The Company used the proceeds from the advances for general corporate and working capital purposes. Emerald Health Sciences elected that the fourth and fifth advances are not convertible into shares of Common Stock and no warrants were issued with the advances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#8220;PPP Loan&#8221;) from City National Bank (the &#8220;PPP Loan Lender&#8221;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &#8220;PPP&#8221;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#8220;CARES Act&#8221;) administered by the U.S. Small Business Administration (&#8220;SBA&#8221;) (Note 4). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 31, 2020, the Company entered into the August 2020 Financing (Note 5), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction were $6.1 million. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#8217;s compensation and 100% of the Board of Director and committee fees indefinitely. Upon the closing of the August 2020 Financing, the Company&#8217;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">9</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&#8217;s ability to raise additional capital and obtain the necessary funds. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of THCVHS from the second half of 2020, to the 2021 timeframe. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&#8217;s ability to continue as a going concern within one year after the date that the financial statements are issued.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>2. Summary of Significant Accounting Policies</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Basis of Presentation</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&#8217;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&#8220;GAAP&#8221;).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&#8217;s audited financial statements as of December 31, 2019, which are included in the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&#8217;s business and the risks inherent therein.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Use of Estimates</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#8217;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">10</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Risks and Uncertainties</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#8217;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#8217;s ability to attract new funding. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Fair Value Measurements</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#8220;exit price&#8221;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:6%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 1:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 2:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Level 3:</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The carrying values of the Company&#8217;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3). The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&#8217;s relatively short term the carrying value approximates fair value. As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was&nbsp;$387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#8217;s Condensed Consolidated Balance Sheets. As of September 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Convertible Instruments</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, <em>Derivatives and Hedging Activities</em> (&#8220;ASC 815&#8221;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">11</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, <em>Debt with Conversion and Other Options</em> (&#8220;ASC 470-20&#8221;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company also follows ASC 480-10, <em>Distinguishing Liabilities from Equity</em> (&#8220;ASC 480-10&#8221;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#8217;s equity shares); (b) variations in something other than the fair value of the issuer&#8217;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#8217;s S&amp;P 500 Index and settled with a variable number of the issuer&#8217;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#8217;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive Loss.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#8217; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Warrants Issued in Connection with Financings</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive Loss.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Debt Issuance Costs and Interest</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">12</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Research and Development Expenses and Licensed Technology</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#8217;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock-Based Compensation Expense </strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#8217;s actual stock volatility adjusted for periods in which significant financial variability was identified.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividends - The dividend yield assumption is based on the Company&#8217;s history and expectation of paying no dividends in the foreseeable future.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Loss Per Common Share </strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company applies FASB ASC No. 260, <em>Earnings per Share</em> in calculating its basic and diluted net loss per common share. Basic loss per share of common stock is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The computations of basic and diluted net loss per common share are as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Three Months </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Ended September 30, </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Nine Months </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Ended September 30, </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Basic net loss per share:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Net loss</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,296,696</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,931,125</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,058,592</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(3,800,227</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Weighted average common shares outstanding &#8211; basic</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">256,758,472</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">133,001,746</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">207,536,173</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">132,885,675</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 22.5pt; text-align:justify;"><strong>Net loss per share - basic</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(0.01</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(0.04</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(0.02</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(0.03</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Diluted net loss per share:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Net loss (as adjusted)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,720,835</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(4,931,125</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,401,484</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(5,656,982</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 11.25pt; text-align:justify;">Weighted average common shares outstanding &#8211; diluted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">257,255,653</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">133,001,746</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">208,434,966</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;">167,690,989</td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px 0px 0px 22.5pt; text-align:justify;"><strong>Net loss per share - diluted</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(0.01</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(0.04</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(0.03</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>(0.03</strong></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">13</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Three Months </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Ended September 30, </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Nine Months </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Ended September 30, </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>(Unaudited)</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Stock options </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000,678</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,512,715</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">25,000,678</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4,512,715</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unvested restricted stock</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,093,501</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,093,501</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Common shares underlying convertible debt</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,215,457</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5,215,457</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,000,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">145,336,155</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">57,943,250</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">22,304,750</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">144,934,542</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Recent Accounting Pronouncements</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2020, the FASB issued ASU 2020-06, <em>Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity</em>. This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#8217;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, the FASB issued ASU No. 2019-12 <em>Income Taxes </em>(Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#8217;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>3. Warrants and Derivative Liabilities</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Warrants</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s warrants. These judgments and estimates include assumptions regarding the Company&#8217;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">14</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Warrants vested and outstanding as of September 30, 2020 are summarized as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Exercise</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Term</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" colspan="2" style="width:9%;vertical-align:bottom;text-align:center;"> <p style="MARGIN: 0px; text-align:center;"><strong>Vested and</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Source</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>(Years)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Outstanding</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Pre 2015 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.00</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">6-10</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1,110,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2015 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td>$</td> <td> <p style="MARGIN: 0px; text-align:right;">1.15-5.00</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">5-10</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">220,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2016 Common Stock Warrants to Service Providers</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.15</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">40,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2016 Series C Common Stock Warrants to Placement Agent </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2017 Series D Common Stock Warrants to Placement Agent </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.25</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">480,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2017 Common Stock Warrants to Service Provider</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.41</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">125,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2018 Emerald Financing Warrants </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.10</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3,400,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Multi-Draw Credit Agreement Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.50</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">7,500,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2019 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.35</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,000,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2020 Common Stock Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.06</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">116,666,668</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2020 Common Stock Warrants to Placement Agent</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.075</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.99</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">8,166,667</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2020 Pre-Funded Warrants</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.001</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;" colspan="2"> <p style="MARGIN: 0px; text-align:right;">indefinite</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">49,800,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total warrants vested and outstanding as of September 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>195,633,335</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Emerald Multi-Draw Credit Agreement Warrants </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2019, the Company issued 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants were equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes Merton option pricing model with the following assumptions: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>At</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Issuance</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">91.6-92.1</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">2.23-2.51</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">%</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td>$</td> <td> <p style="MARGIN: 0px; text-align:right;">0.33-0.69</p></td> <td></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>August 2020 Financing Warrants </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the August 2020 Financing (Note 5), the Company issued 116,666,668 common stock warrants, 8,166,667 common stock warrants to the placement agent and 60,333,334 pre-funded warrants. The warrants were equity classified at issuance and the Company allocated $2,462,462 and $2,986,500 of the gross proceeds to the common stock warrants and pre-funded warrants on a relative fair value basis, respectively. The common stock warrants issued to the placement agent were valued at $261,333 and recorded as equity issuance costs within equity. The warrants vested immediately and were valued utilizing the Black-Scholes Merton option pricing model with the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Common Stock Warrants</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Pre-funded</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Warrants</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Placement Agent Warrants</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91.64</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">93.86</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">91.64</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.19</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.52</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.19</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">5.0</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">10</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.99</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">15</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Derivative Liabilities</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following tables summarize the activity of derivative liabilities for the periods indicated: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30, 2020</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities Issued</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Change in</strong> </p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair value of </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Reclassification</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>of Derivatives</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>to Equity </strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2020,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">90,797</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(90,797</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px">Emerald Financing - warrant liability <sup>(2)</sup> </p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">276,024</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(234,875</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">41,149</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B - warrant liability <sup>(3)</sup></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">134,579</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(108,016</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(26,563</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>501,400</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(433,688</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(26,563</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>41,149</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(90,797</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px"><strong>Current balance of derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>410,603</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>41,149</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp; </p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="18"> <p style="MARGIN: 0px; text-align:center;"><strong>Nine Months Ended September 30, 2019</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2018,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Issued</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Change in</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Reclassification</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>of Derivatives</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>to Equity</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Derivative Liabilities</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Multi Draw Credit Agreement - compound derivative liability (1)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">219,453</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">516,058</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(167,905</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">567,606</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Emerald Financing - warrant liability (2)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">15,251,413</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,895,193</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">13,356,220</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Series B - warrant liability (3)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">487,500</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">38,438</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(144,375</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">381,563</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>15,958,366</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>516,058</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(2,024,660</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>(144,375</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>)</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>14,305,389</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Less, noncurrent portion of derivative liabilities</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(219,453</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(567,606</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Current balance of derivative liabilities</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>15,738,913</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>13,737,783</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)</em> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&#8217;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes model for each payment period. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">16</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. During the nine months ended September 30, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Emerald Financing Warrant Liability (2)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. The warrants contained an anti-dilution protection feature that provided the investors with price protection if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. In connection with the August 2020 Financing, this provision was waived, and the exercise price was permanently set to $0.10. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, <em>Derivatives and Hedging/Contracts in Entity&#8217;s Own Equity</em>, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>September 30, </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>December 31, </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">80.8</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79.5</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.14</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.62</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2.38</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.04</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">17</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Series B Warrant Liability (3)</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. The Series B Financing Warrants also had a &#8220;down-round&#8221; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price. The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing. The strike price for these warrants is now permanently reset. However, because the remaining warrant holders still had certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B Financing Warrant agreements, the warrants continued to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>As of </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility factor</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">79.2</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">1.60</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.64</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Underlying common stock price</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.13</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2020, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. Prior to exercise, these Series B Common Stock Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates. Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&#8217;s common stock on the exercise dates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2020, the remaining Series B Common Stock Warrants expired unexercised. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>4. Debt </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Multi-Draw Credit Agreement- Related Party</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s Debt with Emerald Health Sciences consists of the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Conversion</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>As of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>As of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Total principal value of convertible debt&#8212;related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.40</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,014,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">2,014,500</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unamortized debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,220,838</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,622,344</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Unamortized debt issuance costs</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(3,968</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(5,086</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Carrying value of total convertible debt - related party</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>789,694</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>387,070</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Total principal value of non-convertible debt&#8212;related party</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">n/a</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">450,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>1,239,694</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;"><strong>387,070</strong></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">18</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 8). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement. For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. As of September 30, 2020, interest is no longer being deferred as a result of the August 2020 Financing. The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the Amended Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&#8217; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of September 30, 2020, the unused portion of the credit facility is $13,550,000. The drawdowns are subject to approval by the Company&#8217;s Board, which is controlled by the directors of Emerald Health Sciences. As such, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place; however, there is no guarantee of continued funding.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&#8217;s stockholders (See Note 3).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&#8217;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&#8217;s Condensed Consolidated Balance Sheets.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">19</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Condensed Consolidated Statements of Comprehensive Loss for the nine months ended September 30, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. The Lender has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and gave notice to the Company that no warrants will be issued in connection with the advances.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement. As of September 30, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 2.01 years. As of September 30, 2020, the fair value of the shares underlying the convertible advances under the Amended Credit agreement was $211,523. As of September 30, 2020, the if-converted value did not exceed the principal balance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>PPP Loan</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing seven months from the date of funding. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before February 15, 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and seven-month deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">20</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Interest Expense</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company&#8217;s interest expense consists of the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong><strong>September 30,</strong></strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Nine Months Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Related party interest expense &#8211; stated rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,087</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">107,334</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">117,459</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">272,611</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">PPP loan interest expense &#8211; stated rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">294</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">511</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Non-cash interest expense:</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Amortization of debt discount</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">137,849</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">190,886</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">401,507</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">429,355</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="margin:0px 0px 0px 11.25pt">Amortization of transaction costs</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">384</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">3,327</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">1,117</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">9,609</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>182,614</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>301,547</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>520,594</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>711,575</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>5. Stockholders&#8217; Equity (Deficit) and Capitalization</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Common Stock</em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>August 2020 Financing</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 31, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for the issuance and sale of securities, with H.C. Wainwright &amp; Co., LLC acting as the placement agent, pursuant to which the Company sold 56,333,334 common units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and 60,333,334 pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, in a registered public offering which closed on August 4, 2020 (the &#8220;August 2020 Financing&#8221;). The common units and pre-funded units were sold at a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The common stock warrants have a term of five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full (Note 3). </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the August 2020 Financing, the Company incurred issuance costs of $854,078, for net proceeds of $6,085,589. Additionally, the Company issued warrants to purchase 8,166,667 shares of common stock to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>6. Stock-Based Compensation </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock Incentive Plan</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 31, 2014, after the closing of the Merger, the Board approved the Company&#8217;s 2014 Omnibus Incentive Plan (the &#8220;2014 Plan&#8221;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. In August 2020, the Company approved Amendment No. 2 to the 2014 Plan, which increased the share reserve by an additional 7,876,835 shares over the 10% of the number of issued and outstanding shares of common stock, and removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of September 30, 2020, the Company had 6,040,097 shares available for future grant under the 2014 Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">21</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Stock Options </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following is a summary of option activities under the Company&#8217;s 2014 Plan for the nine months ended September 30, 2020: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Exercise Price</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average Remaining</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Contractual</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Term (Years)</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" colspan="2" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Outstanding, December 31, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>3,317,642</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>0.33</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>8.34</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">24,200,000</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.05</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Cancelled</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">(1,861,964</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.08</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Forfeited</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(655,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.42</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Outstanding, September 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>25,000,678</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.07</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>9.73</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Exercisable, September 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>4,410,668</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>0.07</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>9.73</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2020, no stock options were exercised. The weighted-average fair value of stock options granted during the nine months ended September 30, 2020 was $0.04. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0.35pt; text-align:justify;">The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option pricing model under the following assumptions:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Nine Months</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Dividend yield</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">0.00</td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Risk-free interest rate</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td></td> <td> <p style="MARGIN: 0px; text-align:right;">0.28-0.38</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"> <p style="margin:0px">%</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Expected term (years)</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">5.56-6.01</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Volatility</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td colspan="2"> <p style="MARGIN: 0px; text-align:right;">92.55-93.84</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"> <p style="margin:0px">%</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Restricted Stock Awards </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2020, 643,501 restricted stock awards (&#8220;RSAs&#8221;) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. At September 30, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Awards Granted Outside the 2014 Plan</strong></em> </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Options</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During the nine months ended September 30, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company&#8217;s former CFO. As of September 30, 2020, an additional 869,144 options vested and outstanding with a weighted average exercise price of $0.25 were cancelled unexercised. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Restricted Stock Awards</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following is a summary of RSA activity outside of the Company&#8217;s 2014 Plan during the nine months ended September 30, 2020: </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Number of</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Shares</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>Weighted </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Average</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Grant </strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Date Fair</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>Value</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Unvested, December 31, 2019</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>450,000</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;"><strong>0.19</strong></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Granted</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Released</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">(450,000</td> <td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">)</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">0.19</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Unvested, September 30, 2020</strong></p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>-</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">22</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock-Based Compensation Expense</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognizes compensation expense using the straight-line method over the requisite service period. Stock-based compensation is included in the Condensed Consolidated Statements of Comprehensive Loss in general and administrative or research and development, depending upon the nature of services provided. Stock-based compensation expense (including compensation expense for RSAs discussed above) was as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Three Months Ended</strong><strong> <strong>September 30,</strong></strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="6"> <p style="MARGIN: 0px; text-align:center;"><strong>Nine Months Ended</strong></p> <p style="MARGIN: 0px; text-align:center;"><strong>September 30,</strong></p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2020</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="hdcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;" colspan="2"> <p style="MARGIN: 0px; text-align:center;"><strong>2019</strong></p></td> <td style="PADDING-BOTTOM: 1px;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Research and development</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">44,010</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">82,463</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td> <td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">General and administrative</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">104,355</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">170,106</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">158,753</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">514,683</td> <td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>148,365</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>170,106</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>241,216</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td> <td style="BORDER-BOTTOM: 3px double;width:1%;vertical-align:bottom;white-space: nowrap;"><strong>$</strong></td> <td class="ffcell" style="BORDER-BOTTOM: 3px double;width:9%;vertical-align:bottom;text-align:right;"><strong>514,683</strong></td> <td style="PADDING-BOTTOM: 3px;width:1%;white-space: nowrap;"> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The total amount of unrecognized compensation cost was $879,628 as of September 30, 2020. This amount will be recognized over a weighted average period of 3.59 years.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>7. Significant Contracts - University of Mississippi</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>UM 5050 Prodrug and UM 8930 Analog Agreements</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In July 2018, the Company renewed its ocular licenses for UM 5050, related to the prodrug formulation of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, related to an analog formulation of cannabidiol (&#8220;CBD&#8221;). On May 24, 2019, the ocular delivery licenses were replaced by &#8220;all fields of use&#8221; licenses for both UM 5050 and UM 8930 (collectively, the &#8220;License Agreements&#8221;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">i)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">$100,000 paid within 30 days following the submission of the first Investigational New Drug Application (&#8220;NDA&#8221;) to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product; </p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">ii)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and</p></td></tr> <tr style="height:15px"> <td></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">iii)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">23</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&#8217;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&#8217;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&#8217;s dissolution or cessation of operations, the Company&#8217;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&#8217;s control, or the Company&#8217;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&#8217; written notice to UM.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>UM 5070 License Agreement</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&#8220;UM 5070&#8221;), to research, develop and commercialize products for the treatment of infectious diseases. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&#8217;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&#8217;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&#8217;s control. The Company may terminate the license agreement upon 60 days&#8217; written notice to UM.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2020, none of the milestones under this license agreement have been met.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">24</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>8. Related Party Matters</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Emerald Health Sciences</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company&#8217;s Chief Executive Officer and Emerald Health Sciences&#8217; Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of September 30, 2020, the Company maintains an accrual of $7,032 in expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the three and nine months ended September 30, 2020. Under this agreement, for the three and nine months ended September 30, 2019, the Company incurred expenses of $150,000 and $450,000, respectively.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company&#8217;s completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days&#8217; prior written notice to the other party. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to accrue 100% of Dr. Dhillon&#8217;s consulting fees until the Board of Directors determines that the Company has been sufficiently financed to make such payments at which point the Company agrees to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. The deferral was paid concurrent with the August 2020 Financing. Under this agreement, for the three and nine months ended September 30, 2020, the Company incurred fees of $31,000 and $97,387, respectively. As of September 30, 2020, the Company has accrued $10,000 in expense related to the Independent Contractor Services Agreement.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In addition, on August 10, 2020, Emerald Health Sciences, Inc. transferred Dr. Avatar Dhillon 500,000 shares of the Company&#8217;s common stock at a deemed price of $0.10 in exchange for the cancellation of $50,000 of debt.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">As of September 30, 2020, Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc. As of September 30, 2020, Jim Heppell is also a board member of Emerald Health Sciences, Inc. The Company&#8217;s CEO, Punit Dhillon also served as a board member of Emerald Health Sciences, Inc. until he tendered his resignation from such board on August 10, 2020. Additionally, the Company shares the same office location as Emerald Health Pharmaceuticals. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On August 10, 2020, Emerald Health Sciences, Inc. extinguished debt of $186,667 by transferring 1,566,666 shares of the Company&#8217;s common stock at a deemed price of $0.10 per share to certain officers, employees and directors of the Company.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>9. Subsequent Events</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>Stock Incentive Plan</strong></em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp; &nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 5, 2020, the Company granted 2,000,000 stock options under the 2014 Plan to an employee. The stock options have an exercise price of $0.05 per share and a fair market value of $0.04 per share on the date of grant. The stock options vest 10% on the grant date with the remaining 90% vesting semi-annually over a four-year period.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the departure of the Company&#8217;s Chief Medical Officer, 3,968,271 stock options have been forfeited on November 6, 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">25</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="I2">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements for the three and nine months ended September 30, 2020 and 2019 (unaudited) and the year ended December 31, 2019 together with the notes thereto. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including, but not limited, to those set forth under &#8220;Risk Factors&#8221; and elsewhere in this Quarterly Report on Form 10-Q.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Unless otherwise provided in this Quarterly Report, references to &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company,&#8221; and &#8220;Emerald Bioscience&#8221; in this discussion and analysis refer to Emerald Bioscience, Inc., a Nevada corporation formerly known as Nemus Bioscience, Inc. and Load Guard Logistics, Inc., together with its wholly-owned subsidiaries, Nemus, a California corporation, and EMBI Australia Pty Ltd., an Australian proprietary limited company.</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Overview</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are a biopharmaceutical company targeting the discovery, development, and commercialization of cannabinoid-derived therapeutics, through a number of license agreements with the University of Mississippi (&#8220;UM&#8221;). UM holds the only contract to cultivate cannabis for research purposes on behalf of the Federal Government of the United States and has held that federal license since 1968, and it has significant expertise in cannabis cultivation and the extraction, separation, processing and manufacture of cannabis extracts as well as the chemistry and physiology of cannabinoid molecules. We strive to serve as UM&#8217;s partner for the development and commercialization of cannabinoid- derived therapeutics, and the realization of this partnership will depend on the successful development of these compounds through the regulatory requirements of drug approval agencies, like the Food and Drug Administration (the &#8220;FDA&#8221;) in the United States and the European Medicines Agency in the European Union.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Effective March 25, 2019, we changed our name from Nemus Bioscience, Inc. to Emerald Bioscience, Inc.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2019, we formed a new subsidiary in Australia, EMBI Australia Pty Ltd, in order to qualify for the Australian government&#8217;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for our product candidates.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Recent Events and Significant Contracts. </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Expansion of UM 5050 and UM 8930 Licenses from Ocular Delivery Only to All Fields of Use </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On May 24, 2019, we executed two restated and amended license agreements with UM which expanded our use of UM 5050, a prodrug of tetrahydrocannabinol (&#8220;THC&#8221;), and UM 8930, an analog of cannabidiol (&#8220;CBD&#8221;), expanded our scope of field of use from ocular delivery only to all fields of use. Pursuant to these license agreements, we have exclusive, perpetual, worldwide licenses related to UM 5050 and UM 8930. Additionally, with the prior written consent of UM, we have the right to sublicense the licensed intellectual property.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The exclusive license for tetrahydrocannabinol-valine-hemisuccinate (&#8220;THCVHS&#8221;), the proprietary prodrug of THC, is expected to allow us to explore related uses for the active moiety of the prodrug, namely THC. Independent <em>in vitro</em> and <em>in vivo</em> studies have demonstrated the potential use of THC in a variety of potential indications based on the ability of the cannabinoid to act as an anti-inflammatory, anti-fibrotic, and/or inhibitor of neovascularization. The Company has generated data related to these effects using an <em>ex vivo</em> human tissue model of the eye. The prodrug technology employed in THCVHS is designed to enhance the pharmacokinetic and pharmacodynamics of the active part of the molecule, once introduced into the body through various routes of administration being considered by the development team. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">26</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The exclusive license of cannabidiol-valine-hemisuccinate (&#8220;CBDVHS&#8221;), the analog of CBD, is expected to permit us to expand research and development into organ systems outside of the current ocular space. Potential disease targets over time could involve the central nervous system, the gastrointestinal tract, the endocrine/metabolic system, reproductive system diseases, or as yet unrecognized opportunities. This bioengineered version of CBD is expected to enlarge the disease target pool by virtue of new routes of administration into the body, thereby enhancing bioavailability. The determination by the DEA that CBDVHS is not a controlled substance permits us to enlarge the potential pool of clinical test sites and a more diverse patient pool in the study of disease. We expect to develop strategic collaborations to identify and advance these applications.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>THCVHS</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">THCVHS, our lead ocular compound, is a prodrug of THC. We have delayed our first-in-human studies of THCVHS, from the second half of 2020, to the third quarter of 2021. The first-in-human studies are expected to be conducted in both normal subjects and patients with glaucoma or ocular hypertension in Australia (the &#8220;Clinical Trial&#8221;). We are eligible under the AusIndustry research and development tax incentive program to obtain a cash amount from the Australian Taxation Office. The tax incentive is available to us based on specific criteria with which we must comply. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of COVID-19 there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During 2019 and the nine months ended September 30, 2020, we achieved various milestones related to the research and development of THCVHS, including the following:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">UM completed experiments showing that THCVHS was statistically superior in lowering intraocular pressure (&#8220;IOP&#8221;) in normotensive rabbits compared to the prostaglandin-based therapy, latanoprost, the current standard-of-care for treating glaucoma. Significance was reached across multiple timepoints during a seven-day course of dosing using a validated rabbit normotensive ocular model and THCVHS exerted pharmacologic activity consistent with once or twice-daily dosing.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Glauconix Biosciences Inc. (&#8220;Glauconix&#8221;) completed their pilot study to research the mechanism of action and IOP-lowering ability of THC when administered into an <em>ex vivo</em> model of a 3D-human trabecular meshwork using both healthy and glaucomatous-derived tissues. The Glauconix study is supportive of the mechanism of action of THCVHS in lowering IOP, a defining disease process of hypertensive glaucoma. Additionally, biomarkers associated with inflammation and fibrosis in both normal tissue and tissues affected by glaucoma were significantly decreased, pointing to anti-inflammatory and anti-fibrotic activities that are often associated with the cannabinoid class of molecules in other disease-states. The data also revealed that biomarkers associated with neovascularization, a disease process of new blood vessel formation that can damage the retina in a variety of ocular diseases, were also inhibited by THC, prompting further study for the utility of this drug in diseases of the retina. These data were consistent with the <em>in vivo</em> rabbit IOP response data that was conducted in parallel to the Glauconix study, as were internal Glauconix validation testing using cannabinoid receptor stimulator molecules that acted as proxy receptor agonists for THC, the active moiety of THCVHS.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In August 2019, EMBI Australia Pty Ltd entered into a start-up agreement with Novotech (Australia) Pty Limited (&#8220;Novotech&#8221;). The start-up agreement is being entered into in connection with the launch of the Clinical Trial. We expect to pay approximately $45,000 in professional fees and pass through costs in connection with the services provided for in the start-up agreement. Additionally, on September 26, 2019, EMBI Australia Pty Ltd and Novotech executed a Master Services Agreement and anticipate entering into project agreements covering all anticipated services to be provided by Novotech in connection with the Clinical Trial.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In August 2019, EMBI Australia entered into a master service agreement and initial statement of work with Agilex Biolabs Pty Ltd (&#8220;Agilex&#8221;), pursuant to which Agilex would assist with the assay set up for the anticipated Clinical Trial.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In August 2019, we executed an agreement with Bioscience Laboratories, Inc. to complete Draize testing in advance of the anticipated Clinical Trial.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-size:14pt">&#8226;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">AMRI worked toward closing the synthesis validation pathway to manufacture cGMP API of THCVHS with validation of drug product purity. On April 30, 2019, we entered into an additional agreement with AMRI related to non-GMP synthesis of a demonstration batch of our prodrug, THCVHS. In August 2019, our manufacturing agreement with AMRI for THCVHS that was executed in July 2018 was replaced by the agreement with Noramco, discussed below.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp; </p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">27</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">On August 7, 2019, we entered into a first amendment to our agreement with Noramco to manufacture THCVHS (the &#8220;Noramco Agreement,&#8221; as amended from time to time). CBDVHS was being manufactured pursuant to the Noramco Agreement prior to the amendment. We paid $257,800 upfront to add the manufacture of THCVHS to the Noramco Agreement, and additional payments will be made upon Noramco&#8217;s shipping of the GMP active pharmaceutical ingredient to us. All other material terms of the Noramco Agreement remain the same.</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In January 2019, we engaged RRD International, LLC (&#8220;RRD&#8221;) to provide strategic ophthalmic 505(b)(2) regulatory planning, prepare a Pre- IND meeting briefing book, and schedule and represent us at the Pre-IND meeting with the FDA. In May 2019, we executed a change order to extend our work with RRD as we continue to progress toward our Pre-IND meeting. In August 2019, we executed an additional work order with RRD to assist us in preparing an investigator&#8217;s brochure to support the Clinical Trial.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><font style="font-family:symbol">&#183;</font></p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">In January 2019, we executed an agreement with Pharmaceuticals International, Inc. (&#8220;PII&#8221;) to conduct studies to determine options for producing a sterile dosage form which can be dosed in humans in a clinical study. PII will conduct appropriate formulation studies to determine storage and processing options. Pursuant to the terms of the agreement, we paid $72,500 to initiate the project. After the initial evaluation, we have agreed to pay additional fees and expenses upon the completion of certain milestones.</p></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>CBDVHS </em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">CBDVHS is our proprietary CBD analog. We have embarked on studies with UM exploring the utility of our drug candidate CBDVHS as a topical formulation for the potential treatment and management of several ocular diseases, including but not limited to, uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In July 2019, we engaged Glauconix to conduct research as to whether CBD or CBDVHS is associated with an increase in IOP and, if so, what the potential mechanism of action would be by exposing the 3D-human trabecular meshwork tissue constructs to these molecules. In December 2019, we announced that data generated by Glauconix Biosciences, Inc. showed significant anti-inflammatory and anti-fibrotic activity in ocular tissue with CBDVHS when compared to CBD, indicating therapeutic potential as a neuroprotectant, especially in diseases of the retina. Additionally, CBD was associated with biomarkers related to the elevation of IOP while CBDVHS was not associated with elevating IOP at anti-fibrotic concentrations. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the second quarter of 2019, UM also completed pre-clinical experiments showing that CBDVHS exhibited an ability to penetrate multiple chambers of the eye and reach the optic nerve. These findings support the therapeutic potential to provide ocular neuroprotection of retinal ganglion cells, an important goal in treating diseases that lead to vision loss. The data were published in the peer-reviewed Journal of Ocular Pharmacology and Therapeutics in a paper entitled, &#8220;Analog Derivatization of Cannabidiol for Improved Ocular Permeation&#8221; (2019&#894; volume 35 (5): 1-10).</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In February 2019, we entered into the Noramco Agreement to provide manufacturing and product development services for our analog formulation of CBD. We paid $146,386 upfront and additional payments will be made upon Noramco&#8217;s shipment of the active pharmaceutical ingredient. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We plan to continue to work with UM to explore other potential indications and associated routes of administration based on the expanded UM5050 and UM 8930 exclusive licenses. Our decision to advance a potential therapeutic candidate will be influenced by several criteria, including but not limited to, pre-clinical data, synthesis and formulation capability as well as prevailing market conditions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">28</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp;&nbsp;&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In July 2019, we engaged StemoniX to evaluate CBD and CBDVHS in a human <em>in vitro</em> neural model that has application for epilepsy. The series of experiments are designed to provide insight into how these cannabinoids stabilize neuronal cells. In November and December 2019, we also executed additional pre-clinical research agreements with StemoniX related to CBDVHS. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, we announced data generated by StemoniX, that CBDVHS was both pharmacologically and therapeutically distinct from CBD when studied in an <em>in vitro</em> human neural tissue model mimicking chemically induced seizure-like hyperactivity. Additionally, CBDVHS was observed to gain potency in anti-seizure-like activity over the seven-day observation period, whereas the suppressive effect afforded by CBD dissipated by day three. In the assessment of safety parameters of CBDVHS, the molecule was not found to be toxic to the neurologic cells tested in multiple assays, both in acute and longer-term exposure.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Critical Accounting Policies and Estimates</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations section discusses our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. On an on-going basis, management evaluates its estimates and judgments, including those related to accrued expenses, financing operations, and contingencies and litigation. Management bases its estimates and judgments on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. The most significant accounting estimates inherent in the preparation of our financial statements include estimates as to the appropriate carrying value of certain assets and liabilities which are not readily apparent from other sources. We consider certain accounting policies related to fair value measurements, convertible instruments, warrants issued in connection with financings, stock-based compensation expense, and earnings per share to be critical accounting policies that require the use of significant judgments and estimates relating to matters that are inherently uncertain and may result in materially different results under different assumptions and conditions.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Management assessed the critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019 and determined that there were no changes to our critical accounting policies and estimates during the three and nine months ended September 30, 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>Recently Issued and Adopted Accounting Pronouncements </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">See Note 2 to the accompanying condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for information on recently issued accounting pronouncements and recently adopted accounting pronouncements. While we expect certain recently adopted accounting pronouncements to impact our estimates in future periods, the impact upon adoption was not significant to our current estimates and operations. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Results of Operations </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><em>For the three months ended September 30, 2020 and 2019 </em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Revenues.</strong> To date, we have not generated any revenues, and do not expect to generate any revenue from the sale of products in the near future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">29</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="font-size:10pt;font-family:times new roman;margin:0px">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Operating expenses. </strong>For the three months ended September 30, 2020, our total operating expenses were $1,538,220&nbsp;as compared to $1,503,114 for the three months ended September 30, 2019. The increase in operating expenses was due to the items noted below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Research and development.</u> Research and development expenses for the three months ended September 30, 2020 were $346,217, which consisted of expenses including salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, the annual license maintenance fee paid to UM, and fees related to contract manufacturing paid to Noramco. Research and development expenses for the three months ended September 30, 2019 were $513,004, which consisted of expenses including salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, contract research and development fees paid to Glauconix, StemoniX and Bioscience Laboratories, regulatory consulting fees paid to RRD, fees related to contract manufacturing paid to Noramco, fees related to contract formulation work paid to PII and fees paid to Novotech and Agilex in preparation of the Clinical Trial. The decrease in research and development expense of $166,787 was primarily due to a decrease contract manufacturing activity, regulatory consulting fees and license fees during the three months ended September 30, 2020.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>General and administrative.</u> General and administrative expenses for the three months ended September 30, 2020 were $1,192,003, which primarily consisted of salaries, general legal, insurance, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. By comparison, general and administrative expenses for the three months ended September<strong> </strong>30, 2019 were $990,110, which primarily consisted of salaries, stock compensation expense, general legal and patent related fees, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. General and administrative expenses increased period over period primarily due to increases in severance from the separation of our former CEO, insurance, and audit fees which were offset by a decrease in salaries and stock-based compensation expense. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other expense (income).</strong> For the three months ended September 30, 2020, we had other income of $241,524 related primarily to interest expense of $182,614 and a decrease in the fair value of our derivative liabilities of $424,138. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the three months ended September 30, 2019, the Company had other expense of $3,428,011 related primarily to the increase in fair value of our derivative liabilities by $3,126,464 which was driven by an increase in our stock price. This amount was offset by interest expense of $301,547.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The decrease in interest expense period over period was related to a lower principal balance on the Credit Agreement from the paydown of the facility in December 2019. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Net loss and comprehensive loss.</strong> For the three months ended September 30, 2020, we had a net loss of $1,296,696 as compared to a net loss of $4,931,125 for the three months ended September 30, 2019. The change was primarily attributable to the decrease in other expense. We expect to incur net losses for the foreseeable future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em><strong>For the nine months ended </strong></em><strong><em>September<em> 30, 2020 and 2019</em></em></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Operating expenses. </strong>For the nine months ended<strong> </strong>September 30, 2020, our total operating expenses were $4,970,086 as compared to $4,789,068 for the nine months ended September 30, 2019. The increase in operating expenses was due to the items noted below:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>Research and development.</u> Research and development expenses for the nine months ended September 30, 2020 were $1,574,357, which consisted of salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, contract research and development fees paid to UM, fees related to contract manufacturing paid to Noramco, fees related to contract formulation work paid to PII, a $200,000 license fee incurred under the UM 8930 Analog Agreement for the receipt for the first United States Patent and Trademark Office notice of allowance and the annual license maintenance fee for UM 5070.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Research and development expenses for the nine months ended September 30, 2019 were $1,522,031, which consisted of the upfront payments for the all fields of use licenses for UM 5050 and UM 8930, the annual license maintenance fee for UM 5070, salaries and benefits and consulting fees for the staff involved in our preclinical and clinical drug development activities, contract research and development fees paid to UM, Glauconix, StemoniX and Bioscience Laboratories, regulatory consulting fees paid to RRD, fees related to contract manufacturing paid to AMRI, Noramco and ElSohly Laboratories, fees related to contract formulation work paid to PII and fees paid to Novotech and Agilex in preparation of the Clinical Trial.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">30</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For the nine months ended September 30, 2020, research and development expenses increased by $52,326, as compared to the nine months ended September 30, 2019. R&amp;D expense remained relatively constant period over period.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><u>General and administrative.</u> General and administrative expenses for the nine months ended September 30, 2020 were $3,395,729, which primarily consisted of salaries, severance, insurance, general legal and fees, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. By comparison, general and administrative expenses for the nine months ended September 30, 2019 were $3,267,037, which primarily consisted of salaries, stock compensation expense, general legal and patent related fees, consulting fees and professional fees related to the Company&#8217;s capital raising efforts and regulatory filings. General and administrative expenses increased by $128,692 primarily due to increases in legal, accounting and severance from the departure of the Company&#8217;s former CEO and CFO.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Other expense (income).</strong> For the nine months ended September 30, 2020, the Company had other expense of $86,906 related primarily to interest expense under the Credit Agreement, which was offset by a gain from the decrease in the fair value of our derivative liabilities. For the nine months ended September 30, 2019, the Company had other income of $990,441 related primarily to the decrease in fair value of our derivative liabilities which was driven by the decrease in our stock price. In addition, we initiated drawdowns under the Credit Agreement which required us to bifurcate compound embedded derivatives and record an additional charge for the fair value of such instruments in excess of proceeds. The decrease of $1,077,347 in other income period over period was attributable to the change in fair value of derivative liabilities from fluctuations in the Company&#8217;s stock price during the period and the quantity of outstanding instruments underlying the derivative balance. In December 2019, 40,800,000 of the Emerald Financing Warrants were exercised which caused a decrease in the overall balance of the derivative liability. The proceeds from the exercise of the Emerald Financing Warrants were used to pay down a portion of the Credit Agreement which also decreased interest expense recognized for the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Net (loss) income and comprehensive (loss) income.</strong> For the nine months ended September 30, 2020, we had a net loss of $5,058,592 as compared to a net loss of $3,800,227 for the nine months ended September 30, 2019. The increase in the net loss was primarily attributable to the decrease in other income from our derivative liabilities and offset by an increase in operating expenses. We expect to incur net losses for the foreseeable future.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Liquidity and Capital Resources </strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We have incurred operating losses and negative cash flows from operations since our inception and as of September 30, 2020, had an accumulated deficit of $37,231,874, stockholders&#8217; equity of $1,853,367 and working capital of $3,137,772. We anticipate that we will continue to incur net losses into the foreseeable future in order to advance and develop potential drug candidates into preclinical and clinical development activities and support our corporate infrastructure, which includes the costs associated with being a public company. We had cash of $4,224,601 as of September 30, 2020, as compared to $1,829,977 as of December 31, 2019. The increase was primarily attributable to the proceeds received in the August 2020 Financing. Without additional funding, management believes that we will not have enough funds to meet our obligations beyond one year after the date the Condensed Consolidated Financial Statements are issued. These conditions give rise to substantial doubt as to our ability to continue as a going concern.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 5, 2018, we secured a Credit Agreement with Emerald Health Sciences (the &#8220;Credit Agreement&#8221;), providing us with a credit facility of up to $20,000,000. Under the Credit Agreement, we may draw a remaining amount of up to $14,000,000 in advances from Emerald Health Sciences from time to time. The advances are subject to approval by our Board, which is controlled by the directors of Emerald Health Sciences. As such, we do not consider the facility available until advance requests are approved, drawn down and funded. As of March 31, 2020, we had effected three drawdowns under the Credit Agreement, each in the amount of $2,000,000, for an aggregate principal amount of $6,000,000 in advances, and have issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock at an exercise price of $0.50 per share. On December 20, 2019, we entered into a Warrant Exercise Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences has exercised 40,800,000 of such warrants and paid the aggregate exercise price of approximately $4,080,000 for the related warrant shares in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement. Upon consummation of the transactions under the Warrant Exercise Agreement, the total outstanding principal amount excluding discounts under the Credit Agreement was $2,014,500.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">31</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 22, 2020, we entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#8220;PPP Loan&#8221;) from City National Bank. The PPP Loan was obtained pursuant to the Paycheck Protection Program of the Coronavirus Aid, Relief, and Economic Security Act administered by the U.S. Small Business Administration. We used the proceeds of the PPP loan for payment of payrolls and rent for our office space. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 29, 2020, we entered into an Amended and Restated Multi-Draw Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement, as reported in the current report on the Form 8-K filed with the SEC on April 29, 2020. The Amended Credit Agreement provides for a credit facility to us in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment and advances of at least $150,000 for each of May, June and July 2020. During the nine months ended September 30, 2020, we received the fourth and fifth advances of $150,000 and $300,000 pursuant to the Amended Credit Agreement. The advances bear interest at 7% per annum and mature on October 5, 2022. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On July 28, 2020, we filed a registration statement on Form S-1/A, which has been declared effective as of July 31, 2020, and on July 31, 2020, we filed a related registration statement on a Form S-1MEF that became effective under Rule 462(b). On July 31, 2020, we sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant, which securities were registered under the foregoing registration statements under a securities purchase agreement, as reported in our current report on the Form 8-K filed with the SEC on August 5, 2020. The net proceeds from the transaction were $6.1 million. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. We intend to use the net proceeds of the Offering for general corporate purposes, including working capital.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">During March 2020, we approved a plan to defer up to 50% of the members of senior management&#8217;s compensation and 100% of the Board of Director and committee fees indefinitely. In August 2020, subsequent to closing the August 2020 Financing, our Board of Directors determined that we have been sufficiently financed and authorized us to pay the deferred compensation and fee balances together with a retention bonus of 10% of such balance. </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, a novel strain of coronavirus (&#8220;COVID-19&#8221;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment, and significant economic disruptions to the global financial markets. These disruptions could impact our ability to raise additional capital and obtain the necessary funds.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Notably, we rely on third-party manufacturers to produce our product candidates. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent COVID-19 pandemic, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. Therefore, we have shifted the expected start of our first-in-human studies of the lead drug candidate, THCVHS, from the second half of 2020, to the 2021 timeframe.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The ultimate impact on us and overall delay in our drug product research and development is unknown, but our operations and financial condition will suffer in the event of business interruptions, delayed clinical trials, production or a lack of laboratory resources due to the pandemic. As of the date of this filing, we are aware of the impact on our business as a result of COVID-19 but uncertain as to the extent of this impact on our condensed consolidated financial statements. There is uncertainty as to the duration and hence the potential impact. As a result, we are unable to estimate the potential impact on our business as of the date of this filing.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">32</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Going Concern</em></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Our independent registered public accounting firm has issued a report on our audited financial statements for the fiscal year ended December 31, 2019 that included an explanatory paragraph referring to our recurring operating losses and expressing substantial doubt in our ability to continue as a going concern. Our condensed consolidated financial statements have been prepared on a going concern basis, which assumes the realization of assets and settlement of liabilities in the normal course of business. Our ability to continue as a going concern is dependent upon our ability to generate profitable operations in the future and/or to obtain the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they become due. The outcome of these matters cannot be predicted with any certainty at this time and raise substantial doubt that we will be able to continue as a going concern. Our condensed consolidated financial statements do not include any adjustments to the amount and classification of assets and liabilities that may be necessary should we be unable to continue as a going concern.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Off-Balance Sheet Arrangements</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There are no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="I3">Item 3. Quantitative and Qualitative Disclosures about Market Risk.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="I4">Item 4. Controls and Procedures.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Evaluation of disclosure controls and procedures.</strong> We maintain controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any control and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We conducted an evaluation, under the supervision and with the participation of our principal executive and financial officers, of the effectiveness of the design and operation of our disclosure controls and procedures as of <strong>September</strong> 30, 2020. Based upon their evaluation and subject to the foregoing, the principal executive and financial officers have concluded that, as of the end of the period covered by this report, the disclosure controls and procedures were effective at a reasonable assurance level.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Changes in internal controls.</strong> Management determined there were no changes in our internal control over financial reporting that occurred during the fiscal quarter covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">33</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><a name="P2">PART II - OTHER INFORMATION</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="IT1">Item 1. Legal Proceedings</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">There have been no other material developments with respect to previously reported legal proceedings discussed in our Annual Report on Form 10-K for the year ended December 31, 2019.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="ITA">Item 1A. Risk Factors.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Investing in our common stock involves a high degree of risk. Our Annual Report on Form 10-K for the year ended December 31, 2019 includes a detailed discussion of our risk factors under the heading &#8220;Part I, Item 1A-Risk Factors.&#8221; There are no changes from the risk factors previously disclosed in our Annual Report on Form 10-K. You should carefully consider the risk factors discussed in our Annual Report on Form 10-K, as well as the other information in this report before deciding whether to invest in shares of our common stock. The occurrence of any of the risks discussed in the Annual Report on Form 10-K could harm our business, financial condition, results of operations or growth prospects. In that case, the trading price of our common stock could decline, and you may lose all or part of your investment.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="IT2">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="IT3">Item 3. Defaults Upon Senior Securities.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">None.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="IT4">Item 4. Mine Safety Disclosures.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Not applicable.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="IT5">Item 5. Other Information.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; </p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On October 12, 2020, Mr. Dennis Kim provided notice of his resignation from his position as the Chief Medical Officer of Emerald Bioscience, Inc. His resignation is effective November 6, 2020, and is due to personal reasons and is not the result of any disagreement with the Company on any matter relating to the Company&#8217;s operations, policies, or practices.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong><u><a name="IT6">Item 6. Exhibits.</a></u></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px;background-color:#cceeff"> <td style="width:9%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex41.htm">4.1</a></p></td> <td style="width:2%;"> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex41.htm">Form of Common Warrant<sup>(1)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex42.htm">4.2</a></p></td> <td> <p style="MARGIN: 0px; text-align:justify;">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex42.htm">Form of Pre-Funded Warrant<sup>(1)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex101.htm">10.1</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420001960/embi_ex101.htm">Form of Securities Purchase Agreement, dated as of July 31, 2020, between the Company and certain purchasers set forth in the signature page thereto<sup>(1)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex101.htm">10.2</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex101.htm">Separation and Release Agreement, dated August 7, 2020, by and between Emerald Bioscience, Inc. and Brian Murphy<sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex102.htm">10.3 </a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex102.htm">Employment Agreement, dated August 10, 2020, by and between Emerald Bioscience, Inc. and Punit Dhillon<sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex103.htm">10.4</a></p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="MARGIN: 0px; text-align:justify;"><a href="http://www.sec.gov/Archives/edgar/data/1516551/000164033420002056/embi_ex103.htm">Amendment No. 2 to 2014 Omnibus Incentive Plan<sup>(2)</sup></a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex311.htm">31.1*</a></p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex311.htm">Certification of Principal Executive Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex312.htm">31.2*</a></p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex312.htm">Certification of Principal Financial Officer, pursuant to Rule 13a-14 and 15d-14 of the Securities Exchange Act of 1934</a></p></td></tr> <tr style="height:15px;background-color:#cceeff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex321.htm">32.1*</a></p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex321.htm">Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr> <tr style="height:15px;background-color:#ffffff"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex322.htm">32.2*</a></p></td> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><a href="embi_ex322.htm">Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">________</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:3%;vertical-align:top;"> <p style="margin:0px">(1) </p></td> <td style="vertical-align:top;"> <p style="margin:0px">Included as exhibit to our Current Report on Form 8-K filed on August 5, 2020.</p></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">(2)</p></td> <td style="vertical-align:top;"> <p style="margin:0px">Included as exhibit to our Current Report on Form 8-K filed on August 12, 2020.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">(*) Filed herewith.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td class="hpbhr">&nbsp;</td></tr> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">34</td></tr> <tr style="height:15px"> <td><p style='page-break-after: always'></p></td></tr> <tr style="height:15px"> <td><em><a href="#TOC">Table of Contents</a></em></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong><a name="SIG">SIGNATURES</a></strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td></td> <td colspan="2" style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;"><strong>Emerald Bioscience, Inc.,</strong></p> <p style="MARGIN: 0px; text-align:justify;"><strong>a Nevada corporation</strong></p></td> <td></td></tr> <tr style="height:15px"> <td style="width:50%;"></td> <td style="width:3%;"></td> <td style="width:35%;"></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="margin:0px">November 6, 2020</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon</em></p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><em>Punit Dhillon</em></p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Its:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Chief Executive Officer, Chairman of the Board, and Director</p> <p style="margin:0px">(Principal Executive Officer)</p></td> <td></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:50%;vertical-align:top;"> <p style="margin:0px">November 6, 2020</p></td> <td style="width:3%;"> <p style="MARGIN: 0px; text-align:justify;">By:</p></td> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Richard Janney</em></p></td> <td style="width:12%;"></td></tr> <tr style="height:15px"> <td></td> <td></td> <td style="vertical-align:bottom;"> <p style="MARGIN: 0px; text-align:justify;"><em>Richard Janney</em></p></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Its:</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">Principal Accounting Officer</p> <p style="MARGIN: 0px; text-align:justify;">(Principal Financial and Accounting Officer)</p></td> <td></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font:10pt times new roman;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: black 1px solid; TEXT-INDENT: 0px;text-align:center;">35</td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>embi_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head><title>embi_ex311.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Certification of Principal Executive Officer,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as Amended,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, Punit Dhillon, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of Emerald Bioscience, Inc. for the quarter ended September 30, 2020;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon</em></p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><em>Punit Dhillon </em></p> <p style="MARGIN: 0px; text-align:justify;">Chief Executive Officer, Chairman of the Board, and Director</p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Date: November 6, 2020</p></td> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>embi_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head><title>embi_ex312.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 31.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Certification of Principal Financial Officer,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Required by Rule 13a-14(a) of the Securities Exchange Act of 1934, as Amended,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">I, <em>Richard Janney</em>, certify that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">1.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">I have reviewed this quarterly report on Form 10-Q of Emerald Bioscience, Inc. for the quarter ended September 30, 2020;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">2.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">3.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr> <tr style="height:15px"> <td></td> <td></td></tr> <tr style="height:15px"> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">4.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(c)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr> <tr style="height:15px"> <td></td> <td></td> <td></td></tr> <tr style="height:15px"> <td></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(d)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">5.</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(a)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(b)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;&nbsp; </p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Richard Janney</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><em>Richard Janney</em></p> <p style="MARGIN: 0px; text-align:justify;">Principal Accounting Officer</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">Date: November 6, 2020</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>embi_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head><title>embi_ex321.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.1</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Certification of Principal Executive Officer, pursuant to 18 U.S.C. Section 1350,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the Quarterly Report of Emerald Bioscience, Inc. a Nevada corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Punit Dhillon, Chief Executive Officer, Chairman of the Board, and Director of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Punit Dhillon</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><em>Punit Dhillon</em></p> <p style="margin:0px">Chief Executive Officer, Chairman of the Board, and Director</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">November 6, 2020 </p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>embi_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head><title>embi_ex322.htm</title><!--Document created using EDGARMaster--></head><body style="TEXT-ALIGN: justify; FONT: 10pt times new roman; MARGIN-LEFT: 7%; MARGIN-RIGHT: 7%"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:right;"><strong>EXHIBIT 32.2</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Certification of Principal Financial Officer, pursuant to 18 U.S.C. Section 1350,</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</strong></p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In connection with the Quarterly Report of Emerald Bioscience, Inc. a Nevada corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarter ended September 30, 2020, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), Richard Janney, Principal Accounting Officer of the Company, certifies to the best of his knowledge, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that:</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="width:4%;"> <p style="margin:0px">&nbsp;</p></td> <td style="width:4%;vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(1)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">(2)</p></td> <td style="vertical-align:top;"> <p style="MARGIN: 0px; text-align:justify;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A signed original of this written statement required by Section 906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</p> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp; &nbsp;</p> <table style="border-spacing:0;font-size:10pt;width:100%" cellpadding="0"> <tr style="height:15px"> <td style="BORDER-BOTTOM: 1px solid;width:35%;"> <p style="MARGIN: 0px; text-align:justify;"><em>/s/ Richard Janney</em></p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="MARGIN: 0px; text-align:justify;"><em>Richard Janney</em> </p> <p style="MARGIN: 0px; text-align:justify;">Principal Accounting Officer</p></td> <td></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">&nbsp;</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr> <tr style="height:15px"> <td> <p style="margin:0px">November 6, 2020</p></td> <td> <p style="margin:0px">&nbsp;</p></td></tr></table> <p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">&nbsp;</p><body>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>embi-20200930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--INTEGIX by Ez-XBRL-->
 <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:embi="http://www.emeraldbio.life/20200930" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































  <link:schemaRef xlink:href="embi-20200930.xsd" xlink:type="simple"></link:schemaRef>
  <context id="C_20201105">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-11-05</instant>
    </period>
  </context>
  <context id="C_20201101to20201106_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiChiefMedicalOfficerMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:ChiefMedicalOfficerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:StockOptions2014PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-11-01</startDate>
      <endDate>2020-11-06</endDate>
    </period>
  </context>
  <context id="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:EmployeeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:StockOptions2014PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-10-01</startDate>
      <endDate>2020-10-05</endDate>
    </period>
  </context>
  <context id="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:EmployeeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:StockOptions2014PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-10-01</startDate>
      <endDate>2020-10-05</endDate>
    </period>
  </context>
  <context id="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:EmployeeMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:StockOptions2014PlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-10-01</startDate>
      <endDate>2020-10-05</endDate>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyPreFundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandAndTwentyPreFundedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOfferedPriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOfferedPriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOfferedPriceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PlacementAgentWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-09-30</instant>
    </period>
  </context>
  <context id="C_20200801to20200810_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiOfficersEmployeesAndDirectorsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:OfficersEmployeesAndDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-08-01</startDate>
      <endDate>2020-08-10</endDate>
    </period>
  </context>
  <context id="C_20200731_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_srtTitleOfIndividualAxis_embiPlacementAgentMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:PlacementAgentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-07-31</instant>
    </period>
  </context>
  <context id="C_20200701to20200930">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200701to20200831">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-08-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_srtTitleOfIndividualAxis_embiPlacementAgentMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">embi:PlacementAgentMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-07-01</startDate>
      <endDate>2020-07-31</endDate>
    </period>
  </context>
  <context id="C_20200630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:AmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-29</instant>
    </period>
  </context>
  <context id="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">embi:PaycheckProtectionProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-24</instant>
    </period>
  </context>
  <context id="C_20200422_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramPromissoryNoteMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">embi:PaycheckProtectionProgramPromissoryNoteMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-04-22</instant>
    </period>
  </context>
  <context id="C_20200401to20200630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-06-30</endDate>
    </period>
  </context>
  <context id="C_20200401to20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:AmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-04-29</endDate>
    </period>
  </context>
  <context id="C_20200401to20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">embi:PaycheckProtectionProgramMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-04-01</startDate>
      <endDate>2020-04-24</endDate>
    </period>
  </context>
  <context id="C_20200331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="C_20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="C_20200331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="C_20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2020-03-31</instant>
    </period>
  </context>
  <context id="C_20200301to20200330_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-03-01</startDate>
      <endDate>2020-03-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:PrefundedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyPreFundedWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandAndTwentyPreFundedWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandNineteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandAndTwentyCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiAugustTwoThousandAndTwentyFinancingWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:AugustTwoThousandAndTwentyFinancingWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiFifthAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:FifthAmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiFourthAmendedAndRestatedMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:FourthAmendedAndRestatedMultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:Pre2015CommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_deiLegalEntityAxis_embiEmeraldFinancingMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandFifteenCommonStockWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMaximumMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-09-30</endDate>
    </period>
  </context>
  <context id="C_20200101to20200331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2020-01-01</startDate>
      <endDate>2020-03-31</endDate>
    </period>
  </context>
  <context id="C_20191231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:MonteCarloSimulationsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:PricingModelAxis">embi:PricingModelMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">embi:AvtarDhillonMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-12-01</startDate>
      <endDate>2019-12-19</endDate>
    </period>
  </context>
  <context id="C_20191001to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-10-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190930">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190930_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-09-30</instant>
    </period>
  </context>
  <context id="C_20190701to20190930">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190701to20190930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-07-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="C_20190401to20190630">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-04-01</startDate>
      <endDate>2019-06-30</endDate>
    </period>
  </context>
  <context id="C_20190331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="C_20190331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="C_20190331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="C_20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2019-03-31</instant>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapAwardTypeAxis_usgaapRestrictedStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:IndependentContractorAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-09-30</endDate>
    </period>
  </context>
  <context id="C_20190101to20190331">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2019-01-01</startDate>
      <endDate>2019-03-31</endDate>
    </period>
  </context>
  <context id="C_20181231">



        <entity>


              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_deiLegalEntityAxis_embiEmeraldFinancingMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:SeriesBWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181231_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">embi:TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="C_20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-11-30</instant>
    </period>
  </context>
  <context id="C_20181101to20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-11-01</startDate>
      <endDate>2018-11-30</endDate>
    </period>
  </context>
  <context id="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-10-05</instant>
    </period>
  </context>
  <context id="C_20181001to20181005_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldHealthSciencesIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-01</startDate>
      <endDate>2018-10-05</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:MultiDrawCreditAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:EmeraldFinancingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-10-01</startDate>
      <endDate>2018-10-05</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProDrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProDrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>





                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5050ProDrugAndUm8930AnalogAgreementsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="embi:MilestonePaymentsPayableAxis">embi:Milestone3Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:OptionAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-07-01</startDate>
      <endDate>2018-07-31</endDate>
    </period>
  </context>
  <context id="C_20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-02-16</instant>
    </period>
  </context>
  <context id="C_20180201to20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-02-01</startDate>
      <endDate>2018-02-16</endDate>
    </period>
  </context>
  <context id="C_20180119_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2018-01-19</instant>
    </period>
  </context>
  <context id="C_20180101to20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:EmeraldFinancingWarrantsLiabilityMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2018-01-01</startDate>
      <endDate>2018-01-19</endDate>
    </period>
  </context>
  <context id="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>


                    <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">embi:SeriesBWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2017-12-28</instant>
    </period>
  </context>
  <context id="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>




                    <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">embi:Um5070LicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">embi:UniversityOfMississippiMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2017-01-01</startDate>
      <endDate>2017-01-10</endDate>
    </period>
  </context>
  <context id="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>


              <instant>2014-10-31</instant>
    </period>
  </context>
  <context id="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember">



        <entity>



              <identifier scheme="http://www.sec.gov/CIK">0001516551</identifier>
      <segment>



                    <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">embi:OmnibusIncentivePlan2014Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>



              <startDate>2014-10-01</startDate>
      <endDate>2014-10-31</endDate>
    </period>
  </context>
  <unit id="Percent">


        <measure>embi:Percent</measure>
  </unit>
  <unit id="USD">


        <measure>iso4217:USD</measure>
  </unit>
  <unit id="USD_per_Share">


        <divide>



              <unitNumerator>


                    <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>


                    <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">


        <measure>pure</measure>
  </unit>
  <unit id="shares">


        <measure>shares</measure>
  </unit>
  <dei:EntityCentralIndexKey contextRef="C_20200101to20200930" id="Fdei_EntityCentralIndexKey_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">0001516551</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate contextRef="C_20200101to20200930" id="Fdei_CurrentFiscalYearEndDate_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityFilerCategory contextRef="C_20200101to20200930" id="Fdei_EntityFilerCategory_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:AmendmentFlag contextRef="C_20200101to20200930" id="Fdei_AmendmentFlag_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">false</dei:AmendmentFlag>
  <dei:DocumentFiscalYearFocus contextRef="C_20200101to20200930" id="Fdei_DocumentFiscalYearFocus_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus contextRef="C_20200101to20200930" id="Fdei_DocumentFiscalPeriodFocus_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">Q3</dei:DocumentFiscalPeriodFocus>
  <dei:EntitySmallBusiness contextRef="C_20200101to20200930" id="Fdei_EntitySmallBusiness_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">true</dei:EntitySmallBusiness>
  <dei:EntityEmergingGrowthCompany contextRef="C_20200101to20200930" id="Fdei_EntityEmergingGrowthCompany_Context_6ME_01_Jan_2019T00_00_00_TO_30_Jun_2019T00_00_00">false</dei:EntityEmergingGrowthCompany>
  <dei:EntityShellCompany contextRef="C_20200101to20200930">false</dei:EntityShellCompany>
  <dei:EntityInteractiveDataCurrent contextRef="C_20200101to20200930">Yes</dei:EntityInteractiveDataCurrent>
  <embi:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="C_20190101to20190930" id="Fxbrl_20201102214401370" unitRef="USD" xsi:nil="true"></embi:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <embi:ProceedsFromIssuanceOfCommonStockAndWarrantsNet contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102155031412" unitRef="USD">854078</embi:ProceedsFromIssuanceOfCommonStockAndWarrantsNet>
  <us-gaap:CommitmentsAndContingencies contextRef="C_20200930" id="Fxbrl_20201102150718717" unitRef="USD" xsi:nil="true"></us-gaap:CommitmentsAndContingencies>
  <us-gaap:CommitmentsAndContingencies contextRef="C_20191231" id="Fxbrl_20201102150722468" unitRef="USD" xsi:nil="true"></us-gaap:CommitmentsAndContingencies>
  <dei:DocumentType contextRef="C_20200101to20200930" id="F22_10Q">10-Q</dei:DocumentType>
  <dei:DocumentPeriodEndDate contextRef="C_20200101to20200930" id="F43_June302019">2020-09-30</dei:DocumentPeriodEndDate>
  <dei:EntityRegistrantName contextRef="C_20200101to20200930" id="F73_EmeraldBio">Emerald Bioscience, Inc.</dei:EntityRegistrantName>
  <dei:EntityCommonStockSharesOutstanding contextRef="C_20201105" decimals="INF" id="F229_134095247" unitRef="shares">250074415</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416566_xbrl_20200810102241956_684" unitRef="USD">4224601</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416566_xbrl_20200810102241956_690" unitRef="USD">1829977</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416569_xbrl_20200810102300029_700" unitRef="USD">4538</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416569_xbrl_20200810102300029_707" unitRef="USD">4538</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416574_xbrl_20200810102312875_717" unitRef="USD">116226</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:PrepaidExpenseCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416574_xbrl_20200810102312875_724" unitRef="USD">152695</us-gaap:PrepaidExpenseCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416578_xbrl_20200810102336157_734" unitRef="USD">3333</us-gaap:OtherAssetsCurrent>
  <us-gaap:OtherAssetsCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416578_xbrl_20200810102336157_741" unitRef="USD">7550</us-gaap:OtherAssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416584_xbrl_20200810102350254_751" unitRef="USD">4348698</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416584_xbrl_20200810102350254_758" unitRef="USD">1994760</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416589_xbrl_20200810102521737_xbrl_20200810102404699_787" unitRef="USD">887</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416589_xbrl_20200810102521737_xbrl_20200810102404699_794" unitRef="USD">1983</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Assets contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416593_xbrl_20200810102420323_803" unitRef="USD">4349585</us-gaap:Assets>
  <us-gaap:Assets contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416593_xbrl_20200810102420323_809" unitRef="USD">1996743</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416598_xbrl_20200810102546003_877" unitRef="USD">731632</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416598_xbrl_20200810102546003_883" unitRef="USD">129809</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416602_xbrl_20200810102608610_xbrl_20200506161608137" unitRef="USD">21400</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:AccountsPayableRelatedPartiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416602_xbrl_20200810102608610_xbrl_20200506161655573" unitRef="USD">10000</us-gaap:AccountsPayableRelatedPartiesCurrent>
  <us-gaap:AccruedLiabilitiesCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416606_xbrl_20200810102757250_xbrl_20200506161732559" unitRef="USD">81813</us-gaap:AccruedLiabilitiesCurrent>
  <us-gaap:ShortTermBorrowings contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416610_xbrl_20200810113313032" unitRef="USD">71102</us-gaap:ShortTermBorrowings>
  <us-gaap:OtherSundryLiabilitiesCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416613_xbrl_20200810102839545_893" unitRef="USD">263830</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:OtherSundryLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416613_xbrl_20200810102839545_900" unitRef="USD">420406</us-gaap:OtherSundryLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416617_xbrl_20200810102851226_910" unitRef="USD">41149</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416617_xbrl_20200810102851226_917" unitRef="USD">410603</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20181231" decimals="0" id="Fxbrl_20201102153703270_xbrl_20200810100806908_xbrl_20200506171810074" unitRef="USD">15738913</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:DerivativeLiabilitiesCurrent contextRef="C_20190930" decimals="0" id="Fxbrl_20201102153703270_xbrl_20200810100806908_xbrl_20200506164454119" unitRef="USD">13737783</us-gaap:DerivativeLiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416622_xbrl_20200810102904997_927" unitRef="USD">1210926</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416622_xbrl_20200810102904997_934" unitRef="USD">970818</us-gaap:LiabilitiesCurrent>
  <us-gaap:LongTermDebt contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416626_xbrl_20200810113344516" unitRef="USD">45598</us-gaap:LongTermDebt>
  <embi:MultidrawCreditAgreementRelatedPartyNoncurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416630_xbrl_20200810124124323" unitRef="USD">450000</embi:MultidrawCreditAgreementRelatedPartyNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416635_xbrl_20200810102946919_983" unitRef="USD">789694</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416635_xbrl_20200810102946919_990" unitRef="USD">387070</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20200930_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122227587" unitRef="USD">450000</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:ConvertibleDebtNoncurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122241594" unitRef="USD">0</us-gaap:ConvertibleDebtNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416639_xbrl_20200810103045290_1000" unitRef="USD">90797</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20200930" decimals="0" id="Fxbrl_20200810100656232_xbrl_20200506163009940" unitRef="USD">0</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20181231" decimals="0" id="Fxbrl_20201102153703266_xbrl_20200810100806901_xbrl_20200506171802173" unitRef="USD">219453</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="C_20190930" decimals="0" id="Fxbrl_20201102180947478" unitRef="USD">567606</us-gaap:DerivativeLiabilitiesNoncurrent>
  <us-gaap:Liabilities contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416642_xbrl_20200810103107444_1017" unitRef="USD">2496218</us-gaap:Liabilities>
  <us-gaap:Liabilities contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416642_xbrl_20200810103107444_1024" unitRef="USD">1448685</us-gaap:Liabilities>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="C_20200930" decimals="3" id="Fxbrl_202011021510310410" unitRef="USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="C_20191231" decimals="3" id="Fxbrl_20201102151031041" unitRef="USD_per_Share">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:PreferredStockSharesAuthorized contextRef="C_20200930" decimals="INF" id="Fxbrl_202011021510183100" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="C_20191231" decimals="INF" id="Fxbrl_20201102151018310" unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesOutstanding contextRef="C_20191231" decimals="INF" id="Fxbrl_202011021510419522" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesOutstanding contextRef="C_20200930" decimals="INF" id="Fxbrl_202011021510419520" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:PreferredStockSharesIssued contextRef="C_20191231" decimals="INF" id="Fxbrl_202011021510419521" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockSharesIssued contextRef="C_20200930" decimals="INF" id="Fxbrl_20201102151041952" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockValue contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150735712" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockValue contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150739583" unitRef="USD">0</us-gaap:PreferredStockValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="C_20191231" decimals="3" id="Fxbrl_202011021510539370" unitRef="USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="C_20200930" decimals="3" id="Fxbrl_20201102151053937" unitRef="USD_per_Share">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20191231" decimals="INF" id="Fxbrl_202011021511408550" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized contextRef="C_20200930" decimals="INF" id="Fxbrl_20201102151140855" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesOutstanding contextRef="C_20200930" decimals="INF" id="Fxbrl_202011021511221420" unitRef="shares">250074415</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding contextRef="C_20191231" decimals="INF" id="Fxbrl_202011021512009260" unitRef="shares">182895247</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="C_20200930" decimals="INF" id="Fxbrl_20201102151122142" unitRef="shares">250074415</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued contextRef="C_20191231" decimals="INF" id="Fxbrl_20201102151200926" unitRef="shares">182895247</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockValue contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150559974" unitRef="USD">250074</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150607806" unitRef="USD">182895</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416649_xbrl_20200810103455963_1182" unitRef="USD">38835167</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416649_xbrl_20200810103455963_1189" unitRef="USD">32538445</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150416654_xbrl_20200810103445139_1199_32094209" unitRef="USD">-37231874</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150416654_xbrl_20200810103445139_1205_33225107" unitRef="USD">-32173282</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150802321_xbrl_20200810103422851_1214_11641442" unitRef="USD">1853367</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150802321_xbrl_20200810103422851_1220_15562252" unitRef="USD">548058</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102153907353_xbrl_20200506165353333" unitRef="USD">133908</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102153907353_xbrl_20200506165515074" unitRef="USD">17528947</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102153907353_xbrl_20200506165618603" unitRef="USD">-33225107</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20181231" decimals="0" id="Fxbrl_20201102153907353_xbrl_20200506165621107" unitRef="USD">-15562252</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102153907384_xbrl_20200506165410009" unitRef="USD">133908</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102153907384_xbrl_20200506165523045" unitRef="USD">20001400</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102153907384_xbrl_20200506165627194" unitRef="USD">-47999499</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190331" decimals="0" id="Fxbrl_20201102153907384_xbrl_20200506165629682" unitRef="USD">-27864191</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102153907407_xbrl_20200506165432809" unitRef="USD">134095</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102153907407_xbrl_20200506165549538" unitRef="USD">20318672</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102153907407_xbrl_20200506165557307" unitRef="USD">-32094209</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190630" decimals="0" id="Fxbrl_20201102153907407_xbrl_20200506165601003" unitRef="USD">-11641442</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102154718262" unitRef="USD">134095</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102154755367" unitRef="USD">20488778</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102154804496" unitRef="USD">-37025334</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20190930" decimals="0" id="Fxbrl_20201102154813307" unitRef="USD">-16402461</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102155557271_xbrl_20200810103800952_37" unitRef="USD">182895</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102155557271_xbrl_20200810103800952_311" unitRef="USD">32538445</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102155557271_xbrl_20200810103800952_315" unitRef="USD">-32173282</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102155557310_xbrl_20200810103800952_117" unitRef="USD">183208</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102155557310_xbrl_20200810103800952_1111" unitRef="USD">32628837</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102155557310_xbrl_20200810103800952_1115" unitRef="USD">-34514942</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200331" decimals="0" id="Fxbrl_20201102155557310_xbrl_20200810103800952_1119" unitRef="USD">-1702897</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102155557333_xbrl_20200810103800952_177" unitRef="USD">183208</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102155557333_xbrl_20200810103800952_1711" unitRef="USD">32657546</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102155557333_xbrl_20200810103800952_1715" unitRef="USD">-35935178</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200630" decimals="0" id="Fxbrl_20201102155557333_xbrl_20200810103800952_1719" unitRef="USD">-3094424</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102160310402" unitRef="USD">250074</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102160319481" unitRef="USD">38835167</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="C_20200930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102191526242" unitRef="USD">-37231874</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="C_20200930" decimals="0" id="Fxbrl_20201102150903514" unitRef="USD">4349585</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="C_20191231" decimals="0" id="Fxbrl_20201102150910629" unitRef="USD">1996743</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20200701to20200930" decimals="0" id="F1401" unitRef="USD">346217</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20191105123842957" unitRef="USD">513004</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121037785" unitRef="USD">1574357</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121040912" unitRef="USD">1522031</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20200701to20200930" decimals="0" id="F1429" unitRef="USD">1192003</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20190701to20190930" decimals="0" id="F1436" unitRef="USD">990110</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121047050" unitRef="USD">3395729</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121053051" unitRef="USD">3267037</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses contextRef="C_20200701to20200930" decimals="0" id="F1460" unitRef="USD">1538220</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="C_20190701to20190930" decimals="0" id="F1467" unitRef="USD">1503114</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121102298" unitRef="USD">4970086</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121104593" unitRef="USD">4789068</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="C_20200701to20200930" decimals="0" id="F1527_1770887" unitRef="USD">-1538220</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="C_20190701to20190930" decimals="0" id="F1533_1080190" unitRef="USD">-1503114</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121111311" unitRef="USD">-4970086</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121114903" unitRef="USD">-4789068</us-gaap:OperatingIncomeLoss>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20200507011618917" unitRef="USD">-424138</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20190701to20190930" decimals="0" id="F1631" unitRef="USD">3126464</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102183443242" unitRef="USD">-433688</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:ChangeInFairValueOfDerivativeLiabilities contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102183509058" unitRef="USD">-2024660</embi:ChangeInFairValueOfDerivativeLiabilities>
  <embi:FairValueOfWarrantLiabilityInExcessOfProceeds contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121149352" unitRef="USD">-322644</embi:FairValueOfWarrantLiabilityInExcessOfProceeds>
  <embi:FairValueOfWarrantLiabilityInExcessOfProceeds contextRef="C_20190101to20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124501953" unitRef="USD">-322644</embi:FairValueOfWarrantLiabilityInExcessOfProceeds>
  <us-gaap:InterestExpense contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20191106122017147" unitRef="USD">182614</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20200506174736395" unitRef="USD">301547</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121157844" unitRef="USD">520594</us-gaap:InterestExpense>
  <us-gaap:InterestExpense contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121200682" unitRef="USD">711575</us-gaap:InterestExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20200810121222455" unitRef="USD">241524</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20200810121228027" unitRef="USD">-3428011</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121230928" unitRef="USD">-86906</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102200831759" unitRef="USD">990441</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20201102150102831" unitRef="USD">-1296696</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20200810121309211" unitRef="USD">-4931125</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102150112911" unitRef="USD">-5056992</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102150116342" unitRef="USD">-3798627</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121337577" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121340009" unitRef="USD">1600</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20201102152328435" unitRef="USD">-1296696</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20201102152315793" unitRef="USD">-4931125</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102152353803" unitRef="USD">-5058592</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102152401491" unitRef="USD">-3800227</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102153907379_xbrl_20200506170436345" unitRef="USD">-14774392</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190101to20190331" decimals="0" id="Fxbrl_20201102153907379_xbrl_20200506170425081" unitRef="USD">-14774392</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102155203210" unitRef="USD">15905290</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20201102155206913" unitRef="USD">15905290</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20190701to20190930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102154517137" unitRef="USD">-4931125</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102155557304_xbrl_20200810103800952_915" unitRef="USD">-2341660</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200101to20200331" decimals="0" id="Fxbrl_20201102155557304_xbrl_20200810103800952_919" unitRef="USD">-2341660</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102155557327_xbrl_20200810103800952_1515" unitRef="USD">-1420236</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20201102155557327_xbrl_20200810103800952_1519" unitRef="USD">-1420236</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapRetainedEarningsMember" decimals="0" id="Fxbrl_20201102160209245" unitRef="USD">-1296696</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasic contextRef="C_20200701to20200930" decimals="2" id="Fxbrl_20191106093642166" unitRef="USD_per_Share">-0.01</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="C_20190701to20190930" decimals="2" id="F2104_002" unitRef="USD_per_Share">-0.04</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="C_20200101to20200930" decimals="2" id="Fxbrl_20200810121551067" unitRef="USD_per_Share">-0.02</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareBasic contextRef="C_20190101to20190930" decimals="2" id="Fxbrl_20200810121607921" unitRef="USD_per_Share">-0.03</us-gaap:EarningsPerShareBasic>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20200701to20200930" decimals="2" id="Fxbrl_20191106093656253" unitRef="USD_per_Share">-0.01</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20190701to20190930" decimals="2" id="F2129_002" unitRef="USD_per_Share">-0.04</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20200101to20200930" decimals="2" id="Fxbrl_20200810121620887" unitRef="USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
  <us-gaap:EarningsPerShareDiluted contextRef="C_20190101to20190930" decimals="2" id="Fxbrl_20200810121623769" unitRef="USD_per_Share">-0.03</us-gaap:EarningsPerShareDiluted>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20200701to20200930" decimals="0" id="F2220" unitRef="shares">256758472</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20190701to20190930" decimals="0" id="F2227" unitRef="shares">133001746</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121632541" unitRef="shares">207536173</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121634848" unitRef="shares">132885675</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20200701to20200930" decimals="0" id="F2251" unitRef="shares">257255653</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20190701to20190930" decimals="0" id="F2258" unitRef="shares">133001746</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810121639842" unitRef="shares">208434966</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810121642137" unitRef="shares">167690989</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
  <us-gaap:Depreciation contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606648_xbrl_20200810114320253_2391_731" unitRef="USD">1096</us-gaap:Depreciation>
  <us-gaap:Depreciation contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606648_xbrl_20200810114320253_2397_813" unitRef="USD">1096</us-gaap:Depreciation>
  <us-gaap:ShareBasedCompensation contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606653_xbrl_20200810114320261_2407_344577" unitRef="USD">241216</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606653_xbrl_20200810114320261_2413_330212" unitRef="USD">514683</us-gaap:ShareBasedCompensation>
  <embi:FairValueAdjustmentOfDerivativeLiabilities contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606658_xbrl_20200810114320270_2423_5151124" unitRef="USD">433688</embi:FairValueAdjustmentOfDerivativeLiabilities>
  <embi:FairValueAdjustmentOfDerivativeLiabilities contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606658_xbrl_20200810114320270_2430_602749" unitRef="USD">2024660</embi:FairValueAdjustmentOfDerivativeLiabilities>
  <embi:FairValueOfDerivativeLiabilityExcessOfProceeds contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606662_xbrl_20200810114320278_2446_7174634" unitRef="USD">322644</embi:FairValueOfDerivativeLiabilityExcessOfProceeds>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606665_xbrl_20200810114320286_2472_244751" unitRef="USD">402624</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606665_xbrl_20200810114320286_2478_34608" unitRef="USD">438964</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606670_xbrl_20200810114320292_2500_169079" unitRef="USD">-36469</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606670_xbrl_20200810114320292_xbrl_20200506152346086" unitRef="USD">302248</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606675_xbrl_20200810114320299_xbrl_20191105122516336" unitRef="USD">-4217</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151953846" unitRef="USD">766</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606678_xbrl_20200810114320303_2533_57862" unitRef="USD">601823</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606678_xbrl_20200810114320303_2539_89001" unitRef="USD">191333</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606683_xbrl_20200810114320311_xbrl_20200506152636329" unitRef="USD">11400</us-gaap:IncreaseDecreaseInNotesPayableRelatedPartiesCurrent>
  <embi:IncreaseDecreaseAccruedInterestDueToRelatedParty contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102152034750" unitRef="USD">81813</embi:IncreaseDecreaseAccruedInterestDueToRelatedParty>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606689_xbrl_20200810114320320_xbrl_20200506153154509" unitRef="USD">-156576</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606689_xbrl_20200810114320320_2571_79487" unitRef="USD">134469</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606694_xbrl_20200810114320328_2581_3036246" unitRef="USD">-4268198</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606694_xbrl_20200810114320328_2588_2112575" unitRef="USD">-4524712</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <embi:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102152850159" unitRef="USD">6085589</embi:ProceedsFromIssuanceOfCommonStockAndWarrants>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151819342" unitRef="USD">0</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151855060" unitRef="USD">9301</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="0" id="Fxbrl_20201102181150302" unitRef="USD">854078</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151734765_xbrl_20200810114320341_xbrl_20200506153958644" unitRef="USD">450000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151734765_xbrl_20200810114630567" unitRef="USD">3990699</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
  <us-gaap:ProceedsFromNotesPayable contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606698_xbrl_20200810114320335_xbrl_20200810111849059" unitRef="USD">116700</us-gaap:ProceedsFromNotesPayable>
  <embi:ProceedsFromPreFundedWarrantExercises contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102153044985" unitRef="USD">10533</embi:ProceedsFromPreFundedWarrantExercises>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606704_xbrl_20200810114320345_2736_3731799" unitRef="USD">6662822</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606704_xbrl_20200810114636966" unitRef="USD">3990699</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606709_xbrl_20200810114320351_xbrl_20191106103644979" unitRef="USD">2394624</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606709_xbrl_20200810114320351_2763_1614839" unitRef="USD">-534013</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20191231" decimals="0" id="Fxbrl_20201102151606715_xbrl_20200810114320358_2786_1857885" unitRef="USD">1834515</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20181231" decimals="0" id="Fxbrl_20201102151606715_xbrl_20200810114320358_2793_264383" unitRef="USD">1857885</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20200930" decimals="0" id="Fxbrl_20201102151606719_xbrl_20200810114320366_2815_2812338" unitRef="USD">4229139</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="C_20190930" decimals="0" id="Fxbrl_20201102151606719_xbrl_20200810114320366_2822_1879222" unitRef="USD">1323872</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
  <embi:CashAndCashEquivalents contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606724_xbrl_20200810114320373_2868_2807826" unitRef="USD">4224601</embi:CashAndCashEquivalents>
  <embi:CashAndCashEquivalents contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606724_xbrl_20200810114320373_2875_1874720" unitRef="USD">1319360</embi:CashAndCashEquivalents>
  <embi:SupplementalRestrictedCash contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606729_xbrl_20200810114320380_2885_4512" unitRef="USD">4538</embi:SupplementalRestrictedCash>
  <embi:SupplementalRestrictedCash contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606729_xbrl_20200810114320380_2891_4502" unitRef="USD">4512</embi:SupplementalRestrictedCash>
  <embi:TotalCashEquivalentsAndRestrictedCashShownInConsolidated contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606733_xbrl_20200810114320388_2902_2812338" unitRef="USD">4229139</embi:TotalCashEquivalentsAndRestrictedCashShownInConsolidated>
  <embi:TotalCashEquivalentsAndRestrictedCashShownInConsolidated contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606733_xbrl_20200810114320388_2909_1879222" unitRef="USD">1323872</embi:TotalCashEquivalentsAndRestrictedCashShownInConsolidated>
  <us-gaap:InterestPaidNet contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606738_xbrl_20200810114650162" unitRef="USD">35645</us-gaap:InterestPaidNet>
  <us-gaap:InterestPaidNet contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151627805" unitRef="USD">272611</us-gaap:InterestPaidNet>
  <us-gaap:IncomeTaxesPaidNet contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606741_xbrl_20200810114320400_xbrl_20200810111917159" unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
  <us-gaap:IncomeTaxesPaidNet contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606741_xbrl_20200810114320400_xbrl_20200810111930722" unitRef="USD">1600</us-gaap:IncomeTaxesPaidNet>
  <embi:ExerciseOfWarrants contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102151606746_xbrl_20200810114826634" unitRef="USD">26563</embi:ExerciseOfWarrants>
  <embi:ExerciseOfWarrants contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606746_xbrl_20200810114832227" unitRef="USD">144375</embi:ExerciseOfWarrants>
  <embi:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606751_xbrl_20200810114844457" unitRef="USD">716110</embi:ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement>
  <embi:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606755_xbrl_20200810114854575" unitRef="USD">193414</embi:FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement>
  <embi:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102151606759_xbrl_20200810114904419" unitRef="USD">1584850</embi:BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement>
  <us-gaap:SharesIssued contextRef="C_20181231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102153907353_xbrl_20200506164828091" unitRef="shares">133907747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20190331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102153907384_xbrl_20200506164824730" unitRef="shares">133907747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102153907407_xbrl_20200506164817894" unitRef="shares">134095247</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20190930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102154634527" unitRef="shares">134095247</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20191231_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102155557271_xbrl_20200810103800952_33" unitRef="shares">182895247</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102155557310_xbrl_20200810103800952_113" unitRef="shares">183207747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20200630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102155557333_xbrl_20200810103800952_173" unitRef="shares">183207747</us-gaap:SharesIssued>
  <us-gaap:SharesIssued contextRef="C_20200930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102160249099" unitRef="shares">250074415</us-gaap:SharesIssued>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102153907364_xbrl_20200506165959491" unitRef="USD">171493</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190101to20190331" decimals="0" id="Fxbrl_20201102153907364_xbrl_20200506170006214" unitRef="USD">171493</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102153907393_xbrl_20200506170011322" unitRef="USD">173084</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20201102153907393_xbrl_20200506170022986" unitRef="USD">173084</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190701to20190930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102154445541" unitRef="USD">170106</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20201102154502905" unitRef="USD">170106</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102155557284_xbrl_20200810103800952_511" unitRef="USD">64142</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200101to20200331" decimals="0" id="Fxbrl_20201102155557284_xbrl_20200810103800952_519" unitRef="USD">64142</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200401to20200630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102155557321_xbrl_20200810103800952_1311" unitRef="USD">28709</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200401to20200630" decimals="0" id="Fxbrl_20201102155557321_xbrl_20200810103800952_1319" unitRef="USD">28709</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102160418740" unitRef="USD">148365</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20201102160427724" unitRef="USD">148365</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102153907369_xbrl_20200506170118626" unitRef="USD">716110</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190331" decimals="0" id="Fxbrl_20201102153907369_xbrl_20200506170329670" unitRef="USD">716110</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="F11185_716110" unitRef="USD">716110</embi:WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102153907374_xbrl_20200506170121363" unitRef="USD">1584850</embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue contextRef="C_20190101to20190331" decimals="0" id="Fxbrl_20201102153907374_xbrl_20200506170335027" unitRef="USD">1584850</embi:BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue>
  <embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102153907398_xbrl_20200506170257914" unitRef="shares">187500</embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102155557290_xbrl_20200810103800952_73" unitRef="shares">312500</embi:StockIssuedDuringPeriodSharesSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102153907398_xbrl_20200506170232553" unitRef="USD">187</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190401to20190630_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102153907398_xbrl_20200506170131090" unitRef="USD">144188</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20190401to20190630" decimals="0" id="Fxbrl_20201102153907398_xbrl_20200506170220673" unitRef="USD">144375</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102155557290_xbrl_20200810103800952_77" unitRef="USD">313</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20200331_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102155557290_xbrl_20200810103800952_711" unitRef="USD">26250</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises contextRef="C_20200101to20200331" decimals="0" id="Fxbrl_20201102155557290_xbrl_20200810103800952_719" unitRef="USD">26563</embi:StockIssuedDuringPeriodValueSeriesBWarrantExercises>
  <embi:StockIssuedDuringPeriodSharesCommonStockAndWarrants contextRef="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102162007691" unitRef="shares">56333334</embi:StockIssuedDuringPeriodSharesCommonStockAndWarrants>
  <embi:StockIssuedDuringPeriodValueCommonStockAndWarrants contextRef="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102162025405" unitRef="USD">56333</embi:StockIssuedDuringPeriodValueCommonStockAndWarrants>
  <embi:StockIssuedDuringPeriodValueCommonStockAndWarrants contextRef="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapAdditionalPaidInCapitalMember" decimals="0" id="Fxbrl_20201102162046021" unitRef="USD">6029256</embi:StockIssuedDuringPeriodValueCommonStockAndWarrants>
  <embi:StockIssuedDuringPeriodValueCommonStockAndWarrants contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20201102162055242" unitRef="USD">6085589</embi:StockIssuedDuringPeriodValueCommonStockAndWarrants>
  <embi:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants contextRef="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="INF" id="Fxbrl_20201102162222750" unitRef="shares">10533334</embi:StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants>
  <embi:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants contextRef="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapCommonStockMember" decimals="0" id="Fxbrl_20201102162241654" unitRef="USD">10533</embi:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
  <embi:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20201102162254030" unitRef="USD">10533</embi:StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants>
  <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200810095149487">&lt;div&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;1. Nature of Operations and Business Activities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Nature of Operations&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;Emerald Bioscience, Inc. (the &amp;#x201c;Company&amp;#x201d;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &amp;#x201c;Merger&amp;#x201d;) pursuant to which Nemus, a California corporation (&amp;#x201c;Nemus Sub&amp;#x201d;), became the Company&amp;#x2019;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span&gt;&lt;span&gt;Sub to form a Nevada company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&amp;#x201c;Emerald Health Sciences&amp;#x201d;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &amp;#x201c;Emerald Financing&amp;#x201d;). As part of the transaction, the Company&amp;#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&amp;#x2019;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&amp;#x2019;s Board. On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On February 11, 2019, the Company&amp;#x2019;s Board of Directors (the &amp;#x201c;Board&amp;#x201d;) and majority stockholder unanimously approved an amendment to the Company&amp;#x2019;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&amp;#x2019;s name to Emerald Bioscience, Inc.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&amp;#x201c;EMBI Australia&amp;#x201d;), in order to qualify for the Australian government&amp;#x2019;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&amp;#x2019;s product candidates.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&amp;#x2019;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 8 - Related Party Matters for additional information.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;The Company is a biopharmaceutical company located in &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;San Diego&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&amp;#x201c;UM&amp;#x201d;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of September 30, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away&amp;#160;from potentially being able to do so.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Liquidity and Going Concern&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company has incurred operating losses and negative cash flows from operations since inception and as of September 30, 2020, had an accumulated deficit of $37,231,874, stockholders&amp;#x2019; equity of $1,853,367 and working capital of $3,137,772. The Company anticipates operating losses and negative cash flows from operations into the foreseeable future in order to advance and develop&amp;#160;potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of September 30, 2020, the Company had unrestricted cash in the amount of $4,224,601 as compared to $1,829,977 as of December 31, 2019.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As the Company approaches its first clinical trial, it expects to ramp up research and development spending and&amp;#160;to increase cash used in operating activities. However, based on the Company&amp;#x2019;s expected cash requirements, without obtaining additional funding management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company&amp;#x2019;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to carry out its research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &amp;#x201c;Credit Agreement&amp;#x201d;) with Emerald Health Sciences (See Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &amp;#x201c;Amended Credit Agreement&amp;#x201d;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000, and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of Common Stock, in accordance with the terms of the Credit Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the nine months ended September 30, 2020, the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. The advances bear interest at 7% per annum and mature on October 5, 2022. The Company used the proceeds from the advances for general corporate and working capital purposes. Emerald Health Sciences elected that the fourth and fifth advances are not convertible into shares of Common Stock and no warrants were issued with the advances.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &amp;#x201c;PPP Loan&amp;#x201d;) from City National Bank (the &amp;#x201c;PPP Loan Lender&amp;#x201d;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &amp;#x201c;PPP&amp;#x201d;) of the Coronavirus Aid, Relief, and Economic Security Act (the &amp;#x201c;CARES Act&amp;#x201d;) administered by the U.S. Small Business Administration (&amp;#x201c;SBA&amp;#x201d;) (Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On July 31, 2020, the Company entered into the August 2020 Financing (Note 5), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction were $6.1 million. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&amp;#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely. Upon the closing of the August 2020 Financing, the Company&amp;#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;In December 2019, a novel strain of coronavirus (&amp;#x201c;COVID-19&amp;#x201d;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&amp;#x2019;s ability to raise additional capital and obtain the necessary funds.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of THCVHS from the second half of 2020, to the 2021 timeframe.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&amp;#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
  <embi:WorkingCapitalDeficit contextRef="C_20200930" decimals="0" id="Fxbrl_20201102142140982" unitRef="USD">-3137772</embi:WorkingCapitalDeficit>
  <us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod contextRef="C_20200401to20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810095630243" unitRef="USD">20000000</us-gaap:LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod>
  <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="C_20200401to20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810095645793" unitRef="USD">6000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
  <us-gaap:LineOfCreditFacilityAverageOutstandingAmount contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123144141" unitRef="USD">20000000</us-gaap:LineOfCreditFacilityAverageOutstandingAmount>
  <embi:DrawDownsLoansInAggregatePrincipalAmount contextRef="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506151642434" unitRef="USD">6000000</embi:DrawDownsLoansInAggregatePrincipalAmount>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506151736556" unitRef="shares">7500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="INF" id="Fxbrl_202008101103169120" unitRef="shares">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="INF" id="Fxbrl_20200810110316912" unitRef="shares">44200000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="0" id="Fxbrl_20200506190627034" unitRef="shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_srtTitleOfIndividualAxis_embiPlacementAgentMember" decimals="0" id="Fxbrl_20201102181320493" unitRef="shares">8166667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200506151826801" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember" decimals="2" id="Fxbrl_20201102142607893" unitRef="USD_per_Share">0.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember" decimals="3" id="Fxbrl_20201102142615550" unitRef="USD_per_Share">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember" decimals="2" id="Fxbrl_20191101141039417" unitRef="USD_per_Share">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="2" id="Fxbrl_20201102173818937" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="2" id="Fxbrl_20201102173828036" unitRef="USD_per_Share">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" decimals="2" id="Fxbrl_20191101140403604" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" decimals="2" id="F11042" unitRef="USD_per_Share">0.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" decimals="2" id="F11065" unitRef="USD_per_Share">0.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" decimals="2" id="F11088" unitRef="USD_per_Share">0.41</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="2" id="Fxbrl_20200810164306721" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="Fxbrl_20201102192846053" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="2" id="Fxbrl_20200810153549838" unitRef="USD_per_Share">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsMember" decimals="2" id="Fxbrl_20201102155538627" unitRef="USD_per_Share">0.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" decimals="3" id="Fxbrl_20201102155548364" unitRef="USD_per_Share">0.075</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyPreFundedWarrantsMember" decimals="3" id="Fxbrl_20201102155554375" unitRef="USD_per_Share">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="2" id="Fxbrl_202008101104137530" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="2" id="Fxbrl_20200810110413753" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="2" id="Fxbrl_20200506141753275" unitRef="USD_per_Share">1.15</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_28_Dec_2017T00_00_00_TO_28_Dec_2017T00_00_00_ClassOfWarrantOrRightAxis_SeriesBWarrantsMember" decimals="2" id="Fxbrl_20200506141808360" unitRef="USD_per_Share">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="2" id="Fxbrl_20200506190439870" unitRef="USD_per_Share">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200506123330853" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200808141746389" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200808142230843" unitRef="USD_per_Share">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember" decimals="2" id="Fxbrl_20201102174651353" unitRef="USD_per_Share">0.06</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember" decimals="3" id="Fxbrl_20201102174732434" unitRef="USD_per_Share">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_srtTitleOfIndividualAxis_embiPlacementAgentMember" decimals="3" id="Fxbrl_20201102181503921" unitRef="USD_per_Share">0.075</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiFourthAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810095910754" unitRef="USD">150000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
  <us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount contextRef="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiFifthAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810095917886" unitRef="USD">300000</us-gaap:LineOfCreditFacilityMaximumMonthendOutstandingAmount>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="C_20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200810095947187" unitRef="pure">0.07</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="Context_As_Of_05_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200506123203233" unitRef="pure">0.07</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
  <us-gaap:DebtInstrumentMaturityDate contextRef="C_20200401to20200429_usgaapTypeOfArrangementAxis_embiAmendedAndRestatedMultiDrawCreditAgreementMember" id="Fxbrl_20200810100020231">2022-10-05</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" id="Fxbrl_20200506123222642">2022-10-05</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentMaturityDate contextRef="C_20200401to20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" id="Fxbrl_20200808131031271">2022-04-24</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20200422_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramPromissoryNoteMember" decimals="0" id="Fxbrl_20200810100110446" unitRef="USD">116700</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124256772" unitRef="USD">4000000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="0" id="Fxbrl_20200810114850188" unitRef="USD">116700</us-gaap:DebtInstrumentFaceAmount>
  <embi:NumberOfCommonStockUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" decimals="INF" id="Fxbrl_20201102142549078" unitRef="shares">56333334</embi:NumberOfCommonStockUnitsSold>
  <embi:NumberOfCommonStockUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="0" id="Fxbrl_20201102181635162" unitRef="shares">56333334</embi:NumberOfCommonStockUnitsSold>
  <embi:NumberOfPreFundedUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" decimals="INF" id="Fxbrl_20201102142558900" unitRef="shares">60333334</embi:NumberOfPreFundedUnitsSold>
  <embi:NumberOfPreFundedUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="INF" id="Fxbrl_20201102174217560" unitRef="shares">60333334</embi:NumberOfPreFundedUnitsSold>
  <embi:GrossProceedsOfUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" decimals="-5" id="Fxbrl_20201102214501743" unitRef="USD">6100000</embi:GrossProceedsOfUnitsSold>
  <embi:GrossProceedsOfUnitsSold contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="0" id="Fxbrl_20201102174433655" unitRef="USD">6939667</embi:GrossProceedsOfUnitsSold>
  <embi:TermOfWarrants contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" id="Fxbrl_20201102142623356">P5Y</embi:TermOfWarrants>
  <embi:SeniorManagementCompensationPlanDescription contextRef="C_20200101to20200930" id="Fxbrl_20201102143554516">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&amp;#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely.</embi:SeniorManagementCompensationPlanDescription>
  <embi:SeniorManagementCompensationPlanDescription contextRef="C_20200701to20200831" id="Fxbrl_20201102143620127">Upon the closing of the August 2020 Financing, the Company&amp;#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.</embi:SeniorManagementCompensationPlanDescription>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="C_20200101to20200930" id="Fb4c22e21-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px 0px 0px 1.05pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2. Summary of Significant Accounting Policies&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&amp;#x2019;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&amp;#x201c;GAAP&amp;#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&amp;#x2019;s audited financial statements as of December 31, 2019, which are included in the Company&amp;#x2019;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&amp;#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&amp;#x2019;s business and the risks inherent therein.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Use of Estimates&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&amp;#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Risks and Uncertainties&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&amp;#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&amp;#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&amp;#x2019;s ability to attract new funding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Fair Value Measurements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &amp;#x201c;exit price&amp;#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:6%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying values of the Company&amp;#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3). The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&amp;#x2019;s relatively short term the carrying value approximates fair value. As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&amp;#x2019;s Condensed Consolidated Balance Sheets. As of September 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Convertible Instruments&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities (&amp;#x201c;ASC 815&amp;#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&amp;#x201c;ASC 470-20&amp;#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also follows ASC 480-10, Distinguishing Liabilities from Equity (&amp;#x201c;ASC 480-10&amp;#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#x2019;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive Loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&amp;#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Warrants Issued in Connection with Financings&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive Loss .&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Debt Issuance Costs and Interest&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Research and Development Expenses and Licensed Technology&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&amp;#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Stock-Based Compensation Expense &lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&amp;#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividends - The dividend yield assumption is based on the Company&amp;#x2019;s history and expectation of paying no dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Loss&amp;#160;Per Common Share&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The Company applies FASB ASC No. 260, &lt;em&gt;Earnings per Share&lt;/em&gt; in calculating its basic and diluted net loss per common share. Basic loss per share of common stock is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;The computations of basic and diluted net loss per common share are as follows:&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;border:0px;font-size:10pt;border-collapse:collapse;margin:auto" width="90%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5" rowspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;strong&gt;Three Months&lt;br/&gt;Ended September 30,&lt;br/&gt;(Unaudited)&lt;/strong&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5" rowspan="1" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black"&gt;&lt;strong&gt;Nine Months&lt;br/&gt;Ended September 30,&lt;br/&gt;(Unaudited)&lt;/strong&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:56%" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="line-height:normal;font-size:10pt;font-family:Times New Roman, serif"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(1,296,696&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(4,931,125&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,058,592&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(3,800,227&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Weighted average common shares outstanding &amp;#x2013; basic&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;256,758,472&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;133,001,746&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;207,536,173&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;132,885,675&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss per share - basic&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.01&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.04&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.02&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss (as adjusted)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(1,720,835&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(4,931,125&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,401,484&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,656,982&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Weighted average common shares outstanding &amp;#x2013; diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;257,255,653&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;133,001,746&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;208,434,966&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;167,690,989&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.01&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.04&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Three Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Ended September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Ended September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;25,000,678&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4,512,715&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;25,000,678&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4,512,715&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1,093,501&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1,093,501&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Common shares underlying convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5,215,457&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5,215,457&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;145,336,155&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;57,943,250&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;144,934,542&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Recent Accounting Pronouncements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2020, the FASB issued ASU 2020-06, Debt&amp;#x2014;&lt;em&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&amp;#x2014;Contracts in Entity&amp;#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&amp;#x2019;s Own Equity.&lt;/em&gt; This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&amp;#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2019, the FASB issued ASU No. 2019-12 &lt;em&gt;Income Taxes&lt;/em&gt; (Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506150006585">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Basis of Presentation&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&amp;#x2019;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&amp;#x201c;GAAP&amp;#x201d;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&amp;#x2019;s audited financial statements as of December 31, 2019, which are included in the Company&amp;#x2019;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&amp;#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&amp;#x2019;s business and the risks inherent therein.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="C_20200101to20200930" id="Fxbrl_20200506150017150">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Use of Estimates&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&amp;#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <embi:RisksAndUncertaintiesPolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506150024586">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Risks and Uncertainties&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company&amp;#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&amp;#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&amp;#x2019;s ability to attract new funding.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</embi:RisksAndUncertaintiesPolicyTextBlock>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506150035376">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Fair Value Measurements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &amp;#x201c;exit price&amp;#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:6%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 1:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 2:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Level 3:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The carrying values of the Company&amp;#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3). The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&amp;#x2019;s relatively short term the carrying value approximates fair value. As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&amp;#x2019;s Condensed Consolidated Balance Sheets. As of September 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:AdvancesFairValueDisclosure contextRef="C_20191231" decimals="0" id="Fxbrl_20201102213525971" unitRef="USD">1877938</us-gaap:AdvancesFairValueDisclosure>
  <us-gaap:DerivativesPolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506150047256">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Convertible Instruments&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities (&amp;#x201c;ASC 815&amp;#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&amp;#x201c;ASC 470-20&amp;#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company also follows ASC 480-10, Distinguishing Liabilities from Equity (&amp;#x201c;ASC 480-10&amp;#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&amp;#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&amp;#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&amp;#x2019;s S&amp;amp;P 500 Index and settled with a variable number of the issuer&amp;#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&amp;#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive Loss.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&amp;#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
  <embi:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506150058752">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Warrants Issued in Connection with Financings&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive Loss .&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</embi:WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock>
  <us-gaap:DebtPolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506150104464">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Debt Issuance Costs and Interest&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DebtPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="C_20200101to20200930" id="Fxbrl_20200506150111336">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Research and Development Expenses and Licensed Technology&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&amp;#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506150116241">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Stock-Based Compensation Expense &lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:4%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&amp;#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-family:symbol"&gt;&amp;#xb7;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividends - The dividend yield assumption is based on the Company&amp;#x2019;s history and expectation of paying no dividends in the foreseeable future.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20201102154300313">&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Loss&amp;#160;Per Common Share&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The Company applies FASB ASC No. 260, &lt;em&gt;Earnings per Share&lt;/em&gt; in calculating its basic and diluted net loss per common share. Basic loss per share of common stock is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents.&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;The computations of basic and diluted net loss per common share are as follows:&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;border:0px;font-size:10pt;border-collapse:collapse;margin:auto" width="90%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5" rowspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;strong&gt;Three Months&lt;br/&gt;Ended September 30,&lt;br/&gt;(Unaudited)&lt;/strong&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5" rowspan="1" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black"&gt;&lt;strong&gt;Nine Months&lt;br/&gt;Ended September 30,&lt;br/&gt;(Unaudited)&lt;/strong&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:56%" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="line-height:normal;font-size:10pt;font-family:Times New Roman, serif"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(1,296,696&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(4,931,125&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,058,592&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(3,800,227&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Weighted average common shares outstanding &amp;#x2013; basic&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;256,758,472&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;133,001,746&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;207,536,173&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;132,885,675&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss per share - basic&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.01&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.04&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.02&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss (as adjusted)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(1,720,835&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(4,931,125&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,401,484&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,656,982&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Weighted average common shares outstanding &amp;#x2013; diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;257,255,653&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;133,001,746&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;208,434,966&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;167,690,989&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.01&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.04&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Three Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Ended September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Ended September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;25,000,678&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4,512,715&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;25,000,678&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4,512,715&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1,093,501&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1,093,501&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Common shares underlying convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5,215,457&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5,215,457&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;145,336,155&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;57,943,250&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;144,934,542&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20201102154527163">&lt;div&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="width:100%;border:0px;font-size:10pt;border-collapse:collapse;margin:auto" width="90%"&gt;&lt;tbody&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5" rowspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;strong&gt;Three Months&lt;br/&gt;Ended September 30,&lt;br/&gt;(Unaudited)&lt;/strong&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="5" rowspan="1" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black"&gt;&lt;strong&gt;Nine Months&lt;br/&gt;Ended September 30,&lt;br/&gt;(Unaudited)&lt;/strong&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2020&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;2019&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:56%" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="line-height:normal;font-size:10pt;font-family:Times New Roman, serif"&gt;Basic net loss per share:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(1,296,696&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(4,931,125&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,058,592&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(3,800,227&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Weighted average common shares outstanding &amp;#x2013; basic&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;256,758,472&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;133,001,746&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;207,536,173&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;132,885,675&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss per share - basic&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.01&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.04&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.02&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Diluted net loss per share:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss (as adjusted)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(1,720,835&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(4,931,125&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,401,484&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(5,656,982&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(255, 255, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Weighted average common shares outstanding &amp;#x2013; diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;257,255,653&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;133,001,746&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;208,434,966&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom"&gt;167,690,989&lt;/td&gt;&lt;td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="background-color:rgb(204, 238, 255)"&gt;&lt;td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"&gt;&lt;p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman, serif"&gt;&lt;span style="color:black"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.01&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.04&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%"&gt;&amp;#160;&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;$&lt;/td&gt;&lt;td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom"&gt;(0.03&lt;/td&gt;&lt;td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20201102153735298_83" unitRef="USD">-1720835</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20201102153735298_87" unitRef="USD">-4931125</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102153735298_811" unitRef="USD">-5401484</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102153735298_815" unitRef="USD">-5656982</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20201102154853158">&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Three Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Ended September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Ended September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;(Unaudited)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;25,000,678&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4,512,715&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;25,000,678&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4,512,715&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Unvested restricted stock&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1,093,501&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1,093,501&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Common shares underlying convertible debt&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5,215,457&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5,215,457&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;15,000,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;145,336,155&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;57,943,250&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;22,304,750&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;144,934,542&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200701to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20201102154746404_xbrl_20201102145949659_xbrl_20200506134914728" unitRef="shares">25000678</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190701to20190930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20201102154746404_xbrl_20201102145949659_xbrl_20200506134936546" unitRef="shares">4512715</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20201102154746404_xbrl_20201102145949659_xbrl_20200810094443744" unitRef="shares">25000678</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20190930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20201102154746404_xbrl_20201102145949659_xbrl_20200810094450672" unitRef="shares">4512715</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200701to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102154746427_xbrl_20201102145949681_xbrl_20200506134855200" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190701to20190930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102154746427_xbrl_20201102145949681_xbrl_20200506134830454" unitRef="shares">1093501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102154746427_xbrl_20201102145949681_xbrl_20200810094458264" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20190930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102154746427_xbrl_20201102145949681_xbrl_20200810094504841" unitRef="shares">1093501</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200701to20200930_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember" decimals="0" id="Fxbrl_20201102154746442_xbrl_20201102145949709_xbrl_20200506134958924" unitRef="shares">5215457</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190701to20190930_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember" decimals="0" id="Fxbrl_20201102154746442_xbrl_20201102145949709_xbrl_20200506135018782" unitRef="shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember" decimals="0" id="Fxbrl_20201102154746442_xbrl_20201102145949709_xbrl_20200810094511143" unitRef="shares">5215457</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20190930_usgaapStatementClassOfStockAxis_usgaapConvertibleCommonStockMember" decimals="0" id="Fxbrl_20201102154746442_xbrl_20201102145949709_xbrl_20200810094517815" unitRef="shares">15000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200701to20200930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20201102154746458_xbrl_20201102145949725_xbrl_20200506135049646" unitRef="shares">145336155</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190701to20190930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20201102154746458_xbrl_20201102145949725_xbrl_20200506135107374" unitRef="shares">57943250</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20200101to20200930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20201102154746458_xbrl_20201102145949725_xbrl_20200810094528576" unitRef="shares">22304750</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="C_20190101to20190930_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="Fxbrl_20201102154746458_xbrl_20201102145949725_xbrl_20200810094534870" unitRef="shares">144934542</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506150320510">&lt;div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Recent Accounting Pronouncements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In August 2020, the FASB issued ASU 2020-06, Debt&amp;#x2014;&lt;em&gt;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&amp;#x2014;Contracts in Entity&amp;#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&amp;#x2019;s Own Equity.&lt;/em&gt; This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&amp;#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2019, the FASB issued ASU No. 2019-12 &lt;em&gt;Income Taxes&lt;/em&gt; (Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&amp;#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <embi:WarrantsAndDerivativeLiabilitiesTextBlock contextRef="C_20200101to20200930" id="Fb4c22e22-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;3. Warrants and Derivative Liabilities&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;&lt;i&gt;Warrants&lt;/i&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&amp;#x2019;s warrants. These judgments and estimates include assumptions regarding the Company&amp;#x2019;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Warrants vested and outstanding as of September 30, 2020 are summarized as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Vested and&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Source&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Pre 2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1.00&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:right"&gt;6&amp;#x2014;10&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1,110,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px;text-align:right"&gt;1.15&amp;#x2014;5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:right"&gt;5&amp;#x2014;10&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;220,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2016 Common Stock Warrants to Service Providers&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1.15&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;40,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2016 Series C Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.40&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2017 Series D Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.25&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;480,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2017 Common Stock Warrants to Service Provider&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.41&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2018 Emerald Financing Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;3,400,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.50&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;7,500,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2019 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.35&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;8,000,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2020 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.06&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;116,666,668&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2020 Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.075&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4.99&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;8,166,667&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2020 Pre-Funded Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;0.001&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:right"&gt;indefinite&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;49,800,000&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Total warrants vested and outstanding as of September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;195,633,335&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the nine months ended September 30, 2019&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;, the Company issued&lt;span&gt;&lt;span&gt;&lt;span&gt;&lt;span&gt; 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants were equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes Merton option pricing model with the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:15%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;At&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Issuance&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap"&gt;&lt;p style="margin:0px;text-align:center"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Volatility factor&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;91.6&amp;#x2014;92.1&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;2.23&amp;#x2014;2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap"&gt;&lt;p style="margin:0px;text-align:center"&gt;5.0&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Underlying common stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;$0.33&amp;#x2014;0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;August 2020 Financing Warrants &lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;In connection with the August 2020 Financing (Note 5), the Company issued 116,666,668 common stock warrants, 8,166,667 common stock warrants to the placement agent and 60,333,334 pre-funded warrants. The warrants were equity classified at issuance and the Company allocated $2,462,462 and $2,986,500 of the gross proceeds to the common stock warrants and pre-funded warrants on a relative fair value basis, respectively. The common stock warrants issued to the placement agent were valued at $261,333 and recorded as equity issuance costs within equity. The warrants vested immediately and were valued utilizing the Black-Scholes Merton option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Common Stock Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Pre-funded&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Placement Agent Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Volatility factor&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;91.64&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;93.86&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;91.64&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.19&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.52&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.19&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5.0&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4.99&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Underlying common stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.05&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.05&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.05&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The following tables summarize the activity of derivative liabilities for the periods indicated:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months Ended September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair value of &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;to Equity &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px"&gt;Emerald Multi-Draw Credit Agreement - compound derivative liability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;90,797&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(90,797&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px"&gt;Emerald Financing - warrant liability &lt;sup&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;276,024&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(234,875&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;41,149&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Series B - warrant liability &lt;sup&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;134,579&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(108,016&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(26,563&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;(433,688&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;(26,563&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;41,149&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Less, noncurrent portion of derivative liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(90,797&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px"&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;41,149&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;span style="font-size:10pt"&gt;&amp;#160; &amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months Ended September 30, 2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2018,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;to Equity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Emerald Multi Draw Credit Agreement - compound derivative liability (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;219,453&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;516,058&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(167,905&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;567,606&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Emerald Financing - warrant liability (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;15,251,413&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(1,895,193&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;13,356,220&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Series B - warrant liability (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;487,500&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;38,438&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(144,375&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;381,563&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;516,058&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;(2,024,660&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;(144,375&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;strong&gt;14,305,389&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Less, noncurrent portion of derivative liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(219,453&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(567,606&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;13,737,783&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&amp;#160;&amp;#160; &amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&amp;#x2019;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes model for each payment period.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. During the nine months ended September 30, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;Emerald Financing Warrant Liability (2)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The warrants contained an anti-dilution protection feature that provided the investors with price protection if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. In connection with the August 2020 Financing, this provision was waived, and the exercise price was permanently set to $0.10. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, &lt;em&gt;Distinguishing Liabilities from Equity&lt;/em&gt;, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, &lt;em&gt;Derivatives and Hedging/Contracts in Entity&lt;/em&gt;&lt;em&gt;&amp;#x2019;&lt;/em&gt;&lt;em&gt;s Own Equity&lt;/em&gt;, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, &lt;em&gt;Fair Value Measurement&lt;/em&gt;s.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;December 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Volatility factor&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;80.8&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;79.5&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.14&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1.62&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;2.38&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Underlying common stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.04&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.13&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;em&gt;Series B Warrant Liability (3)&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;The Series B Financing Warrants also had a &amp;#x201c;down-round&amp;#x201d; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price.&lt;/span&gt;&lt;/span&gt;&amp;#160;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt; The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing. The strike price for these warrants is now permanently reset. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span style="font-size:10pt"&gt;However, because the remaining warrant holders still had certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B Financing Warrant agreements, the warrants continued to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;During the nine months ended September 30, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Prior to exercise, these Series B Common Stock Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates.&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt; Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&amp;#x2019;s common stock on the exercise dates.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of September 30, 2020, the remaining Series B Common Stock Warrants expired unexercised.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</embi:WarrantsAndDerivativeLiabilitiesTextBlock>
  <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="C_20200101to20200930" id="Fb4ddf380-fb9e-11e9-95c3-eb6626f9f922">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Exercise&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Term&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Vested and&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Source&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;(Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Outstanding&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Pre 2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1.00&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:right"&gt;6&amp;#x2014;10&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1,110,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2015 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td&gt;$&lt;/td&gt;&lt;td&gt;&lt;p style="margin:0px;text-align:right"&gt;1.15&amp;#x2014;5.00&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:right"&gt;5&amp;#x2014;10&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;220,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2016 Common Stock Warrants to Service Providers&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1.15&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;40,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2016 Series C Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.40&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2017 Series D Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.25&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;480,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2017 Common Stock Warrants to Service Provider&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.41&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;125,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2018 Emerald Financing Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;3,400,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Emerald Multi-Draw Credit Agreement Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.50&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;7,500,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2019 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.35&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;8,000,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2020 Common Stock Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.06&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;116,666,668&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2020 Common Stock Warrants to Placement Agent&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.075&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4.99&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;8,166,667&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;2020 Pre-Funded Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;0.001&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:right"&gt;indefinite&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;49,800,000&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Total warrants vested and outstanding as of September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;195,633,335&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20201102173657042">P6Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20201102173703673">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMinimumMember" id="Fxbrl_20201102173902809">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember_srtRangeAxis_srtMaximumMember" id="Fxbrl_20201102173907484">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="Fxbrl_20191101140300168">P10Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="Fxbrl_20191101140457103">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="Fxbrl_20191101140706851">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="Fxbrl_20191101140714179">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" id="Fxbrl_20191107103627372">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fxbrl_20191101172324097">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" id="Fxbrl_20200506171055008">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsMember" id="Fxbrl_20201102155937119">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" id="Fxbrl_20201102155723823">P4Y11M26D</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20180201to20180216_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" id="Fxbrl_202008101104590470">P5Y</embi:TermOfWarrant>
  <embi:TermOfWarrant contextRef="C_20180101to20180119_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" id="Fxbrl_20200810110459047">P5Y</embi:TermOfWarrant>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiPre2015CommonStockWarrantsMember" decimals="INF" id="F10939" unitRef="shares">1110000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandFifteenCommonStockWarrantsMember" decimals="INF" id="F10962" unitRef="shares">220000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" decimals="INF" id="F11033" unitRef="shares">40000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSixteenSeriesCPlacementAgentWarrantsMember" decimals="INF" id="F11056" unitRef="shares">125000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" decimals="INF" id="F11079" unitRef="shares">480000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" decimals="INF" id="F11102" unitRef="shares">125000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldFinancingWarrantsMember" decimals="INF" id="F11125" unitRef="shares">3400000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="INF" id="F11148" unitRef="shares">7500000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandNineteenCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20200506171102006" unitRef="shares">8000000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsMember" decimals="INF" id="Fxbrl_20201102160134130" unitRef="shares">116666668</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" decimals="INF" id="Fxbrl_20201102160146768" unitRef="shares">8166667</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyPreFundedWarrantsMember" decimals="INF" id="Fxbrl_20201102160150704" unitRef="shares">49800000</embi:WarrantsVestedAndOutstanding>
  <embi:WarrantsVestedAndOutstanding contextRef="C_20200101to20200930" decimals="INF" id="F11176_57943250" unitRef="shares">195633335</embi:WarrantsVestedAndOutstanding>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20190930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="INF" id="F11185_5000000" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsMember" decimals="0" id="Fxbrl_20201102172111499" unitRef="shares">116666668</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" decimals="0" id="Fxbrl_20201102172350746" unitRef="shares">8166667</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember" decimals="0" id="Fxbrl_20201102172354985" unitRef="shares">60333334</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="0" id="Fxbrl_20200506190554150" unitRef="shares">312500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_usgaapStatementEquityComponentsAxis_usgaapWarrantMember" decimals="0" id="F11185_1830573" unitRef="USD">1830573</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506162036611" unitRef="USD">-90797</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20200930_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506162054372" unitRef="USD">-234875</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506162107929" unitRef="USD">-108016</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102200003370" unitRef="USD">-433688</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20201102153703216_xbrl_20200810100806844_xbrl_20200506172705585" unitRef="USD">-167905</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190930_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164300542" unitRef="USD">-1895193</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164309192" unitRef="USD">38438</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102153703257_xbrl_20200810100806886_xbrl_20200506164413240" unitRef="USD">-2024660</us-gaap:FairValueAdjustmentOfWarrants>
  <embi:FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fb4deb6d1-fb9e-11e9-95c3-eb6626f9f922">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:15%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;At&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Issuance&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap"&gt;&lt;p style="margin:0px;text-align:center"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Volatility factor&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;91.6&amp;#x2014;92.1&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;2.23&amp;#x2014;2.51&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap"&gt;&lt;p style="margin:0px;text-align:center"&gt;5.0&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Underlying common stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;$0.33&amp;#x2014;0.69&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;</embi:FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock>
  <embi:FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiAugustTwoThousandAndTwentyFinancingWarrantsMember" id="Fxbrl_20201102162510485">&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Common Stock Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Pre-funded&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Placement Agent Warrants&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Volatility factor&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;91.64&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;93.86&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;91.64&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.19&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.52&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.19&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;5.0&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;10&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;4.99&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Underlying common stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.05&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.05&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.05&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</embi:FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="2" id="Fxbrl_20201102174227211" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="1" id="Fxbrl_20201102160422267" unitRef="Percent">91.6</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="1" id="Fxbrl_20201102160433688" unitRef="Percent">92.1</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="2" id="Fxbrl_20201102160724487" unitRef="Percent">2.23</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="2" id="Fxbrl_20201102160729787" unitRef="Percent">2.51</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20201102162641966_xbrl_20191101141525787" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20201102162710867_xbrl_20191101141525787" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember" decimals="2" id="Fxbrl_20201102162729714_xbrl_20191101141525787" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="2" id="Fxbrl_20201102162641975_xbrl_20201102160422267" unitRef="Percent">91.64</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember" decimals="2" id="Fxbrl_20201102162710873_xbrl_20201102160422267" unitRef="Percent">93.86</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember" decimals="2" id="Fxbrl_20201102162729718_xbrl_20201102160422267" unitRef="Percent">91.64</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20201102162641979_xbrl_20201102160724487" unitRef="Percent">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20201102162710878_xbrl_20201102160724487" unitRef="Percent">0.52</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20201102162729722_xbrl_20201102160724487" unitRef="Percent">0.19</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200506145117729" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20200506145325597" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="1" id="Fxbrl_20200506145134245" unitRef="Percent">80.8</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="1" id="Fxbrl_20201102195712975" unitRef="Percent">79.5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20201102194927027" unitRef="Percent">0.14</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="2" id="Fxbrl_20201102195821980" unitRef="Percent">1.62</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedDividendRateMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200506143011880" unitRef="Percent">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputPriceVolatilityMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="1" id="Fxbrl_20200506143049096" unitRef="Percent">79.2</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingMeasurementInput contextRef="C_20191231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputRiskFreeInterestRateMember" decimals="2" id="Fxbrl_20200506143126941" unitRef="Percent">1.60</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="Fxbrl_20191101172810291">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember" id="Fxbrl_20201102162641982_xbrl_20191101172810291">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20201102162710884_xbrl_20191101172810291">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember" id="Fxbrl_20201102162729726_xbrl_20191101172810291">P4Y11M26D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200930_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" id="Fxbrl_20201102195350002">P2Y4M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiMonteCarloSimulationsMember_deiLegalEntityAxis_embiEmeraldFinancingMember" id="Fxbrl_20201102195452829">P3Y1M17D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20191231_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputExpectedTermMember_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" id="Fxbrl_20200506143246008">P0Y7M20D</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" id="Fxbrl_20201102183020037">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="C_20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_srtTitleOfIndividualAxis_embiPlacementAgentMember" id="Fxbrl_20201102181524817">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200930_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMinimumMember" decimals="2" id="Fxbrl_20201102160619455" unitRef="USD_per_Share">0.33</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200930_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_srtRangeAxis_srtMaximumMember" decimals="2" id="Fxbrl_20201102160626545" unitRef="USD_per_Share">0.69</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember_embiPricingModelAxis_embiPricingModelMember" decimals="2" id="Fxbrl_20201102162641984_xbrl_20201102160619455" unitRef="USD_per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember" decimals="2" id="Fxbrl_20201102162710890_xbrl_20201102160619455" unitRef="USD_per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiPlacementAgentWarrantsMember_embiPricingModelAxis_embiPricingModelMember_usgaapMeasurementInputTypeAxis_usgaapMeasurementInputOfferedPriceMember" decimals="2" id="Fxbrl_20201102162729731_xbrl_20201102160619455" unitRef="USD_per_Share">0.05</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20200930_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember" decimals="2" id="Fxbrl_20200506145205245" unitRef="USD_per_Share">0.04</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember_embiPricingModelAxis_embiMonteCarloSimulationsMember" decimals="2" id="Fxbrl_20200506145256042" unitRef="USD_per_Share">0.13</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:SharesIssuedPricePerShare contextRef="C_20191231_embiPricingModelAxis_embiPricingModelMember_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="2" id="Fxbrl_20200506143224958" unitRef="USD_per_Share">0.13</us-gaap:SharesIssuedPricePerShare>
  <embi:GrossProceedsOfWarrants contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember" decimals="0" id="Fxbrl_20201102172912899" unitRef="USD">2462462</embi:GrossProceedsOfWarrants>
  <embi:GrossProceedsOfWarrants contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember" decimals="0" id="Fxbrl_20201102172917923" unitRef="USD">2986500</embi:GrossProceedsOfWarrants>
  <embi:ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity contextRef="C_20200101to20200930_usgaapClassOfWarrantOrRightAxis_embiTwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" decimals="0" id="Fxbrl_20201102173202478" unitRef="USD">261333</embi:ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity>
  <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200810101652749">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months Ended September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair value of &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;to Equity &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px"&gt;Emerald Multi-Draw Credit Agreement - compound derivative liability &lt;sup&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;90,797&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(90,797&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px"&gt;Emerald Financing - warrant liability &lt;sup&gt;(2)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;276,024&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(234,875&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;41,149&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Series B - warrant liability &lt;sup&gt;(3)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;134,579&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(108,016&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(26,563&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;501,400&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;(433,688&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;(26,563&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;41,149&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Less, noncurrent portion of derivative liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(90,797&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px"&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;410,603&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;41,149&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;span style="font-size:10pt"&gt;&amp;#160; &amp;#160;&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="18" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months Ended September 30, 2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2018,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Issued&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Change in&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Reclassification&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;of Derivatives&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;to Equity&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019,&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Derivative Liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Emerald Multi Draw Credit Agreement - compound derivative liability (1)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;219,453&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;516,058&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(167,905&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;567,606&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Emerald Financing - warrant liability (2)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;15,251,413&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(1,895,193&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;13,356,220&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Series B - warrant liability (3)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;487,500&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;38,438&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(144,375&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;381,563&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Total derivative liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;strong&gt;15,958,366&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;516,058&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;(2,024,660&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;(144,375&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;)&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;strong&gt;14,305,389&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Less, noncurrent portion of derivative liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(219,453&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(567,606&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Current balance of derivative liabilities&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;15,738,913&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;13,737,783&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506151738328" unitRef="USD">90797</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20200930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506162919091" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20201102194617241" unitRef="USD">276024</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20200930_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506162930332" unitRef="USD">41149</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20201102194730737" unitRef="USD">134579</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20200930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506162943171" unitRef="USD">0</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20191231" decimals="0" id="Fxbrl_20201102194840835" unitRef="USD">501400</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20200930" decimals="0" id="Fxbrl_20200810100656211_xbrl_20200506162955205" unitRef="USD">41149</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20201102153703216_xbrl_20200810100806844_xbrl_20200506172638702" unitRef="USD">219453</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20201102153703216_xbrl_20200810100806844_xbrl_20200506172720201" unitRef="USD">567606</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164212355" unitRef="USD">15251413</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190930_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164337940" unitRef="USD">13356220</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164223242" unitRef="USD">487500</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164346159" unitRef="USD">381563</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181231" decimals="0" id="Fxbrl_20201102153703257_xbrl_20200810100806886_xbrl_20200506164357066" unitRef="USD">15958366</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190930" decimals="0" id="Fxbrl_20201102153703257_xbrl_20200810100806886_xbrl_20200506164435986" unitRef="USD">14305389</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123713273" unitRef="USD">204102</us-gaap:DerivativeLiabilities>
  <us-gaap:DerivativeLiabilities contextRef="C_20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124449833" unitRef="USD">516058</us-gaap:DerivativeLiabilities>
  <embi:FairValueOfWarrantsIssued contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506161519971" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20200101to20200930_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506161535400" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506161554205" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810100656211_xbrl_20200506161618939" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20190930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20201102153703216_xbrl_20200810100806844_xbrl_20200506172648672" unitRef="USD">516058</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20190930_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164238992" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20190930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164249140" unitRef="USD">0</embi:FairValueOfWarrantsIssued>
  <embi:FairValueOfWarrantsIssued contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102153703257_xbrl_20200810100806886_xbrl_20200506164404505" unitRef="USD">516058</embi:FairValueOfWarrantsIssued>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20200810100656150_xbrl_20200506162752874" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20200930_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20200810100656174_xbrl_20200506162211890" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20200810100656193_xbrl_20200506162146359" unitRef="USD">-26563</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810100656211_xbrl_20200506162129574" unitRef="USD">-26563</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20190930_usgaapStatementClassOfStockAxis_embiTwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" decimals="0" id="Fxbrl_20201102153703216_xbrl_20200810100806844_xbrl_20200506172713519" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20190930_deiLegalEntityAxis_embiEmeraldFinancingMember" decimals="0" id="Fxbrl_20201102153703240_xbrl_20200810100806860_xbrl_20200506164318857" unitRef="USD">0</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20190930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" decimals="0" id="Fxbrl_20201102153703249_xbrl_20200810100806875_xbrl_20200506164328141" unitRef="USD">-144375</embi:ReclassificationOfDerivativesToEquity>
  <embi:ReclassificationOfDerivativesToEquity contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102153703257_xbrl_20200810100806886_xbrl_20200506164426888" unitRef="USD">-144375</embi:ReclassificationOfDerivativesToEquity>
  <us-gaap:IncreaseDecreaseInDerivativeLiabilities contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102205224142" unitRef="USD">0</us-gaap:IncreaseDecreaseInDerivativeLiabilities>
  <embi:AggregateExercisePriceOfOutstandingCreditAgreement contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="0" id="Fxbrl_20200810110513593" unitRef="USD">4080000</embi:AggregateExercisePriceOfOutstandingCreditAgreement>
  <embi:ClassOfWarrantOrRightWarrantsExercise contextRef="C_20190101to20191231_usgaapClassOfWarrantOrRightAxis_embiEmeraldFinancingWarrantsLiabilityMember" decimals="0" id="Fxbrl_20201102204740774" unitRef="shares">40800000</embi:ClassOfWarrantOrRightWarrantsExercise>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiEmeraldFinancingWarrantsLiabilityMember" id="Fxbrl_20200506144715073">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;December 31, &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.00&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Volatility factor&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;80.8&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;79.5&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.14&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;1.62&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;2.38&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;3.13&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Underlying common stock price&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.04&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.13&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="C_20200101to20200930_usgaapStatementClassOfStockAxis_embiSeriesBWarrantMember" id="Fxbrl_20200506142023739">&lt;div&gt;&lt;table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;As of &lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Dividend yield&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Volatility factor&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;79.2&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Risk-free interest rate&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;1.60&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;%&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#ffffff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Expected term (years)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.64&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:#cceeff"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Underlying common stock price&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:9%;vertical-align:bottom;text-align:right"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;0.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="C_20180119_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="2" id="Fxbrl_20200506141821975" unitRef="USD_per_Share">0.00</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="C_20200930_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="2" id="Fxbrl_20200810101503583" unitRef="USD_per_Share">0.40</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <embi:ValueOfCommonStockCalledByWarrants contextRef="C_20200930_usgaapClassOfWarrantOrRightAxis_embiSeriesBWarrantsMember" decimals="0" id="Fxbrl_20200506190632335" unitRef="USD">26563</embi:ValueOfCommonStockCalledByWarrants>
  <us-gaap:DebtDisclosureTextBlock contextRef="C_20200101to20200930" id="Fb4c22e23-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;4. Debt&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;em&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Multi-Draw Credit Agreement- Related Party&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The Company&amp;#x2019;s Debt with Emerald Health Sciences consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:#000000 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Conversion&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Total principal value of convertible debt&amp;#x2014;related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;2,014,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;2,014,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(1,220,838&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(1,622,344&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(3,968&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(5,086&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Carrying value of total convertible debt - related party&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;789,694&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Total principal value of non-convertible debt&amp;#x2014;related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Total carrying value of advances under the multi-draw credit agreement&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;1,239,694&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 8). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement.&amp;#160;For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. &lt;/span&gt;As of September 30, 2020, interest is no longer being deferred as a result of the August 2020 Financing.&amp;#160;&lt;span&gt;The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the &lt;/span&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;Amended&lt;/span&gt;&lt;/span&gt;&amp;#160;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&amp;#x2019; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of September&amp;#160;30, 2020, the unused portion of the credit facility is $13,550,000. The drawdowns are subject to approval by the Company&amp;#x2019;s Board, which is controlled by the directors of Emerald Health Sciences. As such, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place;&amp;#160;however, there is no guarantee of continued funding.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% &amp;#160;of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&amp;#x2019;s stockholders (See Note 3).&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&amp;#x2019;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&amp;#x2019;s Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;During the nine&amp;#160;months ended September&amp;#160;30, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Condensed Consolidated Statements of Comprehensive Loss&amp;#160;for the nine&amp;#160;months ended September&amp;#160;30, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;During the nine&amp;#160;months ended September&amp;#160;30, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. The Lender has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and gave notice to the Company that no warrants will be issued in connection with the advances.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement. As of September&amp;#160;30, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 2.01 years. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;As of September&amp;#160;30, 2020, t&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;he fair value of the shares underlying the convertible advances under the Amended Credit agreement was $211,523. As of September&amp;#160;30, 2020, the if-converted value did not exceed the principal balance.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;em&gt;PPP Loan&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;em&gt;&amp;#160;&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing seven months from the date of funding. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before February 15, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and seven-month deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;br/&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;em&gt;Interest Expense&lt;/em&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;The Company&amp;#x2019;s interest expense consists of the following:&lt;/span&gt;&lt;/p&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Related party interest expense &amp;#x2013; stated rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;44,087&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;107,334&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;117,459&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;272,611&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;PPP loan interest expense &amp;#x2013; stated rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;294&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Non-cash interest expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Amortization of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;137,849&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;190,886&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;401,507&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;429,355&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Amortization of transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;384&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;3,327&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;1,117&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;9,609&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;182,614&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;301,547&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;520,594&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;711,575&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:ConvertibleDebtTableTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200506122639460">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:#000000 1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Conversion&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Price&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;As of&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Total principal value of convertible debt&amp;#x2014;related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;0.40&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;2,014,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;2,014,500&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unamortized debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(1,220,838&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(1,622,344&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(3,968&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;(5,086&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Carrying value of total convertible debt - related party&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;789,694&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Total principal value of non-convertible debt&amp;#x2014;related party&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;450,000&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Total carrying value of advances under the multi-draw credit agreement&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;1,239,694&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;387,070&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConvertibleDebtTableTextBlock>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="C_20200930_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122019355" unitRef="USD">2014500</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122038961" unitRef="USD">2014500</us-gaap:DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="C_20200930_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122058212" unitRef="USD">1220838</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DebtInstrumentUnamortizedDiscountCurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200810161952946" unitRef="USD">1622344</us-gaap:DebtInstrumentUnamortizedDiscountCurrent>
  <us-gaap:DeferredFinanceCostsCurrentGross contextRef="C_20200930_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122129394" unitRef="USD">3968</us-gaap:DeferredFinanceCostsCurrentGross>
  <us-gaap:DeferredFinanceCostsCurrentGross contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200810162135954" unitRef="USD">5086</us-gaap:DeferredFinanceCostsCurrentGross>
  <us-gaap:ConvertibleDebtCurrent contextRef="C_20200930_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122158922" unitRef="USD">789694</us-gaap:ConvertibleDebtCurrent>
  <us-gaap:ConvertibleDebtCurrent contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122211977" unitRef="USD">387070</us-gaap:ConvertibleDebtCurrent>
  <embi:CurrentConvertibleDebtExcludingNoncurrentPortion contextRef="C_20200930_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122258993" unitRef="USD">1239694</embi:CurrentConvertibleDebtExcludingNoncurrentPortion>
  <embi:CurrentConvertibleDebtExcludingNoncurrentPortion contextRef="C_20191231_usgaapShortTermDebtTypeAxis_usgaapConvertibleDebtMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506122312128" unitRef="USD">387070</embi:CurrentConvertibleDebtExcludingNoncurrentPortion>
  <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet contextRef="C_20181001to20181005_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200810103034545" unitRef="USD">5000000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
  <us-gaap:DebtInstrumentConvertibleConversionPriceDecrease contextRef="C_20181001to20181005_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="3" id="Fxbrl_20200810102506832" unitRef="USD_per_Share">0.25</us-gaap:DebtInstrumentConvertibleConversionPriceDecrease>
  <us-gaap:LineOfCreditFacilityCommitmentFeeAmount contextRef="C_20200101to20200930_deiLegalEntityAxis_embiEmeraldFinancingMember_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123359355" unitRef="USD">13550000</us-gaap:LineOfCreditFacilityCommitmentFeeAmount>
  <embi:PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200506123310924" unitRef="pure">0.50</embi:PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase>
  <us-gaap:WarrantExercisePriceDecrease contextRef="Context_Custom_01_Oct_2018T00_00_00_TO_05_Oct_2018T00_00_00_LegalEntityAxis_EmeraldFinancingMember_TypeOfArrangementAxis_MultiDrawCreditAgreementMember" decimals="2" id="Fxbrl_20200810103639279" unitRef="USD_per_Share">0.35</us-gaap:WarrantExercisePriceDecrease>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="C_20181101to20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123543243" unitRef="USD">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ProceedsFromRelatedPartyDebt contextRef="C_20190101to20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124141212" unitRef="USD">2000000</us-gaap:ProceedsFromRelatedPartyDebt>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="C_20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="INF" id="Fxbrl_20200506123600157" unitRef="shares">2500000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="C_20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124312402" unitRef="shares">5000000</us-gaap:ClassOfWarrantOrRightOutstanding>
  <embi:AllocationOfDebtOnBasisOfRelativeFairValue contextRef="C_20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123619970" unitRef="USD">1684920</embi:AllocationOfDebtOnBasisOfRelativeFairValue>
  <embi:AllocationOfDebtOnBasisOfRelativeFairValue contextRef="C_20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124427672" unitRef="USD">3283890</embi:AllocationOfDebtOnBasisOfRelativeFairValue>
  <embi:AllocationOfWarrantOnBasisOfRelativeFairValue contextRef="C_20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123639937" unitRef="USD">315080</embi:AllocationOfWarrantOnBasisOfRelativeFairValue>
  <embi:AllocationOfWarrantOnBasisOfRelativeFairValue contextRef="C_20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506124438921" unitRef="USD">716110</embi:AllocationOfWarrantOnBasisOfRelativeFairValue>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="C_20181101to20181130_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506123657089" unitRef="USD">90080</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature contextRef="C_20190101to20190930_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506235637465" unitRef="USD">1584850</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:ProceedsFromWarrantExercises contextRef="C_20190101to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506125842036" unitRef="USD">3985500</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="C_20191001to20191231_usgaapTypeOfArrangementAxis_embiMultiDrawCreditAgreementMember" decimals="0" id="Fxbrl_20200506130129184" unitRef="USD">725425</us-gaap:GainsLossesOnExtinguishmentOfDebt>
  <embi:CreditFacilityEffectedFourthAdvances contextRef="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200810105619047" unitRef="USD">150000</embi:CreditFacilityEffectedFourthAdvances>
  <embi:CreditFacilityEffectedFifthAdvances contextRef="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200810105740715" unitRef="USD">300000</embi:CreditFacilityEffectedFifthAdvances>
  <embi:ConvertibleMultiDrawCreditAgreementIssuanceCosts contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810110021274" unitRef="USD">63007</embi:ConvertibleMultiDrawCreditAgreementIssuanceCosts>
  <embi:UnamortizedDebtDiscountPeriod contextRef="C_20200101to20200930" id="Fxbrl_20200808132952699">P2Y3D</embi:UnamortizedDebtDiscountPeriod>
  <embi:FairValueOfSharesUnderlyingConvertibleDebt contextRef="C_20200930" decimals="0" id="Fxbrl_20200810110145735" unitRef="USD">211523</embi:FairValueOfSharesUnderlyingConvertibleDebt>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="4" id="Fxbrl_20200810115254769" unitRef="pure">0.0100</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <embi:PayrollCostsExcludeCompensation contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="0" id="Fxbrl_20200810121822737" unitRef="USD">100000</embi:PayrollCostsExcludeCompensation>
  <embi:PercentageOfForgivenessAmountForNonPayrollCosts contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="2" id="Fxbrl_20200810121954268" unitRef="pure">0.25</embi:PercentageOfForgivenessAmountForNonPayrollCosts>
  <us-gaap:AccruedSalariesCurrentAndNoncurrent contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="0" id="Fxbrl_20200810122000811" unitRef="USD">100000</us-gaap:AccruedSalariesCurrentAndNoncurrent>
  <embi:PercentageOfReductionInAnnualSalary contextRef="C_20200424_usgaapDebtInstrumentAxis_embiPaycheckProtectionProgramMember" decimals="2" id="Fxbrl_20200810121957395" unitRef="pure">0.25</embi:PercentageOfReductionInAnnualSalary>
  <embi:ScheduleOfInterestExpenseTableTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20200808130814632">&lt;div&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"&gt;&lt;tbody&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"&gt;&lt;p style="MARGIN:0px;text-align:center"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Related party interest expense &amp;#x2013; stated rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;44,087&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;107,334&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;117,459&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;272,611&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;PPP loan interest expense &amp;#x2013; stated rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;294&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;511&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&amp;#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Non-cash interest expense:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Amortization of debt discount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;137,849&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;190,886&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;401,507&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;429,355&lt;/span&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#cceeff"&gt;&lt;td valign="top"&gt;&lt;p style="MARGIN:0px 0px 0px 15px"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;Amortization of transaction costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;384&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;3,327&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;1,117&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;9,609&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="HEIGHT:15px;background-color:#ffffff"&gt;&lt;td&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;182,614&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;301,547&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;520,594&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"&gt;&lt;span style="font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;strong&gt;711,575&lt;/strong&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"&gt;&lt;p style="MARGIN:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</embi:ScheduleOfInterestExpenseTableTextBlock>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20200810124906457_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">44087</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20200810124906457_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">107334</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810124906457_xbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">117459</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseRelatedParty contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810124906457_xbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">272611</us-gaap:InterestExpenseRelatedParty>
  <us-gaap:InterestExpenseDebt contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20200810124913513_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">294</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20200810124913513_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">0</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810124913513_xbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">511</us-gaap:InterestExpenseDebt>
  <us-gaap:InterestExpenseDebt contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810124913513_xbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">0</us-gaap:InterestExpenseDebt>
  <embi:AmortizationOfDebtDiscount contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">137849</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfDebtDiscount contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">190886</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfDebtDiscount contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122412576" unitRef="USD">401507</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfDebtDiscount contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810100813348_xbrl_20200810100659335_xbrl_20200506122427258" unitRef="USD">429355</embi:AmortizationOfDebtDiscount>
  <embi:AmortizationOfTransactionCosts contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20200810100659344_xbrl_20200506122454825" unitRef="USD">384</embi:AmortizationOfTransactionCosts>
  <embi:AmortizationOfTransactionCosts contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20200810100659344_xbrl_20200506122523430" unitRef="USD">3327</embi:AmortizationOfTransactionCosts>
  <embi:AmortizationOfTransactionCosts contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20200810100813355_xbrl_20200810100659344_xbrl_20200506122454825" unitRef="USD">1117</embi:AmortizationOfTransactionCosts>
  <embi:AmortizationOfTransactionCosts contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20200810100813355_xbrl_20200810100659344_xbrl_20200506122523430" unitRef="USD">9609</embi:AmortizationOfTransactionCosts>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="C_20200101to20200930" id="Fb4c25530-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;6. Stock-Based Compensation&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;Stock Incentive Plan&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;On October 31, 2014, after the closing of the Merger, the Board approved the Company&amp;#x2019;s 2014 Omnibus Incentive Plan (the &amp;#x201c;2014 Plan&amp;#x201d;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. In August 2020, the Company approved Amendment No. 2 to the 2014 Plan, which increased the share reserve by an additional 7,876,835 shares over the 10% of the number of issued and outstanding shares of common stock, and removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of September 30, 2020, the Company had 6,040,097 shares available for future grant under the 2014 Plan.&lt;/p&gt;&lt;/div&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;Stock Options &lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The following is a summary of option activities under the Company's 2014 Plan for the nine months ended September 30, 2020:&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Average Remaining&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Outstanding, December 31, 2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;3,317,642&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;0.33&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;8.34&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;24,200,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.05&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(1,861,964&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.08&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(655,000&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;0.42&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Outstanding, September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;25,000,678&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;0.07&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;9.73&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Exercisable, September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;4,410,668&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;0.07&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;9.73&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;During the nine months ended September 30, 2020, no stock options were exercised. The weighted-average fair value of stock options granted during the nine months ended September 30, 2020 was $0.04.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px 0px 0px 0.35pt;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option pricing model under the following assumptions:&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:15%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap"&gt;&lt;p style="margin:0px;text-align:center"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;0.28&amp;#x2014;0.38%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;5.56&amp;#x2014;6.01&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;92.55&amp;#x2014;93.84%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;Restricted Stock Awards &lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;During the nine months ended September 30, 2020, 643,501 restricted stock awards ( ''RSAs'' ) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. At September 30, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;&lt;strong&gt;Awards Granted Outside the 2014 Plan&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;Options&lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;During the nine months ended September 30, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company's former CFO. As of September 30, 2020, an additional 869,144 options vested and outstanding with a weighted average exercise price of $0.25 were cancelled unexercised.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;Restricted Stock Awards&lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The following is a summary of RSA activity outside of the Company's 2014 Plan during the nine months ended September 30, 2020:&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Grant &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Date Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Unvested, December 31, 2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;450,000&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;0.19&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Released&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(450,000&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;0.19&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Unvested, September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;&lt;strong&gt;Stock-Based Compensation Expense&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The Company recognizes compensation expense using the straight-line method over the requisite service period. Stock-based compensation is included in the Condensed Consolidated Statements of Comprehensive Loss in general and administrative or research and development, depending upon the nature of services provided. Stock-based compensation expense (including compensation expense for RSAs discussed above) was as follows:&lt;/p&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;strong&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;44,010&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;82,463&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;104,355&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;170,106&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;158,753&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;514,683&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;148,365&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;170,106&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;241,216&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;514,683&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;The total amount of unrecognized compensation cost was $879,628 as of September 30, 2020. This amount will be recognized over a weighted average period of 3.59 years.&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="INF" id="Fxbrl_20200506100939949" unitRef="shares">3200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="C_20200930_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="INF" id="Fxbrl_20200506101132881" unitRef="shares">6040097</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <embi:PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="2" id="Fxbrl_20200506101055802" unitRef="pure">0.10</embi:PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized contextRef="Context_Custom_01_Oct_2014T00_00_00_TO_31_Oct_2014T00_00_00_PlanNameAxis_OmnibusIncentivePlan2014Member_AwardTypeAxis_EmployeeStockOptionMember" decimals="0" id="Fxbrl_20201102162224972" unitRef="shares">7876835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20201102154732847">&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Exercise Price&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Average Remaining&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Contractual&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Term (Years)&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Outstanding, December 31, 2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;3,317,642&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;0.33&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;8.34&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;24,200,000&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.05&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Cancelled&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;(1,861,964&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;0.08&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Forfeited&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(655,000&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;0.42&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Outstanding, September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;25,000,678&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;0.07&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;9.73&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Exercisable, September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;4,410,668&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;0.07&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;9.73&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20201102142722588" unitRef="shares">3317642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="C_20200930_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20201102143125360" unitRef="shares">25000678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="C_20191231_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="Fxbrl_20201102143245259" unitRef="USD_per_Share">0.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="C_20200930_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="Fxbrl_20201102143654229" unitRef="USD_per_Share">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20190101to20191231_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" id="Fxbrl_20201102143829241">P8Y4M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" id="Fxbrl_20201102143926088">P9Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="0" id="Fxbrl_20201102142741357" unitRef="shares">24200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember" decimals="INF" id="Fxbrl_20201102150837931" unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="2" id="Fxbrl_20201102184201303" unitRef="USD_per_Share">0.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember" decimals="2" id="Fxbrl_20201102150902776" unitRef="USD_per_Share">0.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="0" id="Fxbrl_20201102142953980" unitRef="shares">1861964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="2" id="Fxbrl_20201102143556900" unitRef="USD_per_Share">0.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="0" id="Fxbrl_20201102143020541" unitRef="shares">655000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="2" id="Fxbrl_20201102143627934" unitRef="USD_per_Share">0.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="C_20200930_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="0" id="Fxbrl_20201102143217783" unitRef="shares">4410668</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="C_20200930_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="Fxbrl_20201102143727975" unitRef="USD_per_Share">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" id="Fxbrl_20201102144033857">P9Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="C_20200930_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember" decimals="2" id="Fxbrl_20201102151642353" unitRef="USD_per_Share">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="C_20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="Fxbrl_20201102151837617" unitRef="USD_per_Share">0.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20201102154831506">&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:15%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap"&gt;&lt;p style="margin:0px;text-align:center"&gt;0.00%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;0.28&amp;#x2014;0.38%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Expected term (years)&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;5.56&amp;#x2014;6.01&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2"&gt;&lt;p style="margin:0px;text-align:center"&gt;92.55&amp;#x2014;93.84%&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20201102144140391" unitRef="pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20201102144235217" unitRef="pure">0.0028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMaximumMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20201102144404680" unitRef="pure">0.0038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" id="Fxbrl_20201102144444947">P5Y6M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMaximumMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" id="Fxbrl_20201102144517305">P6Y3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMinimumMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20201102144530205" unitRef="pure">0.9255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapEmployeeStockOptionMember_srtRangeAxis_srtMaximumMember_usgaapPlanNameAxis_embiOmnibusIncentivePlan2014Member" decimals="4" id="Fxbrl_20201102144602277" unitRef="pure">0.9384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="INF" id="Fxbrl_20201102183910561" unitRef="shares">643501</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="C_20200101to20200930" decimals="INF" id="Fxbrl_20201102151912091" unitRef="shares">325929</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="C_20200101to20200930" decimals="2" id="Fxbrl_202011021519483710" unitRef="USD_per_Share">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="C_20200701to20200930" decimals="2" id="Fxbrl_20201102151948371" unitRef="USD_per_Share">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="C_20200930" decimals="INF" id="Fxbrl_20201102152006657" unitRef="shares">869144</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="C_20200930" decimals="2" id="Fxbrl_20201102152030827" unitRef="USD_per_Share">0.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
  <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20201102154935320">&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Number of&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Weighted &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Grant &lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Date Fair&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Value&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Unvested, December 31, 2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;450,000&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&lt;strong&gt;0.19&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Released&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;(450,000&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap"&gt;)&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;0.19&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;&lt;strong&gt;Unvested, September 30, 2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;&amp;#x2014;&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102144722488" unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="C_20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102145012920" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="C_20191231_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="Fxbrl_20201102145350751" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="C_20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102145537747" unitRef="USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102144804616" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102145411825" unitRef="USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="0" id="Fxbrl_20201102144949309" unitRef="shares">450000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue contextRef="C_20200101to20200930_usgaapAwardTypeAxis_usgaapRestrictedStockMember" decimals="2" id="Fxbrl_20201102145506023" unitRef="USD_per_Share">0.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20201102155231895">&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Three Months Ended&lt;/strong&gt;&lt;strong&gt; &lt;strong&gt;September 30,&lt;/strong&gt;&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;Nine Months Ended&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;September 30,&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2020&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;&lt;p style="margin:0px;text-align:center"&gt;&lt;strong&gt;2019&lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;44,010&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;82,463&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;white-space:nowrap"&gt;$&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom"&gt;&amp;#x2014;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(255, 255, 255)"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="margin:0px;text-align:justify"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;104,355&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;170,106&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;158,753&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"&gt;514,683&lt;/td&gt;&lt;td style="width:1%;padding-bottom:1px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px;background-color:rgb(204, 238, 255)"&gt;&lt;td&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;148,365&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;170,106&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;241,216&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"&gt;&lt;strong&gt;$&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"&gt;&lt;strong&gt;514,683&lt;/strong&gt;&lt;/td&gt;&lt;td style="width:1%;padding-bottom:3px;white-space:nowrap"&gt;&lt;p style="margin:0px"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20200701to20200930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" decimals="0" id="Fxbrl_20201102153414850" unitRef="USD">44010</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20190701to20190930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" decimals="0" id="Fxbrl_20201102153620354" unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20200101to20200930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" decimals="0" id="Fxbrl_20201102153644770" unitRef="USD">82463</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20190101to20190930_usgaapIncomeStatementLocationAxis_usgaapResearchAndDevelopmentExpenseMember" decimals="0" id="Fxbrl_20201102153708714" unitRef="USD">0</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20200701to20200930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" decimals="0" id="Fxbrl_20201102153731476" unitRef="USD">104355</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20190701to20190930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" decimals="0" id="Fxbrl_20201102153810892" unitRef="USD">170106</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20200101to20200930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" decimals="0" id="Fxbrl_20201102153907628" unitRef="USD">158753</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20190101to20190930_usgaapIncomeStatementLocationAxis_usgaapGeneralAndAdministrativeExpenseMember" decimals="0" id="Fxbrl_20201102153948417" unitRef="USD">514683</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20200701to20200930" decimals="0" id="Fxbrl_20201102153751923" unitRef="USD">148365</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20190701to20190930" decimals="0" id="Fxbrl_20201102153816038" unitRef="USD">170106</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20200101to20200930" decimals="0" id="Fxbrl_20201102153937200" unitRef="USD">241216</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="C_20190101to20190930" decimals="0" id="Fxbrl_20201102154015879" unitRef="USD">514683</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="C_20200930" decimals="0" id="Fxbrl_20201102152133892" unitRef="USD">879628</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="C_20200101to20200930" id="Fxbrl_20201102152213934">P3Y7M2D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <embi:SignificantContractsTextBlock contextRef="C_20200101to20200930" id="Fb4c25531-fb9e-11e9-95c3-eb6626f9f922">&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;strong&gt;7. Significant Contracts - University of Mississippi&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;UM 5050 Prodrug and UM 8930 Analog Agreements&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In July 2018, the Company renewed its ocular licenses for UM 5050, related to the prodrug formulation of tetrahydrocannabinol (&amp;#x201c;THC&amp;#x201d;), and UM 8930, related to an analog formulation of cannabidiol (&amp;#x201c;CBD&amp;#x201d;). On May 24, 2019, the ocular delivery licenses were replaced by &amp;#x201c;all fields of use&amp;#x201d; licenses for both UM 5050 and UM 8930 (collectively, the &amp;#x201c;License Agreements&amp;#x201d;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"&gt;&lt;tbody&gt;&lt;tr style="height:15px"&gt;&lt;td style="width:4%;vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;i)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$100,000 paid within 30 days following the submission of the first Investigational New Drug Application&amp;#160;(&amp;#x201c;NDA&amp;#x201d;) to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;ii)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15px"&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;iii)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="MARGIN:0px;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&amp;#160;&amp;#160;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&amp;#x2019;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&amp;#x2019;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&amp;#x2019;s dissolution or cessation of operations, the Company&amp;#x2019;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&amp;#x2019;s control, or the Company&amp;#x2019;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&amp;#x2019; written notice to UM.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of September 30, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;&lt;em&gt;&lt;strong&gt;UM 5070 License Agreement&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&amp;#x201c;UM 5070&amp;#x201d;), to research, develop and commercialize products for the treatment of infectious diseases.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&amp;#x2019;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;&lt;span&gt;&lt;span&gt;The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&amp;#x2019;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&amp;#x2019;s control. The Company may terminate the license agreement upon 60 days&amp;#x2019; written notice to UM.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Times New Roman,Times,serif"&gt;As of September 30, 2020, none of the milestones under this license agreement have been met.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;</embi:SignificantContractsTextBlock>
  <embi:AnnualMaintenanceFeePayable contextRef="C_20200930" decimals="0" id="Fxbrl_20200506102529475" unitRef="USD">75000</embi:AnnualMaintenanceFeePayable>
  <embi:PaymentForUpfrontFees contextRef="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_LegalEntityAxis_UniversityOfMississippiMember_TypeOfArrangementAxis_OptionAgreementMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" decimals="0" id="Fxbrl_20200506102551587" unitRef="USD">100000</embi:PaymentForUpfrontFees>
  <embi:PaymentForUpfrontFees contextRef="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" decimals="0" id="Fxbrl_20200506102608923" unitRef="USD">200000</embi:PaymentForUpfrontFees>
  <embi:AnnualFeesForLicenseAgreement contextRef="Context_Custom_01_Jul_2018T00_00_00_TO_31_Jul_2018T00_00_00_TypeOfArrangementAxis_LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" decimals="0" id="Fxbrl_20200506102725019" unitRef="USD">200000</embi:AnnualFeesForLicenseAgreement>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member" decimals="0" id="Fxbrl_20200506102819457" unitRef="USD">100000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member" decimals="0" id="Fxbrl_20200506102850433" unitRef="USD">200000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member" decimals="0" id="Fxbrl_20200506102921857" unitRef="USD">400000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:AggregateMilestonePaymentsIfMilestonesAchieved contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" decimals="0" id="Fxbrl_20200506103029010" unitRef="USD">700000</embi:AggregateMilestonePaymentsIfMilestonesAchieved>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone1Member" id="Fxbrl_20200506102837001">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone2Member" id="Fxbrl_20200506102903805">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="C_20180701to20180731_usgaapTypeOfArrangementAxis_embiUm5050ProDrugAndUm8930AnalogAgreementsMember_deiLegalEntityAxis_embiUniversityOfMississippiMember_usgaapFiniteLivedIntangibleAssetsByMajorClassAxis_usgaapIntellectualPropertyMember_embiMilestonePaymentsPayableAxis_embiMilestone3Member" id="Fxbrl_20200506102935274">P30D</embi:TermOfAgreement>
  <embi:TermOfAgreement contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" id="Fxbrl_20200506103205600">P1Y</embi:TermOfAgreement>
  <embi:NoticePeriodForTermination contextRef="Context_Custom_01_Jan_2017T00_00_00_TO_10_Jan_2017T00_00_00_TypeOfArrangementAxis_Um5070LicenseAgreementMember_LegalEntityAxis_UniversityOfMississippiMember_FiniteLivedIntangibleAssetsByMajorClassAxis_IntellectualPropertyMember" id="Fxbrl_20200506103131657">P60D</embi:NoticePeriodForTermination>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="C_20200101to20200930" id="Fb4c27c40-fb9e-11e9-95c3-eb6626f9f922">&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;strong&gt;8. Related Party Matters&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;&lt;strong&gt;Emerald Health Sciences&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company's Chief Executive Officer and Emerald Health Sciences' Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of September 30, 2020, the Company maintains an accrual of $7,032 in expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the three and nine months ended September 30, 2020. Under this agreement, for the three and nine months ended September 30, 2019, the Company incurred expenses of $150,000 and $450,000, respectively.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company's completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days' prior written notice to the other party. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to accrue 100% of Dr. Dhillon's consulting fees until the Board of Directors determines that the Company has been sufficiently financed to make such payments at which point the Company agrees to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. The deferral was paid concurrent with the August 2020 Financing. Under this agreement, for the three and nine months ended September 30, 2020, the Company incurred fees of $31,000 and $97,387, respectively. As of September 30, 2020, the Company has accrued $10,000 in expense related to the Independent Contractor Services Agreement.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"&gt;In addition, on August 10, 2020, Emerald Health Sciences, Inc. transferred Dr. Avatar Dhillon 500,000 shares of the Company&amp;#x2019;s common stock at a deemed price of $0.10 in exchange for the cancellation of $50,000 of debt.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;As of September 30, 2020, Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc. As of September 30, 2020, Jim Heppell is also a board member of Emerald Health Sciences, Inc. The Company's CEO, Punit Dhillon also served as a board member of Emerald Health Sciences, Inc. until he tendered his resignation from such board on August 10, 2020. Additionally, the Company shares the same office location as Emerald Health Pharmaceuticals.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;On August 10, 2020, Emerald Health Sciences, Inc. extinguished debt of $186,667&amp;#160;by transferring 1,566,666 shares of the Company&amp;#x2019;s common stock at a deemed price of $0.10 per share to certain officers,&amp;#160;employees and directors of the Company.&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <embi:InitialTermOfAgreement contextRef="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" id="Fxbrl_20200506114236417">P10Y</embi:InitialTermOfAgreement>
  <embi:AccruedExpenseUnderAgreement contextRef="C_20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506114257085" unitRef="USD">7032</embi:AccruedExpenseUnderAgreement>
  <embi:AccruedExpenseUnderAgreement contextRef="C_20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200506114901777" unitRef="USD">10000</embi:AccruedExpenseUnderAgreement>
  <embi:TotalExpenseIncurredUnderAgreement contextRef="C_20190701to20190930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200506114314106" unitRef="USD">150000</embi:TotalExpenseIncurredUnderAgreement>
  <embi:TotalExpenseIncurredUnderAgreement contextRef="C_20190101to20190930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember" decimals="0" id="Fxbrl_20200810093551296" unitRef="USD">450000</embi:TotalExpenseIncurredUnderAgreement>
  <embi:MonthlyFee contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200506114528458" unitRef="USD">10000</embi:MonthlyFee>
  <embi:MonthlyFeePaidEachMonthInExchangeOfServices contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200506114534476" unitRef="USD">5000</embi:MonthlyFeePaidEachMonthInExchangeOfServices>
  <embi:MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices contextRef="C_20191201to20191219_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200506114537898" unitRef="USD">5000</embi:MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices>
  <embi:PercentageOfAccruedConsultingFees contextRef="C_20200301to20200330_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="2" id="Fxbrl_20200506114839400" unitRef="pure">1</embi:PercentageOfAccruedConsultingFees>
  <embi:PercentageOfBonusForAccruedConsultingFees contextRef="C_20200301to20200330_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="2" id="Fxbrl_20200506114844164" unitRef="pure">0.10</embi:PercentageOfBonusForAccruedConsultingFees>
  <embi:TotalFeesIncurredUnderAgreement contextRef="C_20200701to20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200810095241152" unitRef="USD">31000</embi:TotalFeesIncurredUnderAgreement>
  <embi:TotalFeesIncurredUnderAgreement contextRef="C_20200101to20200930_usgaapTypeOfArrangementAxis_embiIndependentContractorAgreementMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiAvtarDhillonMember" decimals="0" id="Fxbrl_20200810095334198" unitRef="USD">97387</embi:TotalFeesIncurredUnderAgreement>
  <us-gaap:ExtinguishmentOfDebtAmount contextRef="C_20200801to20200810_deiLegalEntityAxis_embiEmeraldHealthSciencesIncMember_usgaapRelatedPartyTransactionsByRelatedPartyAxis_embiOfficersEmployeesAndDirectorsMember" decimals="0" id="Fxbrl_20201102145306180" unitRef="USD">186667</us-gaap:ExtinguishmentOfDebtAmount>
  <us-gaap:SubsequentEventsTextBlock contextRef="C_20200101to20200930" id="Fb4c27c41-fb9e-11e9-95c3-eb6626f9f922">&lt;div&gt;&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;strong&gt;9. Subsequent Events&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;strong&gt;&lt;em&gt;Stock&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;&lt;strong&gt;&amp;#160;Incentive Plan&lt;/strong&gt;&lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;On October 5, 2020, the Company granted 2,000,000 stock options under the 2014 Plan to an employee. The stock options have an exercise price of $0.05 per share and a fair market value of $0.04 per share on the date of grant. The stock options vest 10% on the grant date with the remaining 90% vesting semi-annually over a four-year period.&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt"&gt;In connection with the departure of the Company&amp;#x2019;s Chief Medical Officer, 3,968,271 stock options have been forfeited on November 6, 2020.&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember" decimals="2" id="Fxbrl_20201102150918392" unitRef="USD_per_Share">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheOneMember" decimals="2" id="Fxbrl_20201102151004881" unitRef="pure">0.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember_usgaapVestingAxis_usgaapShareBasedCompensationAwardTrancheTwoMember" decimals="2" id="Fxbrl_20201102151037823" unitRef="pure">0.90</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="C_20201001to20201005_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiEmployeeMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember" id="Fxbrl_20201102151111273">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited contextRef="C_20201101to20201106_usgaapSubsequentEventTypeAxis_usgaapSubsequentEventMember_srtTitleOfIndividualAxis_embiChiefMedicalOfficerMember_usgaapPlanNameAxis_embiStockOptions2014PlanMember" decimals="INF" id="Fxbrl_20201106102116114" unitRef="shares">3968271</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensationForfeited>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="C_20200101to20200930" id="Fxbrl_20201102172556829">&lt;div&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;strong&gt;5. Stockholders' Equity (Deficit) and Capitalization&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;strong&gt;&lt;em&gt;Common Stock&lt;/em&gt;&lt;/strong&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&lt;em&gt;August 2020 Financing&lt;/em&gt;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;On July 31, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for the issuance and sale of securities, with H.C. Wainwright &amp;amp; Co., LLC acting as the placement agent, pursuant to which the Company sold 56,333,334 common units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and 60,333,334 pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, in a registered public offering which closed on August 4, 2020 (the ''August 2020 Financing'' ). The common units and pre-funded units were sold at a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The common stock warrants have a term of five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full (Note 3).&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;&amp;#160;&lt;/p&gt;&lt;p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"&gt;In connection with the August 2020 Financing, the Company incurred issuance costs of $854,078, for net proceeds of $6,085,589. Additionally, the Company issued warrants to purchase 8,166,667 shares of common stock to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years.&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapClassOfWarrantOrRightAxis_embiCommonStockWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" id="Fxbrl_20201102182826068">each consisting of one share of common stock and one warrant to purchase one share of common stock</us-gaap:SaleOfStockDescriptionOfTransaction>
  <us-gaap:SaleOfStockDescriptionOfTransaction contextRef="C_20200701to20200731_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_usgaapClassOfWarrantOrRightAxis_embiPrefundedWarrantsMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" id="Fxbrl_20201102182940169">each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock</us-gaap:SaleOfStockDescriptionOfTransaction>
  <embi:CommonUnitsSoldPricePerUnit contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="2" id="Fxbrl_20201102174314009" unitRef="USD_per_Share">0.06</embi:CommonUnitsSoldPricePerUnit>
  <embi:PreFundedUnitsSoldPricePerUnit contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="3" id="Fxbrl_20201102174333576" unitRef="USD_per_Share">0.059</embi:PreFundedUnitsSoldPricePerUnit>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="C_20200701to20200731_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember" decimals="0" id="Fxbrl_20201102181218606" unitRef="USD">6085589</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <embi:PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering contextRef="C_20200701to20200731_srtTitleOfIndividualAxis_embiPlacementAgentMember_usgaapSubsidiarySaleOfStockAxis_usgaapIPOMember_deiLegalEntityAxis_embiInstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_usgaapTypeOfArrangementAxis_embiSecuritiesPurchaseAgreementMember" decimals="2" id="Fxbrl_20201102181423065" unitRef="pure">0.07</embi:PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>embi-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<schema xmlns:embi="http://www.emeraldbio.life/20200930" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" targetNamespace="http://www.emeraldbio.life/20200930" elementFormDefault="qualified">
  <!-- INTEGIX by Ez-XBRL -->
  <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/currency/2020-01-31" schemaLocation="https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/exch/2020-01-31" schemaLocation="https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <import namespace="http://xbrl.sec.gov/country/2020-01-31" schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <annotation>
    <appinfo>
      <link:roleType roleURI="http://www.emeraldbio.life/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>0001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets" id="CondensedConsolidatedBalanceSheets">
        <link:definition>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheetsParentheticals" id="CondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" id="CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
        <link:definition>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited" id="CondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals" id="CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals">
        <link:definition>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" id="CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited">
        <link:definition>0007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities" id="NatureOfOperationsAndBusinessActivities">
        <link:definition>0008 - Disclosure - Nature of Operations and Business Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
        <link:definition>0009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities" id="WarrantsAndDerivativeLiabilities">
        <link:definition>0010 - Disclosure - Warrants and Derivative Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty" id="ConvertibleDebtRelatedParty">
        <link:definition>0011 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalization" id="StockholdersDeficitAndCapitalization">
        <link:definition>0012 - Disclosure - Stockholders' Equity (Deficit) and Capitalization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensation" id="StockBasedCompensation">
        <link:definition>0013 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi" id="SignificantContractsUniversityOfMississippi">
        <link:definition>0014 - Disclosure - Significant Contracts - University of Mississippi</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/RelatedPartyMatters" id="RelatedPartyMatters">
        <link:definition>0015 - Disclosure - Related Party Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>0016 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>0017 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables" id="SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>0018 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables" id="WarrantsAndDerivativeLiabilitiesTables">
        <link:definition>0019 - Disclosure - Warrants and Derivative Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables" id="ConvertibleDebtRelatedPartyTables">
        <link:definition>0020 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables" id="StockBasedCompensationTables">
        <link:definition>0021 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals" id="NatureOfOperationsAndBusinessActivitiesDetailTextuals">
        <link:definition>0022 - Disclosure - Nature of Operations and Business Activities (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails1" id="SummaryOfSignificantAccountingPoliciesDetails1">
        <link:definition>0023 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>0024 - Disclosure - Summary of Significant Accounting Policies (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals" id="SummaryOfSignificantAccountingPoliciesDetailTextuals">
        <link:definition>0025 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3" id="WarrantsAndDerivativeLiabilitiesDetails3">
        <link:definition>0026 - Disclosure - Warrants and Derivative Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1" id="WarrantsAndDerivativeLiabilitiesDetails1">
        <link:definition>0027 - Disclosure - Warrants and Derivative Liabilities (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6" id="WarrantsAndDerivativeLiabilitiesDetails6">
        <link:definition>0028 - Disclosure - Warrants and Derivative Liabilities (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2" id="WarrantsAndDerivativeLiabilitiesDetails2">
        <link:definition>0029 - Disclosure - Warrants and Derivative Liabilities (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4" id="WarrantsAndDerivativeLiabilitiesDetails4">
        <link:definition>0030 - Disclosure - Warrants and Derivative Liabilities (Details 4)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5" id="WarrantsAndDerivativeLiabilitiesDetails5">
        <link:definition>0031 - Disclosure - Warrants and Derivative Liabilities (Details 5)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals" id="WarrantsAndDerivativeLiabilitiesDetailTextuals">
        <link:definition>0032 - Disclosure - Warrants and Derivative Liabilities (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails" id="ConvertibleDebtRelatedPartyDetails">
        <link:definition>0033 - Disclosure - Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1" id="ConvertibleDebtRelatedPartyDetails1">
        <link:definition>0034 - Disclosure - Debt (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals" id="ConvertibleDebtRelatedPartyDetailTextuals">
        <link:definition>0035 - Disclosure - Debt (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals" id="StockholdersDeficitAndCapitalizationDetailTextuals">
        <link:definition>0036 - Disclosure - Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1" id="StockBasedCompensationDetails1">
        <link:definition>0037 - Disclosure - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2" id="StockBasedCompensationDetails2">
        <link:definition>0038 - Disclosure - Stock-Based Compensation (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails" id="StockBasedCompensationDetails">
        <link:definition>0039 - Disclosure - Stock-Based Compensation (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4" id="StockBasedCompensationDetails4">
        <link:definition>0040 - Disclosure - Stock-Based Compensation (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals" id="StockBasedCompensationDetailTextuals">
        <link:definition>0041 - Disclosure - Stock-Based Compensation (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1" id="StockBasedCompensationDetailTextuals1">
        <link:definition>0042 - Disclosure - Stock-Based Compensation (Detail Textuals 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals" id="SignificantContractsUniversityOfMississippiDetailTextuals">
        <link:definition>0043 - Disclosure - Significant Contracts - University of Mississippi (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals" id="RelatedPartyMattersDetailTextuals">
        <link:definition>0044 - Disclosure - Related Party Matters (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals" id="SubsequentEventsDetailTextuals">
        <link:definition>0045 - Disclosure - Subsequent Events (Detail Textuals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="embi-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
    </appinfo>
  </annotation>
  <element name="AccruedExpenseUnderAgreement" id="embi_AccruedExpenseUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AdditionalConversionLiability" id="embi_AdditionalConversionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AggregateExercisePriceOfOutstandingCreditAgreement" id="embi_AggregateExercisePriceOfOutstandingCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregateMilestonePaymentsIfMilestonesAchieved" id="embi_AggregateMilestonePaymentsIfMilestonesAchieved" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AggregatePrincipalAmount" id="embi_AggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AllocationOfDebtOnBasisOfRelativeFairValue" id="embi_AllocationOfDebtOnBasisOfRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AllocationOfWarrantOnBasisOfRelativeFairValue" id="embi_AllocationOfWarrantOnBasisOfRelativeFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmendedAndRestatedMultiDrawCreditAgreementMember" id="embi_AmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AmortizationOfDebtDiscount" id="embi_AmortizationOfDebtDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AmortizationOfTransactionCosts" id="embi_AmortizationOfTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualFeeForAgreement" id="embi_AnnualFeeForAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualFeesForLicenseAgreement" id="embi_AnnualFeesForLicenseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="AnnualMaintenanceFeePayable" id="embi_AnnualMaintenanceFeePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="AugustTwoThousandAndTwentyFinancingWarrantsMember" id="embi_AugustTwoThousandAndTwentyFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="AvtarDhillonMember" id="embi_AvtarDhillonMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" id="embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" id="embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CapitalRaise" id="embi_CapitalRaise" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CashAndCashEquivalents" id="embi_CashAndCashEquivalents" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CashPaidDuringPeriodForAbstract" id="embi_CashPaidDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ChangeInFairValueOfDerivativeLiabilities" id="embi_ChangeInFairValueOfDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ChangeInFairValueOfWarrantLiability" id="embi_ChangeInFairValueOfWarrantLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ChiefMedicalOfficerMember" id="embi_ChiefMedicalOfficerMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ClassOfWarrantOrRightWarrantsExercise" id="embi_ClassOfWarrantOrRightWarrantsExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockIssuanceCosts" id="embi_CommonStockIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CommonStockWarrantsMember" id="embi_CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonStockWarrantsToSeriesBStockholdersMember" id="embi_CommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="CommonUnitsSoldPricePerUnit" id="embi_CommonUnitsSoldPricePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConsultingAgreementMember" id="embi_ConsultingAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionLiabilityIntoCommonStockPerShare" id="embi_ConversionLiabilityIntoCommonStockPerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" id="embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" id="embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" id="embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" id="embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" id="embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesDPreferredStockToCommonStock" id="embi_ConversionOfSeriesDPreferredStockToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionOfSeriesDPreferredStockToCommonStockShares" id="embi_ConversionOfSeriesDPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesFPreferredStockToCommonStockShares" id="embi_ConversionOfSeriesFPreferredStockToCommonStockShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConversionOfSeriesFPreferredStockToCommonStockValue" id="embi_ConversionOfSeriesFPreferredStockToCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConversionPricePerShare" id="embi_ConversionPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleDebtRelatedPartyTextBlock" id="embi_ConvertibleDebtRelatedPartyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ConvertibleMultiDrawCreditAgreementIssuanceCosts" id="embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ConvertibleMultiDrawCreditFacility" id="embi_ConvertibleMultiDrawCreditFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="CouponInterestExpense" id="embi_CouponInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CreditFacilityEffectedFifthAdvances" id="embi_CreditFacilityEffectedFifthAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CreditFacilityEffectedFourthAdvances" id="embi_CreditFacilityEffectedFourthAdvances" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="CurrentConvertibleDebtExcludingNoncurrentPortion" id="embi_CurrentConvertibleDebtExcludingNoncurrentPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="DebtForgivenessCARESActDescription" id="embi_DebtForgivenessCARESActDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="December2015Member" id="embi_December2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerivativeLiabilitiesLineItems" id="embi_DerivativeLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DerivativeLiabilitiesTable" id="embi_DerivativeLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="DocumentAndEntityInformationAbstract" id="embi_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DouglasCesarioMember" id="embi_DouglasCesarioMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="DrawDownsLoansInAggregatePrincipalAmount" id="embi_DrawDownsLoansInAggregatePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="EmeraldConvertiblePromissoryNoteConversionLiabilityMember" id="embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingIssuanceCosts" id="embi_EmeraldFinancingIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="EmeraldFinancingMember" id="embi_EmeraldFinancingMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingWarrantLiabilityMember" id="embi_EmeraldFinancingWarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingWarrantsLiabilityMember" id="embi_EmeraldFinancingWarrantsLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldFinancingWarrantsMember" id="embi_EmeraldFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldHealthSciencesIncMember" id="embi_EmeraldHealthSciencesIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" id="embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmeraldWarrantLiabilityMember" id="embi_EmeraldWarrantLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EmployeeMember" id="embi_EmployeeMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityLineItems" id="embi_EquityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="EquityTable" id="embi_EquityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="ExerciseOfWarrants" id="embi_ExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairMarketValueOfStockOptions" id="embi_FairMarketValueOfStockOptions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueAdjustmentOfDerivativeLiabilities" id="embi_FairValueAdjustmentOfDerivativeLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" id="embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" id="embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfDerivativeLiabilitiesRollForward" id="embi_FairValueOfDerivativeLiabilitiesRollForward" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FairValueOfDerivativeLiabilityExcessOfProceeds" id="embi_FairValueOfDerivativeLiabilityExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FairValueOfSharesUnderlyingConvertibleDebt" id="embi_FairValueOfSharesUnderlyingConvertibleDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantLiabilityInExcessOfProceeds" id="embi_FairValueOfWarrantLiabilityInExcessOfProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantsIssued" id="embi_FairValueOfWarrantsIssued" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="FairValueOfWarrantsIssuedInConnectionWithFinancings" id="embi_FairValueOfWarrantsIssuedInConnectionWithFinancings" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="FifthAmendedAndRestatedMultiDrawCreditAgreementMember" id="embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="FourthAmendedAndRestatedMultiDrawCreditAgreementMember" id="embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="GrossProceedsOfUnitsSold" id="embi_GrossProceedsOfUnitsSold" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="GrossProceedsOfWarrants" id="embi_GrossProceedsOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IncreaseDecreaseAccruedInterestDueToRelatedParty" id="embi_IncreaseDecreaseAccruedInterestDueToRelatedParty" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="IndependentContractorAgreementMember" id="embi_IndependentContractorAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InitialTermOfAgreement" id="embi_InitialTermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember" id="embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="K2CIncMember" id="embi_K2CIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LegalReimbursementFees" id="embi_LegalReimbursementFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="LicenseAgreementMember" id="embi_LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="LumpSumPaymentInAgreement" id="embi_LumpSumPaymentInAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ManagementDeferralAgreementMember" id="embi_ManagementDeferralAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone1Member" id="embi_Milestone1Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone2Member" id="embi_Milestone2Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Milestone3Member" id="embi_Milestone3Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MilestonePaymentsPayableAxis" id="embi_MilestonePaymentsPayableAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MilestonePaymentsPayableDomain" id="embi_MilestonePaymentsPayableDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonteCarloSimulationsMember" id="embi_MonteCarloSimulationsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthAndYearOfAgreementAxis" id="embi_MonthAndYearOfAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="MonthAndYearOfAgreementDomain" id="embi_MonthAndYearOfAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MonthlyFee" id="embi_MonthlyFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" id="embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MonthlyFeePaidEachMonthInExchangeOfServices" id="embi_MonthlyFeePaidEachMonthInExchangeOfServices" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="MultiDrawCreditAgreementMember" id="embi_MultiDrawCreditAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="MultidrawCreditAgreementRelatedPartyNoncurrent" id="embi_MultidrawCreditAgreementRelatedPartyNoncurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NatureOfOperationsAndBusinessActivitiesAbstract" id="embi_NatureOfOperationsAndBusinessActivitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesLineItems" id="embi_NatureOfOperationsAndBusinessActivitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsAndBusinessActivitiesTable" id="embi_NatureOfOperationsAndBusinessActivitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" id="embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" id="embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities" id="embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="NonCashInterestExpenseAbstract" id="embi_NonCashInterestExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoramcoAgreementMember" id="embi_NoramcoAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NoticePeriodForTermination" id="embi_NoticePeriodForTermination" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfCommonStockUnitsSold" id="embi_NumberOfCommonStockUnitsSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfLicenseAgreements" id="embi_NumberOfLicenseAgreements" type="xbrli:integerItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="NumberOfPreFundedUnitsSold" id="embi_NumberOfPreFundedUnitsSold" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OctoberTwoThousandFifteenMember" id="embi_OctoberTwoThousandFifteenMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OfficersEmployeesAndDirectorsMember" id="embi_OfficersEmployeesAndDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OmnibusIncentivePlan2014Member" id="embi_OmnibusIncentivePlan2014Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="OptionAgreementMember" id="embi_OptionAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaycheckProtectionProgramMember" id="embi_PaycheckProtectionProgramMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaycheckProtectionProgramPromissoryNoteMember" id="embi_PaycheckProtectionProgramPromissoryNoteMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PaymentForUpfrontFees" id="embi_PaymentForUpfrontFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement" id="embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PayrollCostsExcludeCompensation" id="embi_PayrollCostsExcludeCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PercentageOfAccruedConsultingFees" id="embi_PercentageOfAccruedConsultingFees" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAccruedInterestOnOutstandingBalance" id="embi_PercentageOfAccruedInterestOnOutstandingBalance" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" id="embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfBonusForAccruedConsultingFees" id="embi_PercentageOfBonusForAccruedConsultingFees" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfForgivenessAmountForNonPayrollCosts" id="embi_PercentageOfForgivenessAmountForNonPayrollCosts" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfReductionInAnnualSalary" id="embi_PercentageOfReductionInAnnualSalary" type="num:percentItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" id="embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" id="embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" type="num:percentItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" id="embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlacementAgentMember" id="embi_PlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PlacementAgentWarrantsMember" id="embi_PlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Pre2015CommonStockWarrantsMember" id="embi_Pre2015CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PreferredStockPutOptionLiability" id="embi_PreferredStockPutOptionLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="PreFundedUnitsSoldPricePerUnit" id="embi_PreFundedUnitsSoldPricePerUnit" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PrefundedWarrantsMember" id="embi_PrefundedWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PricingModelAxis" id="embi_PricingModelAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" nillable="true"/>
  <element name="PricingModelDomain" id="embi_PricingModelDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="PricingModelMember" id="embi_PricingModelMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" id="embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromConvertibleMultiDrawCreditAgreement" id="embi_ProceedsFromConvertibleMultiDrawCreditAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" id="embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuanceOfCommonStockAndWarrants" id="embi_ProceedsFromIssuanceOfCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromIssuanceOfCommonStockAndWarrantsNet" id="embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProceedsFromPreFundedWarrantExercises" id="embi_ProceedsFromPreFundedWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ProvisionForConversionOfPreferredStock" id="embi_ProvisionForConversionOfPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReclassificationOfDerivativesToEquity" id="embi_ReclassificationOfDerivativesToEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="ReducedFixedConversionPriceOfCommonStock" id="embi_ReducedFixedConversionPriceOfCommonStock" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock" id="embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="RemainingFundsFromPromissoryNote" id="embi_RemainingFundsFromPromissoryNote" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="RestrictedStockAgreementsMember" id="embi_RestrictedStockAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="RisksAndUncertaintiesPolicyTextBlock" id="embi_RisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" id="embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ScheduleOfInterestExpenseTableTextBlock" id="embi_ScheduleOfInterestExpenseTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuredPromissoryNoteAndSecurityAgreementMember" id="embi_SecuredPromissoryNoteAndSecurityAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuritiesPurchaseAgreementMember" id="embi_SecuritiesPurchaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" id="embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeniorManagementCompensationPlanDescription" id="embi_SeniorManagementCompensationPlanDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeparationAgreementMember" id="embi_SeparationAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeparationAndReleaseAgreementMember" id="embi_SeparationAndReleaseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBPreferredStockConversionLiabilityMember" id="embi_SeriesBPreferredStockConversionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantMember" id="embi_SeriesBWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesBWarrantsMember" id="embi_SeriesBWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SeriesFPreferredStockPutOptionLiabilityMember" id="embi_SeriesFPreferredStockPutOptionLiabilityMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ShareIssuanceCosts" id="embi_ShareIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="SignificantContractsAbstract" id="embi_SignificantContractsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SignificantContractsTextBlock" id="embi_SignificantContractsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockholdersDeficitAndCapitalizationTextBlock" id="embi_StockholdersDeficitAndCapitalizationTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesCommonStockAndWarrants" id="embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" id="embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" id="embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesNetOfIssuanceCosts" id="embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodSharesSeriesBWarrantExercises" id="embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="StockIssuedDuringPeriodValueCommonStockAndWarrants" id="embi_StockIssuedDuringPeriodValueCommonStockAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" id="embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockIssuedDuringPeriodValueNetOfIssuanceCosts" id="embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="StockIssuedDuringPeriodValueSeriesBWarrantExercises" id="embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="StockOptions2014PlanMember" id="embi_StockOptions2014PlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SubsequentFinancingPurchasePriceDescription" id="embi_SubsequentFinancingPurchasePriceDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="SupplementalRestrictedCash" id="embi_SupplementalRestrictedCash" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TermOfAgreement" id="embi_TermOfAgreement" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrant" id="embi_TermOfWarrant" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermOfWarrants" id="embi_TermOfWarrants" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TermsOfAgreementRenewed" id="embi_TermsOfAgreementRenewed" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances" id="embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TotalCashEquivalentsAndRestrictedCashShownInConsolidated" id="embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalExpenseIncurredUnderAgreement" id="embi_TotalExpenseIncurredUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TotalFeesIncurredUnderAgreement" id="embi_TotalFeesIncurredUnderAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="TwoThousandAndTwentyCommonStockWarrantsMember" id="embi_TwoThousandAndTwentyCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" id="embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandAndTwentyPreFundedWarrantsMember" id="embi_TwoThousandAndTwentyPreFundedWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandEighteenEmeraldFinancingWarrantsMember" id="embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" id="embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenCommonStockWarrantsMember" id="embi_TwoThousandFifteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" id="embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" id="embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandNineteenCommonStockWarrantsMember" id="embi_TwoThousandNineteenCommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" id="embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" id="embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" id="embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" id="embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Um5050ProDrugAndUm8930AnalogAgreementsMember" id="embi_Um5050ProDrugAndUm8930AnalogAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="Um5070LicenseAgreementMember" id="embi_Um5070LicenseAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnamortizedDebtDiscountPeriod" id="embi_UnamortizedDebtDiscountPeriod" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsAbstract" id="embi_UniversityOfMississippiAgreementsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsLineItems" id="embi_UniversityOfMississippiAgreementsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UniversityOfMississippiAgreementsTable" id="embi_UniversityOfMississippiAgreementsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" nillable="true"/>
  <element name="UniversityOfMississippiMember" id="embi_UniversityOfMississippiMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="UnrestrictedCashPositionDecreased" id="embi_UnrestrictedCashPositionDecreased" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
  <element name="ValueOfCommonStockCalledByWarrants" id="embi_ValueOfCommonStockCalledByWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity" id="embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsAndDerivativeLiabilitiesAbstract" id="embi_WarrantsAndDerivativeLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsAndDerivativeLiabilitiesTextBlock" id="embi_WarrantsAndDerivativeLiabilitiesTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" id="embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit"/>
  <element name="WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" id="embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantsVestedAndOutstanding" id="embi_WarrantsVestedAndOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WarrantToPurchaseNumberOfCommonStockPricePerShare" id="embi_WarrantToPurchaseNumberOfCommonStockPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true"/>
  <element name="WorkingCapitalDeficit" id="embi_WorkingCapitalDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>embi-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MultidrawCreditAgreementRelatedPartyNoncurrent" xlink:label="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_AssetsCurrent_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_Liabilities_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_LiabilitiesCurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccountsPayableCurrent_8" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_9" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_10" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_ShortTermBorrowings_11" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_12" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_13" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_LongTermDebt_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_16" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_LongTermNotesPayable_17" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_18" order="40" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_19" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_7" xlink:to="loc_us-gaap_StockholdersEquity_22" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_PreferredStockValue_22" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_CommonStockValue_23" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_24" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_25" order="30" use="optional" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_10"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_OperatingIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_1" xlink:to="loc_us-gaap_OperatingExpenses_1" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5" xlink:to="loc_embi_ChangeInFairValueOfDerivativeLiabilities_5" order="0" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5" xlink:to="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_6" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5" xlink:to="loc_us-gaap_InterestExpense_7" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_10" order="10" use="optional" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_IncreaseDecreaseAccruedInterestDueToRelatedParty" xlink:label="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromPreFundedWarrantExercises" xlink:label="loc_embi_ProceedsFromPreFundedWarrantExercises_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_18"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_Depreciation_2" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3" order="20" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_ShareBasedCompensation_4" order="30" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_5" order="40" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_6" order="50" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_7" order="60" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_8" order="70" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_9" order="80" use="optional" weight="-1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_10" order="90" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_11" order="100" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_12" order="110" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_13" order="120" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_15" order="0" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_16" order="10" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_embi_ProceedsFromPreFundedWarrantExercises_17" order="20" use="optional" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_15" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_18" order="30" use="optional" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>embi-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <!-- INTEGIX by Ez-XBRL -->
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#NatureOfOperationsAndBusinessActivitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails1" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails2" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails4" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails5" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#ConvertibleDebtRelatedPartyDetailTextuals" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockholdersDeficitAndCapitalizationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetails" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SignificantContractsUniversityOfMississippiDetailTextuals" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#RelatedPartyMattersDetailTextuals" roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetails1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetails2" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetails4" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails3" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails6" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_19"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_StockholdersEquity_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_SharesIssued_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_11" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_12" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_13" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_14" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_15" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_16" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_17" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_18" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8" xlink:to="loc_us-gaap_NetIncomeLoss_19" order="110" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AugustTwoThousandAndTwentyFinancingWarrantsMember" xlink:label="loc_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_embi_EmeraldFinancingWarrantsLiabilityMember_7" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_embi_SeriesBWarrantMember_8" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_13" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_14" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_15" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_16" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WorkingCapitalDeficit" xlink:label="loc_embi_WorkingCapitalDeficit_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeniorManagementCompensationPlanDescription" xlink:label="loc_embi_SeniorManagementCompensationPlanDescription_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_36"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_MultiDrawCreditAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9" xlink:to="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_embi_CommonStockWarrantsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_embi_PrefundedWarrantsMember_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_19" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_20" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_WorkingCapitalDeficit_21" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_23" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_24" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_25" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_26" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_27" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_28" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_29" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_30" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_SeniorManagementCompensationPlanDescription_31" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_NumberOfCommonStockUnitsSold_32" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_NumberOfPreFundedUnitsSold_33" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_GrossProceedsOfUnitsSold_34" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_35" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xlink:to="loc_embi_TermOfWarrants_36" order="180" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_15"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6" xlink:to="loc_us-gaap_ClassOfStockDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6" xlink:to="loc_us-gaap_ConvertibleCommonStockMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_6" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_10" xlink:to="loc_us-gaap_EquityComponentDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_10" xlink:to="loc_us-gaap_WarrantMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_10" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_15" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_9" xlink:to="loc_embi_PricingModelMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_embi_SeriesBWarrantMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_embi_EmeraldFinancingMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_0" xlink:to="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilities_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_embi_FairValueOfWarrantsIssued_12" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_embi_ReclassificationOfDerivativesToEquity_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_15" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_11" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_16" order="50" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_MonteCarloSimulationsMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_12" xlink:to="loc_embi_EmeraldFinancingMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_12" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MinimumMember_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MaximumMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_24" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_9" xlink:to="loc_embi_PricingModelMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_9" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_13" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_13" xlink:to="loc_embi_SeriesBWarrantMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_13" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_25" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldWarrantLiabilityMember" xlink:label="loc_embi_EmeraldWarrantLiabilityMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PlacementAgentWarrantsMember" xlink:label="loc_embi_PlacementAgentWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_19"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_GrossProceedsOfWarrants" xlink:label="loc_embi_GrossProceedsOfWarrants_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ValueOfCommonStockCalledByWarrants" xlink:label="loc_embi_ValueOfCommonStockCalledByWarrants_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity" xlink:label="loc_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_34"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AggregateExercisePriceOfOutstandingCreditAgreement" xlink:label="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_36"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_37"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldFinancingWarrantsLiabilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldWarrantLiabilityMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_SeriesBWarrantsMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_CommonStockWarrantsMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_PrefundedWarrantsMember_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_PlacementAgentWarrantsMember_11" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_15" xlink:to="loc_us-gaap_WarrantMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_15" xlink:to="loc_us-gaap_EquityComponentDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_19" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_19" xlink:to="loc_dei_EntityDomain_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_19" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_19" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_19" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_24" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_GrossProceedsOfWarrants_25" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_ValueOfCommonStockCalledByWarrants_26" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_27" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_28" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_29" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_30" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_TermOfWarrant_31" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_32" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_33" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_34" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_35" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsExercise_36" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_37" order="140" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_16"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_12" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentGross_13" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_14" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_15" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_0" xlink:to="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_16" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaycheckProtectionProgramMember" xlink:label="loc_embi_PaycheckProtectionProgramMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CreditFacilityEffectedFourthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFourthAdvances_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CreditFacilityEffectedFifthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFifthAdvances_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_33"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UnamortizedDebtDiscountPeriod" xlink:label="loc_embi_UnamortizedDebtDiscountPeriod_36"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_37"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfSharesUnderlyingConvertibleDebt" xlink:label="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_39"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_40"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PayrollCostsExcludeCompensation" xlink:label="loc_embi_PayrollCostsExcludeCompensation_41"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfForgivenessAmountForNonPayrollCosts" xlink:label="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_42"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_43"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfReductionInAnnualSalary" xlink:label="loc_embi_PercentageOfReductionInAnnualSalary_44"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_embi_MultiDrawCreditAgreementMember_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_embi_IndependentContractorAgreementMember_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_11" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_11" xlink:to="loc_embi_PaycheckProtectionProgramMember_11" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_11" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_16" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_17" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_18" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_19" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_20" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_21" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_22" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_23" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_24" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_25" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_26" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_27" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_CreditFacilityEffectedFourthAdvances_28" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_CreditFacilityEffectedFifthAdvances_29" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_30" order="150" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DerivativeLiabilities_31" order="160" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_32" order="170" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_33" order="180" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_34" order="190" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_35" order="200" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_UnamortizedDebtDiscountPeriod_36" order="210" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_37" order="220" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_38" order="230" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_39" order="240" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_40" order="250" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PayrollCostsExcludeCompensation_41" order="260" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_42" order="270" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_43" order="280" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_embi_PercentageOfReductionInAnnualSalary_44" order="290" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember" xlink:label="loc_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PlacementAgentMember" xlink:label="loc_embi_PlacementAgentMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonUnitsSoldPricePerUnit" xlink:label="loc_embi_CommonUnitsSoldPricePerUnit_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PreFundedUnitsSoldPricePerUnit" xlink:label="loc_embi_PreFundedUnitsSoldPricePerUnit_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" xlink:label="loc_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_EquityTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_SecuritiesPurchaseAgreementMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9" xlink:to="loc_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_embi_CommonStockWarrantsMember_13" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_13" xlink:to="loc_embi_PrefundedWarrantsMember_14" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_13" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_18" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_18" xlink:to="loc_embi_PlacementAgentMember_18" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_18" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_NumberOfCommonStockUnitsSold_23" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_NumberOfPreFundedUnitsSold_24" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_CommonUnitsSoldPricePerUnit_25" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_26" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_PreFundedUnitsSoldPricePerUnit_27" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_GrossProceedsOfUnitsSold_28" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_29" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_30" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_31" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_33" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_EquityLineItems_0" xlink:to="loc_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_34" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_6" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_12" order="20" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_RestrictedStockMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_15" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_16" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_17" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_18" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensation_19" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_20" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_21" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_embi_FairMarketValueOfStockOptions_22" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_23" order="130" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_24" order="140" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_25" order="150" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Um5050ProDrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_34"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_OptionAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_LicenseAgreementMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5070LicenseAgreementMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_8" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_8" xlink:to="loc_embi_UniversityOfMississippiMember_8" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_8" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_12" xlink:to="loc_us-gaap_IntellectualPropertyMember_12" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MonthAndYearOfAgreementAxis_16" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_16" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_16" xlink:to="loc_embi_December2015Member_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_16" xlink:to="loc_embi_OctoberTwoThousandFifteenMember_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_16" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MilestonePaymentsPayableAxis_21" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_MilestonePaymentsPayableAxis_21" xlink:to="loc_embi_MilestonePaymentsPayableDomain_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_21" xlink:to="loc_embi_Milestone1Member_21" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_21" xlink:to="loc_embi_Milestone2Member_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_MilestonePaymentsPayableDomain_21" xlink:to="loc_embi_Milestone3Member_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_MilestonePaymentsPayableAxis_21" xlink:to="loc_embi_MilestonePaymentsPayableDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_AnnualMaintenanceFeePayable_28" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_TermOfAgreement_29" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_PaymentForUpfrontFees_30" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_NumberOfLicenseAgreements_31" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_NoticePeriodForTermination_32" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_AnnualFeesForLicenseAgreement_33" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_0" xlink:to="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_34" order="70" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OfficersEmployeesAndDirectorsMember" xlink:label="loc_embi_OfficersEmployeesAndDirectorsMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfAccruedConsultingFees" xlink:label="loc_embi_PercentageOfAccruedConsultingFees_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfBonusForAccruedConsultingFees" xlink:label="loc_embi_PercentageOfBonusForAccruedConsultingFees_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TotalFeesIncurredUnderAgreement" xlink:label="loc_embi_TotalFeesIncurredUnderAgreement_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_26"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_IndependentContractorAgreementMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_embi_AvtarDhillonMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_9" xlink:to="loc_embi_OfficersEmployeesAndDirectorsMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9" xlink:to="loc_us-gaap_RelatedPartyDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_InitialTermOfAgreement_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_TotalExpenseIncurredUnderAgreement_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFee_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_18" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_19" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_PercentageOfAccruedConsultingFees_20" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_PercentageOfBonusForAccruedConsultingFees_21" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_TotalFeesIncurredUnderAgreement_22" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_23" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_24" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_us-gaap_SharePrice_25" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_0" xlink:to="loc_embi_AccruedExpenseUnderAgreement_26" order="120" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmployeeMember" xlink:label="loc_embi_EmployeeMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ChiefMedicalOfficerMember" xlink:label="loc_embi_ChiefMedicalOfficerMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockOptions2014PlanMember" xlink:label="loc_embi_StockOptions2014PlanMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_25"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_embi_EmployeeMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_5" xlink:to="loc_embi_ChiefMedicalOfficerMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_10" xlink:to="loc_embi_StockOptions2014PlanMember_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_VestingAxis_14" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_14" xlink:to="loc_us-gaap_VestingDomain_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_14" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_14" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_14" xlink:to="loc_us-gaap_VestingDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_23" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_24" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_25" order="60" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_23"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_11" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_12" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_13" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_14" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_16" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_18" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_19" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_20" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_22" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_22" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_23" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_5" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MinimumMember_5" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5" xlink:to="loc_srt_MaximumMember_6" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5" xlink:to="loc_srt_RangeMember_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_10" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_10" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_10" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_10" xlink:to="loc_us-gaap_PlanNameDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_15" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_16" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_17" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_18" order="40" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" order="10" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyPreFundedWarrantsMember" xlink:label="loc_embi_TwoThousandAndTwentyPreFundedWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_24"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_Pre2015CommonStockWarrantsMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6" order="50" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7" order="60" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8" order="70" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9" order="80" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10" order="90" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_11" order="100" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_12" order="110" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyPreFundedWarrantsMember_13" order="120" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_17" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17" xlink:to="loc_srt_RangeMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MinimumMember_17" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17" xlink:to="loc_srt_MaximumMember_18" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_22" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_TermOfWarrant_23" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_embi_WarrantsVestedAndOutstanding_24" order="30" use="optional"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PlacementAgentWarrantsMember" xlink:label="loc_embi_PlacementAgentWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_Default"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_Default"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_22"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_CommonStockWarrantsMember_9" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_PrefundedWarrantsMember_10" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_9" xlink:to="loc_embi_PlacementAgentWarrantsMember_11" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_15" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_embi_PricingModelAxis_15" xlink:to="loc_embi_PricingModelDomain_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_embi_PricingModelDomain_15" xlink:to="loc_embi_PricingModelMember_15" order="0" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_embi_PricingModelAxis_15" xlink:to="loc_embi_PricingModelDomain_Default" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_20" order="10" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_21" order="20" use="optional"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_22" order="30" use="optional"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>embi-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_15"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_16"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AdditionalConversionLiability" xlink:label="loc_embi_AdditionalConversionLiability_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AggregateExercisePriceOfOutstandingCreditAgreement" xlink:label="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AggregatePrincipalAmount" xlink:label="loc_embi_AggregatePrincipalAmount_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AmortizationOfDebtDiscount" xlink:label="loc_embi_AmortizationOfDebtDiscount_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AmortizationOfTransactionCosts" xlink:label="loc_embi_AmortizationOfTransactionCosts_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AnnualFeeForAgreement" xlink:label="loc_embi_AnnualFeeForAgreement_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AugustTwoThousandAndTwentyFinancingWarrantsMember" xlink:label="loc_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_34"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CapitalRaise" xlink:label="loc_embi_CapitalRaise_36"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CashAndCashEquivalents" xlink:label="loc_embi_CashAndCashEquivalents_37"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CashPaidDuringPeriodForAbstract" xlink:label="loc_embi_CashPaidDuringPeriodForAbstract_38"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_39"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ChangeInFairValueOfWarrantLiability" xlink:label="loc_embi_ChangeInFairValueOfWarrantLiability_40"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ChiefMedicalOfficerMember" xlink:label="loc_embi_ChiefMedicalOfficerMember_41"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_42"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockIssuanceCosts" xlink:label="loc_embi_CommonStockIssuanceCosts_43"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_44"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_45"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonUnitsSoldPricePerUnit" xlink:label="loc_embi_CommonUnitsSoldPricePerUnit_46"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConsultingAgreementMember" xlink:label="loc_embi_ConsultingAgreementMember_47"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionLiabilityIntoCommonStockPerShare" xlink:label="loc_embi_ConversionLiabilityIntoCommonStockPerShare_48"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock" xlink:label="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_49"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_50"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue" xlink:label="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_51"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_52"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares" xlink:label="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_53"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStock" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_54"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfSeriesDPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_55"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockShares" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_56"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionOfSeriesFPreferredStockToCommonStockValue" xlink:label="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_57"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConversionPricePerShare" xlink:label="loc_embi_ConversionPricePerShare_58"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConvertibleDebtRelatedPartyTextBlock" xlink:label="loc_embi_ConvertibleDebtRelatedPartyTextBlock_59"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_60"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConvertibleMultiDrawCreditFacility" xlink:label="loc_embi_ConvertibleMultiDrawCreditFacility_61"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CouponInterestExpense" xlink:label="loc_embi_CouponInterestExpense_62"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CreditFacilityEffectedFifthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFifthAdvances_63"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CreditFacilityEffectedFourthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFourthAdvances_64"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_65"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DebtForgivenessCARESActDescription" xlink:label="loc_embi_DebtForgivenessCARESActDescription_66"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_67"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_68"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_69"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DocumentAndEntityInformationAbstract" xlink:label="loc_embi_DocumentAndEntityInformationAbstract_70"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DouglasCesarioMember" xlink:label="loc_embi_DouglasCesarioMember_71"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_72"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember" xlink:label="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_73"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingIssuanceCosts" xlink:label="loc_embi_EmeraldFinancingIssuanceCosts_74"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_75"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingWarrantLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantLiabilityMember_76"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_77"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingWarrantsMember" xlink:label="loc_embi_EmeraldFinancingWarrantsMember_78"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_79"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_80"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldWarrantLiabilityMember" xlink:label="loc_embi_EmeraldWarrantLiabilityMember_81"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmployeeMember" xlink:label="loc_embi_EmployeeMember_82"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_83"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_84"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ExerciseOfWarrants" xlink:label="loc_embi_ExerciseOfWarrants_85"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_86"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_87"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_88"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_89"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_90"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_91"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfSharesUnderlyingConvertibleDebt" xlink:label="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_92"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_93"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_94"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantsIssuedInConnectionWithFinancings" xlink:label="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_95"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_96"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_97"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_98"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_GrossProceedsOfWarrants" xlink:label="loc_embi_GrossProceedsOfWarrants_99"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_IncreaseDecreaseAccruedInterestDueToRelatedParty" xlink:label="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_100"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_101"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_102"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember" xlink:label="loc_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_103"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_K2CIncMember" xlink:label="loc_embi_K2CIncMember_104"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_LegalReimbursementFees" xlink:label="loc_embi_LegalReimbursementFees_105"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_106"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_LumpSumPaymentInAgreement" xlink:label="loc_embi_LumpSumPaymentInAgreement_107"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ManagementDeferralAgreementMember" xlink:label="loc_embi_ManagementDeferralAgreementMember_108"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_109"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_110"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_111"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_112"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_113"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_114"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_115"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_116"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_117"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_118"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_119"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_120"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MultidrawCreditAgreementRelatedPartyNoncurrent" xlink:label="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_121"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsAndBusinessActivitiesAbstract" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_122"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_123"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_124"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_125"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_126"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities" xlink:label="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NonCashInterestExpenseAbstract" xlink:label="loc_embi_NonCashInterestExpenseAbstract_128"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NoramcoAgreementMember" xlink:label="loc_embi_NoramcoAgreementMember_129"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_130"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_131"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_132"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_133"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_134"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OfficersEmployeesAndDirectorsMember" xlink:label="loc_embi_OfficersEmployeesAndDirectorsMember_135"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_136"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_137"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaycheckProtectionProgramMember" xlink:label="loc_embi_PaycheckProtectionProgramMember_138"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_139"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_140"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement" xlink:label="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_141"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PayrollCostsExcludeCompensation" xlink:label="loc_embi_PayrollCostsExcludeCompensation_142"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfAccruedConsultingFees" xlink:label="loc_embi_PercentageOfAccruedConsultingFees_143"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfAccruedInterestOnOutstandingBalance" xlink:label="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_144"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_145"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfBonusForAccruedConsultingFees" xlink:label="loc_embi_PercentageOfBonusForAccruedConsultingFees_146"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfForgivenessAmountForNonPayrollCosts" xlink:label="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_147"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfReductionInAnnualSalary" xlink:label="loc_embi_PercentageOfReductionInAnnualSalary_148"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_149"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" xlink:label="loc_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_150"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd" xlink:label="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_151"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PlacementAgentMember" xlink:label="loc_embi_PlacementAgentMember_152"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PlacementAgentWarrantsMember" xlink:label="loc_embi_PlacementAgentWarrantsMember_153"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_154"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PreferredStockPutOptionLiability" xlink:label="loc_embi_PreferredStockPutOptionLiability_155"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PreFundedUnitsSoldPricePerUnit" xlink:label="loc_embi_PreFundedUnitsSoldPricePerUnit_156"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_157"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_158"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_159"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_160"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_161"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_162"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants" xlink:label="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_163"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_164"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_165"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromPreFundedWarrantExercises" xlink:label="loc_embi_ProceedsFromPreFundedWarrantExercises_166"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProvisionForConversionOfPreferredStock" xlink:label="loc_embi_ProvisionForConversionOfPreferredStock_167"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_168"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ReducedFixedConversionPriceOfCommonStock" xlink:label="loc_embi_ReducedFixedConversionPriceOfCommonStock_169"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock" xlink:label="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_170"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_RemainingFundsFromPromissoryNote" xlink:label="loc_embi_RemainingFundsFromPromissoryNote_171"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_RestrictedStockAgreementsMember" xlink:label="loc_embi_RestrictedStockAgreementsMember_172"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_embi_RisksAndUncertaintiesPolicyTextBlock_173"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock" xlink:label="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_174"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_embi_ScheduleOfInterestExpenseTableTextBlock_175"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SecuredPromissoryNoteAndSecurityAgreementMember" xlink:label="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_176"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_177"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_178"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeniorManagementCompensationPlanDescription" xlink:label="loc_embi_SeniorManagementCompensationPlanDescription_179"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeparationAgreementMember" xlink:label="loc_embi_SeparationAgreementMember_180"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeparationAndReleaseAgreementMember" xlink:label="loc_embi_SeparationAndReleaseAgreementMember_181"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBPreferredStockConversionLiabilityMember" xlink:label="loc_embi_SeriesBPreferredStockConversionLiabilityMember_182"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_183"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_184"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesFPreferredStockPutOptionLiabilityMember" xlink:label="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_185"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ShareIssuanceCosts" xlink:label="loc_embi_ShareIssuanceCosts_186"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SignificantContractsAbstract" xlink:label="loc_embi_SignificantContractsAbstract_187"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SignificantContractsTextBlock" xlink:label="loc_embi_SignificantContractsTextBlock_188"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockholdersDeficitAndCapitalizationTextBlock" xlink:label="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_189"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_190"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_191"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense" xlink:label="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_192"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_193"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_194"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_195"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_196"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts" xlink:label="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_197"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_198"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockOptions2014PlanMember" xlink:label="loc_embi_StockOptions2014PlanMember_199"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SubsequentFinancingPurchasePriceDescription" xlink:label="loc_embi_SubsequentFinancingPurchasePriceDescription_200"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SupplementalRestrictedCash" xlink:label="loc_embi_SupplementalRestrictedCash_201"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_202"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_203"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_204"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermsOfAgreementRenewed" xlink:label="loc_embi_TermsOfAgreementRenewed_205"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances" xlink:label="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_206"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xlink:label="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_207"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_208"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TotalFeesIncurredUnderAgreement" xlink:label="loc_embi_TotalFeesIncurredUnderAgreement_209"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_210"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_211"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyPreFundedWarrantsMember" xlink:label="loc_embi_TwoThousandAndTwentyPreFundedWarrantsMember_212"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_213"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_214"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_215"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_216"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_217"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_218"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_219"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_220"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_221"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_222"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Um5050ProDrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_223"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_224"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UnamortizedDebtDiscountPeriod" xlink:label="loc_embi_UnamortizedDebtDiscountPeriod_225"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_embi_UniversityOfMississippiAgreementsAbstract_226"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_227"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_228"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_229"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UnrestrictedCashPositionDecreased" xlink:label="loc_embi_UnrestrictedCashPositionDecreased_230"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ValueOfCommonStockCalledByWarrants" xlink:label="loc_embi_ValueOfCommonStockCalledByWarrants_231"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity" xlink:label="loc_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_232"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_233"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsAndDerivativeLiabilitiesTextBlock" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_234"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_235"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_236"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_237"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantToPurchaseNumberOfCommonStockPricePerShare" xlink:label="loc_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_238"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WorkingCapitalDeficit" xlink:label="loc_embi_WorkingCapitalDeficit_239"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ChiefFinancialOfficerMember" xlink:label="loc_srt_ChiefFinancialOfficerMember_240"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_241"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_242"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_243"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_244"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_245"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_246"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_247"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_248"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_249"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_250"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_251"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_252"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_253"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_254"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_256"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvancesFairValueDisclosure" xlink:label="loc_us-gaap_AdvancesFairValueDisclosure_257"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_258"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_259"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_260"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_261"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_262"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_263"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_264"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_265"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_266"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_267"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BridgeLoanMember" xlink:label="loc_us-gaap_BridgeLoanMember_268"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_269"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_270"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_271"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_272"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_274"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_275"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_276"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_278"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_279"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_281"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_282"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_283"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_284"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_285"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_286"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_287"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_288"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_289"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_290"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_291"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaap_ConversionOfStockAmountConverted1_292"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_293"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_294"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_295"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_296"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_297"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_298"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_299"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_300"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_301"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_302"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_303"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_304"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_305"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleThresholdTradingDays" xlink:label="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_306"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_307"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_308"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_309"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_310"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_311"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_312"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_313"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_314"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_315"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_316"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_317"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_318"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_319"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_320"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_321"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_322"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_323"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_324"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_325"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_326"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_327"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_328"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_329"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_330"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_331"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_332"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_333"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_334"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_335"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_336"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_337"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_338"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_339"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_340"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_341"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_342"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_343"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_344"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_345"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_346"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_347"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_348"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_349"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_350"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_351"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_352"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_353"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_354"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_355"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_356"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_357"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_358"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_359"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_360"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_361"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_362"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_363"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_364"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_365"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_366"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_367"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_368"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_369"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_370"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPayableCurrentAndNoncurrent" xlink:label="loc_us-gaap_InterestPayableCurrentAndNoncurrent_371"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaap_InvestorMember_372"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_373"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_374"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_375"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_376"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_377"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_378"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_379"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_380"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_381"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_382"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_383"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_384"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_385"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_386"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_387"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_388"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_389"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_390"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_391"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_392"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_393"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_394"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_395"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_396"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_397"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_398"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_399"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_400"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_401"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_402"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_403"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_404"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_405"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_406"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_407"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseMember_408"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_409"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_410"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_411"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_412"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_413"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_414"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_415"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_416"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_417"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_418"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_419"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_420"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_421"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_422"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_423"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_424"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_425"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_426"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_427"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_428"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_429"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromOtherDebt" xlink:label="loc_us-gaap_ProceedsFromOtherDebt_430"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_431"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_432"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_433"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_434"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_435"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_436"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_437"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_438"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_439"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_440"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_441"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_442"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_443"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_444"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_445"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_446"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_447"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_449"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_450"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_451"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_452"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_453"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_454"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_455"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_456"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_457"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_458"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_459"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_460"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_461"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_462"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesDPreferredStockMember" xlink:label="loc_us-gaap_SeriesDPreferredStockMember_463"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesFPreferredStockMember" xlink:label="loc_us-gaap_SeriesFPreferredStockMember_464"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_465"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_466"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_467"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_468"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_469"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_470"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_471"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_472"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_473"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_474"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_475"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_476"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_477"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_478"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_479"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_480"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_481"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_482"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_483"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_484"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_485"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_486"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_487"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_488"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_489"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_490"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_491"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_492"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_493"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_494"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_495"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_496"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_497"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_498"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_499"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_500"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_501"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_502"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_503"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_505"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_506"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_507"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_508"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_509"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_510"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_511"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_512"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_513"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_514"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_515"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_516"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_517"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_518"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_519"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_520"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_521"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_522"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_523"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_524"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_525"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_526"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_527"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_528"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_529"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_530"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_531"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_532"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_533"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_534"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_535"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_536"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_537"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_538"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_539"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_540"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_541"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_542"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_543"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_544"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_545"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_546"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_547"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_548"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_549"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_550"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag_0" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_AmendmentFlag_1" xml:lang="en-US">Amendment Flag</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CurrentFiscalYearEndDate_0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_CurrentFiscalYearEndDate_1" xml:lang="en-US">Current Fiscal Year End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus_0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalPeriodFocus_1" xml:lang="en-US">Document Fiscal Period Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus_0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentFiscalYearFocus_1" xml:lang="en-US">Document Fiscal Year Focus</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentPeriodEndDate_0" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentPeriodEndDate_1" xml:lang="en-US">Document Period End Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType_0" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_DocumentType_1" xml:lang="en-US">Document Type</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey_0" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCentralIndexKey_1" xml:lang="en-US">Entity Central Index Key</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_1" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain_0" xml:lang="en-US">Entity [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany_0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod_0" xml:lang="en-US">Entity Ex Transition Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory_0" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityFilerCategory_1" xml:lang="en-US">Entity Filer Category</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityInteractiveDataCurrent_0" xml:lang="en-US">Entity Interactive Data Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName_0" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_EntityRegistrantName_1" xml:lang="en-US">Entity Registrant Name</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityShellCompany_0" xml:lang="en-US">Entity Shell Company</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness_0" xml:lang="en-US">Entity Small Business</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis_0" xml:lang="en-US">Legal Entity [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_LegalEntityAxis_1" xml:lang="en-US">UM 5050 Pro-Drug and UM 8930 Analog Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_TradingSymbol_0" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_dei_TradingSymbol_1" xml:lang="en-US">Trading Symbol</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AccruedExpenseUnderAgreement_0" xml:lang="en-US">Represents total accrued expense under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AccruedExpenseUnderAgreement_1" xml:lang="en-US">Accrued Expense Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AccruedExpenseUnderAgreement_2" xml:lang="en-US">Accrued expense under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AdditionalConversionLiability_0" xml:lang="en-US">Threshold number of specified trading days that common stock price to additional conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AdditionalConversionLiability_1" xml:lang="en-US">Additional Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AdditionalConversionLiability_2" xml:lang="en-US">Additional conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_0" xml:lang="en-US">Information about aggregate exercise price of outstanding credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_1" xml:lang="en-US">Aggregate Exercise Price Of outstanding Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_2" xml:lang="en-US">Aggregate exercise price of outstanding credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_0" xml:lang="en-US">This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_1" xml:lang="en-US">Aggregate Milestone Payments If Milestones Achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_2" xml:lang="en-US">Aggregate milestone payments if milestones achieved</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AggregatePrincipalAmount_0" xml:lang="en-US">Represents aggregate principal amount .</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AggregatePrincipalAmount_1" xml:lang="en-US">Aggregate Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_0" xml:lang="en-US">Represents allocation of debt on the basis of relative fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_1" xml:lang="en-US">Allocation Of Debt On Basis Of Relative Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_2" xml:lang="en-US">Allocation of debt on the basis of relative fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_0" xml:lang="en-US">Represents allocation of warrant on the basis of relative fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_1" xml:lang="en-US">Allocation Of Warrant On Basis Of Relative Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_2" xml:lang="en-US">Allocation of warrant on the basis of relative fair value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents information of amended and restated multi draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">Amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmortizationOfDebtDiscount_0" xml:lang="en-US">Amount of amortization expense attributable to debt discount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmortizationOfDebtDiscount_1" xml:lang="en-US">Amortization Of Debt Discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AmortizationOfDebtDiscount_2" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AmortizationOfTransactionCosts_0" xml:lang="en-US">Amount of amortization of transaction costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AmortizationOfTransactionCosts_1" xml:lang="en-US">Amortization Of Transaction Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AmortizationOfTransactionCosts_2" xml:lang="en-US">Amortization of transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualFeeForAgreement_0" xml:lang="en-US">Represents amount of annual fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualFeeForAgreement_1" xml:lang="en-US">Annual Fee For Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_AnnualFeeForAgreement_2" xml:lang="en-US">Annual fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_0" xml:lang="en-US">Represents annual fees for license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_1" xml:lang="en-US">Annual Fees For License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AnnualFeesForLicenseAgreement_2" xml:lang="en-US">Annual fees for license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AnnualMaintenanceFeePayable_0" xml:lang="en-US">Represents the amount of annual maintenance fee payable.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AnnualMaintenanceFeePayable_1" xml:lang="en-US">Annual maintenance fee payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_0" xml:lang="en-US">August Two Thousand And Twenty Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_1" xml:lang="en-US">August Two Thousand And Twenty Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_2" xml:lang="en-US">August 2020 Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_AvtarDhillonMember_0" xml:lang="en-US">Name of board member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_AvtarDhillonMember_1" xml:lang="en-US">Avtar Dhillon [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_AvtarDhillonMember_2" xml:lang="en-US">Dr. Avtar Dhillon</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0" xml:lang="en-US">Represents beneficial conversion feature in connection with convertible multi-draw credit agreement - related party value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1" xml:lang="en-US">Beneficial Conversion Feature In Connection With Convertible Multi Draw Credit Agreement Related Party Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2" xml:lang="en-US">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of beneficial conversion feature recorded on advances under the convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Beneficial Conversion Feature On Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Beneficial conversion feature on convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CapitalRaise_0" xml:lang="en-US">Represents amount of capital raise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CapitalRaise_1" xml:lang="en-US">Capital Raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CashAndCashEquivalents_0" xml:lang="en-US">Represents amount of Cash and cash equivalents.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CashAndCashEquivalents_1" xml:lang="en-US">Cash And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CashAndCashEquivalents_2" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CashPaidDuringPeriodForAbstract_0" xml:lang="en-US">Cash Paid During Period For Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CashPaidDuringPeriodForAbstract_1" xml:lang="en-US">Cash paid during the period for:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CashPaidDuringPeriodForAbstract_2" xml:lang="en-US">Cash paid during the period for</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_0" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_1" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_2" xml:lang="en-US">Change In Fair Value Of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ChangeInFairValueOfDerivativeLiabilities_3" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_0" xml:lang="en-US">Amount of expense (income) related to warrant liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_1" xml:lang="en-US">Change In Fair Value Of Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ChangeInFairValueOfWarrantLiability_2" xml:lang="en-US">Change in fair value of warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ChiefMedicalOfficerMember_0" xml:lang="en-US">Chief Medical Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ChiefMedicalOfficerMember_1" xml:lang="en-US">Information related to chief medical officer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ChiefMedicalOfficerMember_2" xml:lang="en-US">Chief Medical Officer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_0" xml:lang="en-US">Class Of Warrant Or Right Warrants Exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_1" xml:lang="en-US">Represents number of warrants exercise.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ClassOfWarrantOrRightWarrantsExercise_2" xml:lang="en-US">Warrants exercise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockIssuanceCosts_0" xml:lang="en-US">Amount of common stock issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockIssuanceCosts_1" xml:lang="en-US">Common Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CommonStockIssuanceCosts_2" xml:lang="en-US">Common stock issuance costs paid of $7,778</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockWarrantsMember_0" xml:lang="en-US">Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockWarrantsMember_1" xml:lang="en-US">Common stock warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CommonStockWarrantsMember_2" xml:lang="en-US">Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_0" xml:lang="en-US">Represents common stock warrants to series B stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_1" xml:lang="en-US">Common Stock Warrants To Series B Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_2" xml:lang="en-US">Common Stock Warrants to Series B Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CommonUnitsSoldPricePerUnit_0" xml:lang="en-US">Common Units Sold Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CommonUnitsSoldPricePerUnit_1" xml:lang="en-US">Represents the price per unit of common units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CommonUnitsSoldPricePerUnit_2" xml:lang="en-US">Common units sold price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConsultingAgreementMember_0" xml:lang="en-US">Consulting Agreement that involves two or more parties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConsultingAgreementMember_1" xml:lang="en-US">Consulting Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConsultingAgreementMember_2" xml:lang="en-US">Consulting Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_0" xml:lang="en-US">Represents conversion liability into common stock per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_1" xml:lang="en-US">Conversion Liability Into Common Stock Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionLiabilityIntoCommonStockPerShare_2" xml:lang="en-US">Conversion liability into common stock per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_0" xml:lang="en-US">Represents amount of conversion of outstanding preferred stock subject to redemption into common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_1" xml:lang="en-US">Conversion Of Outstanding Preferred Stock Subject To Redemption Into Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_2" xml:lang="en-US">Conversion of outstanding preferred stock subject to redemption into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion liability into common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_1" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.80 and $0.40 per share for December 31, 2016 and $0.25 and $0.15 per share for December 31, 2017 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_2" xml:lang="en-US">Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock, Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_3" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion liability into common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_1" xml:lang="en-US">Conversion Of Preferred Stock Series And Conversion Liability Into Common Stock, Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_2" xml:lang="en-US">Conversion of Series B Preferred Stock and conversion liability into common stock at $0.10 and $0.001 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_3" xml:lang="en-US">Conversion of Series A and Series B Preferred Stock and conversion liability into common stock at $0.80 per share and $0.80 and $0.40 per share for 2015 and 2016, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_0" xml:lang="en-US">Represents value conversion of secured convertible promissory note related party and accrued interest.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_1" xml:lang="en-US">Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_2" xml:lang="en-US">Conversion of secured convertible promissory note - related party and accrued interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_0" xml:lang="en-US">Represents value conversion of secured convertible promissory note related party and accrued interest shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_1" xml:lang="en-US">Conversion Of Secured Convertible Promissory Note Related Party And Accrued Interest Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_2" xml:lang="en-US">Conversion of secured convertible promissory note - related party and accrued interest (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion of series D preferred stock to common stock, value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_1" xml:lang="en-US">Conversion Of Series D Preferred Stock To Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_2" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.10 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_3" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.25 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_0" xml:lang="en-US">Represents conversion of Preferred Stock Series and conversion series D preferred stock common stock, shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series D Preferred Stock To Common Stock,Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.10 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_3" xml:lang="en-US">Conversion of Series D Preferred Stock to common stock at $0.25 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_0" xml:lang="en-US">Number of shares of series F preferred stock converted during the period into common stocks.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_1" xml:lang="en-US">Conversion Of Series F Preferred Stock To Common Stock Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_2" xml:lang="en-US">Conversion of Series F Preferred Stock to common stock at $0.10 per share (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_0" xml:lang="en-US">Value of shares of series F preferred stock converted into common stocks during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_1" xml:lang="en-US">Conversion Of Series F Preferred Stock To Common Stock Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_2" xml:lang="en-US">Conversion of Series F Preferred Stock to common stock at $0.10 per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConversionPricePerShare_0" xml:lang="en-US">Represents the value related to conversion of Series A Preferred Stock and conversion liability into common stock per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConversionPricePerShare_1" xml:lang="en-US">Conversion Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConversionPricePerShare_2" xml:lang="en-US">Conversion of preferred stock price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_0" xml:lang="en-US">The entire disclosure for convertible debt - related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_1" xml:lang="en-US">Convertible Debt Related Party [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConvertibleDebtRelatedPartyTextBlock_2" xml:lang="en-US">Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_0" xml:lang="en-US">Amount of convertible multi-draw credit agreement issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_1" xml:lang="en-US">Convertible Multi Draw Credit Agreement Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2" xml:lang="en-US">Convertible multi-draw credit agreement issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_0" xml:lang="en-US">The carrying value of convertible multi- draw credit facility - related party as of the balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_1" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_2" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_3" xml:lang="en-US">Convertible Multi Draw Credit Facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_4" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ConvertibleMultiDrawCreditFacility_5" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CouponInterestExpense_0" xml:lang="en-US">Amount of interest expense classified as coupon interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CouponInterestExpense_1" xml:lang="en-US">Coupon Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CouponInterestExpense_2" xml:lang="en-US">Interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CreditFacilityEffectedFifthAdvances_0" xml:lang="en-US">Credit Facility Effected Fifth Advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CreditFacilityEffectedFifthAdvances_1" xml:lang="en-US">Represents credit facility fifth advances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CreditFacilityEffectedFifthAdvances_2" xml:lang="en-US">Credit facility effected fifth advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CreditFacilityEffectedFourthAdvances_0" xml:lang="en-US">Credit Facility Effected Fourth Advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CreditFacilityEffectedFourthAdvances_1" xml:lang="en-US">Represents fourth credit facility advances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CreditFacilityEffectedFourthAdvances_2" xml:lang="en-US">Credit facility effected fourth advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_0" xml:lang="en-US">The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_1" xml:lang="en-US">Current Convertible Debt Excluding Noncurrent Portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_2" xml:lang="en-US">Current convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_3" xml:lang="en-US">Total carrying value of advances under the multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DebtForgivenessCARESActDescription_0" xml:lang="en-US">Represents information of debt forgiveness under The Coronavirus Aid, Relief, and Economic Security Act ("the CARES Act").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DebtForgivenessCARESActDescription_1" xml:lang="en-US">Debt Forgiveness CARES Act Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DebtForgivenessCARESActDescription_2" xml:lang="en-US">Debt forgiveness, CARES Act, description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_December2015Member_0" xml:lang="en-US">Represents December 2015 as agreement month and year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_December2015Member_1" xml:lang="en-US">December 2015 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_December2015Member_2" xml:lang="en-US">December 2015</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DerivativeLiabilitiesLineItems_0" xml:lang="en-US">Line item represents derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DerivativeLiabilitiesLineItems_1" xml:lang="en-US">Derivative Liabilities Line Items</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DerivativeLiabilitiesTable_0" xml:lang="en-US">A table or schedule providing information about derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DerivativeLiabilitiesTable_1" xml:lang="en-US">Derivative Liabilities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DocumentAndEntityInformationAbstract_0" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DocumentAndEntityInformationAbstract_1" xml:lang="en-US">Document and Entity Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DouglasCesarioMember_0" xml:lang="en-US">Represents the Douglas Cesario.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DouglasCesarioMember_1" xml:lang="en-US">Douglas Cesario [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_DouglasCesarioMember_2" xml:lang="en-US">Douglas Cesario, CFO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_0" xml:lang="en-US">Represents draw downs loans in aggregate principal amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_1" xml:lang="en-US">Draw Downs Loans In Aggregate Principal Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_2" xml:lang="en-US">Draw downs loans In aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_0" xml:lang="en-US">Information about emerald convertible promissory note - conversion liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_1" xml:lang="en-US">Emerald Convertible Promissory Note Conversion Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_2" xml:lang="en-US">Emerald Convertible Promissory Note Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_3" xml:lang="en-US">Emerald Convertible Promissory Note - conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_0" xml:lang="en-US">Cost incurred for Emerald Financing, issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_1" xml:lang="en-US">Emerald Financing Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldFinancingIssuanceCosts_2" xml:lang="en-US">Emerald financing issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingMember_0" xml:lang="en-US">Represents Emerald financing.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingMember_1" xml:lang="en-US">Emerald Financing [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldFinancingMember_2" xml:lang="en-US">Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldFinancingMember_3" xml:lang="en-US">Emerald Financing - Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingWarrantLiabilityMember_0" xml:lang="en-US">Information regarding Emerald Financing Warrant Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingWarrantLiabilityMember_1" xml:lang="en-US">Emerald Financing Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldFinancingWarrantLiabilityMember_2" xml:lang="en-US">Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingWarrantsLiabilityMember_0" xml:lang="en-US">Information regarding Emerald Financing Warrants Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingWarrantsLiabilityMember_1" xml:lang="en-US">Emerald Financing Warrants Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldFinancingWarrantsLiabilityMember_2" xml:lang="en-US">Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldFinancingWarrantsMember_0" xml:lang="en-US">Emerald Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldFinancingWarrantsMember_1" xml:lang="en-US">Emerald Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldFinancingWarrantsMember_2" xml:lang="en-US">Emerald Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_0" xml:lang="en-US">Represents information about Emerald Health Sciences, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_1" xml:lang="en-US">Emerald Health Sciences Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_2" xml:lang="en-US">Emerald Health Sciences Inc</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldHealthSciencesIncMember_3" xml:lang="en-US">Emerald Health Sciences</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_0" xml:lang="en-US">Information regarding emerald multi-draw credit agreement compound derivative liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Compound Derivative Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_2" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Compound Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_0" xml:lang="en-US">Represents the information about Emerald Warrant Liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_1" xml:lang="en-US">Emerald Warrant Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_2" xml:lang="en-US">Emerald Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_EmeraldWarrantLiabilityMember_3" xml:lang="en-US">Emerald Warrant Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EmployeeMember_0" xml:lang="en-US">Employee [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EmployeeMember_1" xml:lang="en-US">Information of employee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_EmployeeMember_2" xml:lang="en-US">Employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EquityLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EquityLineItems_1" xml:lang="en-US">Equity [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_EquityTable_0" xml:lang="en-US">Represents tabular disclosure of Equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_EquityTable_1" xml:lang="en-US">Equity [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ExerciseOfWarrants_0" xml:lang="en-US">The amount express exercise of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ExerciseOfWarrants_1" xml:lang="en-US">Exercise Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ExerciseOfWarrants_2" xml:lang="en-US">Reclassification of warrant liabilities to equity from exercise of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairMarketValueOfStockOptions_0" xml:lang="en-US">Represents the fair market value of stock options.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairMarketValueOfStockOptions_1" xml:lang="en-US">Fair Market Value Of Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairMarketValueOfStockOptions_2" xml:lang="en-US">Fair market value of stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_0" xml:lang="en-US">It represents fair value adjustment of derivative liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_1" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_2" xml:lang="en-US">Fair Value Adjustment Of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_3" xml:lang="en-US">Change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_0" xml:lang="en-US">Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of derivative asset and liability measured on recurring and nonrecurring basis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_1" xml:lang="en-US">Fair Value Measurement Inputs And Valuation Techniques Derivative Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_2" xml:lang="en-US">Schedule of input and valuation technique used to value derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Represents the initial fair value of the compound derivative liability that was bifurcated from advances under the convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Fair Value Of Compound Derivative Liability Issued With Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_0" xml:lang="en-US">Represents the amount of derivative liabilities at fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_1" xml:lang="en-US">Fair Value Of Derivative Liabilities [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_0" xml:lang="en-US">It represents fair value of derivative liability excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_1" xml:lang="en-US">Fair Value Of Derivative Liability Excess Of Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_2" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfSharesUnderlyingConvertibleDebt_0" xml:lang="en-US">Fair Value Of Shares Underlying Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfSharesUnderlyingConvertibleDebt_1" xml:lang="en-US">Fair value of shares underlying convertible debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfSharesUnderlyingConvertibleDebt_2" xml:lang="en-US">Fair value of shares underlying convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfSharesUnderlyingConvertibleDebt_3" xml:lang="en-US">Total principal value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_0" xml:lang="en-US">Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_1" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_2" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_3" xml:lang="en-US">Fair Value Of Warrant Liability In Excess Of Proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_4" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_5" xml:lang="en-US">Fair value of derivative liabilities in excess of proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfWarrantsIssued_0" xml:lang="en-US">The fair value of warrants issued in noncash investing or financing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_1" xml:lang="en-US">Initial Fair Value of Emerald Financing Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfWarrantsIssued_2" xml:lang="en-US">Fair Value Of Warrants Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_3" xml:lang="en-US">Fair value of warrants issued in connection with financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssued_4" xml:lang="en-US">Fair Value of Derivative Liabilities Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_0" xml:lang="en-US">Amount of fair value of warrants issued in connection with financings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_1" xml:lang="en-US">Fair Value Of Warrants Issued In Connection With Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_2" xml:lang="en-US">Fair value of warrants issued in connection with financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Fifth Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Represents Fifth Amended And Restated Multi Draw Credit Agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">Fifth amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_0" xml:lang="en-US">Fourth Amended And Restated Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_1" xml:lang="en-US">Represents Fourth Amended And Restated Multi Draw Credit Agreement member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_2" xml:lang="en-US">fourth amended and Restated Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_GrossProceedsOfUnitsSold_0" xml:lang="en-US">Gross Proceeds Of Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_GrossProceedsOfUnitsSold_1" xml:lang="en-US">Represents the amount of gross proceeds of units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_GrossProceedsOfUnitsSold_2" xml:lang="en-US">Gross proceeds of units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_GrossProceedsOfWarrants_0" xml:lang="en-US">Gross Proceeds Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_GrossProceedsOfWarrants_1" xml:lang="en-US">Represents the gross proceeds of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_GrossProceedsOfWarrants_2" xml:lang="en-US">Gross proceeds of warrants on a relative fair value basis</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_0" xml:lang="en-US">Represents increase decrease in accrued interest due to related party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_1" xml:lang="en-US">Increase Decrease Accrued Interest Due To Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_2" xml:lang="en-US">Accrued interest due to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_IndependentContractorAgreementMember_0" xml:lang="en-US">Represents name of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_IndependentContractorAgreementMember_1" xml:lang="en-US">Independent Contractor Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_IndependentContractorAgreementMember_2" xml:lang="en-US">Independent contractor agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_InitialTermOfAgreement_0" xml:lang="en-US">Represents the initial term of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_InitialTermOfAgreement_1" xml:lang="en-US">Initial Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_InitialTermOfAgreement_2" xml:lang="en-US">Initial term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_0" xml:lang="en-US">Institutional Investors And H C Wainwright And Company L L C [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_1" xml:lang="en-US">Information of institutional investors and H.C. Wainwright &amp; Co., LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_2" xml:lang="en-US">Institutional investors and H.C. Wainwright &amp; Co., LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_K2CIncMember_0" xml:lang="en-US">Represents name of party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_K2CIncMember_1" xml:lang="en-US">K2C Inc [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_K2CIncMember_2" xml:lang="en-US">K2C, Inc.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LegalReimbursementFees_0" xml:lang="en-US">Represent legal reimburse fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LegalReimbursementFees_1" xml:lang="en-US">Legal Reimbursement Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_LegalReimbursementFees_2" xml:lang="en-US">Legal reimbursement fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LicenseAgreementMember_0" xml:lang="en-US">Represents license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LicenseAgreementMember_1" xml:lang="en-US">License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_LicenseAgreementMember_2" xml:lang="en-US">UM 8930 analogue agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LicenseAgreementMember_3" xml:lang="en-US">License Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_LumpSumPaymentInAgreement_0" xml:lang="en-US">The amount related to lump sum payment in the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_LumpSumPaymentInAgreement_1" xml:lang="en-US">Lump Sum Payment In Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_LumpSumPaymentInAgreement_2" xml:lang="en-US">Lump sum payment in agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ManagementDeferralAgreementMember_0" xml:lang="en-US">Management Deferral Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ManagementDeferralAgreementMember_1" xml:lang="en-US">Management Deferral Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ManagementDeferralAgreementMember_2" xml:lang="en-US">Management Deferral Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone1Member_0" xml:lang="en-US">It represents milestone 1 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone1Member_1" xml:lang="en-US">Milestone 1 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Milestone1Member_2" xml:lang="en-US">Milestone 1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone2Member_0" xml:lang="en-US">It represents milestone 2 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone2Member_1" xml:lang="en-US">Milestone 2 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Milestone2Member_2" xml:lang="en-US">Milestone 2</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Milestone3Member_0" xml:lang="en-US">It represents milestone 3 member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Milestone3Member_1" xml:lang="en-US">Milestone 3 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Milestone3Member_2" xml:lang="en-US">Milestone 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MilestonePaymentsPayableAxis_0" xml:lang="en-US">It represents milestone payments payable axis.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MilestonePaymentsPayableAxis_1" xml:lang="en-US">Milestone Payments Payable [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MilestonePaymentsPayableDomain_0" xml:lang="en-US">It represents milestone payments payable domain.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MilestonePaymentsPayableDomain_1" xml:lang="en-US">Milestone Payments Payable [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonteCarloSimulationsMember_0" xml:lang="en-US">Represents monte carlo simulations.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonteCarloSimulationsMember_1" xml:lang="en-US">Monte Carlo Simulations [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MonteCarloSimulationsMember_2" xml:lang="en-US">Monte Carlo simulations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthAndYearOfAgreementAxis_0" xml:lang="en-US">Information regarding month and year of agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthAndYearOfAgreementAxis_1" xml:lang="en-US">Month And Year Of Agreement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthAndYearOfAgreementDomain_0" xml:lang="en-US">Represents month and year of agreement in which company entered into.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthAndYearOfAgreementDomain_1" xml:lang="en-US">Month And Year Of Agreement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFee_0" xml:lang="en-US">Represents amount of monthly fee.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFee_1" xml:lang="en-US">Monthly Fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MonthlyFee_2" xml:lang="en-US">Monthly fee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_0" xml:lang="en-US">Represents amount of monthly fees accruing from the effective date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_1" xml:lang="en-US">Monthly Fee Accruing From Effective Date In Exchange Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_2" xml:lang="en-US">Monthly fee accruing from effective date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_0" xml:lang="en-US">Represents amount of monthly fee paid in exchange of services.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_1" xml:lang="en-US">Monthly Fee Paid Each Month In Exchange Of Services</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_2" xml:lang="en-US">Monthly fee paid each month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MultiDrawCreditAgreementMember_0" xml:lang="en-US">Represents the information about Multi-Draw Credit Agreement (the "Credit Agreement").</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MultiDrawCreditAgreementMember_1" xml:lang="en-US">Multi Draw Credit Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MultiDrawCreditAgreementMember_2" xml:lang="en-US">Multi-Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_0" xml:lang="en-US">Multidraw Credit Agreement Related Party Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_1" xml:lang="en-US">Represents the multidraw credit agreement related party noncurrent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_2" xml:lang="en-US">Multi-draw credit agreement - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0" xml:lang="en-US">Represents nature of operations and business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_1" xml:lang="en-US">Nature Of Operations And Business Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_1" xml:lang="en-US">Nature Of Operations And Business Activities [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_0" xml:lang="en-US">Represents nature of operations and business activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xml:lang="en-US">Nature Of Operations And Business Activities [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_1" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_2" xml:lang="en-US">Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_0" xml:lang="en-US">Represents Tabular disclosure of nature of operations, business activities and Summary of significant accounting policies.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xml:lang="en-US">Nature Of Operations Business Activities And Summary Of Significant Accounting Policies [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_0" xml:lang="en-US">Represents net loss available to common shareholders, adjusted as appropriate for gains or losses from dilutive securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_1" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_2" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_3" xml:lang="en-US">Net loss (as adjusted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_4" xml:lang="en-US">Net Loss Available To Common Shareholders Adjusted As Appropriate For Gains Or Losses From Dilutive Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_5" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_6" xml:lang="en-US">Net Income (Loss) Attributable to Parent, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_7" xml:lang="en-US">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NonCashInterestExpenseAbstract_0" xml:lang="en-US">Non Cash Interest Expense [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_NonCashInterestExpenseAbstract_1" xml:lang="en-US">Non-cash interest expense:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NoramcoAgreementMember_0" xml:lang="en-US">It represents Noramco Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NoramcoAgreementMember_1" xml:lang="en-US">Noramco Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NoramcoAgreementMember_2" xml:lang="en-US">Noramco Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NoticePeriodForTermination_0" xml:lang="en-US">This element represents written notice period for termination under agreement by either party.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NoticePeriodForTermination_1" xml:lang="en-US">Notice Period For Termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NoticePeriodForTermination_2" xml:lang="en-US">Notice period for termination</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfCommonStockUnitsSold_0" xml:lang="en-US">Number Of Common Stock Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfCommonStockUnitsSold_1" xml:lang="en-US">Represents the number of common stock units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfCommonStockUnitsSold_2" xml:lang="en-US">Number of common stock units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfLicenseAgreements_0" xml:lang="en-US">Represents number of license agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfLicenseAgreements_1" xml:lang="en-US">Number Of License Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfLicenseAgreements_2" xml:lang="en-US">Number of license agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_NumberOfPreFundedUnitsSold_0" xml:lang="en-US">Number Of Pre Funded Units Sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_NumberOfPreFundedUnitsSold_1" xml:lang="en-US">Number of pre funded units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_NumberOfPreFundedUnitsSold_2" xml:lang="en-US">Number of pre-funded units sold</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_0" xml:lang="en-US">Represents agreement date of the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_1" xml:lang="en-US">October Two Thousand Fifteen [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OctoberTwoThousandFifteenMember_2" xml:lang="en-US">October 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OfficersEmployeesAndDirectorsMember_0" xml:lang="en-US">Officers, Employees And Directors [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OfficersEmployeesAndDirectorsMember_1" xml:lang="en-US">This member stands for officers, employees and directors.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_OfficersEmployeesAndDirectorsMember_2" xml:lang="en-US">Officers, employees and directors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_0" xml:lang="en-US">Represents information of Omnibus Incentive Plan 2014.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_1" xml:lang="en-US">Omnibus Incentive Plan 2014 [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_2" xml:lang="en-US">2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OmnibusIncentivePlan2014Member_3" xml:lang="en-US">Omnibus Incentive Plan 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_OptionAgreementMember_0" xml:lang="en-US">Represents information regarding option agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_OptionAgreementMember_1" xml:lang="en-US">Option Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_OptionAgreementMember_2" xml:lang="en-US">UM 5050 pro-drug agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_OptionAgreementMember_3" xml:lang="en-US">Option Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaycheckProtectionProgramMember_0" xml:lang="en-US">Paycheck Protection Program[Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaycheckProtectionProgramMember_1" xml:lang="en-US">PaycheckProtectionProgram.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaycheckProtectionProgramMember_2" xml:lang="en-US">Paycheck Protection Program</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_0" xml:lang="en-US">Represents information of Paycheck protection program promissory note.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_1" xml:lang="en-US">Paycheck Protection Program Promissory Note [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_2" xml:lang="en-US">Paycheck Protection Program Promissory Note (PPP Note)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaymentForUpfrontFees_0" xml:lang="en-US">It represents payment for upfront fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaymentForUpfrontFees_1" xml:lang="en-US">Payment For Upfront Fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaymentForUpfrontFees_2" xml:lang="en-US">Payment for upfront fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_0" xml:lang="en-US">Represents amount of payment in consideration for restrictive covenants in separation agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_1" xml:lang="en-US">Payment in consideration for restrictive covenants in Separation Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_2" xml:lang="en-US">Payment in consideration for restrictive covenants in Separation Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PayrollCostsExcludeCompensation_0" xml:lang="en-US">Payroll Costs Exclude Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PayrollCostsExcludeCompensation_1" xml:lang="en-US">Represents the amount of payroll costs exclude compensation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_PayrollCostsExcludeCompensation_2" xml:lang="en-US">Excess payroll costs exclude compensation of an individual employee</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfAccruedConsultingFees_0" xml:lang="en-US">Represents percentage of accrued consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfAccruedConsultingFees_1" xml:lang="en-US">Percentage of accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_PercentageOfAccruedConsultingFees_2" xml:lang="en-US">Percentage of accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_0" xml:lang="en-US">Represents percentage of interest on accrued the outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_1" xml:lang="en-US">Percentage Of Accrued Interest On Outstanding Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_2" xml:lang="en-US">Percentage of accrued interest on outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_0" xml:lang="en-US">Percentage of amount need to be issued against warrant purchase.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_1" xml:lang="en-US">Percentage Of Amount Need To Be Issued Against Warrant Purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_2" xml:lang="en-US">Warrant coverage on the debt facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfBonusForAccruedConsultingFees_0" xml:lang="en-US">Represents percentage of bonus for accrued consulting fees.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfBonusForAccruedConsultingFees_1" xml:lang="en-US">Percentage of bonus for accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfBonusForAccruedConsultingFees_2" xml:lang="en-US">Percentage of bonus for accrued consulting fees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_0" xml:lang="en-US">Percentage Of Forgiveness Amount For Non Payroll Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_1" xml:lang="en-US">Represents the percentage of forgiveness amount for non payroll costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_2" xml:lang="en-US">Percentage of forgiveness amount for nonpayroll costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfReductionInAnnualSalary_0" xml:lang="en-US">Percentage Of Reduction In Annual Salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfReductionInAnnualSalary_1" xml:lang="en-US">Percentage of reduction in annual salary.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfReductionInAnnualSalary_2" xml:lang="en-US">Percentage of reduction in annual salary</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_0" xml:lang="en-US">Percentage of share reserve of the number of issued and outstanding shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_1" xml:lang="en-US">Percentage Of Share Reserve Of Number Of Issued And Outstanding Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_2" xml:lang="en-US">Percentage of share reserve of the number of issued and outstanding shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_0" xml:lang="en-US">Percentage Of Total Shares Of Common Stock And Prefunded Warrants Sold In Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_1" xml:lang="en-US">Percentage of total shares of common stock and pre-funded warrants sold in the offering.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_2" xml:lang="en-US">Percentage of total shares of common stock and pre-funded warrants sold in offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_0" xml:lang="en-US">Period of discretionary annual bonus payable to contractor after each fiscal year end.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_1" xml:lang="en-US">Period Of Discretionary Annual Bonus Payable To Contractor After Each Fiscal Year End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_2" xml:lang="en-US">Period of discretionary annual bonus payable to contractor after each fiscal year end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PlacementAgentMember_0" xml:lang="en-US">Placement Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PlacementAgentMember_1" xml:lang="en-US">Information of placement agent.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PlacementAgentMember_2" xml:lang="en-US">Placement agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PlacementAgentWarrantsMember_0" xml:lang="en-US">Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PlacementAgentWarrantsMember_1" xml:lang="en-US">Placement agent warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PlacementAgentWarrantsMember_2" xml:lang="en-US">Placement agent warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_0" xml:lang="en-US">Represents Pre 2015 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_1" xml:lang="en-US">Pre 2015 Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_Pre2015CommonStockWarrantsMember_2" xml:lang="en-US">Pre 2015 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PreferredStockPutOptionLiability_0" xml:lang="en-US">Represents the value of preferred stock put option liability.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PreferredStockPutOptionLiability_1" xml:lang="en-US">Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PreferredStockPutOptionLiability_2" xml:lang="en-US">Series F put option liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PreFundedUnitsSoldPricePerUnit_0" xml:lang="en-US">Pre Funded Units Sold Price Per Unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PreFundedUnitsSoldPricePerUnit_1" xml:lang="en-US">Represents the price per unit of pre-funded units sold.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PreFundedUnitsSoldPricePerUnit_2" xml:lang="en-US">Pre-funded units sold price per unit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PrefundedWarrantsMember_0" xml:lang="en-US">Prefunded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PrefundedWarrantsMember_1" xml:lang="en-US">Prefunded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PrefundedWarrantsMember_2" xml:lang="en-US">Pre-funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelAxis_0" xml:lang="en-US">Pricing Model [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelDomain_0" xml:lang="en-US">Pricing Model [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_PricingModelMember_0" xml:lang="en-US">Represents option pricing model,</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_PricingModelMember_1" xml:lang="en-US">Pricing Model [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_PricingModelMember_2" xml:lang="en-US">Pricing Model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of proceeds allocated on a relative fair value basis to equity classified warrants issued with convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Proceeds Allocated To Equity Classified Warrants Issued With Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_0" xml:lang="en-US">Amount of convertible multi-draw credit agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_1" xml:lang="en-US">Proceeds From Convertible Multi Draw Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_2" xml:lang="en-US">Proceeds from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_3" xml:lang="en-US">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs for the June 30, 2020 and June 30, 2019 periods, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_0" xml:lang="en-US">Represents the amount related to proceeds from financing between the conversion liability and the warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_1" xml:lang="en-US">Proceeds From Financing Between Conversion Liability And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_2" xml:lang="en-US">Proceeds from financing between conversion liability and warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_0" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_1" xml:lang="en-US">Represents the proceeds from issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_2" xml:lang="en-US">Proceeds from the sale of common stock and warrants - net of $854,078 issuance costs for September 30, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_0" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_1" xml:lang="en-US">Represents the proceeds from issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_2" xml:lang="en-US">Proceeds from the sale of common stock and warrants net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProceedsFromPreFundedWarrantExercises_0" xml:lang="en-US">Proceeds From Pre Funded Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProceedsFromPreFundedWarrantExercises_1" xml:lang="en-US">The cash inflow from pre-funded warrant exercises.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProceedsFromPreFundedWarrantExercises_2" xml:lang="en-US">Proceeds from pre-funded warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_0" xml:lang="en-US">Represents the amount related to provision for conversion of preferred stock as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_1" xml:lang="en-US">Provision For Conversion Of Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_2" xml:lang="en-US">Fair value of the conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ProvisionForConversionOfPreferredStock_3" xml:lang="en-US">Provision for conversion of Series B preferred stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_0" xml:lang="en-US">Amount of reclassification of derivatives to equity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_1" xml:lang="en-US">Reclassification Of Derivatives To Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ReclassificationOfDerivativesToEquity_2" xml:lang="en-US">Reclassification of Derivatives to Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ReducedFixedConversionPriceOfCommonStock_0" xml:lang="en-US">Represents amount of reduced fixed conversion price of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ReducedFixedConversionPriceOfCommonStock_1" xml:lang="en-US">Reduced Fixed Conversion Price Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ReducedFixedConversionPriceOfCommonStock_2" xml:lang="en-US">Reduced fixed conversion price of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_0" xml:lang="en-US">Amount of reduction to APIC from the issuance of common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_1" xml:lang="en-US">Reduction To Additional Paid In Capital From Issuance Of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_2" xml:lang="en-US">Reduction to APIC from the issuance of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RemainingFundsFromPromissoryNote_0" xml:lang="en-US">Represents amount of remaining funds from promissory note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RemainingFundsFromPromissoryNote_1" xml:lang="en-US">Remaining Funds From Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_RemainingFundsFromPromissoryNote_2" xml:lang="en-US">Remaining funds from promissory note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RestrictedStockAgreementsMember_0" xml:lang="en-US">Information of Restricted Stock Agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RestrictedStockAgreementsMember_1" xml:lang="en-US">Restricted Stock Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_RestrictedStockAgreementsMember_2" xml:lang="en-US">Restricted Stock Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_0" xml:lang="en-US">Represents policy for Risks and Uncertainties.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_1" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_RisksAndUncertaintiesPolicyTextBlock_2" xml:lang="en-US">Risks and Uncertainties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_0" xml:lang="en-US">Represent Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_1" xml:lang="en-US">Schedule Of Adjustment For Difference Between Fair Value Of Warrant Liabilities And Total Proceeds Received Table [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_2" xml:lang="en-US">Schedule of the adjustment for the difference between the fair value of the warrant liabilities and the total proceeds received</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_0" xml:lang="en-US">Tabular disclosure of interest expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_1" xml:lang="en-US">Schedule Of Interest Expense [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_ScheduleOfInterestExpenseTableTextBlock_2" xml:lang="en-US">Schedule of interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_0" xml:lang="en-US">Represents Secured Promissory Note and Security Agreement for a convertible loan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_1" xml:lang="en-US">Secured Promissory Note And Security Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_2" xml:lang="en-US">Secured promissory note and security agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_0" xml:lang="en-US">Represents information regarding securities purchase agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_1" xml:lang="en-US">Securities Purchase Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SecuritiesPurchaseAgreementMember_2" xml:lang="en-US">Securities purchase agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_0" xml:lang="en-US">Securities Purchase Agreement With H C Wainwright And Co LLC [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_1" xml:lang="en-US">Securities Purchase Agreement with H C Wainwright And Co LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_2" xml:lang="en-US">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeniorManagementCompensationPlanDescription_0" xml:lang="en-US">Represents description of senior management compensation plan description.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeniorManagementCompensationPlanDescription_1" xml:lang="en-US">Senior Management Compensation Plan Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeniorManagementCompensationPlanDescription_2" xml:lang="en-US">Description of senior management's compensation plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeparationAgreementMember_0" xml:lang="en-US">Represents information of separation agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeparationAgreementMember_1" xml:lang="en-US">Separation Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeparationAgreementMember_2" xml:lang="en-US">Separation Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_0" xml:lang="en-US">Represents separation and release agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_1" xml:lang="en-US">Separation And Release Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_2" xml:lang="en-US">Separation Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeparationAndReleaseAgreementMember_3" xml:lang="en-US">Separation and release agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_0" xml:lang="en-US">Series B Preferred Stock Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_1" xml:lang="en-US">Series B Preferred Stock Conversion Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_2" xml:lang="en-US">Series B Preferred Stock - conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBPreferredStockConversionLiabilityMember_3" xml:lang="en-US">Series B conversion liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBWarrantMember_0" xml:lang="en-US">Represents information regarding Series B warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBWarrantMember_1" xml:lang="en-US">Series B Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_SeriesBWarrantMember_2" xml:lang="en-US">Series B Warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBWarrantMember_3" xml:lang="en-US">Series B warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesBWarrantsMember_0" xml:lang="en-US">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesBWarrantsMember_1" xml:lang="en-US">Series B Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesBWarrantsMember_2" xml:lang="en-US">Series B Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_0" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_1" xml:lang="en-US">Series F Preferred Stock Put Option Liability [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_2" xml:lang="en-US">Series F Preferred Stock Put Option Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ShareIssuanceCosts_0" xml:lang="en-US">Represents costs related to issuance of shares.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ShareIssuanceCosts_1" xml:lang="en-US">Share Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ShareIssuanceCosts_2" xml:lang="en-US">Share issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SignificantContractsAbstract_0" xml:lang="en-US">Significant Contracts [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SignificantContractsTextBlock_0" xml:lang="en-US">The entire disclosure for Significant Contracts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SignificantContractsTextBlock_1" xml:lang="en-US">Significant Contracts [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SignificantContractsTextBlock_2" xml:lang="en-US">Significant Contracts - University of Mississippi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_0" xml:lang="en-US">The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity which includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and the accumulated deficit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_1" xml:lang="en-US">Stockholders Deficit And Capitalization [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_2" xml:lang="en-US">Stockholders' Equity (Deficit) and Capitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_0" xml:lang="en-US">Stock Issued During Period Shares Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_1" xml:lang="en-US">Represents number of shares related to issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_2" xml:lang="en-US">Common stock and warrants issued (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_0" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Pre Funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_1" xml:lang="en-US">Represents number of shares related to exercise of pre-funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_2" xml:lang="en-US">Exercise of pre-funded warrants (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_0" xml:lang="en-US">Number of shares issued in lieu of cash for Stock based compensation expense contributed to the entity.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_1" xml:lang="en-US">Stock Issued During Period Shares Issued For Stock Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_2" xml:lang="en-US">Stock based compensation expense (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_0" xml:lang="en-US">Number of shares of stock issued during the period net of issuance costs value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Shares Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common stock net of issuance costs of $16,900 (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_0" xml:lang="en-US">Number of Series B warrant exercises for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_1" xml:lang="en-US">Stock Issued During Period Shares Series B Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_2" xml:lang="en-US">Series B warrant exercises (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_0" xml:lang="en-US">Stock Issued During Period Value Common Stock And Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_1" xml:lang="en-US">Represents amount related to issuance of common stock and warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_2" xml:lang="en-US">Common stock and warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_0" xml:lang="en-US">Stock Issued During Period Value Exercise Of Pre Funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_1" xml:lang="en-US">Represents amount related to exercise of pre funded warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_2" xml:lang="en-US">Exercise of pre-funded warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_0" xml:lang="en-US">Value of shares of common stock issued during the period net of issuance costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_1" xml:lang="en-US">Stock Issued During Period Value Net Of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_2" xml:lang="en-US">Issuance of common stock net of issuance costs of $16,900</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_0" xml:lang="en-US">Value of Series B warrant exercises for common stock issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_1" xml:lang="en-US">Stock Issued During Period Value Series B Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_2" xml:lang="en-US">Series B warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_StockOptions2014PlanMember_0" xml:lang="en-US">Stock Options 2014 Plan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_StockOptions2014PlanMember_1" xml:lang="en-US">This member stands for 2014 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_StockOptions2014PlanMember_2" xml:lang="en-US">2014 Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_0" xml:lang="en-US">Represents subsequent financing purchase price description to protect against anti-dilution.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_1" xml:lang="en-US">Subsequent Financing Purchase Price Description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SubsequentFinancingPurchasePriceDescription_2" xml:lang="en-US">Subsequent financing purchase price, description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_SupplementalRestrictedCash_0" xml:lang="en-US">Represents amount of supplemental restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_SupplementalRestrictedCash_1" xml:lang="en-US">Supplemental Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_SupplementalRestrictedCash_2" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfAgreement_0" xml:lang="en-US">Represents time to pay, after milestone is met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfAgreement_1" xml:lang="en-US">Term Of Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TermOfAgreement_2" xml:lang="en-US">Term of agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfWarrant_0" xml:lang="en-US">Represents term of warrant.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfWarrant_1" xml:lang="en-US">Term Of Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermOfWarrant_2" xml:lang="en-US">Term of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TermOfWarrant_3" xml:lang="en-US">Term (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermOfWarrants_0" xml:lang="en-US">Represents term of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermOfWarrants_1" xml:lang="en-US">Term Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermOfWarrants_2" xml:lang="en-US">Term of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TermsOfAgreementRenewed_0" xml:lang="en-US">Represents tem of agreement renewed.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TermsOfAgreementRenewed_1" xml:lang="en-US">Terms Of Agreement Renewed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TermsOfAgreementRenewed_2" xml:lang="en-US">Terms of agreement renewed</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_0" xml:lang="en-US">Threshold Exercise Price Of Warrants To Waive Rights To Anti Dilution Protection Upon Subsequent Issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_1" xml:lang="en-US">Threshold exercise price of warrants to waive rights to anti dilution protection upon subsequent issuances.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_2" xml:lang="en-US">Threshold exercise price of warrants to waive rights to anti dilution protection upon subsequent issuances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_0" xml:lang="en-US">Represents amount of total cash, cash equivalents and restricted cash shown in the consolidated.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_1" xml:lang="en-US">Total Cash Equivalents And Restricted Cash Shown In Consolidated</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_2" xml:lang="en-US">Total cash and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_0" xml:lang="en-US">Represents total expense incurred under the agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_1" xml:lang="en-US">Total Expense Incurred Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_2" xml:lang="en-US">Expense incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TotalExpenseIncurredUnderAgreement_3" xml:lang="en-US">Total expense incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TotalFeesIncurredUnderAgreement_0" xml:lang="en-US">Total Fees Incurred Under Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TotalFeesIncurredUnderAgreement_1" xml:lang="en-US">Represents the total fees incurred under agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TotalFeesIncurredUnderAgreement_2" xml:lang="en-US">Fees incurred under agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandAndTwentyCommonStockWarrantsMember_0" xml:lang="en-US">Two Thousand And Twenty Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandAndTwentyCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand And Twenty Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandAndTwentyCommonStockWarrantsMember_2" xml:lang="en-US">2020 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_0" xml:lang="en-US">Two Thousand And Twenty Common Stock Warrants To Placement Agent [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_1" xml:lang="en-US">Two Thousand And Twenty Common Stock Warrants To Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_2" xml:lang="en-US">2020 Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandAndTwentyPreFundedWarrantsMember_0" xml:lang="en-US">Two Thousand And Twenty Pre Funded Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandAndTwentyPreFundedWarrantsMember_1" xml:lang="en-US">Two Thousand And Twenty Pre Funded Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandAndTwentyPreFundedWarrantsMember_2" xml:lang="en-US">2020 Pre-Funded Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_0" xml:lang="en-US">Represents 2018 Emerald Financing Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_1" xml:lang="en-US">Two Thousand Eighteen Emerald Financing Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_2" xml:lang="en-US">2018 Emerald Financing Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_0" xml:lang="en-US">Information about 2018 emerald multi-draw credit agreement warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1" xml:lang="en-US">Emerald Multi-Draw Credit Agreement - compound derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_2" xml:lang="en-US">Two Thousand Eighteen Emerald Multi Draw Credit Agreement Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" xml:lang="en-US">Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4" xml:lang="en-US">2018 Emerald Multi-Draw Credit Agreement Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_0" xml:lang="en-US">Represents 2015 Common Stock Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand Fifteen Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_2" xml:lang="en-US">2015 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_0" xml:lang="en-US">Represents two thousand fifteen series B financing Common Stock Warrants to Series B Stockholders.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_1" xml:lang="en-US">Two Thousand Fifteen Series B Financing Common Stock Warrants To Series B Stockholders [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_2" xml:lang="en-US">Common Stock Warrants to Series B Stockholders</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents two thousand fifteen series B financing Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Fifteen Series B Financing Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_2" xml:lang="en-US">2015 Series B financing Placement Agent Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_3" xml:lang="en-US">Need to Delete from Editor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_0" xml:lang="en-US">Information about 2019 common stock warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_1" xml:lang="en-US">Two Thousand Nineteen Common Stock Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_2" xml:lang="en-US">2019 Common Stock Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_0" xml:lang="en-US">Represents two thousand seventeen Common Stock Warrants to Service Providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_1" xml:lang="en-US">Two Thousand Seventeen Common Stock Warrants To Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_2" xml:lang="en-US">2017 Common Stock Warrants to Service Provider</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents two thousand sixteen Series D Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Seventeen Series D Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_2" xml:lang="en-US">2017 Series D Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_0" xml:lang="en-US">Represents two thousand sixteen Common Stock Warrants to Service Providers.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_1" xml:lang="en-US">Two Thousand Sixteen Common Stock Warrants To Service Providers [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_2" xml:lang="en-US">2016 Common Stock Warrants to Service Providers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_0" xml:lang="en-US">Represents 2016 Series C Placement Agent Warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_1" xml:lang="en-US">Two Thousand Sixteen Series C Placement Agent Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_2" xml:lang="en-US">2016 Series C Common Stock Warrants to Placement Agent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_0" xml:lang="en-US">It represents UM 5050 Pro-Drug and UM 8930 Analog Agreements member.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_1" xml:lang="en-US">Um 5050 Pro Drug And Um 8930 Analog Agreements [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_2" xml:lang="en-US">Um 5050 Pro-Drug And Um 8930 Analog Agreements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_Um5070LicenseAgreementMember_0" xml:lang="en-US">UM 5070 license agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_Um5070LicenseAgreementMember_1" xml:lang="en-US">Um 5070 License Agreement [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_Um5070LicenseAgreementMember_2" xml:lang="en-US">UM 5070 license agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_0" xml:lang="en-US">Period of unamortized discount of debt.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_1" xml:lang="en-US">Unamortized Debt Discount Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_UnamortizedDebtDiscountPeriod_2" xml:lang="en-US">Unamortized debt discount period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiAgreementsAbstract_0" xml:lang="en-US">University Of Mississippi Agreements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiAgreementsLineItems_0" xml:lang="en-US">Line item represents information regarding University of Mississippi agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiAgreementsLineItems_1" xml:lang="en-US">University Of Mississippi Agreements [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiAgreementsTable_0" xml:lang="en-US">Tabular disclosure of information regarding University of Mississippi agreements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiAgreementsTable_1" xml:lang="en-US">University Of Mississippi Agreements [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UniversityOfMississippiMember_0" xml:lang="en-US">Represents information regarding university of Mississippi.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UniversityOfMississippiMember_1" xml:lang="en-US">University Of Mississippi [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_UniversityOfMississippiMember_2" xml:lang="en-US">University of Mississippi</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_UnrestrictedCashPositionDecreased_0" xml:lang="en-US">Represents amount of unrestricted cash position decreased.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_UnrestrictedCashPositionDecreased_1" xml:lang="en-US">Unrestricted cash position decreased</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_0" xml:lang="en-US">Represents amount of common stock called by warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_1" xml:lang="en-US">Value Of Common Stock Called By Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ValueOfCommonStockCalledByWarrants_2" xml:lang="en-US">Value of common stock called by warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_0" xml:lang="en-US">Value Of Warrants Issued Recorded As Equity Issuance Costs Within Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_1" xml:lang="en-US">Value Of Warrants Issued recorded as equity issuance costs within equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_2" xml:lang="en-US">Value of warrants issued recorded as equity issuance costs within equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xml:lang="en-US">Warrants And Derivative Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_0" xml:lang="en-US">The entire disclosure for Warrants and Derivative Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1" xml:lang="en-US">Warrants And Derivative Liabilities [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_2" xml:lang="en-US">Warrants and Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0" xml:lang="en-US">Represents warrants issued in connection with convertible multi draw credit agreement related party value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1" xml:lang="en-US">Warrants Issued In Connection With Convertible Multi Draw Credit Agreement Related Party Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2" xml:lang="en-US">Warrants issued in connection with convertible multi draw credit agreement related party value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_3" xml:lang="en-US">Warrants issued in connection with convertible multi-draw credit agreement, related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_0" xml:lang="en-US">Warrants Issued in Connection with Financings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_1" xml:lang="en-US">Warrants Issued In Connection With Financings [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_2" xml:lang="en-US">Warrants Issued in Connection with Financings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantsVestedAndOutstanding_0" xml:lang="en-US">Represents warrants vested and outstanding as of balance sheet date.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantsVestedAndOutstanding_1" xml:lang="en-US">Warrants Vested And Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_WarrantsVestedAndOutstanding_2" xml:lang="en-US">Amount Vested and Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_0" xml:lang="en-US">Represents warrant to purchase number of common stock price per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_1" xml:lang="en-US">Warrant To Purchase Number Of Common Stock Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_2" xml:lang="en-US">Warrant to purchase number of shares of Common Stock equal to dollar amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_embi_WorkingCapitalDeficit_0" xml:lang="en-US">Represent working capital deficit.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_embi_WorkingCapitalDeficit_1" xml:lang="en-US">Working capital deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_embi_WorkingCapitalDeficit_2" xml:lang="en-US">Working Capital Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_embi_WorkingCapitalDeficit_3" xml:lang="en-US">Working capital deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_ChiefFinancialOfficerMember_0" xml:lang="en-US">Chief Financial Officer [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_1" xml:lang="en-US">Elizabeth Berecz, CFO</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_ChiefFinancialOfficerMember_2" xml:lang="en-US">Douglas Cesario</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember_0" xml:lang="en-US">Maximum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember_1" xml:lang="en-US">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MaximumMember_2" xml:lang="en-US">Maximum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember_0" xml:lang="en-US">Minimum [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember_1" xml:lang="en-US">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_srt_MinimumMember_2" xml:lang="en-US">Minimum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis_0" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember_0" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis_0" xml:lang="en-US">Title of Individual [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0" xml:lang="en-US">Title of Individual [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_0" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_1" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent_0" xml:lang="en-US">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0" xml:lang="en-US">Accounts Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_1" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_0" xml:lang="en-US">Accounts Payable, Related Parties</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_1" xml:lang="en-US">Accrued and accounts payable - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_0" xml:lang="en-US">Accrued Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_1" xml:lang="en-US">Accrued Liabilities, Current, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_2" xml:lang="en-US">Accrued interest due to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_0" xml:lang="en-US">Accrued Salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_1" xml:lang="en-US">Amount of salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1" xml:lang="en-US">Additional paid-in-capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1" xml:lang="en-US">Additional Paid-In Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2" xml:lang="en-US">Stock based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3" xml:lang="en-US">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdvancesFairValueDisclosure_0" xml:lang="en-US">Advances, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AdvancesFairValueDisclosure_1" xml:lang="en-US">Fair value of advances under the Credit Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_0" xml:lang="en-US">Share-based Payment Arrangement, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_2" xml:lang="en-US">Recognized additional stock based compensation expense of restricted stock and option awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_3" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_4" xml:lang="en-US">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_0" xml:lang="en-US">Amortization of Debt Discount (Premium)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AmortizationOfDebtDiscountPremium_1" xml:lang="en-US">Amortization of debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1" xml:lang="en-US">Anti-dilutive excluded from the calculation of diluted loss per common share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets_0" xml:lang="en-US">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets_1" xml:lang="en-US">Total assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract_0" xml:lang="en-US">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsAbstract_1" xml:lang="en-US">ASSETS</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent_0" xml:lang="en-US">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent_1" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrent_2" xml:lang="en-US">Total current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract_1" xml:lang="en-US">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis_0" xml:lang="en-US">Award Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" xml:lang="en-US">Basis of Presentation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BridgeLoanMember_0" xml:lang="en-US">Bridge Loan [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BridgeLoanMember_1" xml:lang="en-US">Bridge Loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_BridgeLoanMember_2" xml:lang="en-US">Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" xml:lang="en-US">Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4" xml:lang="en-US">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0" xml:lang="en-US">Cash and restricted cash, end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1" xml:lang="en-US">Cash and restricted cash, beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3" xml:lang="en-US">Total cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1" xml:lang="en-US">Reconciliation of cash and restricted cash:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1" xml:lang="en-US">Net increase (decrease) in cash and restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1" xml:lang="en-US">Supplemental disclosures of non-cash financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain_0" xml:lang="en-US">Class of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_0" xml:lang="en-US">Class of Warrant or Right [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_0" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_1" xml:lang="en-US">Class of Warrant or Right [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" xml:lang="en-US">Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3" xml:lang="en-US">Warrant exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_0" xml:lang="en-US">Class of Warrant or Right [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0" xml:lang="en-US">Warrants to purchase an aggregate shares of common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1" xml:lang="en-US">Number of common stock called by warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2" xml:lang="en-US">Total number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4" xml:lang="en-US">Warrants to purchase shares of common stock issued and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5" xml:lang="en-US">Number of warrants issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1" xml:lang="en-US">Number of warrant issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_0" xml:lang="en-US">Class of Warrant or Right [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies_0" xml:lang="en-US">Commitments and Contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies_1" xml:lang="en-US">Commitments and contingencies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1" xml:lang="en-US">Number of shares reserved for future grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember_0" xml:lang="en-US">Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember_1" xml:lang="en-US">Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_1" xml:lang="en-US">Par value of common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_2" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_1" xml:lang="en-US">Common stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued_0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued_1" xml:lang="en-US">Common stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_3" xml:lang="en-US">Common stock outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_4" xml:lang="en-US">Common stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue_0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue_1" xml:lang="en-US">Common stock, $0.001 par value; 500,000,000 shares authorized; 250,074,415 and 182,895,247 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_1" xml:lang="en-US">Stock-Based Compensation for Employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_2" xml:lang="en-US">Stock-Based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_0" xml:lang="en-US">Conversion of Stock, Amount Converted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountConverted1_1" xml:lang="en-US">Conversion of outstanding preferred stock into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleCommonStockMember_0" xml:lang="en-US">Convertible Common Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleCommonStockMember_1" xml:lang="en-US">Common shares underlying convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_0" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_1" xml:lang="en-US">Carrying value of total convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_2" xml:lang="en-US">Convertible Debt, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_3" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtCurrent_4" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember_0" xml:lang="en-US">Convertible Debt [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember_1" xml:lang="en-US">Convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_0" xml:lang="en-US">Less, noncurrent portion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_1" xml:lang="en-US">Convertible Debt, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_2" xml:lang="en-US">Total principal value of non-convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_3" xml:lang="en-US">Convertible multi-draw credit agreement - related party, net of discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ConvertibleDebtNoncurrent_4" xml:lang="en-US">Convertible multi-draw credit agreement - related party, net of discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_0" xml:lang="en-US">Convertible Debt [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_1" xml:lang="en-US">Schedule of convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtTableTextBlock_2" xml:lang="en-US">Schedule of convertible and non-convertible advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1" xml:lang="en-US">Fair value of common stock issued in extinguishment of convertible debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_2" xml:lang="en-US">Number of shares issued in conversion</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureAbstract_0" xml:lang="en-US">Debt Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_0" xml:lang="en-US">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_1" xml:lang="en-US">Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentAxis_0" xml:lang="en-US">Debt Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_0" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1" xml:lang="en-US">Beneficial conversion feature</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0" xml:lang="en-US">Debt Instrument, Convertible, Carrying Amount of Equity Component</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1" xml:lang="en-US">Total principal value of convertible debt - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_2" xml:lang="en-US">Total principal value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2" xml:lang="en-US">Conversion price, per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3" xml:lang="en-US">Initial conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1" xml:lang="en-US">Reduction in conversion price per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_2" xml:lang="en-US">Conversion price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0" xml:lang="en-US">Debt Instrument, Convertible, Threshold Trading Days</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1" xml:lang="en-US">Number of trading days as of financing close date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_0" xml:lang="en-US">Draw downs in aggregate principal amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_1" xml:lang="en-US">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_2" xml:lang="en-US">Principal amount of promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1" xml:lang="en-US">Effective interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1" xml:lang="en-US">Interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2" xml:lang="en-US">Bridge loan interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentLineItems_0" xml:lang="en-US">Debt Instrument [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_0" xml:lang="en-US">Debt Instrument, Maturity Date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_1" xml:lang="en-US">Bridge loan maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtInstrumentMaturityDate_2" xml:lang="en-US">Maturity date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_0" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentTable_0" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0" xml:lang="en-US">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_1" xml:lang="en-US">Debt Instrument, Unamortized Discount, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2" xml:lang="en-US">Unamortized debt discount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtPolicyTextBlock_0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtPolicyTextBlock_1" xml:lang="en-US">Debt Issuance Costs and Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_0" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_1" xml:lang="en-US">Debt Related Commitment Fees and Debt Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2" xml:lang="en-US">Financing transaction costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_3" xml:lang="en-US">Issuance costs related to warrant liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_0" xml:lang="en-US">Unamortized debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_1" xml:lang="en-US">Debt Issuance Costs, Gross, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentGross_2" xml:lang="en-US">Unamortized debt issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Depreciation_0" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_Depreciation_1" xml:lang="en-US">Depreciation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_0" xml:lang="en-US">Derivative Contract [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_0" xml:lang="en-US">Derivative Instrument [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_0" xml:lang="en-US">Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_1" xml:lang="en-US">Fair Value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilities_2" xml:lang="en-US">Derivative Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilities_3" xml:lang="en-US">Derivative liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_0" xml:lang="en-US">Derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_1" xml:lang="en-US">Derivative Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_2" xml:lang="en-US">Current balance of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_3" xml:lang="en-US">Derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0" xml:lang="en-US">Less, noncurrent portion of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1" xml:lang="en-US">Derivative liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2" xml:lang="en-US">Derivative Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_3" xml:lang="en-US">Derivative liabilities, non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_4" xml:lang="en-US">Less, noncurrent portion of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_0" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_1" xml:lang="en-US">Convertible Instruments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" xml:lang="en-US">Stock-Based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract_0" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareAbstract_1" xml:lang="en-US">Loss per common share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic_0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_1" xml:lang="en-US">Basic (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic_2" xml:lang="en-US">Net loss per share - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_0" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_1" xml:lang="en-US">Basic net loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted_0" xml:lang="en-US">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_1" xml:lang="en-US">Diluted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted_2" xml:lang="en-US">Net loss per share - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_0" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_1" xml:lang="en-US">Diluted net loss per share:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_1" xml:lang="en-US">Loss Per Common Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1" xml:lang="en-US">Recognized weighted average period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2" xml:lang="en-US">Recognized period of non-vested stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2" xml:lang="en-US">Total amount of unrecognized compensation cost related to non-vested stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember_0" xml:lang="en-US">Employee Stock Option [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1" xml:lang="en-US">Stock Incentive Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember_2" xml:lang="en-US">Stock options</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract_0" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityAbstract_1" xml:lang="en-US">Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain_0" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EquityComponentDomain_1" xml:lang="en-US">Equity Component [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_0" xml:lang="en-US">Extinguishment of Debt, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_1" xml:lang="en-US">Number of of common shares shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_0" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_1" xml:lang="en-US">Change in fair value of warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_2" xml:lang="en-US">Change in fair market of the warrant Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_3" xml:lang="en-US">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_4" xml:lang="en-US">Fair Value Adjustment of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_5" xml:lang="en-US">Change in fair market value at the re-measurement date recorded as non-operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_6" xml:lang="en-US">Change in Fair value of Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1" xml:lang="en-US">Schedule of input and valuation technique used to value warrant liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1" xml:lang="en-US">Fair Value Measurements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_0" xml:lang="en-US">Loss on disposal of assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0" xml:lang="en-US">Loss on extinguishment of secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2" xml:lang="en-US">Loss on extinguishment of secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4" xml:lang="en-US">Loss on extinguishment of debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_0" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_1" xml:lang="en-US">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_2" xml:lang="en-US">General and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_3" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1" xml:lang="en-US">General and administrative</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1" xml:lang="en-US">Loss before income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract_0" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeStatementAbstract_1" xml:lang="en-US">Income Statement [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_0" xml:lang="en-US">Income Statement Location [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_0" xml:lang="en-US">Income Statement Location [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaid_0" xml:lang="en-US">Income Taxes Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaid_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_0" xml:lang="en-US">Income Taxes Paid, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_1" xml:lang="en-US">Income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_1" xml:lang="en-US">Provision for income taxes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1" xml:lang="en-US">Accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_0" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_0" xml:lang="en-US">Increase (Decrease) in Derivative Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1" xml:lang="en-US">Decrease in derivative liability through an adjustment to change in fair value of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_0" xml:lang="en-US">Increase (Decrease) in Notes Payable, Related Parties, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_1" xml:lang="en-US">Accounts payable to related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0" xml:lang="en-US">Increase (Decrease) In Operating Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_1" xml:lang="en-US">Changes in assets and liabilities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IntellectualPropertyMember_0" xml:lang="en-US">Intellectual Property [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IntellectualPropertyMember_1" xml:lang="en-US">Intellectual Property</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestExpense_0" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpense_1" xml:lang="en-US">Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpense_2" xml:lang="en-US">Net income (loss) and comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpense_3" xml:lang="en-US">Interest expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseDebt_0" xml:lang="en-US">Interest Expense, Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestExpenseDebt_1" xml:lang="en-US">PPP loan interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestExpenseRelatedParty_0" xml:lang="en-US">Interest Expense, Related Party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestExpenseRelatedParty_1" xml:lang="en-US">Related party interest expense - stated rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeOther_0" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOther_1" xml:lang="en-US">Interest Income, Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOther_2" xml:lang="en-US">Interest income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPaidNet_0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_InterestPaidNet_1" xml:lang="en-US">Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_0" xml:lang="en-US">Interest Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestPayableCurrentAndNoncurrent_1" xml:lang="en-US">Accrued interest on outstanding balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InvestorMember_0" xml:lang="en-US">Investor [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InvestorMember_1" xml:lang="en-US">Accredited investor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IPOMember_0" xml:lang="en-US">IPO [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_IPOMember_1" xml:lang="en-US">August 2020 Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities_0" xml:lang="en-US">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities_1" xml:lang="en-US">Total liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0" xml:lang="en-US">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_1" xml:lang="en-US">Total liabilities and stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_2" xml:lang="en-US">Total Liabilities and Shareholders' Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent_0" xml:lang="en-US">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent_1" xml:lang="en-US">Total current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_1" xml:lang="en-US">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_1" xml:lang="en-US">Noncurrent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract_2" xml:lang="en-US">Noncurrent liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0" xml:lang="en-US">Line of Credit Facility, Average Outstanding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1" xml:lang="en-US">Maximum amount that can be borrowed over the life of the credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_2" xml:lang="en-US">Credit facility advances</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0" xml:lang="en-US">Line of Credit Facility, Commitment Fee Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1" xml:lang="en-US">Unused portion of the credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1" xml:lang="en-US">Principal amounts of borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1" xml:lang="en-US">Fair value of advance under credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_0" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_1" xml:lang="en-US">Amount of capital raise</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_1" xml:lang="en-US">Interest rate percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2" xml:lang="en-US">Interest rates per annum</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_0" xml:lang="en-US">Line of Credit Facility, Maximum Amount Outstanding During Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_1" xml:lang="en-US">Principal amount of credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1" xml:lang="en-US">Maximum borrowing capacity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2" xml:lang="en-US">Maximum borrowing capacity of credit facility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_0" xml:lang="en-US">Line of Credit Facility, Maximum Month-end Outstanding Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_1" xml:lang="en-US">Credit facility advances per month</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongTermDebt_0" xml:lang="en-US">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LongTermDebt_1" xml:lang="en-US">PPP loan non-current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1" xml:lang="en-US">Benchmarked yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember_2" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_0" xml:lang="en-US">Measurement Input, Expected Term [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_1" xml:lang="en-US">Remaining term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember_2" xml:lang="en-US">Expected term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_0" xml:lang="en-US">Measurement Input, Offered Price [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputOfferedPriceMember_1" xml:lang="en-US">Weighted-average fair value of warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_0" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_1" xml:lang="en-US">Volatility factor</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember_2" xml:lang="en-US">Measurement Input, Price Volatility [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeAxis_0" xml:lang="en-US">Measurement Input Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_MeasurementInputTypeDomain_0" xml:lang="en-US">Measurement Input Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2" xml:lang="en-US">Net cash provided by financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1" xml:lang="en-US">Cash flows from financing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1" xml:lang="en-US">Net cash used in investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2" xml:lang="en-US">Net cash provided by (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1" xml:lang="en-US">Cash flows from investing activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Total</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1" xml:lang="en-US">Cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2" xml:lang="en-US">Net cash used in operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3" xml:lang="en-US">Cash flows provided from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xml:lang="en-US">Cash flows from operating activities:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="lab_us-gaap_NetIncomeLoss_0" xml:lang="en-US">Net income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_NetIncomeLoss_1" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_2" xml:lang="en-US">Net loss (as adjusted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss_3" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_4" xml:lang="en-US">Net Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss_5" xml:lang="en-US">Net loss and comprehensive loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLoss_6" xml:lang="en-US">Net (loss) income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1" xml:lang="en-US">Net loss (as adjusted)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1" xml:lang="en-US">Recent Accounting Pronouncements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0" xml:lang="en-US">Total other expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_1" xml:lang="en-US">Total other expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_2" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_3" xml:lang="en-US">Total other expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_4" xml:lang="en-US">Total other expense (income), net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1" xml:lang="en-US">Other expense (income)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_0" xml:lang="en-US">Nonoperating Income (Expense) [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_1" xml:lang="en-US">Non-operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseMember_2" xml:lang="en-US">Non-operating expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses_0" xml:lang="en-US">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses_1" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpenses_2" xml:lang="en-US">Total operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract_0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract_1" xml:lang="en-US">Operating expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_0" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_1" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_2" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss_3" xml:lang="en-US">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_4" xml:lang="en-US">Operating loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss_5" xml:lang="en-US">Loss from operations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0" xml:lang="en-US">Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" xml:lang="en-US">Nature of Operations and Business Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsCurrent_0" xml:lang="en-US">Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_1" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OtherAssetsCurrent_2" xml:lang="en-US">Other current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherSundryLiabilitiesCurrent_0" xml:lang="en-US">Other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1" xml:lang="en-US">Common stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_2" xml:lang="en-US">Stock issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0" xml:lang="en-US">Purchases of property and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2" xml:lang="en-US">Purchases of equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis_0" xml:lang="en-US">Plan Name [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain_0" xml:lang="en-US">Plan Name [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2" xml:lang="en-US">Preferred stock (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_1" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_2" xml:lang="en-US">Preferred stock, shares authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued_1" xml:lang="en-US">Preferred stock, shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_0" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_1" xml:lang="en-US">Preferred stock, shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue_0" xml:lang="en-US">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockValue_1" xml:lang="en-US">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_0" xml:lang="en-US">Prepaid Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1" xml:lang="en-US">Prepaid expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_0" xml:lang="en-US">Proceeds from Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt_1" xml:lang="en-US">Proceeds from secured convertible promissory note - related party</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1" xml:lang="en-US">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs for the September 30, 2020 and September 30, 2019 periods, respectively</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0" xml:lang="en-US">Less: Proceeds from Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1" xml:lang="en-US">Common stock gross proceeds</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2" xml:lang="en-US">Proceeds from Common stock issuance, net of $16,901 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3" xml:lang="en-US">Less: Proceeds from Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5" xml:lang="en-US">Proceeds from stock issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6" xml:lang="en-US">Proceeds from Common stock issuance, net of $16,901 issuance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3" xml:lang="en-US">Excess over proceeds adjustment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_0" xml:lang="en-US">Proceeds from Notes Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromNotesPayable_1" xml:lang="en-US">Proceeds from PPP loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_0" xml:lang="en-US">Proceeds from Other Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromOtherDebt_1" xml:lang="en-US">Proceeds from Emerald Financing</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_0" xml:lang="en-US">Proceeds from Related Party Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromRelatedPartyDebt_1" xml:lang="en-US">Proceeds from related party debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_1" xml:lang="en-US">Proceeds from warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises_2" xml:lang="en-US">Proceeds from Series B warrant exercises</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_1" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_2" xml:lang="en-US">Net equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3" xml:lang="en-US">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyDomain_0" xml:lang="en-US">Related Party [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems_0" xml:lang="en-US">Related Party Transaction [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract_0" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0" xml:lang="en-US">Related Party [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" xml:lang="en-US">Related Party Matters</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_0" xml:lang="en-US">Funding of remaining bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_1" xml:lang="en-US">Issuance costs from convertible multi-draw credit agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_2" xml:lang="en-US">Repayments of Convertible Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_3" xml:lang="en-US">Payments received from convertible bridge loan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt_4" xml:lang="en-US">Funds received under the Secured Promissory Note</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_0" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_1" xml:lang="en-US">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_2" xml:lang="en-US">Research and development expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_3" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1" xml:lang="en-US">Research and development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1" xml:lang="en-US">Research and Development Expenses and Licensed Technology</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1" xml:lang="en-US">Restricted cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember_0" xml:lang="en-US">Restricted Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RestrictedStockMember_1" xml:lang="en-US">Unvested restricted stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockMember_2" xml:lang="en-US">Restricted stock awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2" xml:lang="en-US">Accumulated deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3" xml:lang="en-US">Retained earnings during the development stage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember_0" xml:lang="en-US">Retained Earnings [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember_1" xml:lang="en-US">Accumulated Deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction_0" xml:lang="en-US">Sale of Stock, Description of Transaction</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SaleOfStockDescriptionOfTransaction_1" xml:lang="en-US">Common stock and pre-funded stock units sold description</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0" xml:lang="en-US">Sale of Stock [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1" xml:lang="en-US">Schedule of outstanding shares of common stock equivalents were excluded from the computation of diluted earnings per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1" xml:lang="en-US">Schedule of the activity of derivative liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" xml:lang="en-US">Schedule of basic and diluted net loss per share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1" xml:lang="en-US">Schedule of RSA activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_1" xml:lang="en-US">Schedule of stock-Based compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" xml:lang="en-US">Schedule of summary of stock option activity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1" xml:lang="en-US">Schedule of fair value assumptions of stock option granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_0" xml:lang="en-US">Schedule of Short-term Debt [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1" xml:lang="en-US">Schedule of warrants vested and outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_0" xml:lang="en-US">Series B Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_1" xml:lang="en-US">Series B Preferred Stock Conversion Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesBPreferredStockMember_2" xml:lang="en-US">Redeemable Convertible Series B Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_0" xml:lang="en-US">Series C Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_1" xml:lang="en-US">Convertible Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember_2" xml:lang="en-US">Series C Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_0" xml:lang="en-US">Series D Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_1" xml:lang="en-US">Convertible Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesDPreferredStockMember_2" xml:lang="en-US">Series D Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_0" xml:lang="en-US">Series F Preferred Stock [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_1" xml:lang="en-US">Convertible Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SeriesFPreferredStockMember_2" xml:lang="en-US">Series F Preferred Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation_0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_1" xml:lang="en-US">Stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation_2" xml:lang="en-US">Total stock-based compensation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1" xml:lang="en-US">Vesting period of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1" xml:lang="en-US">Vesting percentage</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2" xml:lang="en-US">Number of restricted common stock granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xml:lang="en-US">Unvested, September 30, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1" xml:lang="en-US">Unvested, December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1" xml:lang="en-US">Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Unvested, September 30, 2020</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Unvested, December 31, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2" xml:lang="en-US">Number of unrestricted stock awards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3" xml:lang="en-US">Number of restricted common stock vested</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Released</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1" xml:lang="en-US">Dividend Yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1" xml:lang="en-US">Expected term (years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2" xml:lang="en-US">Expected term (in years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2" xml:lang="en-US">Volatility</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2" xml:lang="en-US">Risk-free interest rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1" xml:lang="en-US">Number of additional shares reserved for future grants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, additional disclosures</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1" xml:lang="en-US">Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2" xml:lang="en-US">Options to purchase shares of common stock, exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Exercisable, September 30, 2019</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2" xml:lang="en-US">Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years), Exercisable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2" xml:lang="en-US">Options cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1" xml:lang="en-US">Aggregate number of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted-average fair value of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1" xml:lang="en-US">Number of forfeiture of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1" xml:lang="en-US">Weighted average exercise price of forfeiture of shares (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xml:lang="en-US">Balance at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" xml:lang="en-US">Options outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1" xml:lang="en-US">Shares Available for Grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2" xml:lang="en-US">Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Balance at the ending</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1" xml:lang="en-US">Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2" xml:lang="en-US">Remaining contractual life</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1" xml:lang="en-US">Weighted average exercise price of vested and outstanding (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1" xml:lang="en-US">Vested and Expected to Vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xml:lang="en-US">Expected to vest, September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1" xml:lang="en-US">Expected to vest, September 30, 2018</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xml:lang="en-US">Vested and expected to vest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3" xml:lang="en-US">Weighted-average fair value of stock options granted (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1" xml:lang="en-US">Number of shares granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0" xml:lang="en-US">Award Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Options cancelled</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1" xml:lang="en-US">Granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2" xml:lang="en-US">Options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3" xml:lang="en-US">Exercise price of stock options granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1" xml:lang="en-US">Vesting on grant date</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1" xml:lang="en-US">Over a one-year period commencing on the date of grant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2" xml:lang="en-US">November 21, 2014</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0" xml:lang="en-US">Share Based Compensation Award Tranche Two [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1" xml:lang="en-US">Each of the next thirty-six months thereafter</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2" xml:lang="en-US">Vesting semi-annually</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharePrice_0" xml:lang="en-US">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharePrice_1" xml:lang="en-US">Share price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesIssued_0" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesIssued_1" xml:lang="en-US">Balance (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssued_2" xml:lang="en-US">Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssued_3" xml:lang="en-US">Number of additional shares issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_0" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_1" xml:lang="en-US">Shares Issued, Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_2" xml:lang="en-US">Underlying common stock price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_3" xml:lang="en-US">Shares issued, price per share (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermBorrowings_0" xml:lang="en-US">Short-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShortTermBorrowings_1" xml:lang="en-US">PPP loan current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtLineItems_0" xml:lang="en-US">Short-term Debt [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_0" xml:lang="en-US">Short-term Debt, Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_0" xml:lang="en-US">Short-term Debt, Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1" xml:lang="en-US">Summary of Significant Accounting Policies</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis_0" xml:lang="en-US">Class of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_0" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_1" xml:lang="en-US">Equity Components [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems_0" xml:lang="en-US">Statement [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_1" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_0" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_1" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_0" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable_0" xml:lang="en-US">Statement [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity_0" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity_1" xml:lang="en-US">Balance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity_2" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquity_3" xml:lang="en-US">Stockholders' deficit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity_4" xml:lang="en-US">Total stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract_1" xml:lang="en-US">Stockholders' equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_0" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract_1" xml:lang="en-US">Stockholders' Equity Note [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" xml:lang="en-US">Stockholders' Equity (Deficit) and Capitalization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Units</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_1" xml:lang="en-US">Number of notes converted into common stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0" xml:lang="en-US">Common stock issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2" xml:lang="en-US">Issuance of common stock to investors in prior entity (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3" xml:lang="en-US">Number of common shares issued to individual investors</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_0" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, Forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1" xml:lang="en-US">Number of stock options forfeited</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems_0" xml:lang="en-US">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember_0" xml:lang="en-US">Subsequent Event [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventMember_1" xml:lang="en-US">Subsequent Event</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract_0" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_1" xml:lang="en-US">Subsequent Events</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable_0" xml:lang="en-US">Subsequent Event [Table]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_0" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_0" xml:lang="en-US">Sale of Stock [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_0" xml:lang="en-US">Supplemental Cash Flow Elements [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SupplementalCashFlowElementsAbstract_1" xml:lang="en-US">Supplemental disclosures of cash-flow information:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfArrangementAxis_0" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates_0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates_1" xml:lang="en-US">Use of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_UseOfEstimates_2" xml:lang="en-US">Use of Estimates</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis_0" xml:lang="en-US">Vesting [Axis]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain_0" xml:lang="en-US">Vesting [Domain]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_1" xml:lang="en-US">Decrease in exercise price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantExercisePriceDecrease_2" xml:lang="en-US">Reduced exercise price of warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantMember_0" xml:lang="en-US">Warrant [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantMember_1" xml:lang="en-US">Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantMember_2" xml:lang="en-US">Warrant</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xml:lang="en-US">Warrants and Rights Note Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1" xml:lang="en-US">Warrants and rights outstanding measurement input</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2" xml:lang="en-US">Dividend yield</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_0" xml:lang="en-US">Warrants and Rights Outstanding, Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1" xml:lang="en-US">Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2" xml:lang="en-US">Warrants and rights outstanding term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1" xml:lang="en-US">Diluted (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2" xml:lang="en-US">Weighted average common shares outstanding - diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1" xml:lang="en-US">Weighted average common shares outstanding - basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" xml:lang="en-US">Basic (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1" xml:lang="en-US">Weighted average shares of common stock outstanding used to compute earnings per share:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1" xlink:to="lab_dei_AmendmentFlag_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_1" xlink:to="lab_dei_AmendmentFlag_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2" xlink:to="lab_dei_CurrentFiscalYearEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_2" xlink:to="lab_dei_CurrentFiscalYearEndDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_3" xlink:to="lab_dei_DocumentFiscalPeriodFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_3" xlink:to="lab_dei_DocumentFiscalPeriodFocus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_4" xlink:to="lab_dei_DocumentFiscalYearFocus_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_4" xlink:to="lab_dei_DocumentFiscalYearFocus_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_5" xlink:to="lab_dei_DocumentPeriodEndDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_5" xlink:to="lab_dei_DocumentPeriodEndDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_6" xlink:to="lab_dei_DocumentType_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_6" xlink:to="lab_dei_DocumentType_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7" xlink:to="lab_dei_EntityCentralIndexKey_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7" xlink:to="lab_dei_EntityCentralIndexKey_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_8" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_9" xlink:to="lab_dei_EntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_10" xlink:to="lab_dei_EntityEmergingGrowthCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod_11" xlink:to="lab_dei_EntityExTransitionPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_12" xlink:to="lab_dei_EntityFilerCategory_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_12" xlink:to="lab_dei_EntityFilerCategory_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_13" xlink:to="lab_dei_EntityInteractiveDataCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_14" xlink:to="lab_dei_EntityRegistrantName_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_14" xlink:to="lab_dei_EntityRegistrantName_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_15" xlink:to="lab_dei_EntityShellCompany_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_16" xlink:to="lab_dei_EntitySmallBusiness_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="lab_dei_LegalEntityAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="lab_dei_LegalEntityAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_18" xlink:to="lab_dei_TradingSymbol_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_18" xlink:to="lab_dei_TradingSymbol_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_19" xlink:to="lab_embi_AccruedExpenseUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_19" xlink:to="lab_embi_AccruedExpenseUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AccruedExpenseUnderAgreement_19" xlink:to="lab_embi_AccruedExpenseUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_20" xlink:to="lab_embi_AdditionalConversionLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_20" xlink:to="lab_embi_AdditionalConversionLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AdditionalConversionLiability_20" xlink:to="lab_embi_AdditionalConversionLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_21" xlink:to="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_21" xlink:to="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_21" xlink:to="lab_embi_AggregateExercisePriceOfOutstandingCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_22" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_22" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_22" xlink:to="lab_embi_AggregateMilestonePaymentsIfMilestonesAchieved_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregatePrincipalAmount_23" xlink:to="lab_embi_AggregatePrincipalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AggregatePrincipalAmount_23" xlink:to="lab_embi_AggregatePrincipalAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_24" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_24" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_24" xlink:to="lab_embi_AllocationOfDebtOnBasisOfRelativeFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_25" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_25" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_25" xlink:to="lab_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_26" xlink:to="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_26" xlink:to="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_26" xlink:to="lab_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_27" xlink:to="lab_embi_AmortizationOfDebtDiscount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_27" xlink:to="lab_embi_AmortizationOfDebtDiscount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfDebtDiscount_27" xlink:to="lab_embi_AmortizationOfDebtDiscount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_28" xlink:to="lab_embi_AmortizationOfTransactionCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_28" xlink:to="lab_embi_AmortizationOfTransactionCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AmortizationOfTransactionCosts_28" xlink:to="lab_embi_AmortizationOfTransactionCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_29" xlink:to="lab_embi_AnnualFeeForAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_29" xlink:to="lab_embi_AnnualFeeForAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeeForAgreement_29" xlink:to="lab_embi_AnnualFeeForAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_30" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_30" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualFeesForLicenseAgreement_30" xlink:to="lab_embi_AnnualFeesForLicenseAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualMaintenanceFeePayable_31" xlink:to="lab_embi_AnnualMaintenanceFeePayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AnnualMaintenanceFeePayable_31" xlink:to="lab_embi_AnnualMaintenanceFeePayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_32" xlink:to="lab_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_32" xlink:to="lab_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_32" xlink:to="lab_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_33" xlink:to="lab_embi_AvtarDhillonMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_33" xlink:to="lab_embi_AvtarDhillonMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_AvtarDhillonMember_33" xlink:to="lab_embi_AvtarDhillonMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_34" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_34" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_34" xlink:to="lab_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_35" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_35" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_35" xlink:to="lab_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CapitalRaise_36" xlink:to="lab_embi_CapitalRaise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CapitalRaise_36" xlink:to="lab_embi_CapitalRaise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashAndCashEquivalents_37" xlink:to="lab_embi_CashAndCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashAndCashEquivalents_37" xlink:to="lab_embi_CashAndCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashAndCashEquivalents_37" xlink:to="lab_embi_CashAndCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_38" xlink:to="lab_embi_CashPaidDuringPeriodForAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_38" xlink:to="lab_embi_CashPaidDuringPeriodForAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_38" xlink:to="lab_embi_CashPaidDuringPeriodForAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_39" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_39" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_39" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfDerivativeLiabilities_39" xlink:to="lab_embi_ChangeInFairValueOfDerivativeLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_40" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_40" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChangeInFairValueOfWarrantLiability_40" xlink:to="lab_embi_ChangeInFairValueOfWarrantLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChiefMedicalOfficerMember_41" xlink:to="lab_embi_ChiefMedicalOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChiefMedicalOfficerMember_41" xlink:to="lab_embi_ChiefMedicalOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ChiefMedicalOfficerMember_41" xlink:to="lab_embi_ChiefMedicalOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_42" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_42" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ClassOfWarrantOrRightWarrantsExercise_42" xlink:to="lab_embi_ClassOfWarrantOrRightWarrantsExercise_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockIssuanceCosts_43" xlink:to="lab_embi_CommonStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockIssuanceCosts_43" xlink:to="lab_embi_CommonStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockIssuanceCosts_43" xlink:to="lab_embi_CommonStockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsMember_44" xlink:to="lab_embi_CommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsMember_44" xlink:to="lab_embi_CommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsMember_44" xlink:to="lab_embi_CommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_45" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_45" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_45" xlink:to="lab_embi_CommonStockWarrantsToSeriesBStockholdersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonUnitsSoldPricePerUnit_46" xlink:to="lab_embi_CommonUnitsSoldPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonUnitsSoldPricePerUnit_46" xlink:to="lab_embi_CommonUnitsSoldPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CommonUnitsSoldPricePerUnit_46" xlink:to="lab_embi_CommonUnitsSoldPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_47" xlink:to="lab_embi_ConsultingAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_47" xlink:to="lab_embi_ConsultingAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConsultingAgreementMember_47" xlink:to="lab_embi_ConsultingAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_48" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_48" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionLiabilityIntoCommonStockPerShare_48" xlink:to="lab_embi_ConversionLiabilityIntoCommonStockPerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_49" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_49" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_49" xlink:to="lab_embi_ConversionOfOutstandingPreferredStockSubjectToRedemptionIntoCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_50" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_50" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_50" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_50" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_51" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_51" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_51" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_51" xlink:to="lab_embi_ConversionOfPreferredStockSeriesAndConversionLiabilityIntoCommonStockValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_52" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_52" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_52" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterest_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_53" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_53" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_53" xlink:to="lab_embi_ConversionOfSecuredConvertiblePromissoryNoteRelatedPartyAndAccruedInterestShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_54" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_54" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_54" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStock_54" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_55" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_55" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_55" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_55" xlink:to="lab_embi_ConversionOfSeriesDPreferredStockToCommonStockShares_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_56" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_56" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_56" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_57" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_57" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_57" xlink:to="lab_embi_ConversionOfSeriesFPreferredStockToCommonStockValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_58" xlink:to="lab_embi_ConversionPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_58" xlink:to="lab_embi_ConversionPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConversionPricePerShare_58" xlink:to="lab_embi_ConversionPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_59" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_59" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleDebtRelatedPartyTextBlock_59" xlink:to="lab_embi_ConvertibleDebtRelatedPartyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_60" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_60" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_60" xlink:to="lab_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_61" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_61" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_61" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_61" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_61" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ConvertibleMultiDrawCreditFacility_61" xlink:to="lab_embi_ConvertibleMultiDrawCreditFacility_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_62" xlink:to="lab_embi_CouponInterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_62" xlink:to="lab_embi_CouponInterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CouponInterestExpense_62" xlink:to="lab_embi_CouponInterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFifthAdvances_63" xlink:to="lab_embi_CreditFacilityEffectedFifthAdvances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFifthAdvances_63" xlink:to="lab_embi_CreditFacilityEffectedFifthAdvances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFifthAdvances_63" xlink:to="lab_embi_CreditFacilityEffectedFifthAdvances_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFourthAdvances_64" xlink:to="lab_embi_CreditFacilityEffectedFourthAdvances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFourthAdvances_64" xlink:to="lab_embi_CreditFacilityEffectedFourthAdvances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CreditFacilityEffectedFourthAdvances_64" xlink:to="lab_embi_CreditFacilityEffectedFourthAdvances_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_65" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_65" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_65" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_65" xlink:to="lab_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DebtForgivenessCARESActDescription_66" xlink:to="lab_embi_DebtForgivenessCARESActDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DebtForgivenessCARESActDescription_66" xlink:to="lab_embi_DebtForgivenessCARESActDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DebtForgivenessCARESActDescription_66" xlink:to="lab_embi_DebtForgivenessCARESActDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_67" xlink:to="lab_embi_December2015Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_67" xlink:to="lab_embi_December2015Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_December2015Member_67" xlink:to="lab_embi_December2015Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_68" xlink:to="lab_embi_DerivativeLiabilitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_68" xlink:to="lab_embi_DerivativeLiabilitiesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesTable_69" xlink:to="lab_embi_DerivativeLiabilitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DerivativeLiabilitiesTable_69" xlink:to="lab_embi_DerivativeLiabilitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_70" xlink:to="lab_embi_DocumentAndEntityInformationAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_70" xlink:to="lab_embi_DocumentAndEntityInformationAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_71" xlink:to="lab_embi_DouglasCesarioMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_71" xlink:to="lab_embi_DouglasCesarioMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DouglasCesarioMember_71" xlink:to="lab_embi_DouglasCesarioMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_72" xlink:to="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_72" xlink:to="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_72" xlink:to="lab_embi_DrawDownsLoansInAggregatePrincipalAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_73" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_73" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_73" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_73" xlink:to="lab_embi_EmeraldConvertiblePromissoryNoteConversionLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_74" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_74" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingIssuanceCosts_74" xlink:to="lab_embi_EmeraldFinancingIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_75" xlink:to="lab_embi_EmeraldFinancingMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_75" xlink:to="lab_embi_EmeraldFinancingMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_75" xlink:to="lab_embi_EmeraldFinancingMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingMember_75" xlink:to="lab_embi_EmeraldFinancingMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantLiabilityMember_76" xlink:to="lab_embi_EmeraldFinancingWarrantLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantLiabilityMember_76" xlink:to="lab_embi_EmeraldFinancingWarrantLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantLiabilityMember_76" xlink:to="lab_embi_EmeraldFinancingWarrantLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsLiabilityMember_77" xlink:to="lab_embi_EmeraldFinancingWarrantsLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsLiabilityMember_77" xlink:to="lab_embi_EmeraldFinancingWarrantsLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsLiabilityMember_77" xlink:to="lab_embi_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsMember_78" xlink:to="lab_embi_EmeraldFinancingWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsMember_78" xlink:to="lab_embi_EmeraldFinancingWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldFinancingWarrantsMember_78" xlink:to="lab_embi_EmeraldFinancingWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_79" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_79" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_79" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldHealthSciencesIncMember_79" xlink:to="lab_embi_EmeraldHealthSciencesIncMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_80" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_80" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_80" xlink:to="lab_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_81" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_81" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_81" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmeraldWarrantLiabilityMember_81" xlink:to="lab_embi_EmeraldWarrantLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmployeeMember_82" xlink:to="lab_embi_EmployeeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmployeeMember_82" xlink:to="lab_embi_EmployeeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EmployeeMember_82" xlink:to="lab_embi_EmployeeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityLineItems_83" xlink:to="lab_embi_EquityLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityLineItems_83" xlink:to="lab_embi_EquityLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityTable_84" xlink:to="lab_embi_EquityTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_EquityTable_84" xlink:to="lab_embi_EquityTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_85" xlink:to="lab_embi_ExerciseOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_85" xlink:to="lab_embi_ExerciseOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ExerciseOfWarrants_85" xlink:to="lab_embi_ExerciseOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_86" xlink:to="lab_embi_FairMarketValueOfStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_86" xlink:to="lab_embi_FairMarketValueOfStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairMarketValueOfStockOptions_86" xlink:to="lab_embi_FairMarketValueOfStockOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_87" xlink:to="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_87" xlink:to="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_87" xlink:to="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_87" xlink:to="lab_embi_FairValueAdjustmentOfDerivativeLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_88" xlink:to="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_88" xlink:to="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_88" xlink:to="lab_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_89" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_89" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_89" xlink:to="lab_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_90" xlink:to="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_90" xlink:to="lab_embi_FairValueOfDerivativeLiabilitiesRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_91" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_91" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_91" xlink:to="lab_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_92" xlink:to="lab_embi_FairValueOfSharesUnderlyingConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_92" xlink:to="lab_embi_FairValueOfSharesUnderlyingConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_92" xlink:to="lab_embi_FairValueOfSharesUnderlyingConvertibleDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_92" xlink:to="lab_embi_FairValueOfSharesUnderlyingConvertibleDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_93" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_93" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_93" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_93" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_93" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_93" xlink:to="lab_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_94" xlink:to="lab_embi_FairValueOfWarrantsIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_94" xlink:to="lab_embi_FairValueOfWarrantsIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_94" xlink:to="lab_embi_FairValueOfWarrantsIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_94" xlink:to="lab_embi_FairValueOfWarrantsIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssued_94" xlink:to="lab_embi_FairValueOfWarrantsIssued_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_95" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_95" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_95" xlink:to="lab_embi_FairValueOfWarrantsIssuedInConnectionWithFinancings_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_96" xlink:to="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_96" xlink:to="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_96" xlink:to="lab_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_97" xlink:to="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_97" xlink:to="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_97" xlink:to="lab_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfUnitsSold_98" xlink:to="lab_embi_GrossProceedsOfUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfUnitsSold_98" xlink:to="lab_embi_GrossProceedsOfUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfUnitsSold_98" xlink:to="lab_embi_GrossProceedsOfUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfWarrants_99" xlink:to="lab_embi_GrossProceedsOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfWarrants_99" xlink:to="lab_embi_GrossProceedsOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_GrossProceedsOfWarrants_99" xlink:to="lab_embi_GrossProceedsOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_100" xlink:to="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_100" xlink:to="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_100" xlink:to="lab_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_101" xlink:to="lab_embi_IndependentContractorAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_101" xlink:to="lab_embi_IndependentContractorAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_IndependentContractorAgreementMember_101" xlink:to="lab_embi_IndependentContractorAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_102" xlink:to="lab_embi_InitialTermOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_102" xlink:to="lab_embi_InitialTermOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InitialTermOfAgreement_102" xlink:to="lab_embi_InitialTermOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_103" xlink:to="lab_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_103" xlink:to="lab_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_103" xlink:to="lab_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_104" xlink:to="lab_embi_K2CIncMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_104" xlink:to="lab_embi_K2CIncMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_K2CIncMember_104" xlink:to="lab_embi_K2CIncMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LegalReimbursementFees_105" xlink:to="lab_embi_LegalReimbursementFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LegalReimbursementFees_105" xlink:to="lab_embi_LegalReimbursementFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LegalReimbursementFees_105" xlink:to="lab_embi_LegalReimbursementFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_106" xlink:to="lab_embi_LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_106" xlink:to="lab_embi_LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_106" xlink:to="lab_embi_LicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LicenseAgreementMember_106" xlink:to="lab_embi_LicenseAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_107" xlink:to="lab_embi_LumpSumPaymentInAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_107" xlink:to="lab_embi_LumpSumPaymentInAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_LumpSumPaymentInAgreement_107" xlink:to="lab_embi_LumpSumPaymentInAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ManagementDeferralAgreementMember_108" xlink:to="lab_embi_ManagementDeferralAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ManagementDeferralAgreementMember_108" xlink:to="lab_embi_ManagementDeferralAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ManagementDeferralAgreementMember_108" xlink:to="lab_embi_ManagementDeferralAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_109" xlink:to="lab_embi_Milestone1Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_109" xlink:to="lab_embi_Milestone1Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone1Member_109" xlink:to="lab_embi_Milestone1Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_110" xlink:to="lab_embi_Milestone2Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_110" xlink:to="lab_embi_Milestone2Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone2Member_110" xlink:to="lab_embi_Milestone2Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_111" xlink:to="lab_embi_Milestone3Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_111" xlink:to="lab_embi_Milestone3Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Milestone3Member_111" xlink:to="lab_embi_Milestone3Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableAxis_112" xlink:to="lab_embi_MilestonePaymentsPayableAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableAxis_112" xlink:to="lab_embi_MilestonePaymentsPayableAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableDomain_113" xlink:to="lab_embi_MilestonePaymentsPayableDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MilestonePaymentsPayableDomain_113" xlink:to="lab_embi_MilestonePaymentsPayableDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_114" xlink:to="lab_embi_MonteCarloSimulationsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_114" xlink:to="lab_embi_MonteCarloSimulationsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonteCarloSimulationsMember_114" xlink:to="lab_embi_MonteCarloSimulationsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_115" xlink:to="lab_embi_MonthAndYearOfAgreementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_115" xlink:to="lab_embi_MonthAndYearOfAgreementAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_116" xlink:to="lab_embi_MonthAndYearOfAgreementDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_116" xlink:to="lab_embi_MonthAndYearOfAgreementDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_117" xlink:to="lab_embi_MonthlyFee_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_117" xlink:to="lab_embi_MonthlyFee_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFee_117" xlink:to="lab_embi_MonthlyFee_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_118" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_118" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_118" xlink:to="lab_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_119" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_119" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_119" xlink:to="lab_embi_MonthlyFeePaidEachMonthInExchangeOfServices_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_120" xlink:to="lab_embi_MultiDrawCreditAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_120" xlink:to="lab_embi_MultiDrawCreditAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultiDrawCreditAgreementMember_120" xlink:to="lab_embi_MultiDrawCreditAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_121" xlink:to="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_121" xlink:to="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_121" xlink:to="lab_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_122" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_122" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_123" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_123" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_124" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_124" xlink:to="lab_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_125" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_125" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_125" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_126" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_126" xlink:to="lab_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_127" xlink:to="lab_embi_NetLossAvailableToCommonShareholdersAdjustedAsAppropriateForGainsOrLossesFromDilutiveSecurities_7"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NonCashInterestExpenseAbstract_128" xlink:to="lab_embi_NonCashInterestExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NonCashInterestExpenseAbstract_128" xlink:to="lab_embi_NonCashInterestExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_129" xlink:to="lab_embi_NoramcoAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_129" xlink:to="lab_embi_NoramcoAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoramcoAgreementMember_129" xlink:to="lab_embi_NoramcoAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_130" xlink:to="lab_embi_NoticePeriodForTermination_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_130" xlink:to="lab_embi_NoticePeriodForTermination_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NoticePeriodForTermination_130" xlink:to="lab_embi_NoticePeriodForTermination_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockUnitsSold_131" xlink:to="lab_embi_NumberOfCommonStockUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockUnitsSold_131" xlink:to="lab_embi_NumberOfCommonStockUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfCommonStockUnitsSold_131" xlink:to="lab_embi_NumberOfCommonStockUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_132" xlink:to="lab_embi_NumberOfLicenseAgreements_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_132" xlink:to="lab_embi_NumberOfLicenseAgreements_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfLicenseAgreements_132" xlink:to="lab_embi_NumberOfLicenseAgreements_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfPreFundedUnitsSold_133" xlink:to="lab_embi_NumberOfPreFundedUnitsSold_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfPreFundedUnitsSold_133" xlink:to="lab_embi_NumberOfPreFundedUnitsSold_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_NumberOfPreFundedUnitsSold_133" xlink:to="lab_embi_NumberOfPreFundedUnitsSold_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_134" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_134" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OctoberTwoThousandFifteenMember_134" xlink:to="lab_embi_OctoberTwoThousandFifteenMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OfficersEmployeesAndDirectorsMember_135" xlink:to="lab_embi_OfficersEmployeesAndDirectorsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OfficersEmployeesAndDirectorsMember_135" xlink:to="lab_embi_OfficersEmployeesAndDirectorsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OfficersEmployeesAndDirectorsMember_135" xlink:to="lab_embi_OfficersEmployeesAndDirectorsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_136" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_136" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_136" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OmnibusIncentivePlan2014Member_136" xlink:to="lab_embi_OmnibusIncentivePlan2014Member_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_137" xlink:to="lab_embi_OptionAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_137" xlink:to="lab_embi_OptionAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_137" xlink:to="lab_embi_OptionAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_OptionAgreementMember_137" xlink:to="lab_embi_OptionAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramMember_138" xlink:to="lab_embi_PaycheckProtectionProgramMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramMember_138" xlink:to="lab_embi_PaycheckProtectionProgramMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramMember_138" xlink:to="lab_embi_PaycheckProtectionProgramMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_139" xlink:to="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_139" xlink:to="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_139" xlink:to="lab_embi_PaycheckProtectionProgramPromissoryNoteMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_140" xlink:to="lab_embi_PaymentForUpfrontFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_140" xlink:to="lab_embi_PaymentForUpfrontFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentForUpfrontFees_140" xlink:to="lab_embi_PaymentForUpfrontFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_141" xlink:to="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_141" xlink:to="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_141" xlink:to="lab_embi_PaymentInConsiderationForRestrictiveCovenantsInSeparationAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PayrollCostsExcludeCompensation_142" xlink:to="lab_embi_PayrollCostsExcludeCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PayrollCostsExcludeCompensation_142" xlink:to="lab_embi_PayrollCostsExcludeCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PayrollCostsExcludeCompensation_142" xlink:to="lab_embi_PayrollCostsExcludeCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedConsultingFees_143" xlink:to="lab_embi_PercentageOfAccruedConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedConsultingFees_143" xlink:to="lab_embi_PercentageOfAccruedConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedConsultingFees_143" xlink:to="lab_embi_PercentageOfAccruedConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_144" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_144" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAccruedInterestOnOutstandingBalance_144" xlink:to="lab_embi_PercentageOfAccruedInterestOnOutstandingBalance_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_145" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_145" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_145" xlink:to="lab_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfBonusForAccruedConsultingFees_146" xlink:to="lab_embi_PercentageOfBonusForAccruedConsultingFees_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfBonusForAccruedConsultingFees_146" xlink:to="lab_embi_PercentageOfBonusForAccruedConsultingFees_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfBonusForAccruedConsultingFees_146" xlink:to="lab_embi_PercentageOfBonusForAccruedConsultingFees_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_147" xlink:to="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_147" xlink:to="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_147" xlink:to="lab_embi_PercentageOfForgivenessAmountForNonPayrollCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfReductionInAnnualSalary_148" xlink:to="lab_embi_PercentageOfReductionInAnnualSalary_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfReductionInAnnualSalary_148" xlink:to="lab_embi_PercentageOfReductionInAnnualSalary_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfReductionInAnnualSalary_148" xlink:to="lab_embi_PercentageOfReductionInAnnualSalary_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_149" xlink:to="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_149" xlink:to="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_149" xlink:to="lab_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_150" xlink:to="lab_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_150" xlink:to="lab_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_150" xlink:to="lab_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_151" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_151" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_151" xlink:to="lab_embi_PeriodOfDiscretionaryAnnualBonusPayableToContractorAfterEachFiscalYearEnd_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PlacementAgentMember_152" xlink:to="lab_embi_PlacementAgentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PlacementAgentMember_152" xlink:to="lab_embi_PlacementAgentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PlacementAgentMember_152" xlink:to="lab_embi_PlacementAgentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PlacementAgentWarrantsMember_153" xlink:to="lab_embi_PlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PlacementAgentWarrantsMember_153" xlink:to="lab_embi_PlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PlacementAgentWarrantsMember_153" xlink:to="lab_embi_PlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_154" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_154" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Pre2015CommonStockWarrantsMember_154" xlink:to="lab_embi_Pre2015CommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_155" xlink:to="lab_embi_PreferredStockPutOptionLiability_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_155" xlink:to="lab_embi_PreferredStockPutOptionLiability_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreferredStockPutOptionLiability_155" xlink:to="lab_embi_PreferredStockPutOptionLiability_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreFundedUnitsSoldPricePerUnit_156" xlink:to="lab_embi_PreFundedUnitsSoldPricePerUnit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreFundedUnitsSoldPricePerUnit_156" xlink:to="lab_embi_PreFundedUnitsSoldPricePerUnit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PreFundedUnitsSoldPricePerUnit_156" xlink:to="lab_embi_PreFundedUnitsSoldPricePerUnit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PrefundedWarrantsMember_157" xlink:to="lab_embi_PrefundedWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PrefundedWarrantsMember_157" xlink:to="lab_embi_PrefundedWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PrefundedWarrantsMember_157" xlink:to="lab_embi_PrefundedWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelAxis_158" xlink:to="lab_embi_PricingModelAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelDomain_159" xlink:to="lab_embi_PricingModelDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_160" xlink:to="lab_embi_PricingModelMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_160" xlink:to="lab_embi_PricingModelMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_PricingModelMember_160" xlink:to="lab_embi_PricingModelMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_161" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_161" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_161" xlink:to="lab_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_162" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_162" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_162" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_162" xlink:to="lab_embi_ProceedsFromConvertibleMultiDrawCreditAgreement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_163" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_163" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_163" xlink:to="lab_embi_ProceedsFromFinancingBetweenConversionLiabilityAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_164" xlink:to="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_164" xlink:to="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_164" xlink:to="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_165" xlink:to="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_165" xlink:to="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_165" xlink:to="lab_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromPreFundedWarrantExercises_166" xlink:to="lab_embi_ProceedsFromPreFundedWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromPreFundedWarrantExercises_166" xlink:to="lab_embi_ProceedsFromPreFundedWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProceedsFromPreFundedWarrantExercises_166" xlink:to="lab_embi_ProceedsFromPreFundedWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_167" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_167" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_167" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ProvisionForConversionOfPreferredStock_167" xlink:to="lab_embi_ProvisionForConversionOfPreferredStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_168" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_168" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReclassificationOfDerivativesToEquity_168" xlink:to="lab_embi_ReclassificationOfDerivativesToEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReducedFixedConversionPriceOfCommonStock_169" xlink:to="lab_embi_ReducedFixedConversionPriceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReducedFixedConversionPriceOfCommonStock_169" xlink:to="lab_embi_ReducedFixedConversionPriceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReducedFixedConversionPriceOfCommonStock_169" xlink:to="lab_embi_ReducedFixedConversionPriceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_170" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_170" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_170" xlink:to="lab_embi_ReductionToAdditionalPaidInCapitalFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RemainingFundsFromPromissoryNote_171" xlink:to="lab_embi_RemainingFundsFromPromissoryNote_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RemainingFundsFromPromissoryNote_171" xlink:to="lab_embi_RemainingFundsFromPromissoryNote_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RemainingFundsFromPromissoryNote_171" xlink:to="lab_embi_RemainingFundsFromPromissoryNote_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_172" xlink:to="lab_embi_RestrictedStockAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_172" xlink:to="lab_embi_RestrictedStockAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RestrictedStockAgreementsMember_172" xlink:to="lab_embi_RestrictedStockAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_173" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_173" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_RisksAndUncertaintiesPolicyTextBlock_173" xlink:to="lab_embi_RisksAndUncertaintiesPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_174" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_174" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_174" xlink:to="lab_embi_ScheduleOfAdjustmentForDifferenceBetweenFairValueOfWarrantLiabilitiesAndTotalProceedsReceivedTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_175" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_175" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ScheduleOfInterestExpenseTableTextBlock_175" xlink:to="lab_embi_ScheduleOfInterestExpenseTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_176" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_176" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuredPromissoryNoteAndSecurityAgreementMember_176" xlink:to="lab_embi_SecuredPromissoryNoteAndSecurityAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_177" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_177" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementMember_177" xlink:to="lab_embi_SecuritiesPurchaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_178" xlink:to="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_178" xlink:to="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_178" xlink:to="lab_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeniorManagementCompensationPlanDescription_179" xlink:to="lab_embi_SeniorManagementCompensationPlanDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeniorManagementCompensationPlanDescription_179" xlink:to="lab_embi_SeniorManagementCompensationPlanDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeniorManagementCompensationPlanDescription_179" xlink:to="lab_embi_SeniorManagementCompensationPlanDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAgreementMember_180" xlink:to="lab_embi_SeparationAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAgreementMember_180" xlink:to="lab_embi_SeparationAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAgreementMember_180" xlink:to="lab_embi_SeparationAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_181" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_181" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_181" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeparationAndReleaseAgreementMember_181" xlink:to="lab_embi_SeparationAndReleaseAgreementMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_182" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_182" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_182" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBPreferredStockConversionLiabilityMember_182" xlink:to="lab_embi_SeriesBPreferredStockConversionLiabilityMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_183" xlink:to="lab_embi_SeriesBWarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_183" xlink:to="lab_embi_SeriesBWarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_183" xlink:to="lab_embi_SeriesBWarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantMember_183" xlink:to="lab_embi_SeriesBWarrantMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_184" xlink:to="lab_embi_SeriesBWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_184" xlink:to="lab_embi_SeriesBWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesBWarrantsMember_184" xlink:to="lab_embi_SeriesBWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_185" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_185" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SeriesFPreferredStockPutOptionLiabilityMember_185" xlink:to="lab_embi_SeriesFPreferredStockPutOptionLiabilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_186" xlink:to="lab_embi_ShareIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_186" xlink:to="lab_embi_ShareIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ShareIssuanceCosts_186" xlink:to="lab_embi_ShareIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsAbstract_187" xlink:to="lab_embi_SignificantContractsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_188" xlink:to="lab_embi_SignificantContractsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_188" xlink:to="lab_embi_SignificantContractsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SignificantContractsTextBlock_188" xlink:to="lab_embi_SignificantContractsTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_189" xlink:to="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_189" xlink:to="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockholdersDeficitAndCapitalizationTextBlock_189" xlink:to="lab_embi_StockholdersDeficitAndCapitalizationTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_190" xlink:to="lab_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_190" xlink:to="lab_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_190" xlink:to="lab_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_191" xlink:to="lab_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_191" xlink:to="lab_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_191" xlink:to="lab_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_192" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_192" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_192" xlink:to="lab_embi_StockIssuedDuringPeriodSharesIssuedForStockBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_193" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_193" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_193" xlink:to="lab_embi_StockIssuedDuringPeriodSharesNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_194" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_194" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_194" xlink:to="lab_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_195" xlink:to="lab_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_195" xlink:to="lab_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_195" xlink:to="lab_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_196" xlink:to="lab_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_196" xlink:to="lab_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_196" xlink:to="lab_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_197" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_197" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_197" xlink:to="lab_embi_StockIssuedDuringPeriodValueNetOfIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_198" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_198" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_198" xlink:to="lab_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockOptions2014PlanMember_199" xlink:to="lab_embi_StockOptions2014PlanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockOptions2014PlanMember_199" xlink:to="lab_embi_StockOptions2014PlanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_StockOptions2014PlanMember_199" xlink:to="lab_embi_StockOptions2014PlanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_200" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_200" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SubsequentFinancingPurchasePriceDescription_200" xlink:to="lab_embi_SubsequentFinancingPurchasePriceDescription_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SupplementalRestrictedCash_201" xlink:to="lab_embi_SupplementalRestrictedCash_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SupplementalRestrictedCash_201" xlink:to="lab_embi_SupplementalRestrictedCash_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_SupplementalRestrictedCash_201" xlink:to="lab_embi_SupplementalRestrictedCash_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_202" xlink:to="lab_embi_TermOfAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_202" xlink:to="lab_embi_TermOfAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfAgreement_202" xlink:to="lab_embi_TermOfAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_203" xlink:to="lab_embi_TermOfWarrant_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_203" xlink:to="lab_embi_TermOfWarrant_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_203" xlink:to="lab_embi_TermOfWarrant_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrant_203" xlink:to="lab_embi_TermOfWarrant_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_204" xlink:to="lab_embi_TermOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_204" xlink:to="lab_embi_TermOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermOfWarrants_204" xlink:to="lab_embi_TermOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_205" xlink:to="lab_embi_TermsOfAgreementRenewed_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_205" xlink:to="lab_embi_TermsOfAgreementRenewed_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TermsOfAgreementRenewed_205" xlink:to="lab_embi_TermsOfAgreementRenewed_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_206" xlink:to="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_206" xlink:to="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_206" xlink:to="lab_embi_ThresholdExercisePriceOfWarrantsToWaiveRightsToAntiDilutionProtectionUponSubsequentIssuances_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_207" xlink:to="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_207" xlink:to="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_207" xlink:to="lab_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_208" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_208" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_208" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalExpenseIncurredUnderAgreement_208" xlink:to="lab_embi_TotalExpenseIncurredUnderAgreement_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalFeesIncurredUnderAgreement_209" xlink:to="lab_embi_TotalFeesIncurredUnderAgreement_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalFeesIncurredUnderAgreement_209" xlink:to="lab_embi_TotalFeesIncurredUnderAgreement_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TotalFeesIncurredUnderAgreement_209" xlink:to="lab_embi_TotalFeesIncurredUnderAgreement_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_210" xlink:to="lab_embi_TwoThousandAndTwentyCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_210" xlink:to="lab_embi_TwoThousandAndTwentyCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_210" xlink:to="lab_embi_TwoThousandAndTwentyCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_211" xlink:to="lab_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_211" xlink:to="lab_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_211" xlink:to="lab_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyPreFundedWarrantsMember_212" xlink:to="lab_embi_TwoThousandAndTwentyPreFundedWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyPreFundedWarrantsMember_212" xlink:to="lab_embi_TwoThousandAndTwentyPreFundedWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandAndTwentyPreFundedWarrantsMember_212" xlink:to="lab_embi_TwoThousandAndTwentyPreFundedWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_213" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_213" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_213" xlink:to="lab_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_214" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_214" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_214" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_214" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_214" xlink:to="lab_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_215" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_215" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_215" xlink:to="lab_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_216" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_216" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_216" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingCommonStockWarrantsToSeriesBStockholdersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_217" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_217" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_217" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_217" xlink:to="lab_embi_TwoThousandFifteenSeriesBFinancingPlacementAgentWarrantsMember_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_218" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_218" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_218" xlink:to="lab_embi_TwoThousandNineteenCommonStockWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_219" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_219" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_219" xlink:to="lab_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_220" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_220" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_220" xlink:to="lab_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_221" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_221" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_221" xlink:to="lab_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_222" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_222" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_222" xlink:to="lab_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_223" xlink:to="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_223" xlink:to="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_223" xlink:to="lab_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_224" xlink:to="lab_embi_Um5070LicenseAgreementMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_224" xlink:to="lab_embi_Um5070LicenseAgreementMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_Um5070LicenseAgreementMember_224" xlink:to="lab_embi_Um5070LicenseAgreementMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_225" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_225" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnamortizedDebtDiscountPeriod_225" xlink:to="lab_embi_UnamortizedDebtDiscountPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsAbstract_226" xlink:to="lab_embi_UniversityOfMississippiAgreementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_227" xlink:to="lab_embi_UniversityOfMississippiAgreementsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_227" xlink:to="lab_embi_UniversityOfMississippiAgreementsLineItems_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_228" xlink:to="lab_embi_UniversityOfMississippiAgreementsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_228" xlink:to="lab_embi_UniversityOfMississippiAgreementsTable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_229" xlink:to="lab_embi_UniversityOfMississippiMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_229" xlink:to="lab_embi_UniversityOfMississippiMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UniversityOfMississippiMember_229" xlink:to="lab_embi_UniversityOfMississippiMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnrestrictedCashPositionDecreased_230" xlink:to="lab_embi_UnrestrictedCashPositionDecreased_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_UnrestrictedCashPositionDecreased_230" xlink:to="lab_embi_UnrestrictedCashPositionDecreased_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_231" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_231" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfCommonStockCalledByWarrants_231" xlink:to="lab_embi_ValueOfCommonStockCalledByWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_232" xlink:to="lab_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_232" xlink:to="lab_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_232" xlink:to="lab_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_233" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_234" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_234" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_234" xlink:to="lab_embi_WarrantsAndDerivativeLiabilitiesTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_235" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_235" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_235" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_235" xlink:to="lab_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_236" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_236" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_236" xlink:to="lab_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_237" xlink:to="lab_embi_WarrantsVestedAndOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_237" xlink:to="lab_embi_WarrantsVestedAndOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantsVestedAndOutstanding_237" xlink:to="lab_embi_WarrantsVestedAndOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_238" xlink:to="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_238" xlink:to="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_238" xlink:to="lab_embi_WarrantToPurchaseNumberOfCommonStockPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_239" xlink:to="lab_embi_WorkingCapitalDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_239" xlink:to="lab_embi_WorkingCapitalDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_239" xlink:to="lab_embi_WorkingCapitalDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_embi_WorkingCapitalDeficit_239" xlink:to="lab_embi_WorkingCapitalDeficit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_240" xlink:to="lab_srt_ChiefFinancialOfficerMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_240" xlink:to="lab_srt_ChiefFinancialOfficerMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefFinancialOfficerMember_240" xlink:to="lab_srt_ChiefFinancialOfficerMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_241" xlink:to="lab_srt_MaximumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_241" xlink:to="lab_srt_MaximumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_241" xlink:to="lab_srt_MaximumMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_242" xlink:to="lab_srt_MinimumMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_242" xlink:to="lab_srt_MinimumMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_242" xlink:to="lab_srt_MinimumMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_243" xlink:to="lab_srt_RangeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_244" xlink:to="lab_srt_RangeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_245" xlink:to="lab_srt_TitleOfIndividualAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_246" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_247" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_247" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_248" xlink:to="lab_us-gaap_AccountsPayableCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_248" xlink:to="lab_us-gaap_AccountsPayableCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_249" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_249" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_250" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_250" xlink:to="lab_us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_251" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_251" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_251" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_252" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_252" xlink:to="lab_us-gaap_AccruedSalariesCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_253" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_253" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_254" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_254" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_255" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_256" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_256" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvancesFairValueDisclosure_257" xlink:to="lab_us-gaap_AdvancesFairValueDisclosure_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvancesFairValueDisclosure_257" xlink:to="lab_us-gaap_AdvancesFairValueDisclosure_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_258" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_258" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_258" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_258" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_258" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_259" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfDebtDiscountPremium_259" xlink:to="lab_us-gaap_AmortizationOfDebtDiscountPremium_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_260" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_260" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_261" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_262" xlink:to="lab_us-gaap_Assets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_262" xlink:to="lab_us-gaap_Assets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_263" xlink:to="lab_us-gaap_AssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_263" xlink:to="lab_us-gaap_AssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_264" xlink:to="lab_us-gaap_AssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_264" xlink:to="lab_us-gaap_AssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_264" xlink:to="lab_us-gaap_AssetsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_265" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_265" xlink:to="lab_us-gaap_AssetsCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_266" xlink:to="lab_us-gaap_AwardTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_267" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_267" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_268" xlink:to="lab_us-gaap_BridgeLoanMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_268" xlink:to="lab_us-gaap_BridgeLoanMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BridgeLoanMember_268" xlink:to="lab_us-gaap_BridgeLoanMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_269" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_269" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_269" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_269" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_269" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_270" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_270" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_270" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_270" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_271" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_271" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_272" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_272" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_273" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_274" xlink:to="lab_us-gaap_ClassOfStockDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_275" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_276" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_276" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_277" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_278" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_279" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_279" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_280" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_281" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_281" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_282" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_283" xlink:to="lab_us-gaap_CommitmentsAndContingencies_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_283" xlink:to="lab_us-gaap_CommitmentsAndContingencies_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_284" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_284" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_285" xlink:to="lab_us-gaap_CommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_285" xlink:to="lab_us-gaap_CommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_286" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_286" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_286" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_287" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_287" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_288" xlink:to="lab_us-gaap_CommonStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_288" xlink:to="lab_us-gaap_CommonStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_289" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_289" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_289" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_289" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_289" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_290" xlink:to="lab_us-gaap_CommonStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_290" xlink:to="lab_us-gaap_CommonStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_291" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_291" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_291" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_292" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountConverted1_292" xlink:to="lab_us-gaap_ConversionOfStockAmountConverted1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleCommonStockMember_293" xlink:to="lab_us-gaap_ConvertibleCommonStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleCommonStockMember_293" xlink:to="lab_us-gaap_ConvertibleCommonStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_294" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_294" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_294" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_294" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtCurrent_294" xlink:to="lab_us-gaap_ConvertibleDebtCurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_295" xlink:to="lab_us-gaap_ConvertibleDebtMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember_295" xlink:to="lab_us-gaap_ConvertibleDebtMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_296" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_296" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_296" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_296" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtNoncurrent_296" xlink:to="lab_us-gaap_ConvertibleDebtNoncurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_297" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_297" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtTableTextBlock_297" xlink:to="lab_us-gaap_ConvertibleDebtTableTextBlock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_298" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_298" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_298" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_299" xlink:to="lab_us-gaap_DebtDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_300" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_300" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_301" xlink:to="lab_us-gaap_DebtInstrumentAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_302" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_302" xlink:to="lab_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_303" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_303" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_303" xlink:to="lab_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_304" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_304" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_304" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_304" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_305" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_305" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_305" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_306" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_306" xlink:to="lab_us-gaap_DebtInstrumentConvertibleThresholdTradingDays_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_307" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_307" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_307" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_308" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_308" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_309" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_309" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_309" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_310" xlink:to="lab_us-gaap_DebtInstrumentLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_311" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_311" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentMaturityDate_311" xlink:to="lab_us-gaap_DebtInstrumentMaturityDate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_312" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_313" xlink:to="lab_us-gaap_DebtInstrumentTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_314" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_314" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_314" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_315" xlink:to="lab_us-gaap_DebtPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtPolicyTextBlock_315" xlink:to="lab_us-gaap_DebtPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_316" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_316" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_316" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_316" xlink:to="lab_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_317" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_317" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentGross_317" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_318" xlink:to="lab_us-gaap_Depreciation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_318" xlink:to="lab_us-gaap_Depreciation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_319" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_320" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_321" xlink:to="lab_us-gaap_DerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_321" xlink:to="lab_us-gaap_DerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_321" xlink:to="lab_us-gaap_DerivativeLiabilities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_321" xlink:to="lab_us-gaap_DerivativeLiabilities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_322" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_322" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_322" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_322" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_323" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_323" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_323" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_323" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_323" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_324" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_324" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_325" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_326" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_326" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_327" xlink:to="lab_us-gaap_EarningsPerShareAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_327" xlink:to="lab_us-gaap_EarningsPerShareAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_328" xlink:to="lab_us-gaap_EarningsPerShareBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_328" xlink:to="lab_us-gaap_EarningsPerShareBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_328" xlink:to="lab_us-gaap_EarningsPerShareBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_329" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_329" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_330" xlink:to="lab_us-gaap_EarningsPerShareDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_330" xlink:to="lab_us-gaap_EarningsPerShareDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_330" xlink:to="lab_us-gaap_EarningsPerShareDiluted_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_331" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_331" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_332" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_332" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_333" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_334" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_334" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_334" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_335" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_335" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_335" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_336" xlink:to="lab_us-gaap_EmployeeStockOptionMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_336" xlink:to="lab_us-gaap_EmployeeStockOptionMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_336" xlink:to="lab_us-gaap_EmployeeStockOptionMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_337" xlink:to="lab_us-gaap_EquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_337" xlink:to="lab_us-gaap_EquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_338" xlink:to="lab_us-gaap_EquityComponentDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_338" xlink:to="lab_us-gaap_EquityComponentDomain_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount_339" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount_339" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_340" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_340" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_340" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_340" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_340" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_340" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_340" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_341" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_341" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_342" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_342" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_343" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_344" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_345" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_345" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_346" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_346" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_346" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_346" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_346" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_347" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_347" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_347" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_347" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_348" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_348" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_349" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_349" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_350" xlink:to="lab_us-gaap_IncomeStatementAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_350" xlink:to="lab_us-gaap_IncomeStatementAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_351" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_352" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_353" xlink:to="lab_us-gaap_IncomeTaxesPaid_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid_353" xlink:to="lab_us-gaap_IncomeTaxesPaid_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_354" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_354" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_355" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_355" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_356" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_356" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_357" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_358" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_358" xlink:to="lab_us-gaap_IncreaseDecreaseInDerivativeLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_359" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_359" xlink:to="lab_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_360" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_360" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_361" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_361" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentAssets_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_362" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_362" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_363" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_363" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_364" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_365" xlink:to="lab_us-gaap_IntellectualPropertyMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntellectualPropertyMember_365" xlink:to="lab_us-gaap_IntellectualPropertyMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_366" xlink:to="lab_us-gaap_InterestExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_366" xlink:to="lab_us-gaap_InterestExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_366" xlink:to="lab_us-gaap_InterestExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_366" xlink:to="lab_us-gaap_InterestExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_367" xlink:to="lab_us-gaap_InterestExpenseDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt_367" xlink:to="lab_us-gaap_InterestExpenseDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty_368" xlink:to="lab_us-gaap_InterestExpenseRelatedParty_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseRelatedParty_368" xlink:to="lab_us-gaap_InterestExpenseRelatedParty_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_369" xlink:to="lab_us-gaap_InterestIncomeOther_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_369" xlink:to="lab_us-gaap_InterestIncomeOther_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_369" xlink:to="lab_us-gaap_InterestIncomeOther_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_370" xlink:to="lab_us-gaap_InterestPaidNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_370" xlink:to="lab_us-gaap_InterestPaidNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_371" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrentAndNoncurrent_371" xlink:to="lab_us-gaap_InterestPayableCurrentAndNoncurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_372" xlink:to="lab_us-gaap_InvestorMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestorMember_372" xlink:to="lab_us-gaap_InvestorMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_373" xlink:to="lab_us-gaap_IPOMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember_373" xlink:to="lab_us-gaap_IPOMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_374" xlink:to="lab_us-gaap_Liabilities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_374" xlink:to="lab_us-gaap_Liabilities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_375" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_375" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_375" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_376" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_376" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_377" xlink:to="lab_us-gaap_LiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_377" xlink:to="lab_us-gaap_LiabilitiesCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_378" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_378" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_379" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_379" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_379" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_380" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_380" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_380" xlink:to="lab_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_381" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_381" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_382" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_382" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_383" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_383" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_384" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_384" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_385" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_385" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_385" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_386" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_386" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_387" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_387" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_387" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_388" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_388" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_389" xlink:to="lab_us-gaap_LongTermDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_389" xlink:to="lab_us-gaap_LongTermDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_390" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_390" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember_390" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_391" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_391" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember_391" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_392" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOfferedPriceMember_392" xlink:to="lab_us-gaap_MeasurementInputOfferedPriceMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_393" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_393" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember_393" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_394" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_394" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_394" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_395" xlink:to="lab_us-gaap_MeasurementInputTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_396" xlink:to="lab_us-gaap_MeasurementInputTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_397" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_397" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_397" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_398" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_398" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_399" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_399" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_399" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_400" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_400" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_401" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_401" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_401" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_401" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_402" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_402" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_403" xlink:to="lab_us-gaap_NetIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_403" xlink:to="lab_us-gaap_NetIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_403" xlink:to="lab_us-gaap_NetIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_403" xlink:to="lab_us-gaap_NetIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_403" xlink:to="lab_us-gaap_NetIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_403" xlink:to="lab_us-gaap_NetIncomeLoss_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_403" xlink:to="lab_us-gaap_NetIncomeLoss_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_404" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_404" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_405" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_405" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_406" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_406" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_406" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_406" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_406" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_407" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_407" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_408" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_408" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseMember_408" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_409" xlink:to="lab_us-gaap_OperatingExpenses_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_409" xlink:to="lab_us-gaap_OperatingExpenses_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_409" xlink:to="lab_us-gaap_OperatingExpenses_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_410" xlink:to="lab_us-gaap_OperatingExpensesAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_410" xlink:to="lab_us-gaap_OperatingExpensesAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_411" xlink:to="lab_us-gaap_OperatingIncomeLoss_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_411" xlink:to="lab_us-gaap_OperatingIncomeLoss_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_411" xlink:to="lab_us-gaap_OperatingIncomeLoss_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_411" xlink:to="lab_us-gaap_OperatingIncomeLoss_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_411" xlink:to="lab_us-gaap_OperatingIncomeLoss_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_411" xlink:to="lab_us-gaap_OperatingIncomeLoss_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_412" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_412" xlink:to="lab_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_413" xlink:to="lab_us-gaap_OtherAssetsCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_413" xlink:to="lab_us-gaap_OtherAssetsCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_413" xlink:to="lab_us-gaap_OtherAssetsCurrent_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherSundryLiabilitiesCurrent_414" xlink:to="lab_us-gaap_OtherSundryLiabilitiesCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_415" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_415" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_415" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_416" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_416" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_416" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_417" xlink:to="lab_us-gaap_PlanNameAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_418" xlink:to="lab_us-gaap_PlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_419" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_419" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_419" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_420" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_420" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_420" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_421" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_421" xlink:to="lab_us-gaap_PreferredStockSharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_422" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_422" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_423" xlink:to="lab_us-gaap_PreferredStockValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_423" xlink:to="lab_us-gaap_PreferredStockValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_424" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_424" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_425" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt_425" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_426" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_426" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_427" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_427" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_427" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_427" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_427" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_427" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_5"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_427" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_6"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_428" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_428" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_428" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_428" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_429" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromNotesPayable_429" xlink:to="lab_us-gaap_ProceedsFromNotesPayable_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_430" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromOtherDebt_430" xlink:to="lab_us-gaap_ProceedsFromOtherDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_431" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRelatedPartyDebt_431" xlink:to="lab_us-gaap_ProceedsFromRelatedPartyDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_432" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_432" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises_432" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_433" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_433" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_433" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_433" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain_434" xlink:to="lab_us-gaap_RelatedPartyDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_435" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_436" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_437" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_438" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_438" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_439" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_439" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_439" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_439" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt_439" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_440" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_440" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_440" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_440" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_441" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_441" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_442" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_442" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_443" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_443" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_444" xlink:to="lab_us-gaap_RestrictedStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_444" xlink:to="lab_us-gaap_RestrictedStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember_444" xlink:to="lab_us-gaap_RestrictedStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_445" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_445" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_445" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_445" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_446" xlink:to="lab_us-gaap_RetainedEarningsMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_446" xlink:to="lab_us-gaap_RetainedEarningsMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction_447" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockDescriptionOfTransaction_447" xlink:to="lab_us-gaap_SaleOfStockDescriptionOfTransaction_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_448" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_449" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_449" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_450" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_450" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_451" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_451" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_452" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_453" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_453" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_454" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_455" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_456" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_456" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_457" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_457" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_458" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_458" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_459" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_460" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_460" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_461" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_461" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember_461" xlink:to="lab_us-gaap_SeriesBPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_462" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_462" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember_462" xlink:to="lab_us-gaap_SeriesCPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_463" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_463" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesDPreferredStockMember_463" xlink:to="lab_us-gaap_SeriesDPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_464" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_464" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesFPreferredStockMember_464" xlink:to="lab_us-gaap_SeriesFPreferredStockMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_465" xlink:to="lab_us-gaap_ShareBasedCompensation_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_465" xlink:to="lab_us-gaap_ShareBasedCompensation_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_465" xlink:to="lab_us-gaap_ShareBasedCompensation_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_466" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_466" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_467" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_467" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_468" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_468" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_468" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_469" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_469" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_470" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_470" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_470" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_471" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_471" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_472" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_472" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_472" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_473" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_473" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_474" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_474" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_474" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_474" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_475" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_475" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_476" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_476" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_477" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_477" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_477" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_478" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_478" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_478" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_479" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_479" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_479" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_480" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_481" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_481" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_482" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_482" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_483" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_483" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_483" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_484" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_484" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_484" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_485" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_485" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_485" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_486" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_486" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_486" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_486" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_487" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_487" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_487" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_487" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_488" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_488" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_488" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_488" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_488" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_489" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_489" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_490" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_490" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_491" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_491" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_492" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_492" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_492" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_492" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_492" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_493" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_493" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_493" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_494" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_494" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_494" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_495" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_495" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_496" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_496" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_496" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_497" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_497" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_498" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_498" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_498" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_499" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_499" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_499" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_499" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_500" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_500" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_501" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_502" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_502" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_502" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_503" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_503" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_503" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_504" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_505" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_505" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_506" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_506" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_506" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_507" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_507" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_507" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_508" xlink:to="lab_us-gaap_SharePrice_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_508" xlink:to="lab_us-gaap_SharePrice_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_509" xlink:to="lab_us-gaap_SharesIssued_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_509" xlink:to="lab_us-gaap_SharesIssued_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_509" xlink:to="lab_us-gaap_SharesIssued_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_509" xlink:to="lab_us-gaap_SharesIssued_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_510" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_510" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_510" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_510" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings_511" xlink:to="lab_us-gaap_ShortTermBorrowings_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings_511" xlink:to="lab_us-gaap_ShortTermBorrowings_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems_512" xlink:to="lab_us-gaap_ShortTermDebtLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_513" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_514" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_515" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_515" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_516" xlink:to="lab_us-gaap_StatementClassOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_517" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_517" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_518" xlink:to="lab_us-gaap_StatementLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_519" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_519" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_520" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_520" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_521" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_522" xlink:to="lab_us-gaap_StatementTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_523" xlink:to="lab_us-gaap_StockholdersEquity_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_523" xlink:to="lab_us-gaap_StockholdersEquity_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_523" xlink:to="lab_us-gaap_StockholdersEquity_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_523" xlink:to="lab_us-gaap_StockholdersEquity_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_523" xlink:to="lab_us-gaap_StockholdersEquity_4"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_524" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_524" xlink:to="lab_us-gaap_StockholdersEquityAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_525" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_525" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_526" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_526" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_527" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_527" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_528" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_528" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_528" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_528" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_3"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_529" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_529" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_530" xlink:to="lab_us-gaap_SubsequentEventLineItems_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_531" xlink:to="lab_us-gaap_SubsequentEventMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_531" xlink:to="lab_us-gaap_SubsequentEventMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_532" xlink:to="lab_us-gaap_SubsequentEventsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_533" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_533" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_534" xlink:to="lab_us-gaap_SubsequentEventTable_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_535" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_536" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_537" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_538" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_538" xlink:to="lab_us-gaap_SupplementalCashFlowElementsAbstract_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_539" xlink:to="lab_us-gaap_TypeOfArrangementAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_540" xlink:to="lab_us-gaap_UseOfEstimates_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_540" xlink:to="lab_us-gaap_UseOfEstimates_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_540" xlink:to="lab_us-gaap_UseOfEstimates_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_541" xlink:to="lab_us-gaap_VestingAxis_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_542" xlink:to="lab_us-gaap_VestingDomain_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_543" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_543" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantExercisePriceDecrease_543" xlink:to="lab_us-gaap_WarrantExercisePriceDecrease_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_544" xlink:to="lab_us-gaap_WarrantMember_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_544" xlink:to="lab_us-gaap_WarrantMember_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember_544" xlink:to="lab_us-gaap_WarrantMember_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_545" xlink:to="lab_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_546" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_546" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_546" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_547" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_547" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm_547" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_548" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_548" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_548" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_549" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_549" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_549" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_550" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0"/>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_550" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_1"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>embi-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <!-- INTEGIX by Ez-XBRL -->
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#DocumentAndEntityInformation" roleURI="http://www.emeraldbio.life/role/DocumentAndEntityInformation"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedBalanceSheets" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheetsParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedStatementsOfCashFlowsUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited" roleURI="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#NatureOfOperationsAndBusinessActivities" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilities" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#ConvertibleDebtRelatedParty" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockholdersDeficitAndCapitalization" roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalization"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensation" roleURI="http://www.emeraldbio.life/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SignificantContractsUniversityOfMississippi" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#RelatedPartyMatters" roleURI="http://www.emeraldbio.life/role/RelatedPartyMatters"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SubsequentEvents" roleURI="http://www.emeraldbio.life/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesTables" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#ConvertibleDebtRelatedPartyTables" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationTables" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#NatureOfOperationsAndBusinessActivitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails1" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails2" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails4" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails5" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetailTextuals" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#ConvertibleDebtRelatedPartyDetails" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#ConvertibleDebtRelatedPartyDetails1" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#ConvertibleDebtRelatedPartyDetailTextuals" roleURI="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockholdersDeficitAndCapitalizationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetails" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetailTextuals" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetailTextuals1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SignificantContractsUniversityOfMississippiDetailTextuals" roleURI="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#RelatedPartyMattersDetailTextuals" roleURI="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SubsequentEventsDetailTextuals" roleURI="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals" roleURI="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetails1" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetails2" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails2"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#SummaryOfSignificantAccountingPoliciesDetails1" roleURI="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails1"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#StockBasedCompensationDetails4" roleURI="http://www.emeraldbio.life/role/StockBasedCompensationDetails4"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails3" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3"/>
  <roleRef xlink:type="simple" xlink:href="embi-20200930.xsd#WarrantsAndDerivativeLiabilitiesDetails6" roleURI="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DocumentAndEntityInformationAbstract" xlink:label="loc_embi_DocumentAndEntityInformationAbstract_0"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_8"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_9"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_11"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_12"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_13"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_15"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_4" order="30" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_5" order="40" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6" order="50" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_7" order="60" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_8" order="70" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_9" order="80" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_10" order="90" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_11" order="100" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityShellCompany_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntitySmallBusiness_13" order="120" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityEmergingGrowthCompany_14" order="130" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityInteractiveDataCurrent_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherSundryLiabilitiesCurrent_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MultidrawCreditAgreementRelatedPartyNoncurrent" xlink:label="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_31"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_OtherAssetsCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1" xlink:to="loc_us-gaap_AssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableCurrent_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccountsPayableRelatedPartiesCurrent_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_ShortTermBorrowings_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_OtherSundryLiabilitiesCurrent_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10" xlink:to="loc_us-gaap_LiabilitiesCurrent_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_LongTermDebt_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_embi_MultidrawCreditAgreementRelatedPartyNoncurrent_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_18" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_Liabilities_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_CommitmentsAndContingencies_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_PreferredStockValue_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_CommonStockValue_26" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_27" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_28" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25" xlink:to="loc_us-gaap_StockholdersEquity_29" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheetsParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_8"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ChangeInFairValueOfDerivativeLiabilities" xlink:label="loc_embi_ChangeInFairValueOfDerivativeLiabilities_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_1" xlink:to="loc_us-gaap_OperatingExpenses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_embi_ChangeInFairValueOfDerivativeLiabilities_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_InterestExpense_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_6" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14" xlink:to="loc_us-gaap_EarningsPerShareBasic_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_14" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_17" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueAdjustmentOfDerivativeLiabilities" xlink:label="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfDerivativeLiabilityExcessOfProceeds" xlink:label="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="loc_us-gaap_AmortizationOfDebtDiscountPremium_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent" xlink:label="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_IncreaseDecreaseAccruedInterestDueToRelatedParty" xlink:label="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:label="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromPreFundedWarrantExercises" xlink:label="loc_embi_ProceedsFromPreFundedWarrantExercises_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowElementsAbstract_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CashAndCashEquivalents" xlink:label="loc_embi_CashAndCashEquivalents_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SupplementalRestrictedCash" xlink:label="loc_embi_SupplementalRestrictedCash_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated" xlink:label="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CashPaidDuringPeriodForAbstract" xlink:label="loc_embi_CashPaidDuringPeriodForAbstract_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_31"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ExerciseOfWarrants" xlink:label="loc_embi_ExerciseOfWarrants_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_34"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_35"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement" xlink:label="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_36"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_Depreciation_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_ShareBasedCompensation_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_embi_FairValueAdjustmentOfDerivativeLiabilities_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_embi_FairValueOfDerivativeLiabilityExcessOfProceeds_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_AmortizationOfDebtDiscountPremium_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrants_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_embi_ProceedsFromPreFundedWarrantExercises_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_17" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_23" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_25" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowElementsAbstract_26" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_26" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_26" xlink:to="loc_embi_CashAndCashEquivalents_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_26" xlink:to="loc_embi_SupplementalRestrictedCash_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_26" xlink:to="loc_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_26" xlink:to="loc_embi_CashPaidDuringPeriodForAbstract_30" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_30" xlink:to="loc_us-gaap_InterestPaidNet_30" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_CashPaidDuringPeriodForAbstract_30" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_31" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowElementsAbstract_26" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33" xlink:to="loc_embi_ExerciseOfWarrants_33" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33" xlink:to="loc_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement_34" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33" xlink:to="loc_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement_35" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_33" xlink:to="loc_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement_36" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueCommonStockAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants" xlink:label="loc_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises" xlink:label="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_CommonStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_RetainedEarningsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1" xlink:to="loc_us-gaap_EquityComponentDomain_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_StockholdersEquity_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_SharesIssued_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants_11" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants_12" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_13" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_14" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises_15" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises_16" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_NetIncomeLoss_17" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_StockholdersEquity_18" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6" xlink:to="loc_us-gaap_SharesIssued_19" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsAndDerivativeLiabilitiesTextBlock" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_embi_WarrantsAndDerivativeLiabilitiesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalization">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SignificantContractsAbstract" xlink:label="loc_embi_SignificantContractsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SignificantContractsTextBlock" xlink:label="loc_embi_SignificantContractsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_SignificantContractsAbstract_0" xlink:to="loc_embi_SignificantContractsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMatters">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_RisksAndUncertaintiesPolicyTextBlock" xlink:label="loc_embi_RisksAndUncertaintiesPolicyTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock" xlink:label="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtPolicyTextBlock" xlink:label="loc_us-gaap_DebtPolicyTextBlock_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_embi_RisksAndUncertaintiesPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_DebtPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsAndDerivativeLiabilitiesAbstract" xlink:label="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AugustTwoThousandAndTwentyFinancingWarrantsMember" xlink:label="loc_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock" xlink:label="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_WarrantsAndDerivativeLiabilitiesAbstract_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4" xlink:to="loc_us-gaap_ClassOfStockDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_embi_AugustTwoThousandAndTwentyFinancingWarrantsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_embi_EmeraldFinancingWarrantsLiabilityMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4" xlink:to="loc_embi_SeriesBWarrantMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_embi_DerivativeLiabilitiesLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_10" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtTableTextBlock" xlink:label="loc_us-gaap_ConvertibleDebtTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ScheduleOfInterestExpenseTableTextBlock" xlink:label="loc_embi_ScheduleOfInterestExpenseTableTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_embi_ScheduleOfInterestExpenseTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_4"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsAndBusinessActivitiesAbstract" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsAndBusinessActivitiesTable" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember" xlink:label="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaycheckProtectionProgramPromissoryNoteMember" xlink:label="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsAndBusinessActivitiesLineItems" xlink:label="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WorkingCapitalDeficit" xlink:label="loc_embi_WorkingCapitalDeficit_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DrawDownsLoansInAggregatePrincipalAmount" xlink:label="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeniorManagementCompensationPlanDescription" xlink:label="loc_embi_SeniorManagementCompensationPlanDescription_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_28"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_29"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfWarrants" xlink:label="loc_embi_TermOfWarrants_32"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesAbstract_0" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_MultiDrawCreditAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_AmendedAndRestatedMultiDrawCreditAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_8" xlink:to="loc_embi_PaycheckProtectionProgramPromissoryNoteMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_embi_CommonStockWarrantsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_11" xlink:to="loc_embi_PrefundedWarrantsMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesTable_1" xlink:to="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_StockholdersEquity_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_embi_WorkingCapitalDeficit_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_22" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_embi_DrawDownsLoansInAggregatePrincipalAmount_23" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_24" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_25" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_26" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_embi_SeniorManagementCompensationPlanDescription_27" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_embi_NumberOfCommonStockUnitsSold_28" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_embi_NumberOfPreFundedUnitsSold_29" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_embi_GrossProceedsOfUnitsSold_30" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_31" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsAndBusinessActivitiesLineItems_15" xlink:to="loc_embi_TermOfWarrants_32" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleCommonStockMember" xlink:label="loc_us-gaap_ConvertibleCommonStockMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_11"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5" xlink:to="loc_us-gaap_ClassOfStockDomain_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5" xlink:to="loc_us-gaap_ConvertibleCommonStockMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8" xlink:to="loc_us-gaap_EquityComponentDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_WarrantMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems_11" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_PricingModelMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesTable" xlink:label="loc_embi_DerivativeLiabilitiesTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_2"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_DerivativeLiabilitiesLineItems" xlink:label="loc_embi_DerivativeLiabilitiesLineItems_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfDerivativeLiabilitiesRollForward" xlink:label="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantsIssued" xlink:label="loc_embi_FairValueOfWarrantsIssued_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ReclassificationOfDerivativesToEquity" xlink:label="loc_embi_ReclassificationOfDerivativesToEquity_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_embi_DerivativeLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_embi_SeriesBWarrantMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_5" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_5" xlink:to="loc_embi_EmeraldFinancingMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesTable_1" xlink:to="loc_embi_DerivativeLiabilitiesLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_DerivativeLiabilitiesLineItems_8" xlink:to="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilities_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_embi_FairValueOfWarrantsIssued_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_embi_ReclassificationOfDerivativesToEquity_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilities_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_FairValueOfDerivativeLiabilitiesRollForward_8" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonteCarloSimulationsMember" xlink:label="loc_embi_MonteCarloSimulationsMember_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_19"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_7" xlink:to="loc_embi_PricingModelDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_7" xlink:to="loc_embi_MonteCarloSimulationsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_embi_EmeraldFinancingMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_13" xlink:to="loc_srt_RangeMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MinimumMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_13" xlink:to="loc_srt_MaximumMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_17" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantMember" xlink:label="loc_embi_SeriesBWarrantMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_8" xlink:to="loc_embi_PricingModelDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_8" xlink:to="loc_embi_PricingModelMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_11" xlink:to="loc_us-gaap_ClassOfStockDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11" xlink:to="loc_embi_SeriesBWarrantMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_14" xlink:to="loc_srt_RangeMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MinimumMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_14" xlink:to="loc_srt_MaximumMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_18" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember" xlink:label="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingWarrantsLiabilityMember" xlink:label="loc_embi_EmeraldFinancingWarrantsLiabilityMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldWarrantLiabilityMember" xlink:label="loc_embi_EmeraldWarrantLiabilityMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SeriesBWarrantsMember" xlink:label="loc_embi_SeriesBWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PlacementAgentWarrantsMember" xlink:label="loc_embi_PlacementAgentWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_14"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_17"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_GrossProceedsOfWarrants" xlink:label="loc_embi_GrossProceedsOfWarrants_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ValueOfCommonStockCalledByWarrants" xlink:label="loc_embi_ValueOfCommonStockCalledByWarrants_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity" xlink:label="loc_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDerivativeLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue" xlink:label="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts" xlink:label="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_30"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AggregateExercisePriceOfOutstandingCreditAgreement" xlink:label="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ClassOfWarrantOrRightWarrantsExercise" xlink:label="loc_embi_ClassOfWarrantOrRightWarrantsExercise_32"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_33"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldMultiDrawCreditAgreementCompoundDerivativeLiabilityMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldFinancingWarrantsLiabilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_EmeraldWarrantLiabilityMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_SeriesBWarrantsMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_CommonStockWarrantsMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_PrefundedWarrantsMember_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_PlacementAgentWarrantsMember_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_14" xlink:to="loc_us-gaap_EquityComponentDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_14" xlink:to="loc_us-gaap_WarrantMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_dei_LegalEntityAxis_17" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_17" xlink:to="loc_dei_EntityDomain_17" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_17" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_GrossProceedsOfWarrants_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_ValueOfCommonStockCalledByWarrants_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity_23" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_us-gaap_IncreaseDecreaseInDerivativeLiabilities_24" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_25" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_26" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_TermOfWarrant_27" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue_28" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_29" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveVerboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_us-gaap_DebtRelatedCommitmentFeesAndDebtIssuanceCosts_30" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_AggregateExercisePriceOfOutstandingCreditAgreement_31" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_ClassOfWarrantOrRightWarrantsExercise_32" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_33" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent" xlink:label="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountCurrent" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFinanceCostsCurrentGross" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentGross_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtCurrent" xlink:label="loc_us-gaap_ConvertibleDebtCurrent_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CurrentConvertibleDebtExcludingNoncurrentPortion" xlink:label="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_13"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_1" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_1" xlink:to="loc_us-gaap_ConvertibleDebtMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_1" xlink:to="loc_us-gaap_ShortTermDebtLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountCurrent_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentGross_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebtCurrent_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_7" xlink:to="loc_embi_CurrentConvertibleDebtExcludingNoncurrentPortion_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseRelatedParty" xlink:label="loc_us-gaap_InterestExpenseRelatedParty_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="loc_us-gaap_InterestExpenseDebt_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NonCashInterestExpenseAbstract" xlink:label="loc_embi_NonCashInterestExpenseAbstract_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AmortizationOfDebtDiscount" xlink:label="loc_embi_AmortizationOfDebtDiscount_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AmortizationOfTransactionCosts" xlink:label="loc_embi_AmortizationOfTransactionCosts_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_6"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpenseRelatedParty_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpenseDebt_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_embi_NonCashInterestExpenseAbstract_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NonCashInterestExpenseAbstract_3" xlink:to="loc_embi_AmortizationOfDebtDiscount_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_NonCashInterestExpenseAbstract_3" xlink:to="loc_embi_AmortizationOfTransactionCosts_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_InterestExpense_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldFinancingMember" xlink:label="loc_embi_EmeraldFinancingMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MultiDrawCreditAgreementMember" xlink:label="loc_embi_MultiDrawCreditAgreementMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaycheckProtectionProgramMember" xlink:label="loc_embi_PaycheckProtectionProgramMember_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAverageOutstandingAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaap_DebtInstrumentMaturityDate_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPriceDecrease" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeeAmount" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase" xlink:label="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRelatedPartyDebt" xlink:label="loc_us-gaap_ProceedsFromRelatedPartyDebt_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AllocationOfDebtOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AllocationOfWarrantOnBasisOfRelativeFairValue" xlink:label="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CreditFacilityEffectedFourthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFourthAdvances_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CreditFacilityEffectedFifthAdvances" xlink:label="loc_embi_CreditFacilityEffectedFifthAdvances_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:label="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts" xlink:label="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_28"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_29"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantExercisePriceDecrease" xlink:label="loc_us-gaap_WarrantExercisePriceDecrease_30"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UnamortizedDebtDiscountPeriod" xlink:label="loc_embi_UnamortizedDebtDiscountPeriod_32"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfWarrantLiabilityInExcessOfProceeds" xlink:label="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_33"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairValueOfSharesUnderlyingConvertibleDebt" xlink:label="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_34"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_35"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PayrollCostsExcludeCompensation" xlink:label="loc_embi_PayrollCostsExcludeCompensation_37"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfForgivenessAmountForNonPayrollCosts" xlink:label="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_38"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedSalariesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_39"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfReductionInAnnualSalary" xlink:label="loc_embi_PercentageOfReductionInAnnualSalary_40"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_1" xlink:to="loc_dei_EntityDomain_1" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldFinancingMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_MultiDrawCreditAgreementMember_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5" xlink:to="loc_embi_IndependentContractorAgreementMember_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9" xlink:to="loc_embi_PaycheckProtectionProgramMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityAverageOutstandingAmount_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentMaturityDate_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeeAmount_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase_18" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_19" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_ProceedsFromRelatedPartyDebt_20" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_21" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_AllocationOfDebtOnBasisOfRelativeFairValue_22" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_AllocationOfWarrantOnBasisOfRelativeFairValue_23" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_CreditFacilityEffectedFourthAdvances_24" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_CreditFacilityEffectedFifthAdvances_25" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_26" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DerivativeLiabilities_27" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts_28" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_29" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_WarrantExercisePriceDecrease_30" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_31" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_UnamortizedDebtDiscountPeriod_32" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_FairValueOfWarrantLiabilityInExcessOfProceeds_33" order="210" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_FairValueOfSharesUnderlyingConvertibleDebt_34" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_35" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_PayrollCostsExcludeCompensation_37" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_PercentageOfForgivenessAmountForNonPayrollCosts_38" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_us-gaap_AccruedSalariesCurrentAndNoncurrent_39" order="270" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_12" xlink:to="loc_embi_PercentageOfReductionInAnnualSalary_40" order="280" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EquityTable" xlink:label="loc_embi_EquityTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaap_IPOMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_SecuritiesPurchaseAgreementMember" xlink:label="loc_embi_SecuritiesPurchaseAgreementMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember" xlink:label="loc_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PlacementAgentMember" xlink:label="loc_embi_PlacementAgentMember_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EquityLineItems" xlink:label="loc_embi_EquityLineItems_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfCommonStockUnitsSold" xlink:label="loc_embi_NumberOfCommonStockUnitsSold_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfPreFundedUnitsSold" xlink:label="loc_embi_NumberOfPreFundedUnitsSold_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonUnitsSoldPricePerUnit" xlink:label="loc_embi_CommonUnitsSoldPricePerUnit_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="loc_us-gaap_SaleOfStockDescriptionOfTransaction_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PreFundedUnitsSoldPricePerUnit" xlink:label="loc_embi_PreFundedUnitsSoldPricePerUnit_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_GrossProceedsOfUnitsSold" xlink:label="loc_embi_GrossProceedsOfUnitsSold_22"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_23"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_25"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering" xlink:label="loc_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_embi_EquityTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:to="loc_us-gaap_IPOMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4" xlink:to="loc_embi_SecuritiesPurchaseAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="20" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_10" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_10" xlink:to="loc_embi_CommonStockWarrantsMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_10" xlink:to="loc_embi_PrefundedWarrantsMember_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_14" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_14" xlink:to="loc_embi_PlacementAgentMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityTable_1" xlink:to="loc_embi_EquityLineItems_17" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_embi_NumberOfCommonStockUnitsSold_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_embi_NumberOfPreFundedUnitsSold_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_embi_CommonUnitsSoldPricePerUnit_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_us-gaap_SaleOfStockDescriptionOfTransaction_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_embi_PreFundedUnitsSoldPricePerUnit_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_embi_GrossProceedsOfUnitsSold_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_26" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_27" order="100" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_EquityLineItems_17" xlink:to="loc_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering_28" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_RestrictedStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares" xlink:label="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_FairMarketValueOfStockOptions" xlink:label="loc_embi_FairMarketValueOfStockOptions_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" xlink:to="loc_us-gaap_RestrictedStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_12" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_13" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_14" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_15" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensation_16" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares_17" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_18" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_embi_FairMarketValueOfStockOptions_19" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_20" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_21" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_22" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals">
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiAgreementsAbstract" xlink:label="loc_embi_UniversityOfMississippiAgreementsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiAgreementsTable" xlink:label="loc_embi_UniversityOfMississippiAgreementsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OptionAgreementMember" xlink:label="loc_embi_OptionAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_LicenseAgreementMember" xlink:label="loc_embi_LicenseAgreementMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Um5070LicenseAgreementMember" xlink:label="loc_embi_Um5070LicenseAgreementMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Um5050ProDrugAndUm8930AnalogAgreementsMember" xlink:label="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_7"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiMember" xlink:label="loc_embi_UniversityOfMississippiMember_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="loc_us-gaap_IntellectualPropertyMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthAndYearOfAgreementAxis" xlink:label="loc_embi_MonthAndYearOfAgreementAxis_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthAndYearOfAgreementDomain" xlink:label="loc_embi_MonthAndYearOfAgreementDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_December2015Member" xlink:label="loc_embi_December2015Member_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OctoberTwoThousandFifteenMember" xlink:label="loc_embi_OctoberTwoThousandFifteenMember_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MilestonePaymentsPayableAxis" xlink:label="loc_embi_MilestonePaymentsPayableAxis_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MilestonePaymentsPayableDomain" xlink:label="loc_embi_MilestonePaymentsPayableDomain_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone1Member" xlink:label="loc_embi_Milestone1Member_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone2Member" xlink:label="loc_embi_Milestone2Member_18"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Milestone3Member" xlink:label="loc_embi_Milestone3Member_19"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_UniversityOfMississippiAgreementsLineItems" xlink:label="loc_embi_UniversityOfMississippiAgreementsLineItems_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AnnualMaintenanceFeePayable" xlink:label="loc_embi_AnnualMaintenanceFeePayable_22"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfAgreement" xlink:label="loc_embi_TermOfAgreement_23"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PaymentForUpfrontFees" xlink:label="loc_embi_PaymentForUpfrontFees_24"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NumberOfLicenseAgreements" xlink:label="loc_embi_NumberOfLicenseAgreements_25"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_NoticePeriodForTermination" xlink:label="loc_embi_NoticePeriodForTermination_26"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AnnualFeesForLicenseAgreement" xlink:label="loc_embi_AnnualFeesForLicenseAgreement_27"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AggregateMilestonePaymentsIfMilestonesAchieved" xlink:label="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_28"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsAbstract_0" xlink:to="loc_embi_UniversityOfMississippiAgreementsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_OptionAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_LicenseAgreementMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5070LicenseAgreementMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_Um5050ProDrugAndUm8930AnalogAgreementsMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_dei_LegalEntityAxis_7" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_7" xlink:to="loc_dei_EntityDomain_7" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7" xlink:to="loc_embi_UniversityOfMississippiMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_10" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:to="loc_us-gaap_IntellectualPropertyMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MonthAndYearOfAgreementAxis_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementAxis_13" xlink:to="loc_embi_MonthAndYearOfAgreementDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_13" xlink:to="loc_embi_December2015Member_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MonthAndYearOfAgreementDomain_13" xlink:to="loc_embi_OctoberTwoThousandFifteenMember_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_MilestonePaymentsPayableAxis_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableAxis_17" xlink:to="loc_embi_MilestonePaymentsPayableDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone1Member_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone2Member_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_MilestonePaymentsPayableDomain_17" xlink:to="loc_embi_Milestone3Member_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsTable_1" xlink:to="loc_embi_UniversityOfMississippiAgreementsLineItems_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AnnualMaintenanceFeePayable_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_TermOfAgreement_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_PaymentForUpfrontFees_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_NumberOfLicenseAgreements_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_NoticePeriodForTermination_26" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AnnualFeesForLicenseAgreement_27" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_UniversityOfMississippiAgreementsLineItems_22" xlink:to="loc_embi_AggregateMilestonePaymentsIfMilestonesAchieved_28" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_IndependentContractorAgreementMember" xlink:label="loc_embi_IndependentContractorAgreementMember_1"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_4"/>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmeraldHealthSciencesIncMember" xlink:label="loc_embi_EmeraldHealthSciencesIncMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaap_RelatedPartyDomain_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AvtarDhillonMember" xlink:label="loc_embi_AvtarDhillonMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OfficersEmployeesAndDirectorsMember" xlink:label="loc_embi_OfficersEmployeesAndDirectorsMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_InitialTermOfAgreement" xlink:label="loc_embi_InitialTermOfAgreement_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TotalExpenseIncurredUnderAgreement" xlink:label="loc_embi_TotalExpenseIncurredUnderAgreement_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFee" xlink:label="loc_embi_MonthlyFee_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFeePaidEachMonthInExchangeOfServices" xlink:label="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_14"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices" xlink:label="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_15"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfAccruedConsultingFees" xlink:label="loc_embi_PercentageOfAccruedConsultingFees_16"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PercentageOfBonusForAccruedConsultingFees" xlink:label="loc_embi_PercentageOfBonusForAccruedConsultingFees_17"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TotalFeesIncurredUnderAgreement" xlink:label="loc_embi_TotalFeesIncurredUnderAgreement_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_AccruedExpenseUnderAgreement" xlink:label="loc_embi_AccruedExpenseUnderAgreement_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:to="loc_embi_IndependentContractorAgreementMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_dei_LegalEntityAxis_4" order="10" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_4" xlink:to="loc_dei_EntityDomain_4" order="0" use="optional"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4" xlink:to="loc_embi_EmeraldHealthSciencesIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_7" xlink:to="loc_us-gaap_RelatedPartyDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7" xlink:to="loc_embi_AvtarDhillonMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7" xlink:to="loc_embi_OfficersEmployeesAndDirectorsMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_1" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_InitialTermOfAgreement_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_TotalExpenseIncurredUnderAgreement_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_MonthlyFee_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_MonthlyFeePaidEachMonthInExchangeOfServices_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_PercentageOfAccruedConsultingFees_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_PercentageOfBonusForAccruedConsultingFees_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_TotalFeesIncurredUnderAgreement_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_us-gaap_SharePrice_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_11" xlink:to="loc_embi_AccruedExpenseUnderAgreement_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_EmployeeMember" xlink:label="loc_embi_EmployeeMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ChiefMedicalOfficerMember" xlink:label="loc_embi_ChiefMedicalOfficerMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_StockOptions2014PlanMember" xlink:label="loc_embi_StockOptions2014PlanMember_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_20"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1" xlink:to="loc_us-gaap_SubsequentEventMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_srt_TitleOfIndividualAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_4" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_embi_EmployeeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4" xlink:to="loc_embi_ChiefMedicalOfficerMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_PlanNameAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8" xlink:to="loc_us-gaap_PlanNameDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8" xlink:to="loc_embi_StockOptions2014PlanMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_VestingAxis_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_11" xlink:to="loc_us-gaap_VestingDomain_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_11" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_11" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_15" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_15" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_15" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdvancesFairValueDisclosure" xlink:label="loc_us-gaap_AdvancesFairValueDisclosure_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertibleDebtNoncurrent" xlink:label="loc_us-gaap_ConvertibleDebtNoncurrent_2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_AdvancesFairValueDisclosure_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ConvertibleDebtNoncurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_19"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_21"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1" xlink:to="loc_us-gaap_PlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails2">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_OmnibusIncentivePlan2014Member" xlink:label="loc_embi_OmnibusIncentivePlan2014Member_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_14"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_srt_RangeAxis_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4" xlink:to="loc_srt_RangeMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4" xlink:to="loc_srt_MinimumMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4" xlink:to="loc_srt_MaximumMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_8" xlink:to="loc_us-gaap_PlanNameDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8" xlink:to="loc_embi_OmnibusIncentivePlan2014Member_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails1">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_7"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_1" xlink:to="loc_us-gaap_EarningsPerShareBasic_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_5" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/StockBasedCompensationDetails4">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_Pre2015CommonStockWarrantsMember" xlink:label="loc_embi_Pre2015CommonStockWarrantsMember_1"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandFifteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsToSeriesBStockholdersMember" xlink:label="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember" xlink:label="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember" xlink:label="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldFinancingWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember" xlink:label="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandNineteenCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_11"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember" xlink:label="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_12"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TwoThousandAndTwentyPreFundedWarrantsMember" xlink:label="loc_embi_TwoThousandAndTwentyPreFundedWarrantsMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_20"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_TermOfWarrant" xlink:label="loc_embi_TermOfWarrant_21"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_WarrantsVestedAndOutstanding" xlink:label="loc_embi_WarrantsVestedAndOutstanding_22"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_Pre2015CommonStockWarrantsMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandFifteenCommonStockWarrantsMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_CommonStockWarrantsToSeriesBStockholdersMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldFinancingWarrantsMember_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandNineteenCommonStockWarrantsMember_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyCommonStockWarrantsMember_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_1" xlink:to="loc_embi_TwoThousandAndTwentyPreFundedWarrantsMember_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_srt_RangeAxis_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_16" xlink:to="loc_srt_RangeMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MinimumMember_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_16" xlink:to="loc_srt_MaximumMember_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_TermOfWarrant_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_20" xlink:to="loc_embi_WarrantsVestedAndOutstanding_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6">
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsNoteDisclosureAbstract" xlink:label="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_2"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_4"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOfferedPriceMember" xlink:label="loc_us-gaap_MeasurementInputOfferedPriceMember_5"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_8"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_CommonStockWarrantsMember" xlink:label="loc_embi_CommonStockWarrantsMember_8"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PrefundedWarrantsMember" xlink:label="loc_embi_PrefundedWarrantsMember_9"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PlacementAgentWarrantsMember" xlink:label="loc_embi_PlacementAgentWarrantsMember_10"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelAxis" xlink:label="loc_embi_PricingModelAxis_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelDomain" xlink:label="loc_embi_PricingModelDomain_13"/>
    <loc xlink:type="locator" xlink:href="embi-20200930.xsd#embi_PricingModelMember" xlink:label="loc_embi_PricingModelMember_13"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_16"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17"/>
    <loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_18"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WarrantsAndRightsNoteDisclosureAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_1" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_1" xlink:to="loc_us-gaap_MeasurementInputOfferedPriceMember_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_8" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8" xlink:to="loc_embi_CommonStockWarrantsMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8" xlink:to="loc_embi_PrefundedWarrantsMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_8" xlink:to="loc_embi_PlacementAgentWarrantsMember_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_embi_PricingModelAxis_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelAxis_13" xlink:to="loc_embi_PricingModelDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_embi_PricingModelDomain_13" xlink:to="loc_embi_PricingModelMember_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_16" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210807480552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 05, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Emerald Bioscience, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001516551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,074,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804153080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash</a></td>
<td class="nump">$ 4,224,601<span></span>
</td>
<td class="nump">$ 1,829,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="nump">4,538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">116,226<span></span>
</td>
<td class="nump">152,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">3,333<span></span>
</td>
<td class="nump">7,550<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">4,348,698<span></span>
</td>
<td class="nump">1,994,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">4,349,585<span></span>
</td>
<td class="nump">1,996,743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">731,632<span></span>
</td>
<td class="nump">129,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="nump">21,400<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued interest due to related party</a></td>
<td class="nump">81,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">PPP loan current</a></td>
<td class="nump">71,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">263,830<span></span>
</td>
<td class="nump">420,406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative liabilities</a></td>
<td class="nump">41,149<span></span>
</td>
<td class="nump">410,603<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,210,926<span></span>
</td>
<td class="nump">970,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">PPP loan non-current</a></td>
<td class="nump">45,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MultidrawCreditAgreementRelatedPartyNoncurrent', window );">Multi-draw credit agreement - related party</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">789,694<span></span>
</td>
<td class="nump">387,070<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative liabilities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">90,797<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,496,218<span></span>
</td>
<td class="nump">1,448,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20,000,000 shares authorized; no shares issued and outstanding at September 30, 2020 and December 31, 2019</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 500,000,000 shares authorized; 250,074,415 and 182,895,247 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively</a></td>
<td class="nump">250,074<span></span>
</td>
<td class="nump">182,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in-capital</a></td>
<td class="nump">38,835,167<span></span>
</td>
<td class="nump">32,538,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(37,231,874)<span></span>
</td>
<td class="num">(32,173,282)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,853,367<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 4,349,585<span></span>
</td>
<td class="nump">$ 1,996,743<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MultidrawCreditAgreementRelatedPartyNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the multidraw credit agreement related party noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MultidrawCreditAgreementRelatedPartyNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210803169624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">250,074,415<span></span>
</td>
<td class="nump">182,895,247<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">250,074,415<span></span>
</td>
<td class="nump">182,895,247<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210807561912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 346,217<span></span>
</td>
<td class="nump">$ 513,004<span></span>
</td>
<td class="nump">$ 1,574,357<span></span>
</td>
<td class="nump">$ 1,522,031<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,192,003<span></span>
</td>
<td class="nump">990,110<span></span>
</td>
<td class="nump">3,395,729<span></span>
</td>
<td class="nump">3,267,037<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">1,538,220<span></span>
</td>
<td class="nump">1,503,114<span></span>
</td>
<td class="nump">4,970,086<span></span>
</td>
<td class="nump">4,789,068<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(1,538,220)<span></span>
</td>
<td class="num">(1,503,114)<span></span>
</td>
<td class="num">(4,970,086)<span></span>
</td>
<td class="num">(4,789,068)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other expense (income)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ChangeInFairValueOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(424,138)<span></span>
</td>
<td class="nump">3,126,464<span></span>
</td>
<td class="num">(433,688)<span></span>
</td>
<td class="num">(2,024,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">182,614<span></span>
</td>
<td class="nump">301,547<span></span>
</td>
<td class="nump">520,594<span></span>
</td>
<td class="nump">711,575<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense (income), net</a></td>
<td class="num">(241,524)<span></span>
</td>
<td class="nump">3,428,011<span></span>
</td>
<td class="nump">86,906<span></span>
</td>
<td class="num">(990,441)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(1,296,696)<span></span>
</td>
<td class="num">(4,931,125)<span></span>
</td>
<td class="num">(5,056,992)<span></span>
</td>
<td class="num">(3,798,627)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (1,296,696)<span></span>
</td>
<td class="num">$ (4,931,125)<span></span>
</td>
<td class="num">$ (5,058,592)<span></span>
</td>
<td class="num">$ (3,800,227)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Loss per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted average shares of common stock outstanding used to compute earnings per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">256,758,472<span></span>
</td>
<td class="nump">133,001,746<span></span>
</td>
<td class="nump">207,536,173<span></span>
</td>
<td class="nump">132,885,675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">257,255,653<span></span>
</td>
<td class="nump">133,001,746<span></span>
</td>
<td class="nump">208,434,966<span></span>
</td>
<td class="nump">167,690,989<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ChangeInFairValueOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ChangeInFairValueOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantLiabilityInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804324216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (5,058,592)<span></span>
</td>
<td class="num">$ (3,800,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">1,096<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">241,216<span></span>
</td>
<td class="nump">514,683<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueAdjustmentOfDerivativeLiabilities', window );">Change in fair value of derivative liabilities</a></td>
<td class="num">(433,688)<span></span>
</td>
<td class="num">(2,024,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilityExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">402,624<span></span>
</td>
<td class="nump">438,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">36,469<span></span>
</td>
<td class="num">(302,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Other current assets</a></td>
<td class="nump">4,217<span></span>
</td>
<td class="num">(766)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">601,823<span></span>
</td>
<td class="nump">191,333<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent', window );">Accounts payable to related party</a></td>
<td class="nump">11,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty', window );">Accrued interest due to related party</a></td>
<td class="nump">81,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="num">(156,576)<span></span>
</td>
<td class="nump">134,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(4,268,198)<span></span>
</td>
<td class="num">(4,524,712)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from the sale of common stock and warrants - net of $854,078 issuance costs for September 30, 2020</a></td>
<td class="nump">6,085,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from multi-draw credit agreement - related party, net of $0 and $9,301 issuance costs for the September 30, 2020 and September 30, 2019 periods, respectively</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">3,990,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from PPP loan</a></td>
<td class="nump">116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsFromPreFundedWarrantExercises', window );">Proceeds from pre-funded warrant exercises</a></td>
<td class="nump">10,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">6,662,822<span></span>
</td>
<td class="nump">3,990,699<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and restricted cash</a></td>
<td class="nump">2,394,624<span></span>
</td>
<td class="num">(534,013)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, beginning of period</a></td>
<td class="nump">1,834,515<span></span>
</td>
<td class="nump">1,857,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and restricted cash, end of period</a></td>
<td class="nump">4,229,139<span></span>
</td>
<td class="nump">1,323,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and restricted cash:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CashAndCashEquivalents', window );">Cash</a></td>
<td class="nump">4,224,601<span></span>
</td>
<td class="nump">1,319,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SupplementalRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">4,538<span></span>
</td>
<td class="nump">4,512<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated', window );">Total cash and restricted cash shown in the consolidated statements of cash flows</a></td>
<td class="nump">4,229,139<span></span>
</td>
<td class="nump">1,323,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CashPaidDuringPeriodForAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">35,645<span></span>
</td>
<td class="nump">272,611<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ExerciseOfWarrants', window );">Reclassification of warrant liabilities to equity from exercise of warrants</a></td>
<td class="nump">$ 26,563<span></span>
</td>
<td class="nump">144,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement', window );">Proceeds allocated to equity classified warrants issued with convertible multi-draw credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement', window );">Fair value of compound derivative liability bifurcated from convertible multi-draw credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">193,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement', window );">Beneficial conversion feature on convertible multi-draw credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,584,850<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of beneficial conversion feature recorded on advances under the convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_BeneficialConversionFeatureOnConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of Cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CashPaidDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CashPaidDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount express exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueAdjustmentOfDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents fair value adjustment of derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueAdjustmentOfDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial fair value of the compound derivative liability that was bifurcated from advances under the convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfCompoundDerivativeLiabilityIssuedWithConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfDerivativeLiabilityExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents fair value of derivative liability excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfDerivativeLiabilityExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_IncreaseDecreaseAccruedInterestDueToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase decrease in accrued interest due to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_IncreaseDecreaseAccruedInterestDueToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of proceeds allocated on a relative fair value basis to equity classified warrants issued with convertible multi-draw credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ProceedsAllocatedToEquityClassifiedWarrantsIssuedWithConvertibleMultiDrawCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ProceedsFromPreFundedWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from pre-funded warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ProceedsFromPreFundedWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SupplementalRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of supplemental restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SupplementalRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of total cash, cash equivalents and restricted cash shown in the consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TotalCashEquivalentsAndRestrictedCashShownInConsolidated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the current portion (due within one year or one business cycle, whichever is longer) of the amount owed by the reporting entity in the form of loans and obligations (generally evidenced by promissory notes) made by the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; an entity and its principal owners, management, or member of their immediate families; affiliates; or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInNotesPayableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210807339416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet', window );">Proceeds from the sale of common stock and warrants net</a></td>
<td class="nump">$ 854,078<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Common stock issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,301<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the proceeds from issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ProceedsFromIssuanceOfCommonStockAndWarrantsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210805015240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">$ 17,528,947<span></span>
</td>
<td class="num">$ (33,225,107)<span></span>
</td>
<td class="num">$ (15,562,252)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,493<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi-draw credit agreement, related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Beneficial conversion feature in connection with convertible multi-draw credit agreement - related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,774,392)<span></span>
</td>
<td class="num">(14,774,392)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">20,001,400<span></span>
</td>
<td class="num">(47,999,499)<span></span>
</td>
<td class="num">(27,864,191)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">17,528,947<span></span>
</td>
<td class="num">(33,225,107)<span></span>
</td>
<td class="num">(15,562,252)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2018</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,800,227)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 134,095<span></span>
</td>
<td class="nump">20,488,778<span></span>
</td>
<td class="num">(37,025,334)<span></span>
</td>
<td class="num">(16,402,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">134,095,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2019</a></td>
<td class="nump">$ 133,908<span></span>
</td>
<td class="nump">20,001,400<span></span>
</td>
<td class="num">(47,999,499)<span></span>
</td>
<td class="num">(27,864,191)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2019</a></td>
<td class="nump">133,907,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,084<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises', window );">Series B warrant exercises</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">144,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises', window );">Series B warrant exercises (in shares)</a></td>
<td class="nump">187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,905,290<span></span>
</td>
<td class="nump">15,905,290<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2019</a></td>
<td class="nump">$ 134,095<span></span>
</td>
<td class="nump">20,318,672<span></span>
</td>
<td class="num">(32,094,209)<span></span>
</td>
<td class="num">(11,641,442)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2019</a></td>
<td class="nump">134,095,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,931,125)<span></span>
</td>
<td class="num">(4,931,125)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2019</a></td>
<td class="nump">$ 134,095<span></span>
</td>
<td class="nump">20,488,778<span></span>
</td>
<td class="num">(37,025,334)<span></span>
</td>
<td class="num">(16,402,461)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Sep. 30, 2019</a></td>
<td class="nump">134,095,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 182,895<span></span>
</td>
<td class="nump">32,538,445<span></span>
</td>
<td class="num">(32,173,282)<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">182,895,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises', window );">Series B warrant exercises</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">26,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises', window );">Series B warrant exercises (in shares)</a></td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,341,660)<span></span>
</td>
<td class="num">(2,341,660)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 183,208<span></span>
</td>
<td class="nump">32,628,837<span></span>
</td>
<td class="num">(34,514,942)<span></span>
</td>
<td class="num">(1,702,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 182,895<span></span>
</td>
<td class="nump">32,538,445<span></span>
</td>
<td class="num">(32,173,282)<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">182,895,247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,058,592)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 250,074<span></span>
</td>
<td class="nump">38,835,167<span></span>
</td>
<td class="num">(37,231,874)<span></span>
</td>
<td class="nump">1,853,367<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">250,074,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2020</a></td>
<td class="nump">$ 183,208<span></span>
</td>
<td class="nump">32,628,837<span></span>
</td>
<td class="num">(34,514,942)<span></span>
</td>
<td class="num">(1,702,897)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Mar. 31, 2020</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,709<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,709<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,420,236)<span></span>
</td>
<td class="num">(1,420,236)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Jun. 30, 2020</a></td>
<td class="nump">$ 183,208<span></span>
</td>
<td class="nump">32,657,546<span></span>
</td>
<td class="num">(35,935,178)<span></span>
</td>
<td class="num">(3,094,424)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Jun. 30, 2020</a></td>
<td class="nump">183,207,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148,365<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants', window );">Common stock and warrants issued</a></td>
<td class="nump">$ 56,333<span></span>
</td>
<td class="nump">6,029,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,085,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants', window );">Common stock and warrants issued (in shares)</a></td>
<td class="nump">56,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants</a></td>
<td class="nump">$ 10,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,533<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants', window );">Exercise of pre-funded warrants (in shares)</a></td>
<td class="nump">10,533,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,296,696)<span></span>
</td>
<td class="num">(1,296,696)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2020</a></td>
<td class="nump">$ 250,074<span></span>
</td>
<td class="nump">$ 38,835,167<span></span>
</td>
<td class="num">$ (37,231,874)<span></span>
</td>
<td class="nump">$ 1,853,367<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Sep. 30, 2020</a></td>
<td class="nump">250,074,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents beneficial conversion feature in connection with convertible multi-draw credit agreement - related party value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_BeneficialConversionFeatureInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares related to issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodSharesCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of shares related to exercise of pre-funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodSharesExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Series B warrant exercises for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodSharesSeriesBWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodValueCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to issuance of common stock and warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodValueCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to exercise of pre funded warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodValueExerciseOfPreFundedWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of Series B warrant exercises for common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_StockIssuedDuringPeriodValueSeriesBWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants issued in connection with convertible multi draw credit agreement related party value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210811288184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Business Activities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Nature of Operations and Business Activities</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><strong>1. Nature of Operations and Business Activities</strong></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><strong><i>Nature of Operations</i></strong></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span>Emerald Bioscience, Inc. (the &#x201c;Company&#x201d;) was initially incorporated in Nevada on March 16, 2011 as Load Guard Logistics, Inc. On October 31, 2014, the Company closed a reverse merger transaction (the &#x201c;Merger&#x201d;) pursuant to which Nemus, a California corporation (&#x201c;Nemus Sub&#x201d;), became the Company&#x2019;s wholly-owned subsidiary, and the Company assumed the operations of Nemus Sub. Nemus Sub was incorporated in the State of California on July 17, 2012. On November 3, 2014, the Company changed its name to Nemus Bioscience, Inc. by merging with Nemus </span></span></span></span></span></span></span></span></span><span><span>Sub to form a Nevada company.</span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>In January 2018, the Company entered into a securities purchase agreement with Emerald Health Sciences, Inc. (&#x201c;Emerald Health Sciences&#x201d;), pursuant to which Emerald Health Sciences purchased a majority of the equity interest in the Company, resulting in a change in control (the &#x201c;Emerald Financing&#x201d;). As part of the transaction, the Company&#x2019;s Board members, with the exception of Dr. Brian Murphy, the Company&#x2019;s CEO/CMO, tendered their resignation and Emerald Health Sciences appointed two new nominees to the Board. Later, in October 2018, the Board appointed Dr. Avtar Dhillon, the Chairman, Chief Executive Officer and President of Emerald Health Sciences, as the Executive Chairman of the Company&#x2019;s Board. On August 7, 2020, Dr. Brian Murphy resigned and Punit Dhillon was appointed as the Chief Executive Officer of the Company.</span></span></span></span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>On February 11, 2019, the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) and majority stockholder unanimously approved an amendment to the Company&#x2019;s articles of incorporation to change the name of the Company to Emerald Bioscience, Inc. Effective March 25, 2019, the Company filed a Certificate of Amendment with the Nevada Secretary of State changing the Company&#x2019;s name to Emerald Bioscience, Inc.</span></span></span></span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span>In August 2019, the Company formed a new subsidiary in Australia, EMBI Australia Pty Ltd., an Australian proprietary limited company (&#x201c;EMBI Australia&#x201d;), in order to qualify for the Australian government&#x2019;s research and development tax credit for research and development dollars spent in Australia. The primary purpose of EMBI Australia is to conduct clinical trials for the Company&#x2019;s product candidates.</span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Company&#x2019;s Board and the Company entered into a Board Observer Agreement with Emerald Health Sciences. Refer to Note 8 - Related Party Matters for additional information.</span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span>The Company is a biopharmaceutical company located in </span></span></span></span></span></span></span>San Diego<span><span><span><span><span><span><span>, California that plans to research, develop and commercialize therapeutics derived from cannabinoids through several license agreements with the University of Mississippi (&#x201c;UM&#x201d;). UM is the only entity federally permitted and licensed to cultivate cannabis for research purposes in the United States.</span></span></span></span></span></span></span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of September 30, 2020, the Company has devoted substantially all its efforts to securing product licenses, carrying out research and development, building infrastructure and raising capital. The Company has not yet realized revenue from its planned principal operations and is a number of years away&#160;from potentially being able to do so.</span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><span><span><span><strong><i>Liquidity and Going Concern</i></strong></span></span></span></span></span></span></span></span></span></span></span></p><p style="margin:0px;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company has incurred operating losses and negative cash flows from operations since inception and as of September 30, 2020, had an accumulated deficit of $37,231,874, stockholders&#x2019; equity of $1,853,367 and working capital of $3,137,772. The Company anticipates operating losses and negative cash flows from operations into the foreseeable future in order to advance and develop&#160;potential drug candidates into preclinical and clinical development activities and support its corporate infrastructure which includes the costs associated with being a public company. As of September 30, 2020, the Company had unrestricted cash in the amount of $4,224,601 as compared to $1,829,977 as of December 31, 2019.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As the Company approaches its first clinical trial, it expects to ramp up research and development spending and&#160;to increase cash used in operating activities. However, based on the Company&#x2019;s expected cash requirements, without obtaining additional funding management believes that the Company will not have enough funds to commence clinical studies. These conditions give rise to substantial doubt as to the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying Condensed Consolidated Financial Statements do not include any adjustments that might result from the outcome of this uncertainty.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company&#x2019;s continued existence is dependent on its ability to raise sufficient additional funding to cover operating expenses and to carry out its research and development activities. On October 5, 2018, the Company entered into a Multi-Draw Credit Agreement (the &#x201c;Credit Agreement&#x201d;) with Emerald Health Sciences (See Note 4).</span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 29, 2020, the Company entered into an Amended and Restated Multi-Draw Credit Agreement (the &#x201c;Amended Credit Agreement&#x201d;) with Emerald Health Sciences, which amends and restates the Credit Agreement. The Amended Credit Agreement provides for a credit facility in the principal amount of up to $20,000,000, which includes, without limitation, the advances totaling $6,000,000 that were granted prior to the amendment.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>Prior to the date of the Amended Credit Agreement, the Company had made three drawdowns in an aggregate principal amount of $6,000,000, and had issued to Emerald Health Sciences warrants to purchase an aggregate of 7,500,000 shares of common stock of the Company at an exercise price of $0.50 per share of Common Stock, in accordance with the terms of the Credit Agreement.</span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the nine months ended September 30, 2020, the Company effected the fourth and fifth advances under the Amended Credit Agreement in the amounts of $150,000 and $300,000, respectively. The advances bear interest at 7% per annum and mature on October 5, 2022. The Company used the proceeds from the advances for general corporate and working capital purposes. Emerald Health Sciences elected that the fourth and fifth advances are not convertible into shares of Common Stock and no warrants were issued with the advances.</span></span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 22, 2020, the Company entered into a Paycheck Protection Program Promissory Note in the principal amount of $116,700 (the &#x201c;PPP Loan&#x201d;) from City National Bank (the &#x201c;PPP Loan Lender&#x201d;). The PPP Loan was obtained pursuant to the Paycheck Protection Program (the &#x201c;PPP&#x201d;) of the Coronavirus Aid, Relief, and Economic Security Act (the &#x201c;CARES Act&#x201d;) administered by the U.S. Small Business Administration (&#x201c;SBA&#x201d;) (Note 4).</span></span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On July 31, 2020, the Company entered into the August 2020 Financing (Note 5), pursuant to which the Company sold 56,333,334 common stock units each consisting of one share of common stock and one common stock warrant and 60,333,334 pre-funded units each consisting of one pre-funded warrant and one common stock warrant in a registered public offering. The net proceeds from the transaction were $6.1 million. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The term of the common stock warrants is five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full. The Company intends to use the net proceeds of the offering for general corporate purposes, including working capital.</span></span></p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely. Upon the closing of the August 2020 Financing, the Company&#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>The Company plans to continue to pursue funding through public or private equity or debt financings, licensing arrangements, asset sales, government grants or other arrangements. However, the Company cannot provide any assurances that such additional funds will be available on reasonable terms, or at all. If the Company raises additional funds by issuing equity securities, substantial dilution to existing stockholders would result.</span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>In December 2019, a novel strain of coronavirus (&#x201c;COVID-19&#x201d;) emerged in Wuhan, China. Since then, it has spread to the United States and infections have been reported around the world. On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a global pandemic, which continues to spread throughout the United States, Australia and around the world, where the Company has operations and conducts laboratory research and clinical studies. In response to the outbreak, federal and state authorities in the United States have introduced various recommendations and measures to try to limit the pandemic, including travel restrictions, border closures, nonessential business closures, quarantines, self-isolations, shelters-in-place and social distancing. The COVID-19 outbreak and the response of governmental authorities to try to limit it are having a significant impact on the private sector and individuals, including unprecedented business, employment and significant economic disruptions to the global financial markets. These disruptions are likely to impact the Company&#x2019;s ability to raise additional capital and obtain the necessary funds.</span></span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Notably, the Company relies on third-party manufacturers to produce its product candidates. The manufacturing of the active pharmaceutical ingredient of THCVHS is conducted in the United States. Formulation of the eye drop for testing is also performed in the United States but can rely on regulatory-accepted excipients that can be sourced from countries outside the United States, such as China. In connection with the recent pandemic of a COVID-19, there could possibly be an impact on sourcing materials that are part of the eye drop formulation, as well as impacting volunteer and/or patient recruitment in Australia for clinical studies. The location of the proposed clinical trial is Melbourne, Australia and since the COVID-19 outbreak in that country, the city has experienced multiple health emergency lockdowns which have had a negative impact on the conduct and timelines of clinical studies. Therefore, the Company has shifted its first-in-human studies of THCVHS from the second half of 2020, to the 2021 timeframe.</span></span></p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>After considering the plans to alleviate substantial doubt, management has concluded that there is substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the financial statements are issued.</span></span></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210816618616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="MARGIN:0px 0px 0px 1.05pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2. Summary of Significant Accounting Policies</strong></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Basis of Presentation</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&#x2019;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&#x2019;s audited financial statements as of December 31, 2019, which are included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&#x2019;s business and the risks inherent therein.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Use of Estimates</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</span></span></p></div><p style="MARGIN:0px;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Risks and Uncertainties</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#x2019;s ability to attract new funding.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Fair Value Measurements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#x201c;exit price&#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:6%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></span></p></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying values of the Company&#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3). The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&#x2019;s relatively short term the carrying value approximates fair value. As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#x2019;s Condensed Consolidated Balance Sheets. As of September 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Convertible Instruments</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities (&#x201c;ASC 815&#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&#x201c;ASC 470-20&#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also follows ASC 480-10, Distinguishing Liabilities from Equity (&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#x2019;s S&amp;P 500 Index and settled with a variable number of the issuer&#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive Loss.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Warrants Issued in Connection with Financings</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive Loss .</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Debt Issuance Costs and Interest</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Research and Development Expenses and Licensed Technology</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</span></span></p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Stock-Based Compensation Expense </strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%"><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="width:4%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividends - The dividend yield assumption is based on the Company&#x2019;s history and expectation of paying no dividends in the foreseeable future.</span></span></p></td></tr></tbody></table></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Loss&#160;Per Common Share</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">The Company applies FASB ASC No. 260, <em>Earnings per Share</em> in calculating its basic and diluted net loss per common share. Basic loss per share of common stock is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The computations of basic and diluted net loss per common share are as follows:</p><div><div><div><table border="0" cellpadding="0" cellspacing="0" style="width:100%;border:0px;font-size:10pt;border-collapse:collapse;margin:auto" width="90%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="5" rowspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><strong>Three Months<br/>Ended September 30,<br/>(Unaudited)</strong></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="5" rowspan="1" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black"><strong>Nine Months<br/>Ended September 30,<br/>(Unaudited)</strong></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif">&#160;</span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2020</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2019</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2020</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2019</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:56%" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="line-height:normal;font-size:10pt;font-family:Times New Roman, serif">Basic net loss per share:</span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(1,296,696</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(4,931,125</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,058,592</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(3,800,227</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Weighted average common shares outstanding &#x2013; basic</span></span></span></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">256,758,472</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">133,001,746</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">207,536,173</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">132,885,675</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss per share - basic</span></span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.01</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.04</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.02</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif">&#160;</span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Diluted net loss per share:</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss (as adjusted)</span></span></span></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(1,720,835</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(4,931,125</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,401,484</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,656,982</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Weighted average common shares outstanding &#x2013; diluted</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">257,255,653</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">133,001,746</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">208,434,966</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">167,690,989</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss per share - diluted</span></span></span></strong></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.01</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.04</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr></tbody></table></div></div></div></div></div><div>&#160;</div></div><div><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:</p><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Three Months </strong></p><p style="margin:0px;text-align:center"><strong>Ended September 30, </strong></p><p style="margin:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months </strong></p><p style="margin:0px;text-align:center"><strong>Ended September 30, </strong></p><p style="margin:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Stock options</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">25,000,678</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4,512,715</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">25,000,678</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4,512,715</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Unvested restricted stock</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1,093,501</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1,093,501</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Common shares underlying convertible debt</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5,215,457</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">15,000,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5,215,457</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">15,000,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">145,336,155</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">57,943,250</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">144,934,542</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div></div></div></div></div><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify">&#160;</p><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Recent Accounting Pronouncements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2020, the FASB issued ASU 2020-06, Debt&#x2014;<em>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity.</em> This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2019, the FASB issued ASU No. 2019-12 <em>Income Taxes</em> (Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</span></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210807481016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsAndDerivativeLiabilitiesAbstract', window );"><strong>Warrants And Derivative Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsAndDerivativeLiabilitiesTextBlock', window );">Warrants and Derivative Liabilities</a></td>
<td class="text"><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong>3. Warrants and Derivative Liabilities</strong></span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><span><span><span><span><strong><i>Warrants</i></strong></span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>There are significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s warrants. These judgments and estimates include assumptions regarding the Company&#x2019;s future operating performance, the time to completing a liquidity event and the determination of the appropriate valuation methods. If the Company had made different assumptions, the fair value of the warrants could have been significantly different (See Note 2).</span></span></span></span></p><p style="MARGIN:0px">&#160;</p><p><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Warrants vested and outstanding as of September 30, 2020 are summarized as follows:</span></span></p><div><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"><p style="margin:0px;text-align:center"><strong>Number of</strong></p><p style="margin:0px;text-align:center"><strong>Warrants</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"><p style="margin:0px;text-align:center"><strong>Exercise</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"><p style="margin:0px;text-align:center"><strong>Term</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"><p style="margin:0px;text-align:center"><strong>Vested and</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:justify"><strong>Source</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Price</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>(Years)</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Outstanding</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Pre 2015 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">1.00</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:right">6&#x2014;10</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1,110,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2015 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td>$</td><td><p style="margin:0px;text-align:right">1.15&#x2014;5.00</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:right">5&#x2014;10</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">220,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2016 Common Stock Warrants to Service Providers</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">1.15</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">10</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">40,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2016 Series C Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.40</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">125,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2017 Series D Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.25</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">480,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2017 Common Stock Warrants to Service Provider</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.41</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">125,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2018 Emerald Financing Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.10</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">3,400,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Emerald Multi-Draw Credit Agreement Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.50</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">7,500,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2019 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.35</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">8,000,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2020 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.06</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">116,666,668</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2020 Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.075</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4.99</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">8,166,667</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2020 Pre-Funded Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">0.001</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:right">indefinite</p></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">49,800,000</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Total warrants vested and outstanding as of September 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>195,633,335</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div></div></div><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em>Emerald Multi-Draw Credit Agreement Warrants</em></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><p style="margin:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the nine months ended September 30, 2019</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>, the Company issued<span><span><span><span> 5,000,000 fully vested common stock warrants to Emerald Health Sciences, in conjunction with advances under the Credit Agreement discussed below (See Note 4). The warrants were equity classified at issuance and the Company allocated an aggregate of $716,110 of the gross proceeds to the warrants on a relative fair value basis. The proceeds allocated to the warrants were recorded as discounts to each advance and are being amortized over the term of the debt. The warrants vested immediately and had an estimated aggregate fair value of $1,830,573 utilizing the Black-Scholes Merton option pricing model with the following assumptions:</span></span></span></span></span></span></span></span></p><p style="MARGIN:0px">&#160;</p><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:15%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>At</strong></p><p style="margin:0px;text-align:center"><strong>Issuance</strong></p></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Dividend yield</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap"><p style="margin:0px;text-align:center">0.00%</p></td><td style="white-space:nowrap">&#160;</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Volatility factor</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">91.6&#x2014;92.1</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Risk-free interest rate</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">2.23&#x2014;2.51</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Expected term (years)</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap"><p style="margin:0px;text-align:center">5.0</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Underlying common stock price</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">$0.33&#x2014;0.69</p></td></tr></tbody></table></div></div><p style="MARGIN:0px;text-align:justify">&#160;</p></div><p style="MARGIN:0px">&#160;</p><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em>August 2020 Financing Warrants </em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">In connection with the August 2020 Financing (Note 5), the Company issued 116,666,668 common stock warrants, 8,166,667 common stock warrants to the placement agent and 60,333,334 pre-funded warrants. The warrants were equity classified at issuance and the Company allocated $2,462,462 and $2,986,500 of the gross proceeds to the common stock warrants and pre-funded warrants on a relative fair value basis, respectively. The common stock warrants issued to the placement agent were valued at $261,333 and recorded as equity issuance costs within equity. The warrants vested immediately and were valued utilizing the Black-Scholes Merton option pricing model with the following assumptions:</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Common Stock Warrants</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Pre-funded</strong></p><p style="margin:0px;text-align:center"><strong>Warrants</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Placement Agent Warrants</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Dividend yield</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Volatility factor</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">91.64</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">93.86</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">91.64</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Risk-free interest rate</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.19</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.52</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.19</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Expected term (years)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5.0</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">10</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4.99</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Underlying common stock price</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.05</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.05</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.05</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p></div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Derivative Liabilities</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The following tables summarize the activity of derivative liabilities for the periods indicated:</span></span></p><div><div><div><p style="MARGIN:0px;text-align:justify">&#160;</p><div><div><div><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="18" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months Ended September 30, 2020</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>December 31,</strong></p><p style="margin:0px;text-align:center"><strong>2019,</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities Issued</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Change in</strong></p><p style="margin:0px;text-align:center"><strong>Fair value of </strong></p><p style="margin:0px;text-align:center"><strong>Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Reclassification</strong></p><p style="margin:0px;text-align:center"><strong>of Derivatives</strong></p><p style="margin:0px;text-align:center"><strong>to Equity </strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>September 30,</strong></p><p style="margin:0px;text-align:center"><strong>2020,</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">90,797</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">(90,797</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px">Emerald Financing - warrant liability <sup>(2)</sup></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">276,024</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">(234,875</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">41,149</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Series B - warrant liability <sup>(3)</sup></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">134,579</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">&#x2014;</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(108,016</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(26,563</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">&#x2014;</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Total derivative liabilities</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>501,400</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>&#x2014;</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>(433,688</strong></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"><strong>)</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>(26,563</strong></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"><strong>)</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>41,149</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Less, noncurrent portion of derivative liabilities</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(90,797</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">&#x2014;</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px"><strong>Current balance of derivative liabilities</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>410,603</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>41,149</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><span style="font-size:10pt">&#160; &#160;</span></p><div><div><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="18" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months Ended September 30, 2019</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>December 31,</strong></p><p style="margin:0px;text-align:center"><strong>2018,</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p><p style="margin:0px;text-align:center"><strong>Issued</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Change in</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Reclassification</strong></p><p style="margin:0px;text-align:center"><strong>of Derivatives</strong></p><p style="margin:0px;text-align:center"><strong>to Equity</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>September 30,</strong></p><p style="margin:0px;text-align:center"><strong>2019,</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Emerald Multi Draw Credit Agreement - compound derivative liability (1)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">219,453</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">516,058</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">(167,905</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">567,606</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Emerald Financing - warrant liability (2)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">15,251,413</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">(1,895,193</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">13,356,220</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Series B - warrant liability (3)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">487,500</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">&#x2014;</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">38,438</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(144,375</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">381,563</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Total derivative liabilities</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><strong>15,958,366</strong></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>516,058</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>(2,024,660</strong></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"><strong>)</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>(144,375</strong></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"><strong>)</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><strong>14,305,389</strong></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Less, noncurrent portion of derivative liabilities</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(219,453</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(567,606</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Current balance of derivative liabilities</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>15,738,913</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>13,737,783</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p></div></div></div></div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160; &#160;</span></span></p></div></div><div><div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em>Emerald Multi-Draw Credit Agreement Compound Derivative Liability (1)</em></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In connection with the advances under the Credit Agreement (See Note 4), the Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to Emerald Health Sciences. The Company&#x2019;s estimate of fair value of the compound derivative liability was determined by using a differential cash flows valuation model, wherein the fair value of the underlying debt facility and its conversion right are estimated both with and without the presence of the contingent interest feature, holding all other assumptions constant. The resulting difference between the estimated fair values in both scenarios is the estimated fair value of the compound derivative. The fair value of the underlying debt facility was estimated by calculating the expected cash flows with consideration of the estimated probability of a change in control transaction, defined as an event of default by the agreement, and applying the expected default interest rate from the date of such default through maturity. The expected cash flows are then discounted back to the reporting date using a benchmark market yield. The conversion right component of the compound derivative was measured using a standard Black-Scholes model for each payment period.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">On April 29, 2020, the Company entered into the Amended Credit Agreement which removed the change in control provision as an event of default for advances before and after the amendment. As a result of the modification, the contingent interest feature component of the compound derivative is no longer required to be bifurcated as a derivative liability. During the nine months ended September 30, 2020, the liability has been reduced to $0 through an adjustment to the change in fair value of derivative liabilities.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Because Emerald Health Sciences would forgo the contingent interest if the contingent put option was exercised upon an event of default, the value ascribed to the contingent put option within the compound derivative is considered de minimis before and after the amendment to the Credit Agreement.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em>Emerald Financing Warrant Liability (2)</em></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In January and February 2018, the Company issued 44,200,000 warrants to purchase common stock in conjunction with the Emerald Financing. The warrants vest immediately and have an exercise price of $0.10 per share with a term of five years and are exercisable in cash or through a cashless exercise provision. </span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The warrants contained an anti-dilution protection feature that provided the investors with price protection if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the exercise price of $0.10. In connection with the August 2020 Financing, this provision was waived, and the exercise price was permanently set to $0.10. In addition, the warrants contain a contingent put option if the Company undergoes a subsequent financing that results in a change in control. The warrant holders also have the right to participate in subsequent financing transactions on an as-if converted basis.</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2019, Emerald Health Sciences paid the aggregate exercise price of $4,080,000 in the form of a reduction of the corresponding amount of obligations outstanding under the Credit Agreement to exercise 40,800,000 Emerald Financing Warrants. Under the Warrant Exercise Agreement between the Company and Emerald Health Sciences, the proceeds from the warrants were first applied directly to the accrued interest balance at the exercise date with the remainder applied to the oldest outstanding principal balances under the Credit Agreement. Immediately prior to exercise, the warrants were adjusted to fair value which considered the closing trading price on the exercise date (See Note 4).</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company reviewed the warrants for liability or equity classification under the guidance of ASC 480-10, <em>Distinguishing Liabilities from Equity</em>, and concluded that the warrants should be classified as a liability and re-measured to fair value at the end of each reporting period. The Company also reviewed the warrants under ASC 815, <em>Derivatives and Hedging/Contracts in Entity</em><em>&#x2019;</em><em>s Own Equity</em>, and determined that the warrants also meet the definition of a derivative. With the assistance of a third-party valuation specialist, the Company valued the warrant liabilities utilizing the Monte Carlo valuation method pursuant to the accounting guidance of ASC 820-10, <em>Fair Value Measurement</em>s.</span></span></p></div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The warrant liabilities were valued using Monte Carlo simulations conducted at the balance sheet dates using the following assumptions:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>September 30, </strong></p><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>December 31, </strong></p><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Dividend yield</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Volatility factor</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">80.8</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">79.5</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Risk-free interest rate</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.14</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1.62</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Expected term (years)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">2.38</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">3.13</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Underlying common stock price</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.04</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.13</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p></div></div></div><p style="MARGIN:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em>Series B Warrant Liability (3)</em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In conjunction with the Redeemable Convertible Series B Preferred Stock financing, the Company issued the 2015 Series B Financing Warrants originally exercisable at a price of $1.15 per share. The warrants are exercisable in cash or through a cashless exercise provision and contain certain cash redemption rights. </span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">The Series B Financing Warrants also had a &#x201c;down-round&#x201d; protection feature if the Company subsequently issued or sold any shares of common stock, stock options, or convertible securities at a price less than the current exercise price.</span></span>&#160;<span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> The down round provision was triggered and automatically adjusted down to $0.10 on December 28, 2017, after the Company entered into the Convertible Promissory Note (See Note 4) and again to $0.00 on January 19, 2018, as a result of the Emerald Financing. The strike price for these warrants is now permanently reset. </span></span><span style="font-family:Times New Roman,Times,serif"><span style="font-size:10pt">However, because the remaining warrant holders still had certain cash redemption rights upon the occurrence of certain fundamental transactions, as defined in the Series B Financing Warrant agreements, the warrants continued to require liability classification. Subsequent to the repricing that occurred as a result of the Emerald Financing, the warrants have been valued using a Black Scholes Merton Option Pricing Model.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">To compute the fair value of the warrants, the Company utilized the following assumptions in the Black Scholes Merton Option Pricing Model for the periods indicated:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.2</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.60</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.64</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">During the nine months ended September 30, 2020</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">, 312,500 Series B Common Stock Warrants with an intrinsic value of $26,563 were exercised for no consideration per share, which resulted in the issuance of 312,500 shares of common stock. </span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Prior to exercise, these Series B Common Stock Warrants were adjusted to fair value using a Black Scholes Merton Option Pricing Model which considered the closing trading price on the exercise dates.</span></span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"> Because the exercise price of these options had been reset to $0.00, the fair value derived from the valuation model approximated the market value of the Company&#x2019;s common stock on the exercise dates.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of September 30, 2020, the remaining Series B Common Stock Warrants expired unexercised.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsAndDerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsAndDerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsAndDerivativeLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Warrants and Derivative Liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsAndDerivativeLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210822185128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>4. Debt</strong></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><em><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Multi-Draw Credit Agreement- Related Party</span></em></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Company&#x2019;s Debt with Emerald Health Sciences consists of the following:</span></p><div><div><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:#000000 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Conversion</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Price</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>As of</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>September 30,</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>As of</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>December 31,</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Total principal value of convertible debt&#x2014;related party</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0.40</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2,014,500</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2,014,500</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unamortized debt discount</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1,220,838</span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1,622,344</span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unamortized debt issuance costs</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(3,968</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(5,086</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Carrying value of total convertible debt - related party</strong></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>789,694</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>387,070</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Total principal value of non-convertible debt&#x2014;related party</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">n/a</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">450,000</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>&#x2014;</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>1,239,694</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>387,070</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div><p style="margin:0px">&#160;</p><div><div><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span>On October 5, 2018, the Company entered into the Credit Agreement with Emerald Health Sciences, a related party (See Note 8). On April 29, 2020, the Company entered into the Amended Credit Agreement with Emerald Health Sciences, which amends and restates the Credit Agreement.&#160;For all pre-existing and new advances, the Amended Credit Agreement removed the change in control as an event of default (See Note 3) and defers the quarterly payment of interest until the Company completes a capital raise of at least $5,000,000. </span>As of September 30, 2020, interest is no longer being deferred as a result of the August 2020 Financing.&#160;<span>The amendments to the pre-existing advances were accounted for as a modification. For all advances made after the Credit Agreement was amended, advances will be convertible at a reduced conversion price of $0.25 per share of Common Stock, unless Emerald Health Sciences provides notice that the advance will not be convertible.</span></span></span></div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">For all outstanding advances, the Amended Credit Agreement provides for a credit facility to the Company of up to $20,000,000 and is unsecured. Advances under the </span><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Amended</span></span>&#160;<span style="font-size:10pt;font-family:Times New Roman, Times, serif">Credit Agreement bear interest at an annual rate of 7% and mature on October 5, 2022. At Emerald Health Sciences&#x2019; election, convertible advances and unpaid interest may be converted into common stock at the fixed conversion price of the underlying advance, subject to customary adjustments for stock splits, stock dividends, recapitalizations, etc. As of September&#160;30, 2020, the unused portion of the credit facility is $13,550,000. The drawdowns are subject to approval by the Company&#x2019;s Board, which is controlled by the directors of Emerald Health Sciences. As such, the Company does not consider the facility available until advance requests are approved, drawn down and funded. The Amended Credit Agreement is still in place;&#160;however, there is no guarantee of continued funding.</span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Amended Credit Agreement provides for customary events of default which may result in the acceleration of the maturity of the advances in addition to, but not limited to, cross acceleration to certain other indebtedness of the Company. In the case of an event of default arising from specified events of bankruptcy or insolvency or reorganization, all outstanding advances will become due and payable immediately without further action or notice. If any other event of default under the Amended Credit Agreement occurs or is continuing, Emerald Health Sciences may, by written notice, terminate its commitment to make any advances and/or declare all the advances with any other amounts payable due immediately. If any amount under the Amended Credit Agreement is not paid when due, such overdue amount shall bear interest at an annual default interest rate of the applicable rate plus 10%, until such amount is paid in full.</span></div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">In connection with each advance under the Amended Credit Agreement, the Company has agreed to issue to Emerald Health Sciences warrants to purchase shares of common stock in an amount equal to 50% &#160;of the number of shares of common stock that each advance may be converted into. The warrants have a term of five years that are immediately exercisable upon issuance. Under the Amended Credit Agreement, Emerald Health Sciences may issue notice that no warrants will be granted at the time of the advance request. The warrants issued under the Credit Agreement have an exercise price of $0.50 per share and any warrants issued under the Amended Credit Agreement will have a reduced exercise price of $0.35 per share. The exercise prices are subject to adjustment in the event of certain stock dividends and distributions, stock splits, stock combinations, reclassifications or similar events or upon any distributions of assets, including cash, stock or other property to the Company&#x2019;s stockholders (See Note 3).</span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><span style="font-size:10pt;font-family:Times New Roman, Times, serif">In accounting for each advance and the warrants issued under the Amended Credit Agreement, the Company allocates the proceeds between the debt host and the freestanding warrants on a relative fair value basis for each advance. On the date of each advance, if the effective conversion rate of the debt is less than the market value of the Company&#x2019;s common stock, the Company records a beneficial conversion feature as a discount to the debt and an increase to additional paid-in capital. The debt discounts related to the warrants, beneficial conversion features and compound derivatives, if any, are being amortized over the term of the Amended Credit Agreement using the effective interest rate method. Amortization of the debt discount is recognized as non-cash interest expense and the compound derivatives related to the contingent interest feature and acceleration upon default provision are remeasured at fair value in subsequent periods in the Company&#x2019;s Condensed Consolidated Balance Sheets.</span></div><div>&#160;</div></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On November 1, 2018, an initial advance was made for $2,000,000 and the Company issued 2,500,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advance and warrants under the Credit Agreement, $1,684,920 of the proceeds was allocated to the debt and $315,080 was allocated to equity classified warrants. A beneficial conversion feature of $90,080 and a compound derivative liability of $204,102 were also recorded.</span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">During the nine&#160;months ended September&#160;30, 2019, the Company initiated two advances, each in the amount of $2,000,000, for an aggregate principal amount of $4,000,000, and the Company issued an aggregate of 5,000,000 warrants with an exercise price of $0.50 per share (See Note 3). In accounting for the convertible advances and warrants, an aggregate amount of $3,283,890 was allocated to the debt and $716,110 was allocated to equity classified warrants. A beneficial conversion feature of $1,584,850 and compound derivative liabilities of an aggregate of $516,058 were recorded (See Note 3). Of the $516,058 in compound derivatives, $322,644 was recorded as other expense in the Condensed Consolidated Statements of Comprehensive Loss&#160;for the nine&#160;months ended September&#160;30, 2019, as the value of the beneficial conversion feature exceeded the proceeds allocated to the third draw.</span></p><p style="MARGIN:0px;text-align:justify">&#160;</p></div></div><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">During the year ended December 31, 2019, the Company used $3,985,500 in proceeds from the exercise of the 2018 Emerald Financing Warrants to prepay a portion of the outstanding principal balance. In connection with the prepayment, the Company recorded an extinguishment loss of $725,425 in the fourth quarter of 2019. The extinguishment loss was calculated as the difference between the fair value of the consideration paid to extinguish the debt and carrying value of the debt host plus the related compound derivative liability.</span></p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify">&#160;</p><div><div><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">During the nine&#160;months ended September&#160;30, 2020, the Company effected a fourth and fifth advances in the amounts of $150,000 and $300,000, respectively. The Lender has elected that the fourth and fifth advances will not be convertible into shares of Common Stock and gave notice to the Company that no warrants will be issued in connection with the advances.</span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Aggregate financing costs of $63,007 have been incurred and are recorded as a discount to the debt host and are being amortized using the effective interest rate method and recognized as non-cash interest expense over the term of the Amended Credit Agreement. As of September&#160;30, 2020, the unamortized debt discount on the convertible advances will be amortized over a remaining period of approximately 2.01 years. </span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">As of September&#160;30, 2020, t</span><span style="font-size:10pt;font-family:Times New Roman, Times, serif">he fair value of the shares underlying the convertible advances under the Amended Credit agreement was $211,523. As of September&#160;30, 2020, the if-converted value did not exceed the principal balance.</span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><em>PPP Loan</em></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><em>&#160;</em></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">On April 24, 2020, the Company received funding from the PPP Loan Lender pursuant to the PPP of the CARES Act administered by the SBA for a principal amount of $116,700. The PPP Loan matures on April 24, 2022 and bears interest at a rate of 1.00% per year. Interest and principal are payable monthly commencing seven months from the date of funding. The PPP Loan may be prepaid at any time prior to maturity with no prepayment penalties. Funds from the PPP Loan may only be used by the Company for payroll costs, costs for continuing group healthcare benefits, mortgage interest payments, rent, utility and interest on any other debt obligations that were incurred before February 15, 2020.</span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">All or a portion of the principal from the PPP Loan may be forgiven by the SBA and the PPP Loan Lender upon application by the Company within 60 days but not later than 120 days after loan approval and upon documentation of expenditures in accordance with the SBA requirements. Under the CARES Act, loan forgiveness is available for the sum of documented payroll costs, covered rent payments, and covered utilities during an eight-week period, or a longer period if elected by the Company, commencing on the date of loan approval. For purposes of the CARES Act, payroll costs exclude compensation of an individual employee in excess of $100,000, prorated annually. Not more than 25% of the forgiveness amount may be for non-payroll costs. Forgiveness is reduced if full-time headcount declines, or if salaries and wages of employees with salaries of $100,000 or less annually are reduced by more than 25%. After approval of the forgiveness amount and seven-month deferral period, the PPP Loan Lender will provide the Company with written notification of re-amortization of the PPP Loan and the remaining balance.</span></p><p style="MARGIN:0px;text-align:justify"><br/><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><em>Interest Expense</em></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">The Company&#x2019;s interest expense consists of the following:</span></p><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Three Months Ended<br/>September 30,</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Nine Months Ended</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>September 30,</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Related party interest expense &#x2013; stated rate</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">44,087</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">107,334</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">117,459</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">272,611</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">PPP loan interest expense &#x2013; stated rate</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">294</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#x2014;</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">511</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#x2014;</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Non-cash interest expense:</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px 0px 0px 15px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Amortization of debt discount</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">137,849</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">190,886</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">401,507</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">429,355</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px 0px 0px 15px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Amortization of transaction costs</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">384</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3,327</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1,117</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">9,609</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>182,614</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>301,547</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>520,594</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>711,575</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210811532856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) and Capitalization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity (Deficit) and Capitalization</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><strong>5. Stockholders' Equity (Deficit) and Capitalization</strong></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><strong><em>Common Stock</em></strong></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em>August 2020 Financing</em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">On July 31, 2020, the Company entered into a Securities Purchase Agreement with certain institutional investors for the issuance and sale of securities, with H.C. Wainwright &amp; Co., LLC acting as the placement agent, pursuant to which the Company sold 56,333,334 common units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and 60,333,334 pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, in a registered public offering which closed on August 4, 2020 (the ''August 2020 Financing'' ). The common units and pre-funded units were sold at a price per unit of $0.06 and $0.059, respectively, for gross aggregate proceeds of $6,939,667. The common stock warrants and prefunded warrants have an exercise price of $0.06 and $0.001, respectively. The common stock warrants have a term of five years, and the pre-funded warrants are exercisable until all the pre-funded warrants have been exercised in full (Note 3).</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">In connection with the August 2020 Financing, the Company incurred issuance costs of $854,078, for net proceeds of $6,085,589. Additionally, the Company issued warrants to purchase 8,166,667 shares of common stock to the placement agent, which represent 7% of the total shares of common stock and pre-funded warrants sold in the offering. The placement agent warrants have an exercise price of $0.075 per share and a term of five years.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210815470216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>6. Stock-Based Compensation</strong></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>Stock Incentive Plan</strong></em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify">On October 31, 2014, after the closing of the Merger, the Board approved the Company&#x2019;s 2014 Omnibus Incentive Plan (the &#x201c;2014 Plan&#x201d;). The 2014 Plan initially reserved 3,200,000 shares for future grants. In October 2018, the Company increased the share reserve under the 2014 Plan to equal 10% of the number of issued and outstanding shares of common stock of the Company. In August 2020, the Company approved Amendment No. 2 to the 2014 Plan, which increased the share reserve by an additional 7,876,835 shares over the 10% of the number of issued and outstanding shares of common stock, and removed certain restrictions on the number of shares of common stock and the amount of cash-based awards up to which participants of the 2014 Plan can receive in a calendar year. The 2014 Plan authorizes the issuance of awards including stock options, stock appreciation rights, restricted stock, stock units and performance units to employees, directors, and consultants of the Company. As of September 30, 2020, the Company had 6,040,097 shares available for future grant under the 2014 Plan.</p></div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em>Stock Options </em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">The following is a summary of option activities under the Company's 2014 Plan for the nine months ended September 30, 2020:</p><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Number of</strong></p><p style="margin:0px;text-align:center"><strong>Shares</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Weighted</strong></p><p style="margin:0px;text-align:center"><strong>Average</strong></p><p style="margin:0px;text-align:center"><strong>Exercise Price</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Weighted</strong></p><p style="margin:0px;text-align:center"><strong>Average Remaining</strong></p><p style="margin:0px;text-align:center"><strong>Contractual</strong></p><p style="margin:0px;text-align:center"><strong>Term (Years)</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Outstanding, December 31, 2019</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>3,317,642</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>0.33</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>8.34</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Granted</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">24,200,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.05</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Cancelled</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">(1,861,964</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.08</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Forfeited</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(655,000</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">0.42</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px">&#160;</p></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Outstanding, September 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>25,000,678</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>0.07</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>9.73</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Exercisable, September 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>4,410,668</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>0.07</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>9.73</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">During the nine months ended September 30, 2020, no stock options were exercised. The weighted-average fair value of stock options granted during the nine months ended September 30, 2020 was $0.04.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px 0px 0px 0.35pt;text-align:justify;font-family:times new roman;font-size:10pt">The fair value of each stock option grant was estimated on the date of grant using the Black-Scholes option pricing model under the following assumptions:</p><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:15%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months Ended</strong></p><p style="margin:0px;text-align:center"><strong>September 30, 2020</strong></p></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Dividend yield</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap"><p style="margin:0px;text-align:center">0.00%</p></td><td style="white-space:nowrap">&#160;</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Risk-free interest rate</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">0.28&#x2014;0.38%</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Expected term (years)</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">5.56&#x2014;6.01</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Volatility</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">92.55&#x2014;93.84%</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em>Restricted Stock Awards </em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">During the nine months ended September 30, 2020, 643,501 restricted stock awards ( ''RSAs'' ) with a weighted average grant date fair value of $0.26 vested and were released from their service condition restriction. At September 30, 2020, there are no unvested RSA awards outstanding under the 2014 Plan.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em><strong>Awards Granted Outside the 2014 Plan</strong></em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em>Options</em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">During the nine months ended September 30, 2020, 325,929 stock options with a weighted average exercise price of $0.25 were forfeited in connection with the separation and release of the Company's former CFO. As of September 30, 2020, an additional 869,144 options vested and outstanding with a weighted average exercise price of $0.25 were cancelled unexercised.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em>Restricted Stock Awards</em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">The following is a summary of RSA activity outside of the Company's 2014 Plan during the nine months ended September 30, 2020:</p><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Number of</strong></p><p style="margin:0px;text-align:center"><strong>Shares</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Weighted </strong></p><p style="margin:0px;text-align:center"><strong>Average</strong></p><p style="margin:0px;text-align:center"><strong>Grant </strong></p><p style="margin:0px;text-align:center"><strong>Date Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Unvested, December 31, 2019</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>450,000</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>0.19</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Granted</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Released</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(450,000</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">0.19</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Unvested, September 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>&#x2014;</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>&#x2014;</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div></div></div></div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em><strong>Stock-Based Compensation Expense</strong></em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">The Company recognizes compensation expense using the straight-line method over the requisite service period. Stock-based compensation is included in the Condensed Consolidated Statements of Comprehensive Loss in general and administrative or research and development, depending upon the nature of services provided. Stock-based compensation expense (including compensation expense for RSAs discussed above) was as follows:</p><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Three Months Ended</strong><strong> <strong>September 30,</strong></strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months Ended</strong></p><p style="margin:0px;text-align:center"><strong>September 30,</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Research and development</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">44,010</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">82,463</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">General and administrative</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">104,355</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">170,106</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">158,753</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">514,683</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>148,365</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>170,106</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>241,216</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>514,683</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">The total amount of unrecognized compensation cost was $879,628 as of September 30, 2020. This amount will be recognized over a weighted average period of 3.59 years.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210817082936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts - University of Mississippi<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SignificantContractsAbstract', window );"><strong>Significant Contracts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SignificantContractsTextBlock', window );">Significant Contracts - University of Mississippi</a></td>
<td class="text"><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><strong>7. Significant Contracts - University of Mississippi</strong></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>UM 5050 Prodrug and UM 8930 Analog Agreements</strong></em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In July 2018, the Company renewed its ocular licenses for UM 5050, related to the prodrug formulation of tetrahydrocannabinol (&#x201c;THC&#x201d;), and UM 8930, related to an analog formulation of cannabidiol (&#x201c;CBD&#x201d;). On May 24, 2019, the ocular delivery licenses were replaced by &#x201c;all fields of use&#x201d; licenses for both UM 5050 and UM 8930 (collectively, the &#x201c;License Agreements&#x201d;). Pursuant to the License Agreements, UM granted the Company an exclusive, perpetual license, including, with the prior written consent of UM, the right to sublicense, to intellectual property related to UM 5050 and UM 8930 for all fields of use.</span></span></span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The License Agreements contain certain milestone payments, royalty and sublicensing fees payable by the Company, as defined therein. Each License Agreement provides for an annual maintenance fee of $75,000 payable on the anniversary of the effective date. The upfront payment for UM 5050 is $100,000 and the upfront payment for UM 8930 is $200,000. In addition, in March 2020, the Company was notified by the United States Patent and Trademark Office, that a notice of allowance was issued for the proprietary analog of cannabidiol, CBDVHS, under the UM 8930 License Agreement. As a result, the Company was required to pay UM a fee of $200,000. The milestone payments payable for each license are as follows:</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>i)</span></span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$100,000 paid within 30 days following the submission of the first Investigational New Drug Application&#160;(&#x201c;NDA&#x201d;) to the Food and Drug Administration or an equivalent application to a regulatory agency anywhere in the world, for a product;</span></span></span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>ii)</span></span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$200,000 paid within 30 days following the first submission of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early submitted product(s); and</span></span></span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>iii)</span></span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>$400,000 paid within 30 days following the approval of an NDA, or an equivalent application to a regulatory agency anywhere in the world, for each product that is administered in a different route of administration from that of the early approved product(s).</span></span></span></span></p></td></tr></tbody></table><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>&#160;&#160;</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The royalty percentage due on net sales under each License Agreement is in the mid-single digits. The Company must also pay to UM a portion of all licensing fees received from any sublicensees, subject to a minimum royalty on net sales, and the Company is required to reimburse patent costs incurred by UM related to the licensed products. The royalty obligations apply by country and by licensed product, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after the first commercial sale of such licensed product in such country.</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>Each License Agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or the expiration of the Company&#x2019;s payment obligations under such License Agreement. UM may terminate each License Agreement, by giving written notice of termination, upon the Company&#x2019;s material breach of such License Agreement, including failure to make payments or satisfy covenants, representations or warranties without cure, noncompliance, a bankruptcy event, the Company&#x2019;s dissolution or cessation of operations, the Company&#x2019;s failure to make reasonable efforts to commercialize at least one product or failure to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside the Company&#x2019;s control, or the Company&#x2019;s failure to meet certain pre-established development milestones. The Company may terminate each License Agreement upon 60 days&#x2019; written notice to UM.</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of September 30, 2020, with the exception of the fee due for the notice of allowance for CBDVHS, none of the other milestones under these license agreements have been met.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span><em><strong>UM 5070 License Agreement</strong></em></span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>In January 2017, the Company entered into a license agreement with UM pursuant to which UM granted us an exclusive, perpetual license, including the right to sublicense, to intellectual property related to a platform of cannabinoid-based molecules (&#x201c;UM 5070&#x201d;), to research, develop and commercialize products for the treatment of infectious diseases.</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The Company paid UM an upfront license fee under the license agreement. Under the license agreement, the Company is also responsible for annual maintenance fees that will be credited against royalties in the current fiscal year, contingent milestone payments upon achievement of development and regulatory milestones, and royalties on net sales of licensed products sold for commercial use. The aggregate milestone payments due under the license agreement if all the milestones are achieved is $700,000 and the royalty percentage due on net sales is in the mid-single digits. The Company must also pay to UM a percentage of all licensing fees we receive from any sublicensees, subject to a minimum royalty on net sales by such sublicensees. The Company&#x2019;s royalty obligations apply on a country by country and licensed product by licensed product basis, and end upon the later of the date that no valid claim of a licensed patent covers a licensed product in a given country, or ten years after first commercial sale of such licensed product in such country.</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span><span>The license agreement continues, unless terminated, until the later of the expiration of the last to expire of the patents or patent applications within the licensed technology or expiration of the Company&#x2019;s payment obligations under the license. UM may terminate the license agreement, effective with the giving of notice, if: (a) the Company fails to pay any material amount payable to UM under the license agreement and do not cure such failure within 60 days after UM notifies us of such failure, (b) the Company materially breaches any covenant, representation or warranty in the license agreement and do not cure such breach within 60 days after UM notifies the Company of such breach, (c) the Company fails to comply in any material respect with the terms of the license and do not cure such noncompliance within 60 days after UM notifies us of such failure, (d) the Company is subject to a bankruptcy event, (e) the Company dissolves or ceases operations or (f) if after the first commercial sale of a product during the term of the license agreement, the Company materially fails to make reasonable efforts to commercialize at least one product or fail to keep at least one product on the market after the first commercial sale for a continuous period of one year, other than for reasons outside of the Company&#x2019;s control. The Company may terminate the license agreement upon 60 days&#x2019; written notice to UM.</span></span></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">As of September 30, 2020, none of the milestones under this license agreement have been met.</span></span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SignificantContractsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SignificantContractsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SignificantContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for Significant Contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SignificantContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210815470216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Matters<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Matters</a></td>
<td class="text"><div><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><strong>8. Related Party Matters</strong></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><em><strong>Emerald Health Sciences</strong></em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">On February 1, 2018, the Company entered into an Independent Contractor Agreement with Emerald Health Sciences, pursuant to which Emerald Health Sciences agreed to provide such services as are mutually agreed between the Company and Emerald Health Sciences, including reimbursement for reasonable expenses incurred in the performance of the Independent Contractor Agreement. These services included, but were not limited to, corporate advisory services and technical expertise in the areas of business development, marketing, investor relations, information technology and product development. The Independent Contractor Agreement had an initial term of 10 years and specified compensation which was agreed upon between the Company's Chief Executive Officer and Emerald Health Sciences' Chairman, CEO and President on a month-to-month basis. The fee due under this agreement was payable on a monthly basis. Effective December 31, 2019, the Independent Contractor Agreement was terminated. As of September 30, 2020, the Company maintains an accrual of $7,032 in expenses under the Independent Contractor Agreement which have yet to be paid. Under this agreement, no expenses were incurred for the three and nine months ended September 30, 2020. Under this agreement, for the three and nine months ended September 30, 2019, the Company incurred expenses of $150,000 and $450,000, respectively.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">On December 17, 2019, Dr. Avtar Dhillon resigned as the Chairman of the Board and the position of Chairman of the Finance and Business Development Committee of the Board. Concurrently, the Company entered into a Board Observer Agreement with Emerald Health Sciences to allow Dr. Dhillon to continue as a representative of Emerald Health Sciences as a non-voting observer in future meetings of the Board.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p></div></div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">On December 19, 2019, the Company entered into an Independent Contractor Services Agreement with Dr. Avtar Dhillon, pursuant to which Dr. Dhillon will provide ongoing corporate finance and strategic business advisory services to the Company. In exchange for his services, Dr. Dhillon will receive a monthly fee of $10,000, with (i) $5,000 paid each month and (ii) $5,000 accruing from the effective date and payable upon the Company's completion of a material financing. The Board will review the monthly rate paid to Dr. Dhillon within 90 days of the end of each fiscal year. The Independent Contractor Services Agreement has an initial term of one year and will renew automatically thereafter unless terminated earlier by either party. The Independent Contractor Services Agreement may be terminated by either party for cause upon written notice to the other party if the other party defaults in the performance of the agreement in any material respect or materially breaches the terms of the agreement, or without cause upon 30 days' prior written notice to the other party. On March 30, 2020, the Company and Dr. Dhillon amended the Independent Contractor Services Agreement by agreeing to accrue 100% of Dr. Dhillon's consulting fees until the Board of Directors determines that the Company has been sufficiently financed to make such payments at which point the Company agrees to pay Dr. Dhillon all of his accrued consulting fees, and a bonus of 10% of his accrued consulting fees, less applicable tax and other withholdings. The deferral was paid concurrent with the August 2020 Financing. Under this agreement, for the three and nine months ended September 30, 2020, the Company incurred fees of $31,000 and $97,387, respectively. As of September 30, 2020, the Company has accrued $10,000 in expense related to the Independent Contractor Services Agreement.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">In addition, on August 10, 2020, Emerald Health Sciences, Inc. transferred Dr. Avatar Dhillon 500,000 shares of the Company&#x2019;s common stock at a deemed price of $0.10 in exchange for the cancellation of $50,000 of debt.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">As of September 30, 2020, Jim Heppell and Punit Dhillon are board members of the Company and Emerald Health Pharmaceuticals, a subsidiary of Emerald Health Sciences, Inc. As of September 30, 2020, Jim Heppell is also a board member of Emerald Health Sciences, Inc. The Company's CEO, Punit Dhillon also served as a board member of Emerald Health Sciences, Inc. until he tendered his resignation from such board on August 10, 2020. Additionally, the Company shares the same office location as Emerald Health Pharmaceuticals.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">On August 10, 2020, Emerald Health Sciences, Inc. extinguished debt of $186,667&#160;by transferring 1,566,666 shares of the Company&#x2019;s common stock at a deemed price of $0.10 per share to certain officers,&#160;employees and directors of the Company.</p></div></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210817082936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><strong>9. Subsequent Events</strong></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><strong><em>Stock</em></strong><em><strong>&#160;Incentive Plan</strong></em></p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">On October 5, 2020, the Company granted 2,000,000 stock options under the 2014 Plan to an employee. The stock options have an exercise price of $0.05 per share and a fair market value of $0.04 per share on the date of grant. The stock options vest 10% on the grant date with the remaining 90% vesting semi-annually over a four-year period.</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">In connection with the departure of the Company&#x2019;s Chief Medical Officer, 3,968,271 stock options have been forfeited on November 6, 2020.</p></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210806867064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Basis of Presentation</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements have been prepared on a consistent basis with the Company&#x2019;s Audited Consolidated Financial Statements for the fiscal year ended December 31, 2019, and include all adjustments, consisting of only normal recurring adjustments, necessary to fairly state the information set forth herein. The Condensed Consolidated Financial Statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and therefore, omit certain information and footnote disclosures necessary to present the financial statements in accordance with generally accepted accounting principles in the United States (&#x201c;GAAP&#x201d;).</span></span></p><p style="MARGIN:0px;text-align:justify">&#160;</p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The results of operations for the three and nine months ended September 30, 2020 are not necessarily indicative of the results to be expected for the year ending December 31, 2020 or any future periods. The Condensed Consolidated Balance Sheet as of December 31, 2019 was derived from the Company&#x2019;s audited financial statements as of December 31, 2019, which are included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 20, 2020. The unaudited financial statements included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, which includes a broader discussion of the Company&#x2019;s business and the risks inherent therein.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Use of Estimates</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The preparation of the Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of income and expense during the reporting period. Actual results could differ from those estimates. The most significant accounting estimates inherent in the preparation of the Company&#x2019;s financial statements include estimates as to the appropriate carrying value of certain assets and liabilities, which are not readily apparent from other sources. Such estimates and judgments are utilized for stock-based compensation expense, equity securities, derivative liabilities, and debt with embedded features.</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Risks and Uncertainties</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company&#x2019;s operations are subject to a number of risks and uncertainties, including but not limited to, changes in the general economy, the size and growth of the potential markets for any of the Company&#x2019;s product candidates, results of research and development activities, uncertainties surrounding regulatory developments in the United States and Australia, and the Company&#x2019;s ability to attract new funding.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Fair Value Measurements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Certain assets and liabilities are carried at fair value under GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (the &#x201c;exit price&#x201d;) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. A fair value hierarchy based on three levels of inputs, of which the first two are considered observable, and the last is considered unobservable, is used to measure fair value:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:6%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 1:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Valuations for assets and liabilities traded in active markets from readily available pricing sources such as quoted prices in active markets for identical assets or liabilities.</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 2:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Observable inputs (other than Level 1 quoted prices) such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</span></span></p></td></tr><tr style="height:15px"><td>&#160;</td><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Level 3:</span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</span></span></p></td></tr></tbody></table><p style="margin:0px">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The carrying values of the Company&#x2019;s financial instruments, with the exception of the Amended Credit Agreement and derivative liabilities, including, cash, prepaid expenses, accounts payable, the PPP loan and other current liabilities approximate their fair value due to the short maturities of these financial instruments. The derivative liabilities are valued on a recurring basis utilizing Level 3 inputs (Note 3). The PPP loan is considered conventional debt with an interest rate that approximates current market rates, interest and principal payments will be made through 2022. Due to the PPP loan&#x2019;s relatively short term the carrying value approximates fair value. As of December 31, 2019, the fair value of the advances under the Credit Agreement was $1,877,938, the carrying amount of the liability at December 31, 2019 was $387,070 and is included in Convertible multi-draw credit agreement - related party, net of discount in the Company&#x2019;s Condensed Consolidated Balance Sheets. As of September 30, 2020, the Company no longer engages a third party valuation specialist to value the Credit Agreement, as amended, as it is not practical to do so solely for the purpose of disclosing the estimated fair value of the financial instrument. Information pertinent to estimating the fair value of the Amended Credit Agreement includes valuing the embedded conversion feature and considering the discounted cash flows of the interest and principal payments through maturity (Note 4).</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Convertible Instruments</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Convertible Instruments</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for hybrid contracts with embedded conversion features in accordance with GAAP. ASC 815, Derivatives and Hedging Activities (&#x201c;ASC 815&#x201d;) requires companies to bifurcate conversion options from their host instruments and account for them as free-standing derivative financial instruments according to certain criteria. The criteria includes circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company accounts for convertible debt instruments with embedded conversion features in accordance with ASC 470-20, Debt with Conversion and Other Options (&#x201c;ASC 470-20&#x201d;) if it is determined that the conversion feature should not be bifurcated from their host instruments. Under ASC 470-20, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the difference between the fair value of the underlying common stock at the commitment date and the embedded effective conversion price. When the Company determines that the embedded conversion option should be bifurcated from its host instrument, the embedded feature is accounted for in accordance with ASC 815. Under ASC 815, a portion of the proceeds received upon the issuance of the hybrid contract is allocated to the fair value of the derivative. The derivative is subsequently marked to market at each reporting date based on current fair value, with the changes in fair value reported in the results of operations.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company also follows ASC 480-10, Distinguishing Liabilities from Equity (&#x201c;ASC 480-10&#x201d;) when evaluating the accounting for its hybrid instruments. A financial instrument that embodies an unconditional obligation, or a financial instrument other than an outstanding share that embodies a conditional obligation, that the issuer must or may settle by issuing a variable number of its equity shares shall be classified as a liability (or an asset in some circumstances) if, at inception, the monetary value of the obligation is based solely or predominantly on any one of the following: (a) a fixed monetary amount known at inception (for example, a payable settled with a variable number of the issuer&#x2019;s equity shares); (b) variations in something other than the fair value of the issuer&#x2019;s equity shares (for example, a financial instrument indexed to the Standard and Poor&#x2019;s S&amp;P 500 Index and settled with a variable number of the issuer&#x2019;s equity shares); or (c) variations inversely related to changes in the fair value of the issuer&#x2019;s equity shares (for example, a written put option that could be net share settled). Hybrid instruments meeting these criteria are not further evaluated for any embedded derivatives and are carried as a liability at fair value at each balance sheet date with a re-measurement reported in other expense (income) in the accompanying Condensed Consolidated Statements of Comprehensive Loss.</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">When determining the short-term vs. long-term classification of derivative liabilities, the Company first evaluates the instruments&#x2019; exercise provisions. Generally, if a derivative is a liability and exercisable within one year, it will be classified as short-term. However, because of the unique provisions and circumstances that may impact the accounting for derivative instruments, the Company carefully evaluates all factors that could potentially restrict the instrument from being exercised or create a situation where exercise would be considered remote. The Company re-evaluates its derivative liabilities at each reporting period end and makes updates for any changes in facts and circumstances that may impact classification.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock', window );">Warrants Issued in Connection with Financings</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Warrants Issued in Connection with Financings</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company may need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other expense (income) in the Condensed Consolidated Statements of Comprehensive Loss .</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Debt Issuance Costs and Interest</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Debt Issuance Costs and Interest</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Discounts related to bifurcated derivatives, freestanding instruments issued in bundled transactions, and issuance costs are recorded as a reduction to the carrying value of the debt and amortized over the life of the debt using the effective interest method. The Company makes changes to the effective interest rate, as necessary, on a prospective basis. For debt facilities that provide for multiple advances, the Company initially defers any issuance costs until the first advance is made and then amortizes the costs over the life of the facility.</span></span></p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses and Licensed Technology</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Research and Development Expenses and Licensed Technology</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Research and development costs are expensed when incurred. These costs may consist of external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants; license fees; employee-related expenses, which include salaries and benefits for the personnel involved in the Company&#x2019;s preclinical and clinical drug development activities; facilities expense, depreciation and other allocated expenses; and equipment and laboratory supplies.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Costs incurred for the rights to use licensed technologies in the research and development process, including licensing fees and milestone payments, are charged to research and development expense as incurred in situations where the Company has not identified an alternative future use for the acquired rights, and are capitalized in situations where there is an identified alternative future use. No cost associated with the use of licensed technologies has been capitalized to date.</span></span></p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Stock-Based Compensation Expense </strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.7pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Stock-based compensation expense is estimated at the grant date based on the fair value of the award, and the cost is recognized as expense ratably over the vesting period with forfeitures accounted for as they occur. The Company uses the Black-Scholes Merton option pricing model for estimating the grant date fair value of stock options using the following assumptions:</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%"><tbody><tr style="height:15px"><td style="width:4%"><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="width:4%;vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility - Stock price volatility is estimated over the expected term based on a blended rate of industry peers and the Company&#x2019;s actual stock volatility adjusted for periods in which significant financial variability was identified.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term - The expected term is based on a simplified method which defines the life as the weighted average of the contractual term of the options and the vesting period for each award.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free rate - The risk-free interest rate for the expected term of the option is based on the average market rate on U.S. Treasury securities in effect during the period in which the awards were granted.</span></span></p></td></tr><tr style="height:15px"><td><p style="MARGIN:0px;text-align:justify">&#160;</p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><span style="font-family:symbol">&#xb7;</span></span></span></p></td><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividends - The dividend yield assumption is based on the Company&#x2019;s history and expectation of paying no dividends in the foreseeable future.</span></span></p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Loss Per Common Share</a></td>
<td class="text"><div><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Loss&#160;Per Common Share</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">The Company applies FASB ASC No. 260, <em>Earnings per Share</em> in calculating its basic and diluted net loss per common share. Basic loss per share of common stock is computed by dividing net loss available to common stockholders by the weighted-average number of shares of common stock outstanding for the period. The diluted loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock subject to vesting, warrants to purchase common stock and common shares underlying convertible debt instruments are considered to be common stock equivalents.</p><p style="font-size:10pt;font-family:Times New Roman, Times, serif;margin-top:0pt;margin-bottom:0pt">The computations of basic and diluted net loss per common share are as follows:</p><div><div><div><table border="0" cellpadding="0" cellspacing="0" style="width:100%;border:0px;font-size:10pt;border-collapse:collapse;margin:auto" width="90%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="5" rowspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><strong>Three Months<br/>Ended September 30,<br/>(Unaudited)</strong></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="5" rowspan="1" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black"><strong>Nine Months<br/>Ended September 30,<br/>(Unaudited)</strong></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif">&#160;</span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2020</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2019</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2020</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2019</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:56%" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="line-height:normal;font-size:10pt;font-family:Times New Roman, serif">Basic net loss per share:</span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(1,296,696</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(4,931,125</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,058,592</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(3,800,227</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Weighted average common shares outstanding &#x2013; basic</span></span></span></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">256,758,472</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">133,001,746</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">207,536,173</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">132,885,675</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss per share - basic</span></span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.01</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.04</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.02</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif">&#160;</span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Diluted net loss per share:</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss (as adjusted)</span></span></span></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(1,720,835</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(4,931,125</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,401,484</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,656,982</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Weighted average common shares outstanding &#x2013; diluted</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">257,255,653</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">133,001,746</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">208,434,966</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">167,690,989</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss per share - diluted</span></span></span></strong></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.01</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.04</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr></tbody></table></div></div></div></div></div><div>&#160;</div></div><div><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been anti-dilutive:</p><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Three Months </strong></p><p style="margin:0px;text-align:center"><strong>Ended September 30, </strong></p><p style="margin:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months </strong></p><p style="margin:0px;text-align:center"><strong>Ended September 30, </strong></p><p style="margin:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Stock options</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">25,000,678</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4,512,715</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">25,000,678</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4,512,715</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Unvested restricted stock</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1,093,501</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1,093,501</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Common shares underlying convertible debt</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5,215,457</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">15,000,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5,215,457</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">15,000,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">145,336,155</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">57,943,250</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">144,934,542</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div></div></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><em><strong>Recent Accounting Pronouncements</strong></em></span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify">&#160;</p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In August 2020, the FASB issued ASU 2020-06, Debt&#x2014;<em>Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity.</em> This ASU amends the guidance on convertible instruments and the derivatives scope exception for contracts in an entity&#x2019;s own equity and improves and amends the related EPS guidance for both Subtopics. The ASU will be effective for annual reporting periods after December 15, 2023 and interim periods within those annual periods and early adoption is permitted in annual reporting periods ending after December 15, 2020. We are still assessing the impact of ASU 2020-06 on our condensed consolidated financial statements.</span></span></p><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">&#160;&#160;</span></span></p><p style="MARGIN:0px 0px 0px 0.35pt;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">In December 2019, the FASB issued ASU No. 2019-12 <em>Income Taxes</em> (Topic 740) simplifying the Accounting for Income Taxes. The Board issued this update as part of its Simplification Initiative to improve areas of GAAP and reduce cost and complexity while maintaining usefulness of the financial statements. The main provisions remove certain exceptions, including the exception to the general methodology for calculating income taxes in an interim period when a year-to-date loss exceeds the anticipated loss for the year. In addition, the amendments simplify income tax accounting in the areas such as income-based franchise taxes, eliminating the requirements to allocate consolidated current and deferred tax expense in certain instances and a requirement that an entity reflects the effect of enacted changes in tax laws or rates in the annual effective tax rate computation in the interim period that includes the enactment date. For public companies, the standard is effective for fiscal years beginning after December 15, 2020, and interim periods therein, with early adoption permitted. The Company plans to adopt this ASU on the effective date of January 1, 2021. However, it may adopt the update earlier if circumstances arise making early adoption favorable to the Company. The amendments in the update related to foreign subsidiaries will be applied on a modified retrospective basis, the amendments to franchise taxes will be applied on either a retrospective or modified retrospective basis and all other amendments will be applied on a prospective basis. The Company is still evaluating the impact from adopting this standard. However, because the Company&#x2019;s deferred tax assets and liabilities are fully reserved, it does not expect a material impact from the adoption of this standard.</span></span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents policy for Risks and Uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants Issued in Connection with Financings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsIssuedInConnectionWithFinancingsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210811454712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><div><table border="0" cellpadding="0" cellspacing="0" style="width:100%;border:0px;font-size:10pt;border-collapse:collapse;margin:auto" width="90%"><tbody><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif">&#160;</p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="5" rowspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><strong>Three Months<br/>Ended September 30,<br/>(Unaudited)</strong></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="5" rowspan="1" style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black"><strong>Nine Months<br/>Ended September 30,<br/>(Unaudited)</strong></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:left"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif">&#160;</span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2020</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2019</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2020</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black;width:1%">&#160;</td><td colspan="1" style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;border-bottom:1pt solid black" valign="bottom"><p style="margin-top:0pt;margin-bottom:0pt;text-align:center;font-size:10pt;font-family:Times New Roman, Times, serif;text-align:center"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif">2019</span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-family:Times New Roman, Times, serif;text-align:center;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:56%" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="line-height:normal;font-size:10pt;font-family:Times New Roman, serif">Basic net loss per share:</span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:8%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(1,296,696</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(4,931,125</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,058,592</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(3,800,227</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Weighted average common shares outstanding &#x2013; basic</span></span></span></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">256,758,472</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">133,001,746</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">207,536,173</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">132,885,675</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss per share - basic</span></span></span></strong></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.01</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.04</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.02</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom"><p style="margin-top:0pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif">&#160;</span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Diluted net loss per share:</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss (as adjusted)</span></span></span></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(1,720,835</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(4,931,125</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,401,484</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(5,656,982</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr><tr style="background-color:rgb(255, 255, 255)"><td style="padding:0cm;height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:15px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Weighted average common shares outstanding &#x2013; diluted</span></span></span></span></p></td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">257,255,653</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">133,001,746</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">208,434,966</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black;width:1%">&#160;</td><td colspan="1" style="height:15px;background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;border-bottom:2.5pt double black" valign="bottom">167,690,989</td><td style="background-color:rgb(255, 255, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td></tr><tr style="background-color:rgb(204, 238, 255)"><td style="padding:0cm;height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom" valign="top"><p style="margin-top:0pt;margin-left:30px;margin-bottom:0pt;text-align:justify;font-size:10pt;font-family:Times New Roman, Times, serif"><span style="font-size:11pt;line-height:normal;font-family:Calibri, sans-serif"><strong><span style="font-size:10pt"><span style="font-family:Times New Roman, serif"><span style="color:black">Net loss per share - diluted</span></span></span></strong></span></p></td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.01</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.04</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom;width:1%">&#160;</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">$</td><td colspan="1" style="height:15px;background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:right;vertical-align:bottom" valign="bottom">(0.03</td><td style="background-color:rgb(204, 238, 255);font-size:10pt;font-family:Times New Roman, Times, serif;text-align:left;vertical-align:bottom;width:1%">)</td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of outstanding shares of common stock equivalents were excluded from the computation of diluted earnings per share</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Three Months </strong></p><p style="margin:0px;text-align:center"><strong>Ended September 30, </strong></p><p style="margin:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months </strong></p><p style="margin:0px;text-align:center"><strong>Ended September 30, </strong></p><p style="margin:0px;text-align:center"><strong>(Unaudited)</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Stock options</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">25,000,678</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4,512,715</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">25,000,678</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4,512,715</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Unvested restricted stock</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1,093,501</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1,093,501</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Common shares underlying convertible debt</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5,215,457</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">15,000,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5,215,457</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">15,000,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">145,336,155</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">57,943,250</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">22,304,750</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">144,934,542</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210803269272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of warrants vested and outstanding</a></td>
<td class="text"><div><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"><p style="margin:0px;text-align:center"><strong>Number of</strong></p><p style="margin:0px;text-align:center"><strong>Warrants</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"><p style="margin:0px;text-align:center"><strong>Exercise</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"><p style="margin:0px;text-align:center"><strong>Term</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom"><p style="margin:0px;text-align:center"><strong>Vested and</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td style="vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:justify"><strong>Source</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Price</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>(Years)</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Outstanding</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Pre 2015 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">1.00</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:right">6&#x2014;10</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1,110,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2015 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td>$</td><td><p style="margin:0px;text-align:right">1.15&#x2014;5.00</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:right">5&#x2014;10</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">220,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2016 Common Stock Warrants to Service Providers</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">1.15</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">10</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">40,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2016 Series C Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.40</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">125,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2017 Series D Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.25</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">480,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2017 Common Stock Warrants to Service Provider</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.41</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">125,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2018 Emerald Financing Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.10</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">3,400,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Emerald Multi-Draw Credit Agreement Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.50</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">7,500,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2019 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.35</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">8,000,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2020 Common Stock Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.06</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">116,666,668</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2020 Common Stock Warrants to Placement Agent</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.075</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4.99</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">8,166,667</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">2020 Pre-Funded Warrants</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">0.001</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:right">indefinite</p></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">49,800,000</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Total warrants vested and outstanding as of September 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>195,633,335</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of the activity of derivative liabilities</a></td>
<td class="text"><div><div><div><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="18" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months Ended September 30, 2020</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>December 31,</strong></p><p style="margin:0px;text-align:center"><strong>2019,</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities Issued</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Change in</strong></p><p style="margin:0px;text-align:center"><strong>Fair value of </strong></p><p style="margin:0px;text-align:center"><strong>Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Reclassification</strong></p><p style="margin:0px;text-align:center"><strong>of Derivatives</strong></p><p style="margin:0px;text-align:center"><strong>to Equity </strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>September 30,</strong></p><p style="margin:0px;text-align:center"><strong>2020,</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px">Emerald Multi-Draw Credit Agreement - compound derivative liability <sup>(1)</sup></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">90,797</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">(90,797</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px">Emerald Financing - warrant liability <sup>(2)</sup></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">276,024</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">(234,875</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">41,149</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Series B - warrant liability <sup>(3)</sup></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">134,579</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">&#x2014;</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(108,016</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(26,563</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">&#x2014;</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Total derivative liabilities</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>501,400</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>&#x2014;</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>(433,688</strong></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"><strong>)</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>(26,563</strong></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"><strong>)</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>41,149</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Less, noncurrent portion of derivative liabilities</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(90,797</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">&#x2014;</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px"><strong>Current balance of derivative liabilities</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>410,603</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>41,149</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt"><span style="font-size:10pt">&#160; &#160;</span></p><div><div><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="18" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months Ended September 30, 2019</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>December 31,</strong></p><p style="margin:0px;text-align:center"><strong>2018,</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p><p style="margin:0px;text-align:center"><strong>Issued</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Change in</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Reclassification</strong></p><p style="margin:0px;text-align:center"><strong>of Derivatives</strong></p><p style="margin:0px;text-align:center"><strong>to Equity</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>September 30,</strong></p><p style="margin:0px;text-align:center"><strong>2019,</strong></p><p style="margin:0px;text-align:center"><strong>Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value of</strong></p><p style="margin:0px;text-align:center"><strong>Derivative Liabilities</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Emerald Multi Draw Credit Agreement - compound derivative liability (1)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">219,453</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">516,058</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">(167,905</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">567,606</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Emerald Financing - warrant liability (2)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">15,251,413</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">(1,895,193</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">13,356,220</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Series B - warrant liability (3)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">487,500</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">&#x2014;</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">38,438</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(144,375</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">381,563</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Total derivative liabilities</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><strong>15,958,366</strong></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>516,058</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>(2,024,660</strong></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"><strong>)</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>(144,375</strong></td><td style="width:1%;padding-bottom:3px;vertical-align:bottom;white-space:nowrap"><strong>)</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><strong>14,305,389</strong></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Less, noncurrent portion of derivative liabilities</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(219,453</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(567,606</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Current balance of derivative liabilities</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>15,738,913</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>13,737,783</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div></div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock', window );">Schedule of input and valuation technique used to value derivative liabilities</a></td>
<td class="text"><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:15%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>At</strong></p><p style="margin:0px;text-align:center"><strong>Issuance</strong></p></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Dividend yield</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap"><p style="margin:0px;text-align:center">0.00%</p></td><td style="white-space:nowrap">&#160;</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Volatility factor</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">91.6&#x2014;92.1</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Risk-free interest rate</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">2.23&#x2014;2.51</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Expected term (years)</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap"><p style="margin:0px;text-align:center">5.0</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Underlying common stock price</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">$0.33&#x2014;0.69</p></td></tr></tbody></table></div></div><p style="MARGIN:0px;text-align:justify">&#160;</p></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_AugustTwoThousandAndTwentyFinancingWarrantsMember', window );">August 2020 Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock', window );">Schedule of input and valuation technique used to value derivative liabilities</a></td>
<td class="text"><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Common Stock Warrants</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Pre-funded</strong></p><p style="margin:0px;text-align:center"><strong>Warrants</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Placement Agent Warrants</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Dividend yield</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Volatility factor</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">91.64</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">93.86</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">91.64</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Risk-free interest rate</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.19</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.52</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.19</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Expected term (years)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">5.0</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">10</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">4.99</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Underlying common stock price</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.05</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.05</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.05</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_EmeraldFinancingWarrantsLiabilityMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><div><div><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>September 30, </strong></p><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>December 31, </strong></p><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Dividend yield</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.00</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Volatility factor</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">80.8</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">79.5</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Risk-free interest rate</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.14</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">1.62</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">%</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Expected term (years)</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">2.38</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">3.13</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Underlying common stock price</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.04</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">0.13</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p></div></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember', window );">Series B Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DerivativeLiabilitiesLineItems', window );"><strong>Derivative Liabilities Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of input and valuation technique used to value warrant liabilities</a></td>
<td class="text"><div><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;width:9%;vertical-align:bottom;text-align:center"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>As of </strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>December 31,</strong></span></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif"><strong>2019</strong></span></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Dividend yield</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.00</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Volatility factor</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">79.2</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Risk-free interest rate</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">1.60</span></span></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">%</span></span></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Expected term (years)</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.64</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">Underlying common stock price</span></span></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">$</span></span></td><td style="width:9%;vertical-align:bottom;text-align:right"><span style="font-size:10pt"><span style="font-family:Times New Roman,Times,serif">0.13</span></span></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DerivativeLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents derivative liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DerivativeLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of derivative asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueMeasurementInputsAndValuationTechniquesDerivativeLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_AugustTwoThousandAndTwentyFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_AugustTwoThousandAndTwentyFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_EmeraldFinancingWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_EmeraldFinancingWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210815459528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtTableTextBlock', window );">Schedule of convertible and non-convertible advances</a></td>
<td class="text"><div><div><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:#000000 1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Conversion</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Price</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>As of</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>September 30,</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>As of</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>December 31,</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Total principal value of convertible debt&#x2014;related party</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">0.40</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2,014,500</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">2,014,500</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unamortized debt discount</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1,220,838</span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(1,622,344</span></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Unamortized debt issuance costs</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(3,968</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">(5,086</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">)</span></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Carrying value of total convertible debt - related party</strong></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>789,694</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>387,070</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Total principal value of non-convertible debt&#x2014;related party</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">n/a</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">450,000</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>&#x2014;</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Total carrying value of advances under the multi-draw credit agreement</strong></span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>1,239,694</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>387,070</strong></span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ScheduleOfInterestExpenseTableTextBlock', window );">Schedule of interest expense</a></td>
<td class="text"><div><p style="MARGIN:0px;text-align:justify">&#160;</p><table border="0" cellpadding="0" cellspacing="0" style="TEXT-ALIGN:left;FONT:10pt times new roman" width="100%"><tbody><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Three Months Ended<br/>September 30,</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="6" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>Nine Months Ended</strong></span></p><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>September 30,</strong></span></p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px"><td><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2020</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td colspan="2" style="BORDER-BOTTOM:1px solid;text-align:center;width:9%" valign="bottom"><p style="MARGIN:0px;text-align:center"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>2019</strong></span></p></td><td style="PADDING-BOTTOM:1px;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Related party interest expense &#x2013; stated rate</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">44,087</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">107,334</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">117,459</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">$</span></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">272,611</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">PPP loan interest expense &#x2013; stated rate</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">294</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#x2014;</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">511</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">&#x2014;</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px;text-align:justify"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Non-cash interest expense:</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:9%"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td valign="top"><p style="MARGIN:0px 0px 0px 15px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Amortization of debt discount</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">137,849</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">190,886</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">401,507</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">429,355</span></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#cceeff"><td valign="top"><p style="MARGIN:0px 0px 0px 15px"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">Amortization of transaction costs</span></p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">384</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">3,327</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">1,117</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:1px solid;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif">9,609</span></td><td style="PADDING-BOTTOM:1px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr><tr style="HEIGHT:15px;background-color:#ffffff"><td><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>182,614</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>301,547</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>520,594</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td><td style="BORDER-BOTTOM:3px double;width:1%;white-space:nowrap" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>$</strong></span></td><td style="BORDER-BOTTOM:3px double;text-align:right;width:9%" valign="bottom"><span style="font-size:10pt;font-family:Times New Roman, Times, serif"><strong>711,575</strong></span></td><td style="PADDING-BOTTOM:3px;width:1%;white-space:nowrap"><p style="MARGIN:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ScheduleOfInterestExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ScheduleOfInterestExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210807314120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of summary of stock option activity</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Number of</strong></p><p style="margin:0px;text-align:center"><strong>Shares</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Weighted</strong></p><p style="margin:0px;text-align:center"><strong>Average</strong></p><p style="margin:0px;text-align:center"><strong>Exercise Price</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Weighted</strong></p><p style="margin:0px;text-align:center"><strong>Average Remaining</strong></p><p style="margin:0px;text-align:center"><strong>Contractual</strong></p><p style="margin:0px;text-align:center"><strong>Term (Years)</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Outstanding, December 31, 2019</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>3,317,642</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>0.33</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>8.34</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Granted</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">24,200,000</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.05</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Cancelled</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">(1,861,964</td><td style="width:1%;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">0.08</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Forfeited</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(655,000</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">0.42</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px">&#160;</p></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Outstanding, September 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>25,000,678</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>0.07</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>9.73</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Exercisable, September 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>4,410,668</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>0.07</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>9.73</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value assumptions of stock option granted</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:15%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months Ended</strong></p><p style="margin:0px;text-align:center"><strong>September 30, 2020</strong></p></td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Dividend yield</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap"><p style="margin:0px;text-align:center">0.00%</p></td><td style="white-space:nowrap">&#160;</td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Risk-free interest rate</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">0.28&#x2014;0.38%</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Expected term (years)</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">5.56&#x2014;6.01</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Volatility</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2"><p style="margin:0px;text-align:center">92.55&#x2014;93.84%</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Schedule of RSA activity</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Number of</strong></p><p style="margin:0px;text-align:center"><strong>Shares</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Weighted </strong></p><p style="margin:0px;text-align:center"><strong>Average</strong></p><p style="margin:0px;text-align:center"><strong>Grant </strong></p><p style="margin:0px;text-align:center"><strong>Date Fair</strong></p><p style="margin:0px;text-align:center"><strong>Value</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Unvested, December 31, 2019</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>450,000</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom"><strong>0.19</strong></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Granted</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Released</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">(450,000</td><td style="width:1%;padding-bottom:1px;vertical-align:bottom;white-space:nowrap">)</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">0.19</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify"><strong>Unvested, September 30, 2020</strong></p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>&#x2014;</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>&#x2014;</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock', window );">Schedule of stock-Based compensation Expense</a></td>
<td class="text"><div><p style="margin:0px;text-align:justify;font-family:times new roman;font-size:10pt">&#160;</p><table cellpadding="0" style="font:10pt/normal times new roman;width:100%;text-align:left;border-spacing:0;font-size-adjust:none;font-stretch:normal"><tbody><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Three Months Ended</strong><strong> <strong>September 30,</strong></strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="6" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>Nine Months Ended</strong></p><p style="margin:0px;text-align:center"><strong>September 30,</strong></p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px"><td><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2020</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="white-space:nowrap"><p style="margin:0px">&#160;</p></td><td colspan="2" style="width:9%;text-align:center;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid"><p style="margin:0px;text-align:center"><strong>2019</strong></p></td><td style="padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">Research and development</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">44,010</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">82,463</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;white-space:nowrap">$</td><td style="width:9%;text-align:right;vertical-align:bottom">&#x2014;</td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(255, 255, 255)"><td style="vertical-align:top"><p style="margin:0px;text-align:justify">General and administrative</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">104,355</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">170,106</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">158,753</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:1px;border-bottom-style:solid">514,683</td><td style="width:1%;padding-bottom:1px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr><tr style="height:15px;background-color:rgb(204, 238, 255)"><td><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>148,365</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>170,106</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>241,216</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;white-space:nowrap"><p style="margin:0px">&#160;</p></td><td style="width:1%;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double;white-space:nowrap"><strong>$</strong></td><td style="width:9%;text-align:right;vertical-align:bottom;border-bottom-color:currentColor;border-bottom-width:3px;border-bottom-style:double"><strong>514,683</strong></td><td style="width:1%;padding-bottom:3px;white-space:nowrap"><p style="margin:0px">&#160;</p></td></tr></tbody></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of employee stock purchase plan activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210732582120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations and Business Activities (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Apr. 29, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Apr. 22, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (37,231,874)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (32,173,282)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Stockholders' deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,853,367<span></span>
</td>
<td class="num">$ (3,094,424)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,702,897)<span></span>
</td>
<td class="nump">548,058<span></span>
</td>
<td class="num">$ (16,402,461)<span></span>
</td>
<td class="num">$ (11,641,442)<span></span>
</td>
<td class="num">$ (27,864,191)<span></span>
</td>
<td class="num">$ (15,562,252)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WorkingCapitalDeficit', window );">Working capital deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,137,772)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,224,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,829,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_SeniorManagementCompensationPlanDescription', window );">Description of senior management's compensation plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Upon the closing of the August 2020 Financing, the Company&#x2019;s Board of Directors determined that the Company had been sufficiently financed to pay the deferred salaries and fees, including a 10% retention bonus, to management and the Board in the aggregate amount of $293,078.<span></span>
</td>
<td class="text">During March 2020, the Company approved a plan to defer up to 50% of the members of senior management&#x2019;s compensation and 100% of the Board of Director and committee fees indefinitely.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramPromissoryNoteMember', window );">Paycheck Protection Program Promissory Note (PPP Note)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember', window );">Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_AmendedAndRestatedMultiDrawCreditAgreementMember', window );">Amended and Restated Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod', window );">Principal amount of credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Credit facility advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_DrawDownsLoansInAggregatePrincipalAmount', window );">Draw downs loans In aggregate principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of common stock issued and outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rates per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct.  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember', window );">fourth amended and Restated Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Credit facility advances per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember', window );">Fifth Amended And Restated Multi Draw Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount', window );">Credit facility advances per month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NumberOfCommonStockUnitsSold', window );">Number of common stock units sold</a></td>
<td class="nump">56,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NumberOfPreFundedUnitsSold', window );">Number of pre-funded units sold</a></td>
<td class="nump">60,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_GrossProceedsOfUnitsSold', window );">Gross proceeds of units sold</a></td>
<td class="nump">$ 6,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrants', window );">Term Of Warrants</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember', window );">Securities Purchase Agreement with H.C. Wainwright &amp; Co., LLC | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems', window );"><strong>Nature Of Operations And Business Activities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_DrawDownsLoansInAggregatePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents draw downs loans in aggregate principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_DrawDownsLoansInAggregatePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_GrossProceedsOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gross proceeds of units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_GrossProceedsOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NatureOfOperationsAndBusinessActivitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NatureOfOperationsAndBusinessActivitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NumberOfCommonStockUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common stock units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NumberOfCommonStockUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NumberOfPreFundedUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pre funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NumberOfPreFundedUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_SeniorManagementCompensationPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents description of senior management compensation plan description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_SeniorManagementCompensationPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WorkingCapitalDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent working capital deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WorkingCapitalDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount borrowed under the credit facility at any time during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumAmountOutstandingDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum month-end amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumMonthendOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramPromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramPromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_AmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_AmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_FourthAmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_FifthAmendedAndRestatedMultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementWithHCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804100168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="num">$ (1,296,696)<span></span>
</td>
<td class="num">$ (1,420,236)<span></span>
</td>
<td class="num">$ (2,341,660)<span></span>
</td>
<td class="num">$ (4,931,125)<span></span>
</td>
<td class="nump">$ 15,905,290<span></span>
</td>
<td class="num">$ (14,774,392)<span></span>
</td>
<td class="num">$ (5,058,592)<span></span>
</td>
<td class="num">$ (3,800,227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic</a></td>
<td class="nump">256,758,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,001,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207,536,173<span></span>
</td>
<td class="nump">132,885,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted net loss per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss (as adjusted)</a></td>
<td class="num">$ (1,720,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,931,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,401,484)<span></span>
</td>
<td class="num">$ (5,656,982)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding - diluted</a></td>
<td class="nump">257,255,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">133,001,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,434,966<span></span>
</td>
<td class="nump">167,690,989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted</a></td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.03)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804355544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">145,336,155<span></span>
</td>
<td class="nump">57,943,250<span></span>
</td>
<td class="nump">22,304,750<span></span>
</td>
<td class="nump">144,934,542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember', window );">Common shares underlying convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">5,215,457<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="nump">5,215,457<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">25,000,678<span></span>
</td>
<td class="nump">4,512,715<span></span>
</td>
<td class="nump">25,000,678<span></span>
</td>
<td class="nump">4,512,715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Unvested restricted stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Nature of Operations, Business Activities and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive excluded from the calculation of diluted loss per common share</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,093,501<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,093,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NatureOfOperationsBusinessActivitiesAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertibleCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210807341144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvancesFairValueDisclosure', window );">Fair value of advances under the Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,877,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Convertible multi-draw credit agreement - related party, net of discount</a></td>
<td class="nump">$ 789,694<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvancesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of Federal Home Loan Bank (FHLBank) advances carried under the fair value option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvancesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210809301784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">195,633,335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">1,110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember', window );">Pre 2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember', window );">2015 Common Stock Warrants | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 5.00<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember', window );">2016 Common Stock Warrants to Service Providers</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 1.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember', window );">2016 Series C Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember', window );">2017 Series D Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">480,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember', window );">2017 Common Stock Warrants to Service Provider</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">125,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember', window );">2018 Emerald Financing Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">3,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember', window );">2019 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.06<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">116,666,668<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember', window );">2020 Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term (Years)</a></td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">8,166,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyPreFundedWarrantsMember', window );">2020 Pre-Funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise Price | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsVestedAndOutstanding', window );">Amount Vested and Outstanding | shares</a></td>
<td class="nump">49,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsVestedAndOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants vested and outstanding as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsVestedAndOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_Pre2015CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandFifteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSixteenSeriesCPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenSeriesDPlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandSeventeenCommonStockWarrantsToServiceProvidersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldFinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandNineteenCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyPreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyPreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804073704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 1) - Pricing Model - Emerald Multi-Draw Credit Agreement Warrants<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PricingModelAxis=embi_PricingModelMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PricingModelAxis=embi_PricingModelMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.69<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">91.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">92.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">2.23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">2.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210809290984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 2) - Pricing Model<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">91.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">93.86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">91.64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years) | Placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOfferedPriceMember', window );">Weighted-average fair value of warrants | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOfferedPriceMember', window );">Weighted-average fair value of warrants | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">0.05<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOfferedPriceMember', window );">Weighted-average fair value of warrants | Placement agent warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_PlacementAgentWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_PlacementAgentWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOfferedPriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOfferedPriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210732426696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">$ 501,400<span></span>
</td>
<td class="nump">$ 15,958,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(433,688)<span></span>
</td>
<td class="num">(2,024,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity</a></td>
<td class="num">(26,563)<span></span>
</td>
<td class="num">(144,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">41,149<span></span>
</td>
<td class="nump">14,305,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Less, noncurrent portion of derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(567,606)<span></span>
</td>
<td class="num">$ (90,797)<span></span>
</td>
<td class="num">$ (219,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current balance of derivative liabilities</a></td>
<td class="nump">41,149<span></span>
</td>
<td class="nump">13,737,783<span></span>
</td>
<td class="nump">$ 410,603<span></span>
</td>
<td class="nump">$ 15,738,913<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing - Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">276,024<span></span>
</td>
<td class="nump">15,251,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(234,875)<span></span>
</td>
<td class="num">(1,895,193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">41,149<span></span>
</td>
<td class="nump">13,356,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement - compound derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">90,797<span></span>
</td>
<td class="nump">219,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(90,797)<span></span>
</td>
<td class="num">(167,905)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">567,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember', window );">Series B Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfDerivativeLiabilitiesRollForward', window );"><strong>Fair Value Of Derivative Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">134,579<span></span>
</td>
<td class="nump">487,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantsIssued', window );">Fair Value of Derivative Liabilities Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in Fair value of Derivative Liabilities</a></td>
<td class="num">(108,016)<span></span>
</td>
<td class="nump">38,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ReclassificationOfDerivativesToEquity', window );">Reclassification of Derivatives to Equity</a></td>
<td class="num">(26,563)<span></span>
</td>
<td class="num">(144,375)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Fair Value of Derivative Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 381,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfDerivativeLiabilitiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfDerivativeLiabilitiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantsIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of warrants issued in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantsIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ReclassificationOfDerivativesToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reclassification of derivatives to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ReclassificationOfDerivativesToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804977016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 4) - Monte Carlo simulations - Emerald Financing<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share | $ / shares</a></td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">80.8<span></span>
</td>
<td class="nump">79.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0.14<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">2 years 4 months 17 days<span></span>
</td>
<td class="text">3 years 1 month 17 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_MonteCarloSimulationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_MonteCarloSimulationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210809289352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Details 5) - Pricing Model - Series B warrant<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Percent </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Underlying common stock price | $ / shares</a></td>
<td class="nump">$ 0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Volatility factor</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">79.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and rights outstanding measurement input</a></td>
<td class="nump">1.60<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected Term</a></td>
<td class="text">7 months 20 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PricingModelAxis=embi_PricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PricingModelAxis=embi_PricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=embi_SeriesBWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210805023016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants and Derivative Liabilities (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2018</div></th>
<th class="th"><div>Jan. 19, 2018</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 28, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities', window );">Decrease in derivative liability through an adjustment to change in fair value of derivative liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi draw credit agreement related party value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (433,688)<span></span>
</td>
<td class="num">$ (2,024,660)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldFinancingWarrantsLiabilityMember', window );">Emerald Financing Warrant Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total number of warrants issued</a></td>
<td class="nump">44,200,000<span></span>
</td>
<td class="nump">44,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateExercisePriceOfOutstandingCreditAgreement', window );">Aggregate exercise price of outstanding credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,080,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ClassOfWarrantOrRightWarrantsExercise', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue', window );">Warrants issued in connection with convertible multi draw credit agreement related party value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember', window );">Emerald Multi-Draw Credit Agreement Warrants | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Warrant vested aggregate fair value utilizing the Black-Scholes option pricing model</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,830,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember', window );">Series B Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ValueOfCommonStockCalledByWarrants', window );">Value of common stock called by warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Total number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">312,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price, per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember', window );">Series B Warrants | Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_GrossProceedsOfWarrants', window );">Gross proceeds of warrants on a relative fair value basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,462,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsMember', window );">2020 Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116,666,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember', window );">2020 Common Stock Warrants to Placement Agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity', window );">Value of warrants issued recorded as equity issuance costs within equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 261,333<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfWarrant', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 26 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember', window );">Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of warrants issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_GrossProceedsOfWarrants', window );">Gross proceeds of warrants on a relative fair value basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,986,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AggregateExercisePriceOfOutstandingCreditAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Information about aggregate exercise price of outstanding credit agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AggregateExercisePriceOfOutstandingCreditAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ClassOfWarrantOrRightWarrantsExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants exercise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ClassOfWarrantOrRightWarrantsExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_GrossProceedsOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the gross proceeds of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_GrossProceedsOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents term of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ValueOfCommonStockCalledByWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of common stock called by warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ValueOfCommonStockCalledByWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value Of Warrants Issued recorded as equity issuance costs within equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ValueOfWarrantsIssuedRecordedAsEquityIssuanceCostsWithinEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents warrants issued in connection with convertible multi draw credit agreement related party value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_WarrantsIssuedInConnectionWithConvertibleMultiDrawCreditAgreementRelatedPartyValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying value of derivative instruments reported as liabilities that are due to be disposed of within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldFinancingWarrantsLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_EmeraldFinancingWarrantsLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandEighteenEmeraldMultiDrawCreditAgreementWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_TwoThousandAndTwentyCommonStockWarrantsToPlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210732560840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Total principal value of non-convertible debt - related party</a></td>
<td class="nump">$ 789,694<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible debt | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion price</a></td>
<td class="nump">$ 0.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent', window );">Total principal value of convertible debt - related party</a></td>
<td class="nump">$ 2,014,500<span></span>
</td>
<td class="nump">2,014,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent', window );">Unamortized debt discount</a></td>
<td class="num">(1,220,838)<span></span>
</td>
<td class="num">(1,622,344)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentGross', window );">Unamortized debt issuance costs</a></td>
<td class="num">(3,968)<span></span>
</td>
<td class="num">(5,086)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtCurrent', window );">Carrying value of total convertible debt - related party</a></td>
<td class="nump">789,694<span></span>
</td>
<td class="nump">387,070<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleDebtNoncurrent', window );">Total principal value of non-convertible debt - related party</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CurrentConvertibleDebtExcludingNoncurrentPortion', window );">Total carrying value of advances under the multi-draw credit agreement</a></td>
<td class="nump">$ 1,239,694<span></span>
</td>
<td class="nump">$ 387,070<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CurrentConvertibleDebtExcludingNoncurrentPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CurrentConvertibleDebtExcludingNoncurrentPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the carrying value of long-term convertible debt as of the balance sheet date that is scheduled to be repaid within one year or in the normal operating cycle if longer. Convertible debt is a financial instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of long-term convertible debt as of the balance sheet date, net of the amount due in the next twelve months or greater than the normal operating cycle, if longer. The debt is convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the equity component of convertible debt which may be settled in cash upon conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt discount to be amortized within one year or within the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210824170360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Details 1) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseRelatedParty', window );">Related party interest expense - stated rate</a></td>
<td class="nump">$ 44,087<span></span>
</td>
<td class="nump">$ 107,334<span></span>
</td>
<td class="nump">$ 117,459<span></span>
</td>
<td class="nump">$ 272,611<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">PPP loan interest expense - stated rate</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">511<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NonCashInterestExpenseAbstract', window );"><strong>Non-cash interest expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AmortizationOfDebtDiscount', window );">Amortization of debt discount</a></td>
<td class="nump">137,849<span></span>
</td>
<td class="nump">190,886<span></span>
</td>
<td class="nump">401,507<span></span>
</td>
<td class="nump">429,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AmortizationOfTransactionCosts', window );">Amortization of transaction costs</a></td>
<td class="nump">384<span></span>
</td>
<td class="nump">3,327<span></span>
</td>
<td class="nump">1,117<span></span>
</td>
<td class="nump">9,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">$ 182,614<span></span>
</td>
<td class="nump">$ 301,547<span></span>
</td>
<td class="nump">$ 520,594<span></span>
</td>
<td class="nump">$ 711,575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AmortizationOfDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AmortizationOfDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AmortizationOfTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization of transaction costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AmortizationOfTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NonCashInterestExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NonCashInterestExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense incurred on a debt or other obligation to related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210806484360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 05, 2018</div></th>
<th class="th"><div>Apr. 24, 2020</div></th>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 501,400<span></span>
</td>
<td class="nump">$ 41,149<span></span>
</td>
<td class="nump">$ 14,305,389<span></span>
</td>
<td class="nump">$ 501,400<span></span>
</td>
<td class="nump">$ 15,958,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts', window );">Convertible multi-draw credit agreement issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UnamortizedDebtDiscountPeriod', window );">Unamortized debt discount period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfSharesUnderlyingConvertibleDebt', window );">Fair value of shares underlying convertible debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 211,523<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramMember', window );">Paycheck Protection Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 24,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PayrollCostsExcludeCompensation', window );">Excess payroll costs exclude compensation of an individual employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfForgivenessAmountForNonPayrollCosts', window );">Percentage of forgiveness amount for nonpayroll costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrentAndNoncurrent', window );">Amount of salaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfReductionInAnnualSalary', window );">Percentage of reduction in annual salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember', window );">Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRelatedPartyDebt', window );">Proceeds from related party debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AllocationOfDebtOnBasisOfRelativeFairValue', window );">Allocation of debt on the basis of relative fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,684,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,283,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AllocationOfWarrantOnBasisOfRelativeFairValue', window );">Allocation of warrant on the basis of relative fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion feature</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,985,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds', window );">Fair value of derivative liabilities in excess of proceeds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 276,024<span></span>
</td>
<td class="nump">41,149<span></span>
</td>
<td class="nump">$ 13,356,220<span></span>
</td>
<td class="nump">$ 276,024<span></span>
</td>
<td class="nump">$ 15,251,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember', window );">Emerald Financing | Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount', window );">Maximum amount that can be borrowed over the life of the credit facility</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate percentage</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">Oct.  05,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount', window );">Unused portion of the credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase', window );">Warrant coverage on the debt facility</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Reduced exercise price of warrant</a></td>
<td class="nump">0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc | Multi-Draw Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease', window );">Conversion price</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Amount of capital raise</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc | Independent contractor agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CreditFacilityEffectedFourthAdvances', window );">Credit facility effected fourth advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CreditFacilityEffectedFifthAdvances', window );">Credit facility effected fifth advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AllocationOfDebtOnBasisOfRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents allocation of debt on the basis of relative fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AllocationOfDebtOnBasisOfRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AllocationOfWarrantOnBasisOfRelativeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents allocation of warrant on the basis of relative fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AllocationOfWarrantOnBasisOfRelativeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible multi-draw credit agreement issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_ConvertibleMultiDrawCreditAgreementIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CreditFacilityEffectedFifthAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents credit facility fifth advances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CreditFacilityEffectedFifthAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CreditFacilityEffectedFourthAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents fourth credit facility advances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CreditFacilityEffectedFourthAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfSharesUnderlyingConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares underlying convertible debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfSharesUnderlyingConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_FairValueOfWarrantLiabilityInExcessOfProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to fair value of warrant liability in excess of proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_FairValueOfWarrantLiabilityInExcessOfProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PayrollCostsExcludeCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of payroll costs exclude compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PayrollCostsExcludeCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of amount need to be issued against warrant purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfAmountNeedToBeIssuedAgainstWarrantPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfForgivenessAmountForNonPayrollCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of forgiveness amount for non payroll costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfForgivenessAmountForNonPayrollCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfReductionInAnnualSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reduction in annual salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfReductionInAnnualSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_UnamortizedDebtDiscountPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of unamortized discount of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_UnamortizedDebtDiscountPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in conversion price of debt instrument. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAverageOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average amount borrowed under the credit facility during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAverageOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRelatedPartyDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRelatedPartyDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=embi_PaycheckProtectionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_MultiDrawCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210805596872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Deficit) and Capitalization (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 9,301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">August 2020 Financing | Securities purchase agreement | Institutional investors and H.C. Wainwright &amp; Co., LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NumberOfCommonStockUnitsSold', window );">Number of common stock units sold</a></td>
<td class="nump">56,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NumberOfPreFundedUnitsSold', window );">Number of pre-funded units sold</a></td>
<td class="nump">60,333,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_CommonUnitsSoldPricePerUnit', window );">Common units sold price per unit</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PreFundedUnitsSoldPricePerUnit', window );">Pre-funded units sold price per unit</a></td>
<td class="nump">$ 0.059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_GrossProceedsOfUnitsSold', window );">Gross proceeds of units sold</a></td>
<td class="nump">$ 6,939,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 854,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from stock issuance</a></td>
<td class="nump">$ 6,085,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">August 2020 Financing | Securities purchase agreement | Institutional investors and H.C. Wainwright &amp; Co., LLC | Placement agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and rights outstanding term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase an aggregate shares of common stock</a></td>
<td class="nump">8,166,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering', window );">Percentage of total shares of common stock and pre-funded warrants sold in offering</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">August 2020 Financing | Securities purchase agreement | Institutional investors and H.C. Wainwright &amp; Co., LLC | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Common stock and pre-funded stock units sold description</a></td>
<td class="text">each consisting of one share of common stock and one warrant to purchase one share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">August 2020 Financing | Securities purchase agreement | Institutional investors and H.C. Wainwright &amp; Co., LLC | Pre-funded Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_EquityLineItems', window );"><strong>Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Common stock and pre-funded stock units sold description</a></td>
<td class="text">each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_CommonUnitsSoldPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per unit of common units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_CommonUnitsSoldPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_EquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_EquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_GrossProceedsOfUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of gross proceeds of units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_GrossProceedsOfUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NumberOfCommonStockUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of common stock units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NumberOfCommonStockUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NumberOfPreFundedUnitsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of pre funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NumberOfPreFundedUnitsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of total shares of common stock and pre-funded warrants sold in the offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfTotalSharesOfCommonStockAndPrefundedWarrantsSoldInOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PreFundedUnitsSoldPricePerUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the price per unit of pre-funded units sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PreFundedUnitsSoldPricePerUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_InstitutionalInvestorsAndHCWainwrightAndCompanyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=embi_PlacementAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=embi_PlacementAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=embi_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804263928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details) - Omnibus Incentive Plan 2014 - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning</a></td>
<td class="nump">3,317,642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="nump">24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled</a></td>
<td class="num">(1,861,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited</a></td>
<td class="num">(655,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the ending</a></td>
<td class="nump">25,000,678<span></span>
</td>
<td class="nump">3,317,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">4,410,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning</a></td>
<td class="nump">$ 0.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited</a></td>
<td class="nump">0.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the ending</a></td>
<td class="nump">0.07<span></span>
</td>
<td class="nump">$ 0.33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">$ 0.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based compensation arrangement by share-based payment award, options, additional disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (Years)</a></td>
<td class="text">9 years 8 months 23 days<span></span>
</td>
<td class="text">8 years 4 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (Years), Exercisable</a></td>
<td class="text">9 years 8 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210821204760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 1) - Stock options - Omnibus Incentive Plan 2014<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend Yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.28%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">92.55%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">93.84%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210805701864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 2) - Restricted stock awards<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, December 31, 2019 | shares</a></td>
<td class="nump">450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Released | shares</a></td>
<td class="num">(450,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, September 30, 2020 | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, December 31, 2019 | $ / shares</a></td>
<td class="nump">$ 0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Released | $ / shares</a></td>
<td class="nump">0.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, September 30, 2020 | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210821204168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Details 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 148,365<span></span>
</td>
<td class="nump">$ 170,106<span></span>
</td>
<td class="nump">$ 241,216<span></span>
</td>
<td class="nump">$ 514,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">44,010<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">82,463<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 104,355<span></span>
</td>
<td class="nump">$ 170,106<span></span>
</td>
<td class="nump">$ 158,753<span></span>
</td>
<td class="nump">$ 514,683<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804248440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2014</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Number of forfeiture of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted average exercise price of forfeiture of shares (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and Expected to Vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">869,144<span></span>
</td>
<td class="nump">869,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price of vested and outstanding (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241,216<span></span>
</td>
<td class="nump">$ 514,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">643,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="nump">$ 0.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of restricted common stock granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of restricted common stock vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member', window );">Omnibus Incentive Plan 2014 | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future grants</a></td>
<td class="nump">3,200,000<span></span>
</td>
<td class="nump">6,040,097<span></span>
</td>
<td class="nump">6,040,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-average fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares', window );">Percentage of share reserve of the number of issued and outstanding shares</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Aggregate number of shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for future grants</a></td>
<td class="nump">7,876,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share reserve of the number of issued and outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfShareReserveOfNumberOfIssuedAndOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_OmnibusIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210817082936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Detail Textuals 1)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Total amount of unrecognized compensation cost related to non-vested stock options</a></td>
<td class="nump">$ 879,628<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Recognized weighted average period</a></td>
<td class="text">3 years 7 months 2 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210732615768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts - University of Mississippi (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 10, 2017</div></th>
<th class="th"><div>Jul. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AnnualMaintenanceFeePayable', window );">Annual maintenance fee payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember', window );">UM 5050 pro-drug agreements | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PaymentForUpfrontFees', window );">Payment for upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember', window );">UM 8930 analogue agreements | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PaymentForUpfrontFees', window );">Payment for upfront fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AnnualFeesForLicenseAgreement', window );">Annual fees for license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember', window );">UM 5070 license agreement | University of Mississippi | Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_NoticePeriodForTermination', window );">Notice period for termination</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember', window );">Um 5050 Pro-Drug And Um 8930 Analog Agreements | University of Mississippi | Intellectual Property | Milestone 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_UniversityOfMississippiAgreementsLineItems', window );"><strong>University Of Mississippi Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved', window );">Aggregate milestone payments if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AggregateMilestonePaymentsIfMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of aggregate milestone payments under the license agreements if the milestones are achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AggregateMilestonePaymentsIfMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AnnualFeesForLicenseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents annual fees for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AnnualFeesForLicenseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AnnualMaintenanceFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of annual maintenance fee payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AnnualMaintenanceFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_NoticePeriodForTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents written notice period for termination under agreement by either party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_NoticePeriodForTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PaymentForUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents payment for upfront fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PaymentForUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents time to pay, after milestone is met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_UniversityOfMississippiAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line item represents information regarding University of Mississippi agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_UniversityOfMississippiAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_OptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_UniversityOfMississippiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_UniversityOfMississippiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_Um5070LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_Um5050ProDrugAndUm8930AnalogAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MilestonePaymentsPayableAxis=embi_Milestone3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MilestonePaymentsPayableAxis=embi_Milestone3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804185496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Matters (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Dec. 19, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember', window );">Emerald Health Sciences Inc | Officers, employees and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Number of of common shares shares</a></td>
<td class="nump">$ 186,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember', window );">Independent contractor agreement | Dr. Avtar Dhillon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFee', window );">Monthly fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFeePaidEachMonthInExchangeOfServices', window );">Monthly fee paid each month</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices', window );">Monthly fee accruing from effective date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfAccruedConsultingFees', window );">Percentage of accrued consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_PercentageOfBonusForAccruedConsultingFees', window );">Percentage of bonus for accrued consulting fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalFeesIncurredUnderAgreement', window );">Fees incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AccruedExpenseUnderAgreement', window );">Accrued expense under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember', window );">Independent contractor agreement | Emerald Health Sciences Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_InitialTermOfAgreement', window );">Initial term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_TotalExpenseIncurredUnderAgreement', window );">Expense incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_embi_AccruedExpenseUnderAgreement', window );">Accrued expense under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_AccruedExpenseUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total accrued expense under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_AccruedExpenseUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_InitialTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the initial term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_InitialTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fees accruing from the effective date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFeeAccruingFromEffectiveDateInExchangeOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_MonthlyFeePaidEachMonthInExchangeOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of monthly fee paid in exchange of services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_MonthlyFeePaidEachMonthInExchangeOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfAccruedConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of accrued consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfAccruedConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_PercentageOfBonusForAccruedConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents percentage of bonus for accrued consulting fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_PercentageOfBonusForAccruedConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TotalExpenseIncurredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total expense incurred under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TotalExpenseIncurredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_embi_TotalFeesIncurredUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the total fees incurred under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">embi_TotalFeesIncurredUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>embi_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=embi_EmeraldHealthSciencesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=embi_OfficersEmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=embi_OfficersEmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=embi_IndependentContractorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=embi_AvtarDhillonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=embi_AvtarDhillonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm140210804156680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Detail Textuals) - Subsequent Event - 2014 Plan - $ / shares<br></strong></div></th>
<th class="th"><div>Nov. 06, 2020</div></th>
<th class="th"><div>Oct. 05, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average fair value of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Employee | Vesting on grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Employee | Vesting semi-annually</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Chief Medical Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited', window );">Number of stock options forfeited</a></td>
<td class="nump">3,968,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensationForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=embi_EmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=embi_EmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=embi_StockOptions2014PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=embi_StockOptions2014PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=embi_ChiefMedicalOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=embi_ChiefMedicalOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MI.>T'123.5XR_236=Z1(*#3^(L&4_4?KW+8)QM%2:9$68B!(*<^O^+4HQ(;
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M8P#WYT+HMXDY?<NOK?X_4$L#!!0    ( %F&9E$H7-1UG@4  %45   8
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M0F@78E\.IYC2@6R#6QK!T;M -F12, T)<\VD?G&BCOIH<!@,) [<L@CVTPB
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M$:3E,?)Z'V2S"M1I3\+ 6;PX@],)RD%P<4P2TFV4'(+^C6TICO@ISN 7%40
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M+NWCBC/85R, _U_6M=Z_F 4.=XV7_P=02P,$%     @ 689F48WL=ZRI @
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MDKL[K/PX@8G,M?N%794;>)!LM)%%!28%!1?ER-ZJ<]@#$,]A0%@!PH^ UA%
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M97!Q1<)4V9'*P,BU>]0+::A%N.F*FC@JFT#[F93F/; %ZK^%Z ]02P,$%
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M8>>JDCB (EG]>H3J9P5#E%T#%8OXX)[OY*0'WEH<ZOF 1XU#/9_/ \XTQZ:
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MT^+_BN]1!&&N%4497AB(>+9#5,SFT):4XCQ:PG).:;LB0V=B+A%S^T2C1U\
M'R$M)#69R-^=\- C$%=0NF^[Q)!&SHY(2\;UXB)1$>]80]IJZ357\]C=^00,
M78T\5O?#W_-8C3;/G/9IE"EU3JB YXBD>IV[-4=F3C"66+8DJOM.WS,L;4HB
M)M@Q+&!W;6X-G]&51(^^43?<"Z0O1^=1% %E@Q3[A+'P9$YH=@M[B LDS#>J
M!@)SFS&=%Y/Q^802;Z'##4\A\T!DN% EB/,YYQ==X@]++T.WR1-S>B>Y,;<9
M+'"VE)&%2/RW(KOA1D-LX2Y<ZQM!C(5=T*=D%VV51]@^:+A;V4"0?.Y<Q$8$
M7YPF[4""M30WBHBAW39S"A%=$Q)RO/R.Y87LNBUC^T8F #O -=M)"#F4BZ.X
MS)@\](C>;48.MC05UUU]@K4O\TP5S_B@'?&4CK=,\>R@*$GS%(P0*!ZI;T-9
M)J-8;UQ#JY#TU?66RIX8+;LSD41]B)NSW\9-5-$;9%C8Y=X#>&4 @8]P])+^
M+[&/0U!A5'X&>EY,IQ>C2VAZB*KW]_<T+*DZ%&45W!"*?=(QO%WKZNO>1>HG
M[M+V]2QIMWM(S47)H@B-!AUPHO3<F7:VZECK/-B#K4?KVZ"N;#ZB;H,U"T&4
M]] 8)))1%ZWE%N)5MA/WKCZ_?Z!?^XYC7B(%"R+S^4;JY?'#6#V45.?V,Z[X
MWL[8YN'ZJB/U_3 T\FA$4N=G-2PMKMB@FTWZEGPD=[YW@C DA\PJ5^<7H]-3
M5&:G9]O 1QU?&#^R=#+G0,,P*L47G.]U(+>UA"1)3[=^C,;-#R\FW5XHFXXI
M 3+Y\SL-WAM2.K@-SS" [TDQL2ARP$*"4C&VRC1[T&,XJ6-/?'$QGB)W+(JN
MU[1O2\D+P.<VFT$2^$/18G(AT(E/D^D^X*3(D&QW_[;4O*$4GSL._0#OJ<0$
MF"(;7/K27+G@=LRA%<S\W)B>?:Z?%FVQTT4A2(_%21MB1WPHWGB$I( #T)Q@
M>!0S&I[>;4-U%PUCV_R)=_3=?6[:<(N%>XR2/9U/ODO,Q*$3?0VFHL2F+\T&
MV7Y)27@_/9I.>@I/9A-=GY :;X@1AOL#U"RA%AHI]4L=ZTJ:%$<+/^C#OWLB
MDALR% ;+)Z4DY4FLPK[^*#:Q')/<J=:"6RPG<I>@"^U3FX(.,52(A@B^@ZER
M/P2'F;N*)M2@,ZALDQD*KRESZ'*N06"9O3H=32Y?;IM3UXGM*D])WP+UY%+!
M%#NKR;<]>19W-5/#R>-$*'$729S@4OJ*? PR\66JW'4(,%><F\[:SPDD(0Y$
MRE'#=VO5H&.P-:1&+N.Z-%^E*;J/^3>I)[143FS7@$%J_CE6/&I;L(-RKUX'
MO,/-0LH21\0+Y9_D@1^WTU(N,\-3PO,-IQ-<4HIH^NGU:+LG8(LV#;>XNJ4U
MPYX>W+$M\EA$\W2HZ_/(M$$CE0%\*8ITMI+@T(?<%/9N[G[^^.YX^JJ+?8;O
M2;"E_-*NXERTT@BCW*G$*2ON!5'[4RYWI61@JSDMK=AJ(4G!$+^\H5X;P0*L
M)AHGH*60.6B\!+(5;G^AIRD/O/-+7=E_"0SD)BNT3[<BVF8.?KA&2,>*?9+"
MS2FW!$\&644JUI))2^,[GD5LF2JW)V<:#69%W*?=.0#1I3BUVWS?:5#' 5-0
M,"U"6\KZMEH(3WM)'WE4!,"2YM'PM*,T:)!.)@\:=8O:,]Z)V#<Y$&U8NDX
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M-[M+.EC :!6LYX6K\5T1"DTLLDKO<8WW.!V[B*.^01,9V]G;9D)4;2GE#YQ
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M(=A?%+"47@0F< _*%#G) ]'75'!!$AM<"#RH$KN5T(T;64.@6"Q_PWF@455
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M6(OBJ]HI5_"L41J)@K%Y)<A\=DI7%*#5O5,EYBG/?2Y6U9&VW$[*W0XT#LS
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M[#5ZLX$E $1(@Y3S00 6LRR=]+T>MO*(#9%(C*<@_)$TKT!#4P!"'<OBHH^
MU^1LTH"A$XJB'>S8J#IP L=3%@T< 2C @T%+,[*0C3;RJV(^^_!W@SU+550<
M#U4U] >N=O:2H=YMR0!12:2TGJ(Z/?CW7B.W]C', +Q;0PZ03#C:!0+3LE4\
M,>16MM;9K!&UW3V-:80EV@)-"V::?]Y6K1-9^DT2X(%W##MI)T)"@,6KBAT6
M)JE#B\\Z49+>#YCRLIQ#Z%I3[4&/**"X:U!T<<[4.Q3D,M1)V]:BQD/@<*GA
M/*+T$A,%<!T% =1!+U@U2;^)BJA;S@VX.T.!JX^!>"?SH8>MCK6U?("2V?N(
MXE+C]@FV<IX>.5<_HM2CLH5V'I^WV#NV3M?HJEY6YC-!$=39+Z4 P1V?L<!;
M,2*7,9$W>J,.P#!FB@-!F7S9,_F12WM5U%%&-2@4)VFO4"2\(7\X3_R9-@1R
M!*7'VO3DAJ->9>I%&;YVG-2[8B1FD [/(L8?5"2^?T#=;C7RA2](3I4P<+,%
M09-_PQ+F.-?5\ Q^#GD&2-0!O?7>P?F^OP'G#><4$4</7+4,[,@HZ[@9EGK,
M0@*% HY*VJY(X=?7IBJI_>FW11SWH?'@7 22@[@@L9MG?>-U< !<,T77)(+?
M LC@X*7-3BEO AX*K U!7MAT"5)=1NLX(%WY/I@"<"FU#5W\0CKMCD3@OICI
M!ZCL/X1F?4"HY5+Q6+-?Z?;!-0P_!'<Y"+DZ%!GVJVIZHXX3RN\CSU I< ]C
MR;>@AUK!270W)^']E\IW!=P+=L.:8&-FR$<7N8=5A)CLV[ZVH=D)$/Z*^F1?
M2H=*MS_Y<=U (5"-6DZ>9\G' S7%H$*-M=4/; _'&H5P"<?<0G$QTHV0*-]Y
M, H@^BP M%P?#<TSS'P;A:J%FC*_PZ  '(ZXM&-UKVKF0SH_14(P[2FJQZU"
MG]>YWRGQ#O7ERYB51Y) IS,;&:=?0G*<QQ3.12_KE!1E(;&D 2O#=<^I"8K:
MA2.<IDH9G)C21=0Z=+6/!HJLJ07"%<I%73*O'V3%P7Q/PVW' ?$++,%),HMS
M*G8C>([<]Q$T/^ 9 \7493YHBOM^'# AIRDCO]!+15Q;O2)/O(1*0=F'W2WS
MTFUW/F,E:/F2V]DXF>=I=) .A7A.$@"J/(JORU%&L\WT^#48A1J,B/%JSPD\
M\H68)A7,4Z;+?G+*V]"2R(5O]>CU/!TG69J':5'E3  0:N(^H=<)L5+K&H'A
M3Q5\8!VVR]E\B$/>[BS4SO2&*XR4L<7RY1;S$1TA\8,5V&H%/:^XYNS&M;T%
MX_V",ZXSH($EW1SM_^A*;N!+R9"GGC2C))^-DMG\A$,,_6::W299]C_PFRR9
MP)-GD_0<"G>.HWWQ>ZC>RPE82R<S[TK1BPX4]ZN/DNY='KB> OS+49XGM^,Q
M"]H1PW5H%0.L=IAU$J/N:82\B:TON8=5:SJRA#1_I68\6NYU[BU]H3%(S,\K
M5CT2&(09<P<-1^9MUMJ6/$H9!!WU 8&=HU.=8;#QA I.-)]-^%2&!BMQ-QX%
M-/WZ-;!.$-UU!#^BP$208>=_]+LFJ]"R D@.IE_]J< ^.A<^)9SL^\*<.@S&
M3Y4L/F+5(X54J]V:LW5E_!SD<II/DG$^B09?&AHIQ(D[O4%*B77Z,0GRHD)6
M1>L3;;!DJ5$"6&J!!D5C+U/&:5\8E?F4RTTNA5RWT3!(CP^"AJ4H]]#T4\S[
MS\+T'\3AHQ,:KG)(YJ@TGM/I9;,>C*_V>.P5GDWV>?ER%*$6M<C6%TTTM2!M
M_U5Q?J36G$?&[.QQS'MVPS.3>3\QWC?8_>, )K.BSBWVJ,-1^]F6-:0#?=HI
M(TM R0[-EETP^ -)TL?M"!J8^M9Q09X"KV\MUU:4:ON0=[ZT[CJ14W7L:RO3
M<#[VNKKS#Q7'+X_"SQWVFOI\!HQV.*C8J=^B[U(80[@$Y:Q"D^5'O?'CCOPZ
MS?PXY%G6Q,F@#6[4.TTXR^+9SE,.SKTN\PQI,A^]I">]O-H/?3Q/)2"#_-UG
MA "'1\#Y^?-G)"; X/[8=7PJJ&%]I1_VL_ ]R'<40EQN6TL#HLX-Z7GL*>^^
M_' O[@I(66Y@!^>/<L,)P_V'NW#$=;+\RI# I_&@H]MT$QHY<\!^SCZ[X+G6
M8 C9M</9=9I^P_46F9M22'R+9LM[#A W<8C*,%CQ,2HLQ.'J:/X1\;'326S2
M!P<'/9YY2L?)29=^-/KD!UO8EPH$LY_[,VS4II?*P#/:8BJ*KL6/;=U/N(,M
M3%WQ/IRJA^<^K&>0HR,>CSA) !X^N^B&VF)E3;N%L]/PKO 00M4'O4^QM9*K
M'F($_GAB1!FW;<(!3]T[L@LS(E]4<4B;1:578;#$D,KE7 =V"P6>E/A1+6Q+
MYRF9/U*$(]S1:8$]KA7VQCNMF 6W@BM-ENOY7BSJ#QW:S[7\5)JW.= E60A0
M?YO"[$]N?Q C_8DV"&5Y>.9/N2LBWIW(\;DFM]2F:$E_7?O/B I,8 ?7O@&P
M93AG#LF$&*?QI[:^[.Q/9;MP2_R646B:_6C7.W>+1:EK&; C(_R!QH&//'#$
M6G;#SMR^?O>/O-&I8B]]$4$E%GT*=X5JYVO W<3;K3+UBA##8[%>=OE\J.&D
M'W!F. 8;Z-(?LP. ML8I=X0ZR5 <0L:J+?V$!*FKTSO/$'AF2D-YM=E6YDEQ
MY4]8&LK#+!8HV-KZ$H\/-ZA*0?-!X:&\]?-)-]+O6R! V]XA.:<..&1Y^B:+
M\V.]Y/..*\8,1&?I<R(=#J%<<ZQ>O.. \E9W+>'*ZR0*%)K1[J6>5+2>1X11
MIE!N^-UAG8%TB$3VZ\ZESTM+C#!D7C%D^F]9+ WY@E^<"D!.Y^%T]2CR!L=J
M<4)-'%AU)4_,TSKB,=SW-4&OFPA@]4.H:7X[,:4Z*GR>^:3NMS62^N ;2?$+
MU=6#7TY\8,=?T^VOO@P^FSIB@%G+OA?\'5/I$]VE&(^3=#:E3[W2:3(:T8=>
M639-QI,Y?58W1<^;9:P5#J57$<WGX^Y+M E6Q^M?SA6%;XY&F\-B+AM-D]EX
M+K)YFLQFMV*<HNI![3O.Y\EH,CD>C*+>=N%LU\?R:#86HV243T660#PQ3VY3
M$C";D8#\=1O1'),B)BAN)OS%VY2JJ^E$G/H(]*;W$2U:UA5_*DQS<##LOZ?M
M?NV^1K[S'^'N7_>?,O\L$0@U3=V76)I>3R<7POK/@_U-8[;\2>["-(W9\"5%
MM;+T IXOC6GB#6W0?:/]_K]02P,$%     @ 689F4; 014=$!   OPH  !D
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M$4*!F741&/W<X J%<(&(QK<NYJ"'=([[S[OH;_W9Z2QK9G"EQ%>>V^I\,!M
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MUS0^G0Q AW$I+*QJ_(BR5I8&'O]8T82)VAG0?J%(7=W" ?0SZ^)O4$L#!!0
M   ( %F&9E$KF$G;WP<  &84   9    >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;*U8;6_CN!'^*P,WUR2 8NO=\FX2("^WUP.ZER#9VT-1] ,MT3:QDN@C
MJ7C=7]\94I+EK!WLM@6"6!+)>7WFF9$N-U)]T2O.#7RMREI?C5;&K-]-)CI?
M\8KIL5SS&E<64E7,X*U:3O1:<5;80U4Y"7T_G51,U*/K2_OL45U?RL:4HN:/
M"G1354QM;WDI-U>C8-0]>!++E:$'D^O+-5OR9VY^7S\JO)OT4@I1\5H+68/B
MBZO13?#N-J;]=L-GP3=Z< WDR5S*+W3S:W$U\LD@7O+<D 2&/R_\CI<E"4(S
M_FQECGJ5='!XW4G_8'U'7^9,\SM9_B$*L[H:92,H^((UI7F2F[_QUI^$Y.6R
MU/8_;-S>.!I!WF@CJ_8P6E")VOVRKVT<!@<R_\B!L#T06KN=(FOE/3/L^E+)
M#2C:C=+HPKIJ3Z-QHJ:D/!N%JP+/F>MG(_,O%[?H5P%WLL)<:T;ANIP8E$Y[
M)GDKZ=9)"H](FL%'69N5AI_K@A?[YR=H56]:V)EV&[XI\)FOQQ#Y'H1^Z+\A
M+^I=C:R\Z)B\%5/\8FY=?61;1):!&Z58O>3V^I\W<VT4PN1?;RB+>V6Q51;_
M'^+ZMJ1T#,>$N07XM<[1?@0W/):LA@?\RXV<<P510-$+8@_8PN"]67'(2ZE%
MO02YL+<?N5IRY=GK6\E4 6R]5O(%5=$C4L?J[5__DH7!]+VVTN"AJL6\T:\5
MG]$!VAGZ[^T^>FKO@_?G8_B$J_UC$+4P@I7E%DM;<T7Z(@^IQ/-]'S2E2@-R
M#BP:TR@.2\P3L@^J[)U#69DW-!)EYDA,NC7="NFD0X.H= '8V6 D\#\;5D+@
M_]3%HVXJ$HYW0NL&1;&Z &0S;?""XM;:AAMR6568!&V3T!YO3;&&WC1++& +
MWWT[^PC?(/ *"[[?Y!A",FC/0@\V*Y&OWG1LCO*0W8I"$"30F:F735,OBY+>
MU)?6\__=3<_N4[RRYN=<&>1],L4H86D63]2O%!P)& FBC:R2#0: EIE>M?7)
M-HA$#<V:0N)BL&;*B%RL"0>=%[M4YHS,R#F!$2UB^*#$V#(%6\[4:_"QQJRD
M$O]&LT@,A8 AEDELJQDC7C8N$"Z]:^N=UQF/&>2Y<%6HB/EQJ0L#VM\&RVUN
M$.K:^KOFRO91TN6>$@2K=2FWG*.$0J!4(Y5V<<Y1(W:7H<<]OF[L(^1(PVV@
M.Z+<1]J*%9!Z?HQE-9MVF6 O3)1L7O)O"NQ0E;3T P\N C:2"UEB-Z?H"!37
M=70RR,7)-5L$)&K;B6R-.M6#3) %%B[(>E"Y!L*I@1QP[1W\UH/JV;GRA^VZ
M5$F(<1PBX.>O7.5"(R-A)OBWZT^<)A6R_ Z5$=M3_7_BJH*S?R!2]#D\[*K
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M^N-I,G+O-MV-D6O[)6DNC9&5O5QQAAV0-N#Z0DK3W9""_M/B]7\ 4$L#!!0
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MU,Z!UG.E[,%P =H/R/0W4$L#!!0    ( %F&9E&N%CAEXQ8  "U'   9
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MU:0%.KMF>&F6$B)Q/H? =XB 2XN0MD)$HT""ZY5SEU++F2XC:D=@Q0M!+\1
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MD5B7N)A)2$Q2;R9Y/Z,>7Z#W*;^((3:#BAJY5G(>P)TN"B5BSEK4RJV69Q
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M; "#W?8;QPL[;)YQY]5OG0RWM\-G>;\^V3Q'K@PYDTL6[J>Z(X7A8=/$[?F
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MG9+EE34=FV_W8CKF&U7D%=X+D)NR9.+U!@N^FUB>M?\PSU=KI3\XTW'-5OB
MZEM]+VCG="A97F(E<UZ!P.7$FGG7-T.M;Q2><MS)@S7H3!:</^O-']G$<G5
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MSJ"#<CHA3:$^\_D'VAJ4:'D9+Z3YC^;MV*"#LD8J7K9@T*!DU>*3/+6.6 .
M'#< MP!\*"!J =$+P$Z5XA80'PI(6D#R4J5X!Z#? OJ' M(6D!X*&+2 P:&
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MGJ.:/!L$9 D5 IY)4A"A&4[';T*I/$*LRHHFUUH3% ;_@FV6 D':&0^\:F
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MTDH#U/<UY_+E14_0WCHG_P)02P,$%     @ 689F44+IF"B1 P  & X  !D
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M-*K:4=FZ7([TD"F5)>7F2O!0R.($_?]CEJG=3A%@OT!M]A]02P,$%     @
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M/X!_H%>FVQI\XL'=U=XOHD$TG(7[KI;GC%C2&KWB/6QY#WMYK\1>9$A_KJ-
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M%+4SH/.-4O9EX\:>=LQ=_ M02P,$%     @ 689F426_5UCU @  ?PD  !D
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MT1\2:K> WB=*V?>):]KU/]?D'U!+ P04    " !9AF91\GN?MM(&  #E(
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M%Y1$E.L'U/<SQN3V0ANH_K+AYA]02P,$%     @ 689F47*E)_8V P  6 H
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M:[KEYH/<OX5:T,#RI9)K]TOVE>T(/:9;;611@W%?,%']TQ]U(EJ L'\$$-6
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MR.A+9%;6GVB['SLA(Y14I99Y(PP(<E'L_[/7QA!' J#'+8 ; 7PJ$/<(D$:
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M&7J'OBYFZ,T/9^.>!DH&N!>7RU\5R^.6Y7WT67"]4>@]7])E@_W4;3]RV/?
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MZ%^R*VP[/8.LMD*RM 1C!&F<%?_TJ4S$ 0!YF@%."7#J .\5@%L"W+=Z\$J
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M*^NJ@UN3%XU0,9$LUR_]DDGL&_0PPN81N#+ [VO&Y'ZB'%3MZ/ O4$L#!!0
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M'A]!OV-/J&QIV!>50_Z_?TA,![KQCNX\/@FXA/J2C:+/+([BZ'7YR,X^G9^
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M-.2HW$4'K/!&TY!YW/Y\#J+#*"[,"EQK);Z>6.):+;%?+C^!S&V6OB[<M]C
M: =4^L*I51/[9?,/H4U#D*DJ$[&CB38!,D[M4'0T-+^]?H1BNE.^V&K]Q#T_
M@5-3HY1J,'-'!F82X6Y;V3>&)?6J,M/;FL$+Q$<C[AWN-SY*UUJ+_6+[E.^W
M',/*F[G=<J8\1F;1Z=_4Z5^32O^!YV;]L4H=^XI:RS,>7(_UM03CX0^S?M9B
MH]-.K5J>L5^?+T.M6>GEW#V4U-I-_-I]96H1W^Q92SS!5Z,6:8R\Y,>IU6*C
MG5JD%GC2,@]?AEKD<$KV;<2D5GS2,BA?EUH=7U'KK8!<;Y8FM< 3O\"?1RV_
MC3.H56LW\<_6EZ+6X(!:W6/4"AO_ZNT[F$<J4\85RB QP.AV8'HF]Z\U]B=:
M%.Z/_K/06N3N< TT!FEO,-<3(?3;B7UW4+U<FOP+4$L#!!0    ( %F&9E%S
M;D> ] ,   L/   9    >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;+5786_;
M-A#]*X2P 2W06:)ERW;A&$CCI [0;$'2;A^&?6"DDT64$CV2BF.@/WY'29&]
M66:4#@V,2*3X[AYYCW?D?"O55YT!&/*4BT*?>9DQF_>^K^,,<J8'<@,%?DFE
MRIG!IEK[>J. )14H%_XP""(_9[SP%O.J[U8MYK(T@A=PJX@N\YRIW0<0<GOF
M4>^YXXZO,V,[_,5\P]9P#^;+YE9ARV^M)#R'0G-9$ 7IF7=.WZ_HU *J$;]S
MV.J#=V*G\B#E5]NX3LZ\P#(" ;&Q)A@^'N$"A+"6D,??C5&O]6F!A^_/UJ^J
MR>-D'IB&"RG^X(G)SKRI1Q)(62G,G=RNH)G0V-J+I=#5?[*MQT8CC\2E-C)O
MP,@@YT7]9$_-0AP Z"G L $,^P+"!A#V!8P:P*@O8-P QGT!40.(^@(F#6#2
M%S!M )5<_#H<52R7S+#%7,DM478T6K,OE2 J-(:0%U:[]T;A5XXXL[@#P0PD
MY)8ILR,WS!A0FKQ9@F%<D,_P9$HF]%OR"_EROR1O?GH[]PVZM6 _;EQ\J%T,
M3[@X+]<#0H-W9!@,@P[XA1M^P]2 A*?A2S=\"3%ZGUDXG77 +]WP>]@XO5_U
MAG=Z__C_O*^^V[N/.FG%,FS%,JSLC4[8N\Q!,9&0%3!A,G(?<RABT.2ZB,DW
M\EN:\AC5\XY OA%R!_B%%0E)N,)$)95V, A;!F'%(.PEU\^*%9K52?#/3SB4
M7!O(]5\.1Z/6T<@YU5_+_ $4D:G]Q3+/T87.F,(YU8^N?5";C"J3MF@\+N@T
MBJ+)W'_LH#)NJ8R=5*Z+!+!4)5 89%(8Q>QJ$K96 +GM_$:6N$7.'PU39)EQ
M(63A6(&H=1O]V*6>M(XFSOG=X)PRL2,I0-?VGAPO:H!_W6LZ;7U.^_HD&\83
M BS.2&Y[NSC4QL8'',8G*<Q:"K/>%%@<JY(7:Y(JF1-(4ZA*.DDP EU\9D=K
M<IH/#?:E(' RN@45HY[PR&)%7W'"^*/D-!X$*G;0J?N+%^QBO 9!\+-#*O2@
M7-%7<'R01:E):G?#*]BZ/= 7R>[3)77GRRN; GD1ETHAM1*W\,&V[:Q%PZ/
MAO0PLDW1.!XVFX33$WF&[I,K#9U\SYM%A"?,-QIZ,0Z/ML:_MV?#.'S-+J;[
M+$W=:;I';G04+5>0]]F9CG]LGJ3[C$RC%V;+#6>"X!DMK[:H(S(?7[!% [(#
MYBS*=)_!J3N%7S:">876KVA'8A\?2V?5,6XT=FAG7P*HNP9\C]JG1UPF03C\
MK]A?&%7S]0\.[?::B.?<-2\T$9 B+!A,4':JOGG5#2,WU3G^01J\%52O&=Y6
M0=D!^#V5TCPW[-6@O?\N_@%02P,$%     @ 689F4;LQ27() P  70H  !D
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MP?X!4:AU+;/N&%E4Y<!,&BHNJN:"ZC]4=@'-IU*:3<=6&$U%.?X#4$L#!!0
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M>G ^R,7U*E^NBF4NX%MQ?769G]]"X^+\ZGRU6 H$F1"0R0$A/R<(,B4@TX-
M%K>P>;]<(<B,@,P."#F*Y!$!>71(R!1!S@C(V2$A,P1Y3$ >\T*N9&B=$G8C
MKG?*#?O[='31>FT4@CPA($]X(8NV::3[UE$6^LYH.$U"UCPO2]M"UD20IP3D
M*2_DO](YH!JBERNG'V2G'7&E9><_G,RG5#:?\F+F:ATP"VD69K44P9;W6UM7
MROD78OFE[03X,E=PN@ZOL%IBRBTQLUQZS-<7TJM*+&P#(_G?_$QI)6;V"GXF
M%E!#.2AXO'@M/AJX_YS'F)188F:S?.@Z(80WTL'?_%Z&\ 2.$DK,;)2B77OU
MI>V*L>4#?([ *(G$S!8A<]_(QS&ED9C9(S0F-G),B21F-@F9I,?1I%02,[ND
M2]+B)<Q8:N5?X0J;,D?";([GTN!/4(Q)225AE@I9T8S^XH2<L'!+A7Q@<'68
M4&Y)N-U"8AYA3,HM";-;:,P9QJ0LDS!;ADX_.$LFE',29N?0F*-[DW).PNP<
M&G-T;U+.20[JG-&]23DG.>3\Y?,Q7D*A+)0R6XC&/,&8E(529@O1F*<8D[)0
MRFRAH=#(59"Z'E4:*;E.QBR=$96(1UR495)FRV N<:N^AE8^B1HEEY1["D/-
MIL=KH)1<4NX)S;-E9!]8C$G))>6>T%"8XVA2<DFYE\9(3%Q1I)1<4F:YT)BX
MHL@HN60'F^)TF+BBR"BY9/_'NMFSF+BBR"BY9-Q3'&I=:O0(991M,F;;_'%=
MZE>:QYCD>QGV*<Z3%:JQB3 F9:&LM]!D_W*S CT85:W@)SSTE[(N;YSH-L.R
M:W;4+81LVKI>0-^UN;*RVK\KW;_G??<#4$L#!!0    ( %F&9E&X-L3<J0$
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M;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 689F4;$EGW;N    *P(  !$
M             ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @
M689F49E<G",0!@  G"<  !,              ( !S $  'AL+W1H96UE+W1H
M96UE,2YX;6Q02P$"% ,4    " !9AF91:2)I3H<#  "'#   &
M    @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @
M689F49A+C:G<!0  _18  !@              ("!R@L  'AL+W=O<FMS:&5E
M=',O<VAE970R+GAM;%!+ 0(4 Q0    ( %F&9E'C"3O!Z (  'D)   8
M          " @=P1  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M    " !9AF91*%S4=9X%  !5%0  &               @('Z%   >&PO=V]R
M:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ 689F4;>CPM>'!P  =QP
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M965T.2YX;6Q02P$"% ,4    " !9AF911PE2T]L/  !;,P  &0
M    @(%*5@  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    (
M %F&9E%V-@CLRP\  *\M   9              " @5QF  !X;"]W;W)K<VAE
M971S+W-H965T,3$N>&UL4$L! A0#%     @ 689F4; 014=$!   OPH  !D
M             ("!7G8  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"
M% ,4    " !9AF91*YA)V]\'  !F%   &0              @('9>@  >&PO
M=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( %F&9E$0?CK[" H
M #X@   9              " @>^"  !X;"]W;W)K<VAE971S+W-H965T,30N
M>&UL4$L! A0#%     @ 689F42M-J[XC"   LQ8  !D              ("!
M+HT  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " !9AF91
MRG45H^0"  !,!@  &0              @(&(E0  >&PO=V]R:W-H965T<R]S
M:&5E=#$V+GAM;%!+ 0(4 Q0    ( %F&9E&N%CAEXQ8  "U'   9
M      " @:.8  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%
M  @ 689F4:P[#-[G P  8@D  !D              ("!O:\  'AL+W=O<FMS
M:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " !9AF91:%.EA*(&  "_&
M&0              @(';LP  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+
M 0(4 Q0    ( %F&9E$J2_P&LP,  +H(   9              " @;2Z  !X
M;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ 689F48*316TB
M!   8PH  !D              ("!GKX  'AL+W=O<FMS:&5E=',O<VAE970R
M,2YX;6Q02P$"% ,4    " !9AF91J8OVD.('   M(@  &0
M@('WP@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( %F&
M9E'7,7R7W ,  ($.   9              " @1#+  !X;"]W;W)K<VAE971S
M+W-H965T,C,N>&UL4$L! A0#%     @ 689F44+IF"B1 P  & X  !D
M         ("!(\\  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M    " !9AF915(J$%64"  !)!0  &0              @('KT@  >&PO=V]R
M:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( %F&9E% LO1.Q04  *PF
M   9              " @8?5  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL
M4$L! A0#%     @ 689F4<K/IKB# P  /0X  !D              ("!@]L
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " !9AF91N*)9
M"GH$  !3&0  &0              @($]WP  >&PO=V]R:W-H965T<R]S:&5E
M=#(X+GAM;%!+ 0(4 Q0    ( %F&9E%^BHC0#P4  ,,8   9
M  " @>[C  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @
M689F4?T"4!5  P  \@H  !D              ("!-.D  'AL+W=O<FMS:&5E
M=',O<VAE970S,"YX;6Q02P$"% ,4    " !9AF91);]76/4"  !_"0  &0
M            @(&K[   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4
M Q0    ( %F&9E'R>Y^VT@8  .4@   9              " @=?O  !X;"]W
M;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ 689F47*E)_8V P
M6 H  !D              ("!X/8  'AL+W=O<FMS:&5E=',O<VAE970S,RYX
M;6Q02P$"% ,4    " !9AF91\/K6C$,#  "_"@  &0              @(%-
M^@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %F&9E%'
ML-2LD@<  *XA   9              " @<?]  !X;"]W;W)K<VAE971S+W-H
M965T,S4N>&UL4$L! A0#%     @ 689F41@+ZIO?!   B!0  !D
M     ("!D 4! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %F&9E$D;KQ8CP0  -<1   9              "
M@2P8 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ 689F
M48N'\O)L @  4P4  !D              ("!\AP! 'AL+W=O<FMS:&5E=',O
M<VAE970T,BYX;6Q02P$"% ,4    " !9AF910 &&6_$#  !H$@  &0
M        @(&5'P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0
M   ( %F&9E%S;D> ] ,   L/   9              " @;TC 0!X;"]W;W)K
M<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ 689F4;LQ27() P  70H
M !D              ("!Z"<! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q0
M2P$"% ,4    " !9AF91+.5RC48"  !>"P  #0              @ $H*P$
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( %F&9E&7BKL<P    !,"   +
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4!08     -0 U &H.   _-@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>243</ContextCount>
  <ElementCount>344</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>72</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSParentheticals</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/CondensedConsolidatedStatementsOfStockholdersDeficitUnaudited</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0008 - Disclosure - Nature of Operations and Business Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities</Role>
      <ShortName>Nature of Operations and Business Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0010 - Disclosure - Warrants and Derivative Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities</Role>
      <ShortName>Warrants and Derivative Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0011 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0012 - Disclosure - Stockholders' Equity (Deficit) and Capitalization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalization</Role>
      <ShortName>Stockholders' Equity (Deficit) and Capitalization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0013 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0014 - Disclosure - Significant Contracts - University of Mississippi</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi</Role>
      <ShortName>Significant Contracts - University of Mississippi</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0015 - Disclosure - Related Party Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/RelatedPartyMatters</Role>
      <ShortName>Related Party Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0016 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0017 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0018 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0019 - Disclosure - Warrants and Derivative Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</Role>
      <ShortName>Warrants and Derivative Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilities</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0020 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedParty</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0021 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0022 - Disclosure - Nature of Operations and Business Activities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivitiesDetailTextuals</Role>
      <ShortName>Nature of Operations and Business Activities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/NatureOfOperationsAndBusinessActivities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0023 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0024 - Disclosure - Summary of Significant Accounting Policies (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0025 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>Summary of Significant Accounting Policies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0026 - Disclosure - Warrants and Derivative Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails3</Role>
      <ShortName>Warrants and Derivative Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0027 - Disclosure - Warrants and Derivative Liabilities (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails1</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0028 - Disclosure - Warrants and Derivative Liabilities (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails6</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0029 - Disclosure - Warrants and Derivative Liabilities (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails2</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0030 - Disclosure - Warrants and Derivative Liabilities (Details 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails4</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0031 - Disclosure - Warrants and Derivative Liabilities (Details 5)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetails5</Role>
      <ShortName>Warrants and Derivative Liabilities (Details 5)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0032 - Disclosure - Warrants and Derivative Liabilities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesDetailTextuals</Role>
      <ShortName>Warrants and Derivative Liabilities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/WarrantsAndDerivativeLiabilitiesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0033 - Disclosure - Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails</Role>
      <ShortName>Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0034 - Disclosure - Debt (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetails1</Role>
      <ShortName>Debt (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0035 - Disclosure - Debt (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyDetailTextuals</Role>
      <ShortName>Debt (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/ConvertibleDebtRelatedPartyTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0036 - Disclosure - Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalizationDetailTextuals</Role>
      <ShortName>Stockholders' Equity (Deficit) and Capitalization (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockholdersDeficitAndCapitalization</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0037 - Disclosure - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails1</Role>
      <ShortName>Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0038 - Disclosure - Stock-Based Compensation (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails2</Role>
      <ShortName>Stock-Based Compensation (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0039 - Disclosure - Stock-Based Compensation (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0040 - Disclosure - Stock-Based Compensation (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetails4</Role>
      <ShortName>Stock-Based Compensation (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0041 - Disclosure - Stock-Based Compensation (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0042 - Disclosure - Stock-Based Compensation (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/StockBasedCompensationDetailTextuals1</Role>
      <ShortName>Stock-Based Compensation (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/StockBasedCompensationTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0043 - Disclosure - Significant Contracts - University of Mississippi (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippiDetailTextuals</Role>
      <ShortName>Significant Contracts - University of Mississippi (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SignificantContractsUniversityOfMississippi</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0044 - Disclosure - Related Party Matters (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/RelatedPartyMattersDetailTextuals</Role>
      <ShortName>Related Party Matters (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/RelatedPartyMatters</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="embi-20200930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0045 - Disclosure - Subsequent Events (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.emeraldbio.life/role/SubsequentEventsDetailTextuals</Role>
      <ShortName>Subsequent Events (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.emeraldbio.life/role/SubsequentEvents</ParentRole>
      <Position>45</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>embi-20200930.xml</File>
    <File>embi-20200930.xsd</File>
    <File>embi-20200930_cal.xml</File>
    <File>embi-20200930_def.xml</File>
    <File>embi-20200930_lab.xml</File>
    <File>embi-20200930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>62
<FILENAME>0001640334-20-002732-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001640334-20-002732-xbrl.zip
M4$L#!!0    ( %F&9E$+H7]/N10! &"]#@ 1    96UB:2TR,#(P,#DS,"YX
M;6SLO6MWVT:2,/Q]?P5>OS-[DG,H&7<0=N+GR)*=:->VM)8RV>>3#D0V)4Q
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M.!Y]"??O_-$EDZ]D[(X<[VHR<4<DY*^Q(:\]Q__F3$GVPDT<C/ZZFL5NX$<
MFHX/L#?6WKP-[22,%)&'*<%-J$Q1F[/+!W1$%O1]1W[,/'?D<E1+8Q>F89%[
MP/J[1K2_^8!H?->*^%_>-H[]X3^ZS\T#V>^*F\>G;=^^'N=MH=(W'UH>Z 3
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MYRRRJ@QZ7.1U2&:..^8WZ<VQ79;8+TNO+T51AY9Q5]=K'Q3%5%4S7TPC0"N
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MY5:S+F?IEF& ;U)G(7TXM*R^U?1R:UN9A<!OT76[%I !7UE6P0G0^U]5)Z#
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M6(+QYN/G4XE]3JA>+;-4EL)$N2IRP;MFEC4+,W+:9YV$HCS2QK/)GREIHB4
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M"FS'1>5"[4*NTB?X-I4H(+$04%@Q4Y^I$%T+KVCWP8:%S$?-\!DF'K=P0O)
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M8?/N('4ZBY::$?K1#9)_HF#_3%S4M[B[_08S3=L<]$ @(: 4"BFE BHID+8
M[;NU=@.516ALX+D&&'08K.,V!RT9HN;HE?*Q_#J@IP[@V/G4=&$'M2Q6!K:+
M1Y@5^E"ZPAYA,0,J5=@R,$@Q=P-Z4@1<&*43>ER3K^M1>8GC5@-2>!+-QJ]'
MW0J;C :W0(C10QX\P_;OP:(#VSE>I%RR%=YOL89R0G943%N=@-5$U^0ROWU,
ML@>,+O(Q\*B='@U32Y7-/BM)DQ]"_I.=^>#OQ)M&P7\66(.5LK,Q_G@5UC-,
MIYJY/T"D_Y<%21?,,XO'>&3CLOR?^8(C<!9$*T\NHI5GP2ZN3C(-0"F 4'Y4
MF!%'5X_AJQ!E++>[\3T5_V3V) L6)+"Z["%FQ(+!8  3#E!,6(K=T(5G@[3Z
M6'5E*O[6#HC7I^/?M;T_V_MWLMZX9>O/LE1AFWZ=]1Q4YZ?E5-;&\H:3AT=_
M0[I1],Y(:TR[/8N=%OS,K:-F60IBP\^/'ZC+4UA4Z'P5+MF]&X24V%">T0:^
MS"$KTD'^LXC1OJ'B+FT:#I8 O!51N.6+J8BS8!L':O<6ANW=O?=X&+#;^LZ*
MN!@;&<^ C;ZN:+.7+"0!-D.D<'%2)_]76W%%"FHQ=)-FGE!7A\C?99$S'CMQ
MR\2@DLLV#PZ?V6;XUHHQ*WJ99JNA30'Z$=P=4"LT/C9^K#[$+0VP)%S)QN=#
MW(Q\S6? QK^OFIHEM:>+.8_G E4#;V2,[*,XIVL> GCD)F/^6B4,"Z:A3S),
MF8ORD&_%C.5AB18N+.,DN7:=Q3Y8MRH-;V-T%\.7;CI5)F'\4,DES:/@.9>7
MAOL3F7!=M<^V]43".O 8]JK'K-..P?%*68-:'I*6R;]\E.L9.Z=\!QX%N(+7
M=^"XS,K\UN8H<T$,*D6YRF+W07&H@(%H%O+''.I'YJ#@;-^^?5/"V&79&DRJ
MY_FT-><9(_8_:*097P,2K="IORC2)],IGL3.,+;-7F2;2DDS'-CI1/.F*+/0
M"7C^4)F"P]*'6,P>/W.!5*C:+YAQ8KYBHQ<[K/MJM. D0L##DLH ?9Y&3<"Y
M2]AND6_+[:<%?#B7)RPF6+R%@"R]= !V/;5R!I8S>J/QX@X/Z0WC2GE?PB]?
M;)V&:+HI@ >3BRB 462P>RWJIR>U=988 O>X+1FA1>1@3,'+NZDPXEXF1TR3
M>*&KP\% '6&/E]IRV E7/EP9?0!8-B=<O#"' U4;:"P_JYZ14"U)FBU"O$XC
M<1\4CZW(+59T6>3E8NSB4:77>]#;/I@\7)M+T"5E),T!N9KPHE9'1AT0QM$=
MP9R#._>.YA1DTR#A*U/NBZ@)9M8"4P0I508,"4W@5M$P=)EHH'\'-/B 5MP<
MH[O4=$-U$H.3!?\?(K$4=Y<LDGG,@B?\Z+,H/>#'1WX#$31Q+%8$E!E><\1*
MQ(]L^5#M>JQ5L!6)%_AXL;+\I,PKB^;XH1DOVV"LG#_?I/0*R;R).7-^Y(+K
MD8L0JWLVV.KQ7.?0=RU@?LTYKWC[?7E6O1PBUT>Z8>H7(+T\@'R8TCA./4JN
MZR!A=-,V[-$ GEQ$ 7O]]YOW%[_JP+O NN62UTQ>6V2E*'%?87QK8-@]"..W
M5$^>7QC_Q!96+D@+HP5%V?1QG 1^I=2S?J2^*B@:DT=9G/_ZYAV6P*IM!;:8
M:,'/[^H)H_S%>G"^R&(I"G%H2F,P621YO5*^--[)NL@L!"DYQ3#^<M$KWWDN
MPV<H\R<@,2^+V[ J9E.C<<5W3@5D7&15>"#?L/B!&4?YIU(&UVMGX 46'G_I
MOF)BF1ZT8LG1U$4DP,M &![/-J9GNESF%GBIK+-<71&#\$)>DH,R'60-H>4;
M17G-=G-22.;TH2HOQVS1G' JLU.K#E88^X@K6MC;9<T\]%^;)E?#";GD8?[F
M\R5J7#]@.0^MKO&H3]DYDYF2;N7PNS)\D5:$189N@IYDRD^L'I78 W.5+ORE
M]PJLD)2E]-2V5?@BJ8ME?&!;IL6)UWJ %(=?%</:;7Y6EOL*+EV7NR761,E.
MDA9%)>MEP-HC=&F"L"QJV?M+1Z$3;OWFL1/"PRO4!5DU%WFZ,C(ID&HAE?UU
M,OA*^9UR;74/50L?G%'8*\U&(U%9T5 &7Z@&J,*4Y3?G)CE8I,#<*0BU,N]M
M54D4$ ?HKN"$G6TNYOQLEB4!$H1^?I+;;(?7.F16;CHL #B;!66=:2'TBK64
MQ9J5%=-(\Y7RQY34?*P216F)HB8ZXG5W96;Y,IJPXGL)26I]M!S=09H3-C^,
M;R%-T.)5+%-KP%5HPF49C0%_FA5+%\?[!<"Q0IVUKYA4M4Q5+^0%RX4J6\5&
M*2Q7@B%8?[@8IV!;P&9!1="  SM/Y@%&T&$N*.<R391BK#CTSB,5Y:R5P--F
M95*MT*@5A3Q%EC\+JS5,8WZ%:<HDR%"[U%$*LN*R19!.:=RJ$NVB1)YW:5F1
M@O3]NA2D@F>IYM:M]U:@/+-L^[!DB0:#<<DH C L(NSG$? @63P&F+JL%0 >
M#3</4CGFPCR3Y=M;ER=1VF8HI 5M!)&PQ!',>7$Q[Y8&V\>/]$<:;P+R!3.6
MRMDBQ1"WGV?JLN; \#\L"N>%;IJR FF,JU03<JK9.\ $*:9GUXQB5$"JPJKS
M6>B6"2*0I"3#JK8:?Y=[0GYFK,G#,Y@;!!93C#T/*(-3E8C_4\9@\GMP7U,+
M'&'^ P8HIN)QMK\B[&U379+R$@F _'"QN065:RSJRV''JX8:P58"O1XAJX'R
MU1MJ7=/7F:[BL,HH95>HH%GL;9Q@90.-U!: ^/Y1BM>;O/$!*JUO<;PTP0W]
MB/]^4VQ- P\=WF9G(7N#"BP:+>T:8%#)+?DU2WFL^P#00X*-%T 5+[)<G5(F
M\G*5BN%0QH1\NZ^NE'^LB =E1D@N4-**AY@[;*"6*7*YZ"D2WAZ;G 7NRU93
M[^KL5O>4<H4VYE'7E!;J4:7&,5-Z613_577%:"ZOHGC)*BN*Q+E:87-+L+=2
MLP%80&F>$)"R*2KCW^)4ZKT&O4<MON5#3'I*<4E/*>Y!WV LG'W*Y:Y77L7=
M<J)5-2)97EY.<"DWH,OH6H5) /\D\=#++COQ7"E_S]UL%9T'=\G(JM$C+<2A
M0U !P!MPH4C&&D+:4"(_RJDKD7+/#7TM"M,;SUFK38)HV*,6<J$\BUJ.-Z=H
MT.N-#O82S(#?"&N&4<(-E=\$QHR3M"H:BL1XUCF#7BZS!&-FGHP)+1CB$/9I
MDD="J).@I$'&CS0>INP.=HZ'IA@!MD;*2+V/"'!VN5)4W6W'@BM&+^^80R(F
M][%V+.\95>;XU\Q=+^L"^3JQ/N$HH#U>7E;MY V:/]&^5Y\B$$P1H8FY?P )
M\KJRZ&YO 7=[.+"-\P^XYV!3&-SX<2&''%,:)>QD&'Y'AZ86IBQ#1@\Y\(,"
M^-X2\&G4@@I59KM,"F0P2P"5<DR/$+&W%GT&ZV5"K*9&$51.D??L:/$8:-,W
M7$:S^<9M)A9]X4$"6!QH>Y1_P.9YO4SN=N1;1WD0$6:T<;]C:5WTO)&UXUH&
M"#=:GK[BIJ5BC2L[ZV3K*D,B2T&J%@NS6.RJ2=9FA+&6(FS0YOC!1CML1]-+
MV;5D:4>YNG3>.<[V)'=US;(<Z_SE+HWG?LHC8._BE&O43_RD_?Q$[>D*E]X7
M(>.*@UB)?U;<*96> 18AE:K;5LK@\2+RT9FM%/?P0N0B9.DQA"6$LW/NF-'F
MF-56E*OEV4P:<:GNSM &P\+I^)XG"H7!I/[<HLPV*2+'14(&2TNL6X+,@,OE
M2WX(N/HNGF/17)A*^+VM8]U':C:/T=OTBBH&E/74%O=9$C1-+@)ONLA_JHO3
M@'8812U(N]&E"FM_5P,I6NEAI9B(CX3ZAF9^\6AZ5$ NY4%W?+D1AGS!CT^R
M/U?D5TV^?>=%K->1_[ZL0OW )#A[<6=YI^NFV8/$CN_5.M\*D!0.)2;]?@L\
MIMMN,:>6-FX]/T%X0NA_;ZNF+N45MRMX>ULP+O",@PF0-.<CM-EX*S=J5OX
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MQV$% C_&@TVRK&_EJ?^,L2Z,!FTO%2JU>&>:^_*'FJPJI$C1:I>>RA8"RU6
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M6['S$T-^:PJWI3P6QDUI&/>A$L;-Z>P?Q WQ)CPO('C!CDHO6(JC?R\BC[;
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MA+!=EJLK]YO"I&RQJ4<B-PEB^"9M?7P-=M@BMH DXK "L$? 5N@M@'3Q4;J
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MQ\#?ZJ"">\9HIP:Y$(R[KO).O)JWAB.<\SPZPW?9B6-Q64Q#7J:YI[S,OAY
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MBU'\$M(AAS238NF"[O.ESOIO\X]=I,MSZI@YTM3!:" 0+)X#T*MWZ0H$D><
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MZ')D>^8E&3N.X4Q&DY%AL .I!GVK%/]>F?8\VTW]OEDG2Q4F3)6VF+EUI2
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M(/5@^=E9JMH#3-1TA^L9+;]/$YU0"KW45</0U"&O\WV2&#KX8ALRAR2!')Y
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M%H2TX@'9 \221X7=[,O$(-(;FR.= ZDA(.DGGW<FAB\2PF5]\%\J^. KDGD
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MX+(-\J2;8M(9C\W&2\LWJ+P>T_.WVKEQ$>;6KS3M)^IAHX1#\SA_"M,!RA6
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M_$DB!$HB*,O"D>= (/[QG^\\> 03PEY*MU=#TBEW%L+< 0EC-ZKO*B!_QT[
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M0N0.H(/GU^'TF?*H9[& ,5D$!(\"$@C@&8&%36TCAS" @T' @40B/&P",Z$
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MU_31FX#@B9\7L82;.>QH=A+Y)_0#RZ%A^TZSD@N'087\22LLMI=)QL$3=3;
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MB%ORC=!<QW=C7]]<^C!3PJZJN0@#CP30 OS!0Y]ZZ/&=.SZZVI,%(1%/%&0
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MD:7%%YA/]>#XV^)&*4MR &N8TRF)+VX=Z@UBAK<W1=OHCJ1]*S&IA<QS"\\
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M&H&W-0@? WX5.@$?!0:9Z^8HMIAW]6HW3.XC*B-+DI!G1<<[T+!H(*1<;+(
M53N6&CAK/!S-DEYF0:71"H#%ZBKG@-3RI$*PGT?>F,DJ1@>X-&;.7IZ^$,>/
M%A.7$MS^C )7Q9,2T#Z>5&$:+,\!JYZDRJERF.Y RCZYF!J@3MB=E1^N"9&P
M4'QA4Y]%Z4#9_J?RQA[G.>E:>8=3>&KCEB;+T=OD\!7$+7EIC5.D=H0QG?3:
M8=])E":5BN.2L8A9Y-FK@>L(IZ+O?>\_,8_P37W"<1,D:V2@<8$W_%P3!VNB
MB(.&8!6+0MWX0G1@2MQ%0'_$6*9;%760G>*\"'7+#GUR^=>:]1IW1\0SO&DC
MD^!S4K=F8!I,3L7LN@M]_S)DCP[SY-*JQ[)G^=-V>SU\ E>88S)6Z!+B2:V1
M(6*W%)^D*(CR)_X:BV$4SQ/D<JA%LB4696*4JU<Z1H'9<##!LV8T-!(%3XR=
MENT-3*=9+-_1W&SX]3HWP+9&+!H[( Z*VY>4:(EOT4XN/3/>000M"5@D \#B
M/+-8X]GFTD:.2S5(!T9YJ?.2;:02H@/<C0(P>PZ'A3?YMY2/.X@)WE?89G;E
MV&Z.V@EY>&2%LW%;2C970J0R?\W +9JM(ZR#Z/A3PI;CF6PWHP+(ZR[KT*MM
MZ$;!AH#CC\![Y"!VW+!^N?@&PGUD>$U3W()8KIQ@?75U(=%<6Q(6:?-?IQ>R
M2'WQL47]O2)SQ[\C='D?,RY>8 6;7,]5 -98#HV36*["4U&+"L F!<7+U21>
MID7],%^@:B$T,%U0T[43.'/Q8"!2SQU?K3$#6(N4MRG >%)EI/+*QGZ?JOM]
M:G._S]3]/K.YWUGMSK2@5O^)<AD/4K"7/^SQ*+3*4S=C)\8&0MP&K&6 -BD+
MW$IRX3 _G-!E6B.YFF^@A;*,&RSH\[_$83GWLCSR=%!6#CQYAZOC3@]GFZ+\
M-7A?Y>ZG#ZU9ZM5[N6UWQ=841LHE"Y=)OC]]( /8F8J8JZC2(VZD/=#B38'6
M%*R1CLX1VC"'Q:>&CKL03XQ%8H#5"3&8QNHZ%),37?7T]0&W5SS*/#9 [,!)
MS4U2_&\VAF:3=1$,\'G,*=[ZZ.,\%N>.DOSVQICV'%<:=EV6@]0<M7-LE[.8
MFJ'9F.94Y4 R3@,/MNU+F*%@HK<?LH*5#6\ 8+F:T*>N\:AXG@9L'CL[<%@_
MPG8G;N4X)-%5"$P].%2 ;B[TXY%_6I4L2<LB7I_W5_C1%D9A:;D,V6^P8/(Q
M0WS"T<\:4#]&-TN4%"EG>;UX2UWP76 IQN*AI9O*LJ6L!M"B:1@R9^F&:C=,
M!6"1^W431DF-AZ20*YZET""EGN-##6358<M-C (6R6U9:0[9(:\>K## 7K>&
M2=;1<CB>2YB1P.0YP:KT<\)>G95;1BYC3"'0*48&9)%:QFX40C]SY>XQ/X20
M:O'X6DB+3$%:"I=GUQ%PE1]01O"<N!K&,X*VB;ME0.]CO 0$SV#]O(4EZ_3X
MY&V5L1I FW@2^?'J]4?QWB(.;IVUNR#N]UL61DER&?PUAU6SPDLM9!>X*M[@
M->=1CF<7Q^($/&1?5S,65@[+%>^M<5S5D=G-V3$6QZ5>NB<"1C#_C5$17+T(
M'_"++Q$8C0E9.0F([#SZ.8AU0V8L]'UQ=SNITT+RGQDO"D0/:4O43L,L[#OA
MEX/AY#2O;%M'N3P-ZF'329T464/@5_-R))W--F7C(%<Z^#R1D9Y-/::E3(MZ
M$S>$>-/PG"1YT/TY;LBSNOJW,7,7#E?RWH" G2(X#X,8/]O59&#7X-C):*Z\
M4J(U>' #ZV_./BG8-<+<C>F6-JR.YSOBQ<++& 7)M\LF,!_96L&G$MI*WD1L
M#595PA[@5[:O3*=@X.6,4*7RZ6YD[!S>TS "A8DN%L(>P .6-15[[2P9'+?;
MHP#V=P2#:PK![$+0*A$!W?$,OY[)B$BP9>MD= LKEN;:8,!VDS$-VW>&9\F7
M@./XF!XQ#+RBE)Z+IE6Q-=@'NTENRURVUY2_MFF+4NB@LAR*'LPF?AC!&GHF
MWYBI![6+KUR9Y=LX2J(8LH]6U8-V8;-4B74JOC13!U@PJZ];GKFR!,B&I!S"
MJI%(19FNT"-^*>VO^NKECSB;Y_KE>UE)\).]M%3XDM%3?6E5WY,+=NE'V7'[
MEU2?$=]HHS.Z'?9M*SF\7!.=,)D)\W@>WDYLQI@=D\;F6O8YB1X)"21%(L%#
MEUP,W85(QV24E98L[UMJI%*/]O],#C=$-7.,,#LFC8UWE3*1%=Q2#0<-?#<X
M?Z \.7M0?Z*KR+H1@BWQ>DTFTAUQTS72%5+.5[OAV3*:8]T0WAJM:UGW8A<_
MF_!$<I]=$]N(PEPN<&^*LN/^XQD#@9M0Y33L>R +C,'X> =@%*0?'E=:L3+G
M;:ET8S2@DXR!>3!DJ5'+GS,79%$':LO$5]N\[(PUM57;1*G*]J(6TJ*]QAWE
MWS'WYBMPSR+H"*:$BO1;Z9>0S, +_+U^4;R)NX"YZ..)VJ9.(JQ# XHA9:SM
MFSJJZHI52<ZR"%IGBSB8=0(6W%.6&_Q+6[56XJ4\7 -IU6#8QFGR$<BB.</\
M]B2_>JW.KFJ,:9'5V&:/9R?0-7SJ8;O!&89 *B539 57=J!AE20"&K)M78A\
M8@TF-<J_-=0(RRSH^1?-XTJNE$2O2ABK]+;I)599\TG-[#2 MHH[_)CF>7'?
M:/(]E*:(]O&<>@<JSDJOK>U_U5]6O+>.@\NZ T,%9\9X-G$L-N"*K^W(7EJS
M8U7OX')7#;/D"=EE:#W8"Q_4-5&1I)]2UUH/9YM#C5,DO=4X(-!M*IRD)&)"
M_Q3M2+ELAF<CU\E)VR#&096D 2494K7G#*VP"P/Y=2]$:?N__71%.69N+ (M
MB:[((7E^&3(!=0Y^FI=WKJO?]GT6:EV1S@V)DL1*Z7K5%+,K7!<])]F94SMT
M^_D7$;.VAE&+;(TCHPF]Z_C:R5[64^BZ>-H8"B6B-<+0.+T:EEJ;#SVV-5*I
M&R+I!Z+P>B[&IJK;-PV037LUH$!^Q'B^D*7>9(%'<="JB-0UP;(I4A>O5LD#
MK)^<G;1AS8\"<VH@:X:G>M*JBY;;7:T\Z5UJ$2J]WCRWM\]<U6EN8:]Y;B#<
MD8 \%CY$HX2PBX\%.)>X;<_6CS0U)!/[-/SFT =RAX<E\*,?1#0I820NMZ?7
MW+^NP)';F+-LC2[H\D6;L2=U11P6HYG#M*('Q\>L@_1C*UL3.%F$CT%RB3ST
MJ8?IOWE1M2;1!<.*S*6;VU%2W-$3G^>2VEH#X*[PC)=GS1C607:!VVVM'$R>
M>(0W:Y-+3@WQ+'+_#'L^#6NNX.U(QW*)5+:R1OPKL>SD=HCK%R'!T/3K[2UP
M.\&YZD9&"T&8DK)3+FF]L(86L![+:F[3R,1F"$NM6 J4/S<R$,FNI#LE-\,[
MS[L2LE,F-Q3\F^93QP#-3GXGY &>RWLNAC16NA?W..JF2CM*EDLE&=*#YE.B
M&05+I4"?GF=DM*!CM402G5ZT&!4-\"V2P-?EN^-WQZ"C 8OG> ]@^<N'L^-^
MX/CA7',CHAF:9?S^?%S[O3L]F$W\P#\AB^B?Q,,/D&.1&:PYE9SJY!G2PUD5
M0OP:4)'$&:W'LVO*.?ZW6M'MN)+D>#7 L2?AJ[;3LL\9-$'J$*OESPZ8(KPP
MBZT^):#H>]7*Z.&L,C.L$"Z^#;FX )E]0+EH:FIA=PX[OOCEP/0"5\ZQN7!\
MGWCG:\G!D@GP:[&L8:Y8$.2.N"'#3[GSY 9S(3,"K[G0H'(5>E="UH2?-8D%
M&7-8SWQSSSM_HZ^Z&)FCV&.@Z_HL2]%M@%.P9:^?GEL<L>+<*TC.! WKXN2_
M*B9F@40LSTF\2S-%SO<F=J2YC=R:@J7#ZW<BON%3* PJ85<.5K -KYNSF79T
M&F8)19(OIF3%Y\1Q>97))KCV'+]_"]EW# HGMP[2:PAYYN3OK?-O/AUQ=T&6
MSJ__!U!+ P04    " !9AF91.\R":W8(  #@:   %0   &5M8FDM,C R,# Y
M,S!?8V%L+GAM;.5=WU/;.!!^[U^12Y]#<.@O&&@GA-#)# 4&Z%W?/(J](;K:
M4DZ2(>E??Y(3@Y-8M@2APNE+:8U6VF^U6JT^K]S#+],X:MP!XYB2HZ:WL]ML
M  EHB,GM43,1H]:GYI?/;PXC3'X.$8>&;$[X47,LQ.2@W;Z_O]^9#EFT0]EM
MN[.[N]?.&C;G+0^F'"^UOM_+VGKM']_.KH,QQ*B%"1>(!(]2JILB.6]_?[^=
M_E8VY?B I_)G-$ B!5"I5T/;0OVKE35KJ4<MK]/:\W:F/&Q^?M-H'/[5:C4&
MYS?]KX,?C>&LT?_5^G%\==9HM=+?,AK!%8P:J78'8C:!HR;'\212J-)G8P:C
MHR;$0RR[EP/L[^VJSM_V* F!< CE7SB-<(@$A,<H4A:Y'@,(WFRHWK]?#980
M0@P,1>$0TYT(CZ"MVK0-.FN_A+[70OX9 Q'\8M2C\83!6+;!=S"0[A3#&>7\
M.T%)B&7;Y\*Q&NOET2(^/HWH_0OA6^]]CBA 49!$J=^?2?V7D,%4@.PWS+"I
MH3;B.FID.79$@Z7Q(K4 *5LVY6*X=)6-$!^F2RWAK5N$)FUEXC9$@F=/4J.W
M=KW%BGN[>.QW.4\7P+SG" TA2L?SEQOXNW.SN%"NES F)ZM2QT4[WW.AJO*C
M+@G5C_Y_";Y#D?*OKN@AQF8RVO^-H@1*(!C)NX%V!5PP'$AG?2Y(RY[\C@NX
MEPPF"(?]Z40MUFKG*VSO[[E0_4*,@9DNFO7&_CLW]J838&)V*0.AD#ZA_&&B
MHO,YE)M=+^9_< 'D#*,ACK# P*4^UX(&/\<T"F7RIW03LQ(P5:+^1\> S'3W
M/SE6L]KKUQN[4;H;!#21(>\2S= P,@@SQ0*O0ODKB%0J<XF8V1R8B/O[CH"Q
M!$(KC]+*^)Z3I.EZ3)FX 18?4\;HO=Q,RU9O06O?<Y)FI/O1=4)"-K.R?ZF<
M[SG)(4Z R9Q&R".3%90R,=]SDE*<47*KW.,$AJ5A-=?,]][;:;I^*%1/_&])
M)'#(T'V/@3R9=6\9I*>V7+R8G5,2:,WZA%Y\STWJL##?.160A44#:^>;^YZ3
M'$&>9>]D&H:E!FKN2^>C4L;WG&QGA<O."$F%I.\YV<5Z-(ZQ2 D.=<:B1,BP
M#B0HS^-*I/R.DQW!*H4N2)H[KLZ/(Y#3/T_CJX[$!:T=Z:WFGQ(CI5>;^ATG
M>U,WE $=4X*B2WD 'Y >FF"!HIQV96E;I;#?<7(>O@*!,(&PCQA1Z9C,+Y,X
M23>K$QCA )<%I&IAO_.X.^<XSBY;!HA8D TC_[I&<"YS^XL6;9[$<=I;"PN(
M,_D1H[&&4\R&I.5\7H,RN:R/FE(@X5(1.IG/7+-Q#_AV+(Z:WBO!E-.Y&)HI
MS[=%D.U9OPR\MP7H=?1@AK&S!1@+J<0,X-[K!ZB/1!4L8RT<U8!<U*!?IO;J
M$))6-*Z$]4BCU0Q=3G'-'JKC"[<<J(Y-K-M2-<&MYQUKL;O8H-7PE+789&QP
M5K*9&>)WVX*XBO3, +^O">"2?6>%)*U;2%I']D2&M6[1J7I*5YG8NL4E/<)2
MLK9NP<@R"BTSN74+1);)?@7_6[=@98F^F#ZN1:#2J*ZE(XKXYCH<"JQP%E'4
MM7!A*Y1F)/;V>;$9S6V^"1^V5\I]?V<)L%6Y]>]_'W$.XE&1DE</2^W<U L_
MCG\J_6N^A272/RXF<B[4-/)C&%&V,.P-F@+O3P5#TD\P06PVD/.0;OI24LZ7
MU.]V0 0PX&7O7%YP5#<%OPO%E1H&\U[0VK':"Z[=2.FLK1N5OP)144+F*MTP
MQ@1SP=(<=*%5"8 *26>5XB#COGK'<P)W$-&4*J\&4RKGI@I<KD>Z[-C5,+0R
M_F8*HGIC)#/R 3E%F*5)S<6H\-BB*X4RE=^0NKEA_D&,(2*R,68#TI\&P.6&
M=\EH !!J=;;JQ$W==Q:LJQUDI:6;JNZ';6BAQ;&,)*/2H@*-1+Z^U576N)IT
M:/+%E]VBZW!X>F$+:,CLPM2@#N;2:%X!,Y=,5(-LO2*4><6+,5;G&[6:UFK
M53E)+<@$)ZN^+ VJA=5* 12\ +'(JVH1%FSQV^9HV^8$^O3.@'E[#?-MDT05
MIH$&,]IZ=53;^LU_-]?&5\HAU\HEEQ_D6E[*($-#.2T,$(<3F/^4"RY*PG2/
M"]+ ="4Q]T<C"$KO9/Q61=S0@]+/E>(R$MUAZ4_'L^_2/0;D(2GH!C)@5UUW
M->_$#0?S-+K6B:HG,&$0X'35EVB:;^:&#/J*,%%FNB GF$\H3]^Y7(SFQ:->
MB>KE@FX^$G ]1@R.41H98Q7(J^Q?+&#[L8 JDJ@;_IOP]/6S):MEWL/F>:WU
M869/(+8,>G'#;'5CR@3^A>9>J\H_I!NGU9:7#&*<Q"5>4RGKC/U:VJ0&9+E
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M?-6LTH_/NAEY^/"__7S^'U!+ P04    " !9AF913KB95[LT   4X0, %0
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MBHD4Y:22ZN],K63=(T:/^:)\MY^[7NFD<%^"5;Z:K4@IB'F>D2I/I+14,Z2
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MX)$<"9NXVSB1#'.3Z?O69@5ZW)A&;9_.0Z$4:6*LY+/RYOHG<L-L>>L%".M
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MQ*XMPX*BSPO_\@+K]!*0K<0K<%^6D&HZLW)WWZA8EKT5 1K).US7P.UVO=U
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M@IC%S)T5$=DH.BN?0N=!Y$8>B9=7G2.Y@1S%PA_*#%SA!W=PFKC/)PGR [Q
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MU9I?;#RGXL*#7\ 6H3G97!AW( /L#V0)&]^]I_,RY-DL>.Z[!]!590)MUZ[
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M[>)Q1445-_#)TL2\D+^!*@C"BZ^@9[E=TLBV/#K1 )!>/ I7!N5EW !8)2F
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M<+SX*\A5CFQ18$QE5BR(C'T!E!?_Y3>:8"4Y6!9/YVM0*W1/\,33GGO,TA,
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M.WP3)1B!S6HB7P4A\O=Z^@P[["5MY *S!H'T(3-[YR<GIXK'UNNUG5 J* !
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MW33W;EHL^B/5L:;]P*R R*>Y\[/A5!S&^A)Y3U9 Y-/<+=IP&D\<]R9M=RY
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MOGZ'P03*-"8>0-F'2!Q\&0;C;[S)_^N'O\LUS98@G=^R]*58X05KD!CGK.Q
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MRQQ<<_#Q'U] [J\B(5VRE.\H#3LZ3H4 &2+IL,T-IT0J4G)#GX^ZHW%3R-[
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MNJ/6*NS9BBG-".M=WTG)_OY4S F=2MT:F[_ZH>:+!";?(OE2-"=8*J7[HXO
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M+92[0=&HF5_+36^+%\PH(L9Z(<8ZEX\EZE!A[0:R>EC1_/84=/Z-<G.>&)4
MKBS">M0(:W*3Z(V2,SP*=E2?"<^^]K%+/QOA.M>ZQW-3LB2]Y/&6.:03PN1G
MBU$B6BOTX*X&$W 6=X&N\I$_4_YH_(+&M*!DD:5K<@E.8II-80GX',&^LK=3
MJ-PC?VP_(_48GML'GG7^2A)3]P[M4#43\^-TW<,'^@RMU:"8>7Z.0GJ7I<_1
MCMY@+C]@=/[P*Z3ZC%>%WDDB5AU_L(CA42&&Z6C^3C+13(9?W!5A4A.$FZF+
MP5RW//K:]%HNINFP]8+?8Q9844]0^5U$H%7Z"K#/2]3>RL]U=#3;(*; MV(9
M^DO#/B.,(IBX5>@O#\WT^+F'"DQH7O Y??X6D\# B[7A?*(FP!VLL[I;$4].
MRUW@:[6[@COYQ?_+^L/1AR.8;!=9N3Q-YE_6OWY\=W2:!'&ZK.Y<C!M7?*M6
MJ?>73P3IX>P]1(HLL!]^B40)IUI?Y<C$+OO7]EZH54K^95WA) PGQM7 +S4X
M?0<M],*KTNH&WD,[7J_:_,O1#=B/Q*TN-]/77XY(S+OX?&5AY%VK@\"[Z#*A
M N]&*$KUT@V#/TU*@C66-OHGG5_0I^(BRD-\Q,;SB"E5221$2Q>DK/NR@DKR
M]=L<"'G0*R,2I6(U^,<N1/812=_\F&@S#J56-<<!<52#L1D-AV4H9/&PVT6C
M=%B]<!J+WS5*C]VV2H^U+(W_6GA6E#=10J\+NE8_",>_D@B3$&2V>M/:8FSU
M N+!E>Z!7SW[7(:928D1F?! /V(Q.'4 =O!4QD'6K#>':4/_*XTR![_["+/^
MDQO<MY2'+W4#.9G1,WE;VD'S[FT9L:@-X]2*6'Y)LM83\KLT9Y4=+VB84:QA
MXYYCH&R0XF_#-X(8. &"F@^%LP%4*YT=B[<Q8]ET;Q>-X\#S(([I_.S5->]4
M/6BM>^Z0D2%/KQYOO!W J0:,IT.&!:)U\,.[DK-7[]$8#K!4"T:5]=HR3KZ&
M23+/4S[?TS#-YG1^FO-:H:U\YG]$Q2I*^!\,&;Z;V8=$XFM)EISFL@AI.YT[
MX;3%'WW/RUUE8E3KKDPR*9,@E^6!.[G?7[A,Z&@RZ:'VNXK$."4ZA4JF(!+C
ME)%".$U@'RT?E]R(MR41->]!J_''\[^Z.VGTG\(6U(9QUWK8%?Q "W__ILH=
MK&IJ.XWH!,I(NZ-4S5:'@?.NK'Q58GF3$IXC#!<A^!>(IXA@,ZA[77//Z^C<
M!5GQRI8EF]_57;*P;GKU4;8\X;_E9_D#/:)^H"=K^&SPX[Y**(X@0>-4$<:/
MY^228L-/D<:WC$_8Q <)^R(OHN'G5'4$T1GGWR@:YWM-&E!XJGCG782G?D][
MT);>1)>\*C(\OTOC*'PU6^ONK(Q:LY))IR8XM;5)#W7'!:@F2/[&29()&>^^
M0C N)2[C[5W#?Z<Y3#=P6F[+@M6O :Z<S?,SZ\Q\EK3NCAL+V'<\!3';4^0K
M2@N"B1']*;<2I5&#>0_F=#;Z^+6!2A0J%3SEYU:_U\,S,H8^*O>8RA(OO#IP
MZ[2'9<F]HQDK/.NHAZRXA:SYDE05AUM'03P5[@:+-"%E;YK8 [Q!/5EF)XE8
MU%CNGNGQ)-5 C9<<]KRR]L!M6%,U(UV7=6Q)@/Y9!C%VF:<QWN7QTUQ_ZI]F
M_\!GI\$F*H+X@BZB,+*D724OO \)>2<RY[U&RC:R1,_+/)I*#$I-57.^_WFG
MY%BI8X)CT91<C,>QPY*O9%OI?/L7=)X5L_-51!?"KPGBVP4P03/#92QK3ZH.
M1/3P%V9K Z',E1-'_P0*X-&=T8R&_SP@YU>W'E9:&^\J=;](RV4,GMHYS8,L
M2O>M+Y^"K]&Z7!LT1+3PJQ%M-E4Z(%IX&O4V?ZIQ'I$_X_A&B6U\>0O/X]MB
M4SF^O(6O\6WQIQS?\?@SC>\]\$!/OT:Z@O+@"N5%%,+*_HD&>#_! W^QQR@C
M;>756(M6P^U%N@ZB9._\/D9%3&\7U[!=>X[FX,1JY<Q:HN-;M_4DXRV>\>"$
M'1]B =I5M'E,+Y,B*EZY3-W1>!B#,C]<!L%F=AJR:%Q, 8'G/K:[Q[HYD>U'
MOFNT+" ..%0KWOYQ. Y$?A>\8M#A.>9EU^39ETV): LN&6_M7_Y=]@VRS[%:
M)[:=@+0;=P#XX*R7[)O72-!Y@H.A1N<R-'BR,/IMQ1!C=9K,/Z>\F,&N [=W
MWVQW?)JARTIQ$AITA_%P$J.(_#4N^RW3C*%I-!]U8K':'@X#I8%@&A 5A /"
M2G;X72(T6)2'[0)+E(!&T[P@\W(R:P,R]A#$0=9S-6" 9$>?D]\*0*E==<GT
M$2%8Q3^?LTCH(+X+(KQ3Y =TC7-OM?2K;@3[L>M#WO.@=;SM<W[8D2F'I4:V
M@7Z'47(H#BTG-#R&;6)G9 [KD?'YQ,(-CV4\&)[K"H^?\?A[F1?\95*J <,N
MB)[P40'H&A8%8[O+>PQ4S:."RAP?[/$D1L\N$T9%'W-V>G=]?L OR X97?2
M>-8#O'!:BJ"4ZX2_96 QEAA^2QK4_2V/8TM,I31L>@M9A0V2LDJ;UQDPLCQ4
MUI]?->Y7'OR-S3/]?2)RT9?NRSUH2Z^%!K$D8133S[2 69ZNZ4V:P^_9$RB>
MX6=^]OHEQZ"@VPW- CP6.0U!^O98],:'\,*^^A2!;Q'^,?(]?NX'_#.KI2H_
MB4]QOL>O0KL?2/5A4G]Y(B=+8\A2;:MJ63+?6LHR 5G&\!G\+?[,'J&5.8^[
M2BO!!=5G_N)'YYY9Z>2K(,K8G+FHXO8UJL/;'Q#LP>-O2=W'ZXCKD:@&CO'_
M+-^B!*)WHVYL-_38R_#$<1KB9HTM@V?=95 4+E7?'=A\A\OQ5CHW+\$-V[=F
MZ]U0J2RV,%^8=".H/>#<8L=1>QMO77ES%OBXX3F17X)L/LY6V>GXQ4T>*DL]
MA \\XIE-7V?'31"J"B\3=EEXFAC&Q^VBE5TFH^NH7*N-2*,7JF\[5<[WHNL/
M/F>Q%9?F>*>%JY4ZQ\OP)$4TC^(2U?2!AF7&'(W+KV%<@LMSE:5K5,&R$#@O
M@RQAP>0BXI$?5ZF'L$&9U*2)I,USRS>HHSPD_3KX\X"<CA;[Z&:$!I&04AD2
M?$LB141;<D'W(@SBL(QK7<&6\'?F,F(XL(P2'BM&UJH[]1J;\Y/-H/[-(_R4
M!^SA@"G%X3G&MSZE&7\RV*#(#%3SW[<@$G2[ GR3T.SD]9H]SZDF%P/_DS^K
MRCE39A%EQB(8C3\WH9GWGZS)1#:*;7:5,_GAX?+QP9\LC5=NK,4$;ME:G.KU
M4MR.C*B?O<;=='VV+X9[*8'#O*J484H3K,N^2D/._8L:]TJ/0%X;U\9:$&SB
M(9Q-L@F;ARB_772BIUY=WGRRKNAOU)T/B'CN.(UGCSU!JA2I GG'7ZL$8]V&
M6 <JB^9+>I,&B<%)XHT(MO(7<JSE6"G?FF.?"M)E5;6(WX&['>5YFKV2SVDQ
MSJ4'NWNX3+0/E"3#>-P,GC3^!]/C/ <Q\ZV+<W"L7T'!];>!V.6 GR#3NB=S
MHCMIS@X(35@JW?$2M7+*#T60:8M ]T.LM 4]$#_1993@MFQ<W+;)[@966:T1
M82(T]D.C\P$)"B+[>TIVT0^>ZAP/NWA<)]P85YV[5>/2U4/ORT@'S'TK0R*
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MP%X-49=^DMWYFT[M5D4N"N.9Q!S?O^0Q$8[[TG?<OSX]N3,N7Y1^U&6Y%O'
M//2(#^$5JY'KTE3Z-<(VOK$:B^Y.<#U1U>@YL1PVOHJ:$T=LO$N<X@CP0,S]
MF2>&/9+S^Y O[1WAEWE/W,E"'FVNUL'G2AV4:][B299>88HB(N^#+@CT70V.
M-PH>Q;WP3!33"SR^"&39/\5&723:RP7:,W%G ?T[(5&#(ML%KG\OD. N6"3I
M><2\W\&JXYY*<;=FA$WMU17UID)E4F-ON<;BK+-!$JG%LB)?3Q_!QK0K#+W:
MH6BR":.G#M*-F.90:PY9%-K#C!D-:$SNN=/R[H*8"RGR]!3Q+Y??G7^&[,IW
MHLAX?D>U_R0[&*QZ&*@N!J_+@>QD('L!K!I<@7.%LJ901#76HQ)2>S4DVJT9
M?N?O%SN H^":1FJ2)[;6E,CZ[1^Y8<B]C2<;.+[P1HY\'F+@:@#HS$LT&?PF
M&OV'P%%H)Z ,NX?2?D@B(1WAH'3+T\I1V2RA'XDOCXRJKA)M"P7+@C F&.[@
MJH?=8"SU00:P"70])MUJ#_U0RHO<=L>N6P8V&L^C@=P^ /R^UX/3'D@P#BSP
M95N_DX ON'P^4QUZ<_X5$Z%<L5!)LR&T#B=M(Z>@3JD5B/>H0:#U'04$Y58V
MKVAMYCAJX.C<AGE ..&LP6EJ,#6 M+Y@GQA6L>]7SS/X3<!FZ.JL"'Z4[F2\
M2#C:6_Y=%#4/:)!P9SM2$:4PB"[))&1$/??L_"01=]_,"9E' X<M96*7.%<F
MJB6$/G_--*N0I!U;U4_VQ9KP=PY6+QVLWCIXE:\=I,_+%ZNC@JL7V:G%U.:;
M;5-[QMS#5#,JTC>(1:=PS)$%/.5--U5[M.DHY@_CV*TU(="74NT504OEWZ<Y
MGL:PPH;X60O $((!0T7 H (%X+YNP;C'#M4?>2BZL8%X"ISV*WDKZ [L7'(9
M'TBE7UFIE7\B".2Q:XW<J-6;3E?4[55U.LYG7[^ESULYZ])H^F4"H%/VF(5O
M5%W'%3(,GTUYCT9VG\9=,'1E/4].F*6Q,FW6:O!;UNX_Q(99UG20MH5E?@TN
MW=CD !;V &PU(BPAWI/C.\Q4I<H\(J+I(&N+ U#SXEL&6/WMQ6Y-M^8UN;(V
M IBFKL5R$,]8F$QG?(G&5VAYAD$<#EQ#U@R>ZAB;>A$7;&0VF![6'SNLKO"4
M@0>RL\S;'.455],.K99WVIH8]0IHXIG$\(/'_#?!C;+,CW1SO685MC&F=\$@
M[R+;9,2R.&L(U9S>IJ[_4:!$N*5@F]V>I6P7/=9 BV>$I6Q4Z+0#*!\;9-5Y
MX/80&P$PS'MU7D7ARBJM6=A0[ 37EI_.,CC+7\^FD^>&,'5C6"8ACO)QFXC&
MC"SX JQJ0R9]) OV(V'<FN MK"C#8W$OICT<>8)$W$;'B:FR\1]#W[\-F3@;
MU<:,BAW]>W:Y\#]$9X.T-Z#@3TQ\G[AQXOA\H<D_4?&R8FNC^/@@>][J;D;C
MSZT1A^EFJ0T<H Y 1<VK[#V_#<OB[EX3NA3EK+RU"WI3=5U84QF1-*3RFR_W
M=,1$2QQ(9&3&6ZG[X@J_!^9X$8_^WEUT)#&F,*T3Y<A:\LYV"C8F(8W'X[7;
MW%)M#SX-(G7Y'M3U;FL0"NO%9<,Q**Z)X0IE5^'0EU$H+&W[')?M_+R*_\JI
M:/6PV#L/T91)15$KW;UZ\$@M&,")4Q1;Y_@1:;AZAR@54^T.W?QT_43>=5RH
M59/G$1P58R'BKE/X*&<9815_8$= QLBR ( \P%%5NKLP*M;"_JW87@7 $!V4
M8?[<48I<Z"3F3C*0[$JKQ<.,B3@2&++*58AZ!#Z-:DU8DZJ)1V.I;?4TB%K'
MHRJ-CD<H5G&YD%I-)M.$4_7T^/1XD-\@!J'+NDB:[2!9D]2NNC"8*L@"O-M3
M$)+[K,U82YUVY6)-/8I!T7H,C;0OD42E&!&QAJNA-=8B,Q?Z61\C66EH+?J%
MD7"5^T]ZXN'8;FH,3)N6>3>\O+N_>[Z[>1H,'ZX'3\^CJ__^K]']]<WC$Q^M
M_^_'W?/_#'Z[OKF]N[I[MA(!:3%N5;N^A<?L7M73TC%4;=0J@[&]'[&UGIM:
M1*YO=/:P#D2[WXI._:L)?/,16+7!4,Z_&HRVV,Y*?AP74U5#T,:3>X-0SZ5
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MH#921).Y@70[."=X*<8=)WC9 ".?X!G!5BTK^YG3[4[3350ZYV-&A9^DW\.
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M;SIVPAKUUJ/!ZKVP#.I<BS54L@C:FHM1492[((I9HD[\B8(^SS,G2,.'O\L
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M%1RE:\5\'Q35[FC(8I&M>1DR%KYSM9LV-_ESG^0%1M?D%78FO2FQSAK&X_'
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M9V5C4MZ@$1BYNH<"1J_NH8 1;,HY/N53\5)FZ6A26#1?,<(E+]C"QD)JVY[
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MBLCRNH2%R-ZZA 5G991,OO.EB.OXHPE?P1"6!NS.]7L;Y@9PA.L, ARY.H,
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M*;!Q8=IZ;M4+#G/J"2P.4^@)[(>B,8Y9:YV8F2,S;<%OT==^V*\%X/MARQ:
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M82Z-1"KF9U,0NTEK#-RUA0T#3VUA ^3D&XU4Q8;5)$86W"ULSW%PII!XH^:
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M5E">(A4MDT/5J'XD;L@\X@TC46HC7I8*L/])XQD-U"\X8GWX;<=N@9F+3!O
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M7/PARBV].;Z<H,=7?':^Y,1.MV$^&]? S3H 9%1/" &YUQ/"PV<I8!2Q)X2
M,40AV9ITCZ4JG5SZ\@\*3[Z<?C%&67;K&-@S(=0(L"=#J!%@SX=0(\"><FO!
M5ZO(+\9(93<OV%>_TI^&]M7/J'2ANT#5DLYJ2JNH/O_0\K_,1%S[T8G)S61"
MI"J-4=J>)=E75NZSSH%Y?NN'[R(CG__U+GCCL$2VD;@S/*T$MLH\6N6W%)R
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MS*%7<RO(T>@:"^"XW#J4R<N>AMX_DRA6HF57F;^<G1NCE]4- 4?'$J+#&R/
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MS0%'J =T.,9.'/TNR97M=YT; ](-6D..G#LC7B(D' 8Q]429=?I&GHB;,%F
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MZ-,._6*U72A]0-IY\AJ1OQ,1HWXKQX//S!$L4QO(<2W+E.6YG9FC5-H&^X\
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MR^ZL+]I_@:?]EQWM+R&*\ F93LDM)K7"!#YBD+\D-L?LM^0#+?T.R$?Q9[W
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MN*:015]]-S5<QN_SU9T;1>1_+R\NQ!N/]CG1NX[7!^@M1_N$\/W&[:3YS2;
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M#-0:U9\C27FARKR3#,VJ3>.4H66E/<2,.-CX'%+V$, 3SYS=IHQ>DP>ED1X
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M/T]B+!OZ2TQGN5(SA]VF0Y)JL@-!8/:*CZDU*A&:4:[(-6L8:ZK%0LB9F+O
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MQ,QC1!1A(\;I1EN63<D(G(1,TC%1-TD9A58#]BG[4F@K,R\L%0:X!G8[(YV
M8-!L;$ TTO4'"-.&IDPP=QZ#CLDVEE2C<F0#RC14"ZY9237H+,K 4;$*&R6W
M\/BD[#Q50[1);LZ FXUK^#8CVE^.505X]A9UHS:@B%?*)N0:]TW:<2TPXC@<
M&"7X QQ*C3T?S!!-F[-//[SD_"O,><A#XT?W[# MQP@ 8'P'%(,R34&O,&E'
M%Z.J3D&CR/&K$/K/G.PCO"FP/!<=HZI6];A*N=X_1M6Z@@:5YW1D5-4KT*M:
MQ17*J$)8X/=W>]<JL.)9YDE'M!.3X[S5926MXP>3[S)68'=RJ@CA8:GHQE8@
M:83E$11)D:== =WXRF%!1W<'+( ;7S%UX'A>BP5LXWM%5K:1<8@L8&W]8C%'
MI&'X;Q90M7ZCE!37/68W3+9;.WS'HJZ[]MV5ZV"^#NNF9LE1=*0[9-=PY3@"
M<PN_=A,B2O&:]9=RX"KF4&G[)4WI2DAN+>(%*HCBKK33E#^1FCNI[&QT_D[/
M';8GWE\2N5(J94 7G],#7"6]5)9"39A\AME'#PO$DP[?BR0M&2%(2#ZUO:9,
MEJ"U8K4$4K6M%:N'Z'VVZ-*K2+AR>-WT,%(LALQ02DZCP$^-69*+B-9/3_Z0
M&B7"M41MKX=T4559:CN@]#*@PD8A2_<BVI0D=SWR#:9FZ7H)J1BQUQI?O3E>
M@F7R:_P:(:LKR63W^2KWYWA 89;_4A2:#3)^&1M=/ML\T5S.EPA  #;"Z:]#
M>.CJA+IL;@2*3.88#D7=2.M&0=D51O09X;T@3/1?[1==U@/'?!>Z[LY1WJO+
MK" 9+J=<G77U66?4\4CGD($&_Y5HTOFF;QLRWJUFA<X(N67<KHR7L5$[DLDD
M'9/ZT]MX]WOX/=BQ N 4?*W!L&(\]J 4#EWMCOYLI+FY%^-++0NZLXY.-)A'
M2Z1EYGL2,*M4+%-R!$W5,VD.#"Q[J;B3'IM2O3ZRA!64U64X# A5ZNQ.PV""
M5*PDS]I+?'@N\:% O%&%2G?Y08;!9.KC\T?@X1,KC550Y8_:7X]YLT[:HQO]
M>1TB5/8F5N://8B> GVL]47<CAHOSGUGU6(6W3 U7^%;'RW3M:7,U&%G56,I
M,P<]%HW\]5VP1![C=*:V@ZKL4!J6>;8R6G9 @B@!?[VE'ELIK,N#UC(1C7T>
M@$HP++X'BTV01+:_O"+R$D+^528+LY)*R=5J:#LNS*Q$85R:$?RO^FS@7UF/
M1('.6#V5OUL3B'-4GB8FPK46/=)UY_IIU"./LDJ;/FG;161R:2NWT52B@OI.
MX7E-R'745%3AX!U9BH2M7^(JSU'., /DE,A:#;DC7365@T@U-M%-%"4[R2K7
MXHC<5FE]RH4>-.ESY74:?",4785@E.J;SRD='8YVPBAL>'S*(V.FCP>?4SET
MN-H3DTR;D*"Q5#(&.61 PL75\!B981AR9U941T89U2#1HNJDC,I*U$1:8&G+
MS/!P8G(G ,$L!PH.>P(<C$SJVT:HYNHE#75%HK+*?9'5-)]&;"(!BY2-!*%4
M-<=IJ<FN.]#GFI%^]I M!MM[I:P16XC&UR'G!PII<_: ) !UK;>!C\8F=Z]8
MH0XFS0_IIN'Q2P=*53MOS@;K%+I<]7\JVU$&+ZY]H;-\U(-S*IV.3J5"WP4J
M?MRL.NP>FE+.P#JR'*4?B^%N+$ EG4.\4,]%.2*8;9NX;D;YVHB0\^,Z>/VT
M1"Y>%I,OY(>/Y(?2:L"_LF[1VO:N_)AD&J<O84JK)BE/E"G+/L=<G?4F0)Z%
MNX5R[?JVG^J_N--&;PU$"O7<NQ4EZN#W O(^O+;=,*V5,%]1O_<8>-YU$)(0
M9A:="D/H\5>D4L4Y)JGMX?'.CZI,V)) M]K!TN*S4I S6_Y?$L7DR.66WY;J
M9TU@)))'Y) ;+@W RN*C]E,9+8(LWI %M%1G3=ZJ,"MXHB6"@$K+?> [24A>
M,JI<['M:$RW! E2J+IHQ<Y%S\I/N!V-CWRVQ8&^$JE."364#DQG(2#$J;UTR
M"Q0ZAYW8EMH#]R4#SD?QD'188NP83RZ#U'K*IP_]J<=&1!-?##(/>:F]#YE+
M72,?=1(I"Y7YR#3)&T-YK<H]=LWPQ9#DE0*0VBO;B$NT"=]T08/UHH>"Z26M
MIH0EH%#OU=D>,:'.P;S*RR K3*C?,,KI&6B=2:M<P-R$!B+*=7BHE8JCM_::
M>,F+Q)F,6%6AU+X0:_&*(F4AC4:NI+T"*[4Z>,^ GT;/@(YLV&.ZJ3'=U)AN
M:DPW-::;ZC?=%'1FIE_U9V:"(8$4ET<7=N@%3^XV\;+\GWPW$DX75:)Z= )2
M-;_WX@4$Y!, X@;4!*#.LR%!G%U=9$/JC:X&V9#ZHTT]&Y*6+(&=94-J<-H=
M:3:DP7':.AN2GJR"H-F02AF=CLVC9LR&-&9#&K,AC=F0!@S:F UIS(8T9D,:
M4'Z?7XW.[_.K$(1"[V/$_<9ACX(#7^=T(K'@"GZ07&>, 3E"3@Y>!C0=V>!=
M(0_9$&C:3GO%'BCYC$R1<\9D>Z^I,^(HI_%UR/F!EM*</2 )0%T5:N!+HHL4
M.;_".7L-XD4OP2\=*%65K3D;K%/H<GWPJ6Q'&;RX2N<NPA0&YP/W\^@#UXL=
M;O2!&P #HP_<Z ,W^L#UM4C'DHOLSF/)Q;'DXEARL>WDMT[F-I9&'$LCCJ41
ME=[2)CB4#:[H86<.C5H2RW7IT#B61CQV%?#H##@Z X[.@,,$;70&')T!1V?
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M9G-)1^7 <>/4HPH93B/'4=7D(*\VS=5D^%5-Z+5XQ(XJ)Z+J:1<)5PJ].>Y
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M%?TK7="J$U;J"E4D;^:EK0M%[MP_MR,7?SF%T'U%168'IJ5+>@2HHGGE+^8
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M1?6D,2NLG\ZB#!P5[QRCCB<>GY3M)'8/,BD0 & CW99=C\PJO\1CE X-S9.
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MK=!&Y093@89G"@>[DHX(E-8V=*/R?BF")F.1-RJOER(^(AL_6#*O8\1&QF'
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M%W75796<1=_Y>^4OTA7(%<8;8^=.+';N!I\&+^1(V(>O!J%DO)A,WR:STE,
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MPT[9$&"4)V!;'*4,$V!N@,>_9Y7,(V".?R:L- F##5CYQZ->9W)F(0/K.[;
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MA]PQ9%HU&X$YMS$\4!4C@U'9AT&>V!4+AAD%&:0X55I.;2T<)W"S@: +:^\
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M6E35")BC\)#0@HT\^LT0-Q(I3A7 ,;,PK8!5BH63IUXR44!01XBM\3)2(&@
MD$ !9Z0$H')*,U6#9KCPL-D3P+#73QIQ"//X$R!QZ =[JGM%7@-K5@5O"7[I
M0*FJ<T_.[:T9=+FN^%3<467PXBJD>W6%^_LG0B!)>_]?_Q]02P$"% ,4
M" !9AF91"Z%_3[D4 0!@O0X $0              @ $     96UB:2TR,#(P
M,#DS,"YX;6Q02P$"% ,4    " !9AF91> 'CY!@9   .,0$ $0
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M00( 96UB:2TR,#(P,#DS,%]P<F4N>&UL4$L%!@     &  8 B@$  ,*+ @
!  $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
